SETID,SPL_VERSION,ingredients_names,ingredients_rxcuis,condition_name,pt_meddra_id,pt_meddra_term,file,title
03819118-86f6-4329-adaf-4599e7b71f46,29,buprenorphine,1819,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_03819118-86f6-4329-adaf-4599e7b71f46.json,"These highlights do not include all the information needed to use
 
BUPRENORPHINE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE
 
SUBLINGUAL TABLETS.

       

BUPRENORPHINE 
s
ublingual 
t
ablets, CIII

Initial U.S. Approval: 1981"
03cdbf5b-b572-448f-80e9-b3e812959901,2,estropipate,33747,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20120328_03cdbf5b-b572-448f-80e9-b3e812959901.json,DESCRIPTION
0becbde8-6ec5-4830-a0d9-cfdb7b15eb84,11,minocycline,6980,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240217_0becbde8-6ec5-4830-a0d9-cfdb7b15eb84.json,"Minocycline Hydrochloride Capsules, USP
 

Rx only"
0e98593a-8424-48c8-acc0-671f4b566aee,9,carvedilol,20352,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_0e98593a-8424-48c8-acc0-671f4b566aee.json,"These highlights do not include all the information needed to use CARVEDILOL TABLETS safely and effectively. See full prescribing information for CARVEDILOL TABLETS.
 

CARVEDILOL tablets, for oral use
 
Initial U.S. Approval: 1995"
11344047-7ed4-61e7-e063-6394a90a332d,1,lansoprazole,17128,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240214_11344047-7ed4-61e7-e063-6394a90a332d.json,"These highlights do not include all the information needed to use 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULESsafely and effectively. See full prescribing information for 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULES.
 

LANSOPRAZOLE delayed-release capsules, for oral use
  
Initial U.S. Approval: 1995"
17a8d11b-73b0-4833-a0b4-cf1ef85edefb,29,aripiprazole lauroxil,1673265,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231205_17a8d11b-73b0-4833-a0b4-cf1ef85edefb.json,"These highlights do not include all the information needed to use ARISTADA® safely and effectively. See full prescribing information for ARISTADA®.
ARISTADA® (aripiprazole lauroxil) extended-release injectable suspension, for intramuscular useInitial U.S. Approval: 2015"
1c90aa68-cc12-41ef-aebc-2616ae45683a,11,candesartan,214354,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240221_1c90aa68-cc12-41ef-aebc-2616ae45683a.json,"These highlights do not include all the information needed to use 

candesartan cilexetil 

 safely and effectively.  See full prescribing information for 

candesartan cilexetil 

.

Candesartan cilexetil tablets, for oral use
Initial U.S. Approval: 1998"
235dfc38-0f0b-4037-b501-7a9f4294740c,16,encorafenib,2049106,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231019_235dfc38-0f0b-4037-b501-7a9f4294740c.json,"These highlights do not include all the information needed to use BRAFTOVI safely and effectively. See full prescribing information for BRAFTOVI.
BRAFTOVI® (encorafenib) capsules, for oral useInitial U.S. Approval: 2018"
23f3c1f4-0fc8-4804-a9e3-04cf25dd302e,26,trastuzumab,224905,gi bleed,10030172,oesophageal haemorrhage,../data/2024_latest_labels/gold_xml/20230902_23f3c1f4-0fc8-4804-a9e3-04cf25dd302e.json,"These highlights do not include all the information needed to use KADCYLA safely and effectively.  See full prescribing information for KADCYLA. 
KADCYLA® (ado-trastuzumab emtansine) for injection, for intravenous use Initial U.S. Approval:  2013"
246e0ed0-f8ca-483b-a1ce-91052f3f35f0,9,enalapril,3827,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_246e0ed0-f8ca-483b-a1ce-91052f3f35f0.json,"Enalapril Maleate Tablets, USP"
304a3059-4f7f-4ec4-839d-86492bb5e07b,6,memantine,6719,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240221_304a3059-4f7f-4ec4-839d-86492bb5e07b.json,"These highlights do not include all the information needed to use MEMANTINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for MEMANTINE HYDROCHLORIDE TABLETS.
 
MEMANTINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 2003"
35d0074e-212b-4a1f-9cd7-974ca08d2c95,21,ropinirole,72302,acute myocardial infarction,10002388,angina unstable,../data/2024_latest_labels/latest_labels_ingredients/20240206_35d0074e-212b-4a1f-9cd7-974ca08d2c95.json,"These highlights do not include all the information needed to use ROPINIROLE TABLETS safely and effectively. See full prescribing information for ROPINIROLE TABLETS.
ROPINIROLE tablets, for oral use Initial U.S. Approval: 1997"
35d0074e-212b-4a1f-9cd7-974ca08d2c95,21,ropinirole,72302,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240206_35d0074e-212b-4a1f-9cd7-974ca08d2c95.json,"These highlights do not include all the information needed to use ROPINIROLE TABLETS safely and effectively. See full prescribing information for ROPINIROLE TABLETS.
ROPINIROLE tablets, for oral use Initial U.S. Approval: 1997"
37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,45,mycophenolate mofetil,68149,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_37241e87-4af4-4dc3-a1aa-ea6f20d8dc40.json,"These highlights do not include all the information needed to use CELLCEPT® safely and effectively. See full prescribing information for CELLCEPT® 
CELLCEPT® (mycophenolate mofetil) capsules, for oral use CELLCEPT® (mycophenolate mofetil) tablets, for oral use CELLCEPT®  Oral Suspension (mycophenolate mofetil), for oral suspension CELLCEPT®  Intravenous (mycophenolate mofetil) for injection, for intravenous use Initial U.S. Approval: 1995"
39d53698-57fa-7c99-fc5b-f52a55684826,26,bendamustine,134547,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20221029_39d53698-57fa-7c99-fc5b-f52a55684826.json,"These highlights do not include all the information needed to use TREANDA safely and effectively. See full prescribing information for TREANDA.
TREANDA® (bendamustine hydrochloride) injection, for intravenous useTREANDA® (bendamustine hydrochloride) for injection, for intravenous useInitial U.S. Approval: 2008"
3bc8668e-8ec3-4c54-b46b-5ca0dac87c1b,13,micafungin,325887,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231201_3bc8668e-8ec3-4c54-b46b-5ca0dac87c1b.json,"These highlights do not include all the information needed to use MICAFUNGIN FOR INJECTION safely and effectively. See full prescribing information for MICAFUNGIN FOR INJECTION.
 MICAFUNGIN for Injection, for intravenous infusion only Initial U.S. Approval: 2005"
3c52dddd-0457-41cd-99e0-d30d4fd00ec5,4,maraviroc,620216,acute myocardial infarction,10002388,angina unstable,../data/2024_latest_labels/latest_labels_ingredients/20231111_3c52dddd-0457-41cd-99e0-d30d4fd00ec5.json,"These highlights do not include all the information needed to use SELZENTRY safely and effectively. See full prescribing information for SELZENTRY.
SELZENTRY (maraviroc) tablets, for oral useSELZENTRY (maraviroc) oral solutionInitial U.S. Approval: 2007"
3d30eb8d-a62e-475f-926b-78ba63bee9c8,11,isoflurane,6026,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240130_3d30eb8d-a62e-475f-926b-78ba63bee9c8.json,"FORANE (isoflurane, USP) liquid for inhalation"
413c645e-074d-4276-b39a-d83521077602,14,abiraterone,1100072,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240217_413c645e-074d-4276-b39a-d83521077602.json,"These highlights do not include all the information needed to use ABIRATERONE ACETATE TABLETS safely and effectively. See full prescribing information for ABIRATERONE ACETATE TABLETS.
  

ABIRATERONE ACETATE tablets,
 
for oral use 

Initial U.S. Approval: 2011"
4238a064-1bfd-4ce3-b9d9-12c96eee8af0,2,olmesartan,321064,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240217_4238a064-1bfd-4ce3-b9d9-12c96eee8af0.json,"These highlights do not include all the information needed to use OLMESARTAN MEDOXOMIL TABLETS safely and effectively. See full prescribing information for OLMESARTAN MEDOXOMIL TABLETS.  OLMESARTAN MEDOXOMIL tablets, for oral use   Initial U.S. Approval: 2002"
4260d746-bb58-4e10-9ffe-fc414f22b591,11,gemfibrozil,4719,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240223_4260d746-bb58-4e10-9ffe-fc414f22b591.json,"Gemfibrozil Tablets, USP 600 mg"
4314da8a-40e5-4aba-a32b-57b4166ade30,12,azithromycin,18631,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_4314da8a-40e5-4aba-a32b-57b4166ade30.json,"These highlights do not include all the information needed to use AZITHROMYCIN TABLETS safely and effectively. See full prescribing information for AZITHROMYCIN TABLETS.  AZITHROMYCIN tablets, for oral use Initial U.S. Approval: 1991"
44492772-5aed-4627-bd85-e8e89f308bb3,12,siponimod,2121085,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230817_44492772-5aed-4627-bd85-e8e89f308bb3.json,"These highlights do not include all the information needed to use MAYZENT safely and effectively. See full prescribing information for MAYZENT.


MAYZENT® (siponimod) tablets, for oral use

Initial U.S. Approval: 2019"
44dcbf97-99ec-427c-ba50-207e0069d6d2,9,pitavastatin,861634,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/gold_xml/20240203_44dcbf97-99ec-427c-ba50-207e0069d6d2.json,"These highlights do not include all the information needed to use LIVALO® safely and effectively.  See full prescribing information for LIVALO.
 LIVALO (pitavastatin) tablets, for oral use Initial U.S. Approval: 2009"
4650d12c-b9c8-4525-b07f-a2d773eca155,26,teriflunomide,1310520,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/gold_xml/20240110_4650d12c-b9c8-4525-b07f-a2d773eca155.json,"These highlights do not include all the information needed to use AUBAGIO® safely and effectively. See full prescribing information for AUBAGIO. 
AUBAGIO (teriflunomide) tablets, for oral use Initial U.S. Approval: 2012"
4911f343-68e6-71b0-e054-00144ff8d46c,5,meloxicam,41493,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240223_4911f343-68e6-71b0-e054-00144ff8d46c.json,"These highlights do not include all the information needed to use MELOXICAM TABLETS safely and effectively. See full prescribing information for MELOXICAM TABLETS.
 

Initial U.S. Approval: 2000"
496b38ee-45b6-4bb2-a35e-9023c3b73719,5,tiotropium,69120,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20231215_496b38ee-45b6-4bb2-a35e-9023c3b73719.json,"These highlights do not include all the information needed to use TIOTROPIUM BROMIDE INHALATION POWDER safely and effectively. See full prescribing information for TIOTROPIUM BROMIDE INHALATION POWDER.
TIOTROPIUM BROMIDE inhalation powder, for oral inhalation useInitial U.S. Approval: 2004"
4c486fc7-c8c4-4c6c-b30c-366dabaeaadd,14,gabapentin,25480,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20230830_4c486fc7-c8c4-4c6c-b30c-366dabaeaadd.json,"These highlights do not include all the information needed to use HORIZANT safely and effectively. See full prescribing information for HORIZANT. 
HORIZANT® (gabapentin enacarbil) Extended-Release Tablets for oral use Initial U.S. Approval: 2011"
4c61e68e-f2d1-4998-aae7-62997971dab7,4,foscarnet,33562,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231118_4c61e68e-f2d1-4998-aae7-62997971dab7.json,"FOSCAVIR 
 ® 


(foscarnet sodium) INJECTION"
4c9eb5d2-8d2c-4ce7-b45e-c92d3ce9532a,11,isosorbide,6057,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240222_4c9eb5d2-8d2c-4ce7-b45e-c92d3ce9532a.json,"Isosorbide Mononitrate Tablets, USP




Rx only"
4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213,6,cyclophosphamide,3002,acute liver injury,10019660,hepatic encephalopathy,../data/2024_latest_labels/latest_labels_ingredients/20240113_4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213.json,"""These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE CAPSULES safely and effectively"". ""See full prescribing information for CYCLOPHOSPHAMIDE CAPSULES.""
 



""CYCLOPHOSPHAMIDE capsules""
 

""Initial U.S. Approval: 1959"""
51cdb22b-035f-47d7-8048-38006e2589f2,20,nifedipine,7417,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240217_51cdb22b-035f-47d7-8048-38006e2589f2.json,Rx only
52781229-ee82-43f9-a113-4419a611978d,1,rivastigmine,183379,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240111_52781229-ee82-43f9-a113-4419a611978d.json,"These highlights do not include all the information needed to use RIVASTIGMINE TARTRATE CAPSULES safely and effectively. See full prescribing information for RIVASTIGMINE TARTRATE CAPSULES.
 
RIVASTIGMINE TARTRATE capsules, for oral use
 
Initial U.S. Approval: 2000"
56d64558-1fad-420e-8fcd-7103cd073127,1,celecoxib,140587,acute myocardial infarction,10002388,angina unstable,../data/2024_latest_labels/latest_labels_ingredients/20240207_56d64558-1fad-420e-8fcd-7103cd073127.json,"These highlights do not include all the information needed to use CELECOXIB CAPSULES safely and effectively. See full prescribing information for CELECOXIB CAPSULES.
 

CELECOXIB capsules, for oral use
 

Initial U.S. Approval: 1998"
575da603-b038-421f-9894-6796d9ac33cc,11,sertraline,36437,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_575da603-b038-421f-9894-6796d9ac33cc.json,"These highlights do not include all the information needed to use SERTRALINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for SERTRALINE HYDROCHLORIDE TABLETS.
 

SERTRALINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1991"
57a597d2-03f0-472e-b148-016d7169169d,12,sacituzumab,2360231,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230215_57a597d2-03f0-472e-b148-016d7169169d.json,"These highlights do not include all the information needed to use TRODELVY safely and effectively. See full prescribing information for TRODELVY 
 TRODELVY® (sacituzumab govitecan-hziy) for injection, for intravenous use Initial U.S. Approval: 2020"
57f8aac6-3bd3-4ae1-aab2-759c8bc23292,4,trandolapril,38454,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231111_57f8aac6-3bd3-4ae1-aab2-759c8bc23292.json,Trandolapril Tablets USP Rx only
58d80bc6-bdfb-4908-93e7-aace447c8d1a,1,octreotide,7617,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240131_58d80bc6-bdfb-4908-93e7-aace447c8d1a.json,"These highlights do not include all the information needed to use MYCAPSSA® safely and effectively. See full prescribing information for MYCAPSSA.
 MYCAPSSA (octreotide) delayed-release capsules, for oral use Initial U.S. Approval: 1988"
5c4841b4-fbc0-4163-8ee1-cb28629cbfbf,13,dihematoporphyrin ether,23066,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20230816_5c4841b4-fbc0-4163-8ee1-cb28629cbfbf.json,"These highlights do not include all the information needed to use PHOTOFRIN 
 ® safely and effectively. See full prescribing information for PHOTOFRIN.
 



PHOTOFRIN (porfimer sodium) for injection, for intravenous useInitial U.S. Approval: 1995"
5cd725a1-2fa4-408a-a651-57a7b84b2118,18,avelumab,1875534,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240131_5cd725a1-2fa4-408a-a651-57a7b84b2118.json,"These highlights do not include all the information needed to use BAVENCIO safely and effectively. See full prescribing information for BAVENCIO.
 BAVENCIO® (avelumab) injection, for intravenous use Initial U.S. Approval: 2017"
5f01e40a-b6f6-40fb-b37c-3d06f1428e86,27,glatiramer,214582,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240123_5f01e40a-b6f6-40fb-b37c-3d06f1428e86.json,"These highlights do not include all the information needed to use GLATOPA safely and effectively. See full prescribing information for GLATOPA.
GLATOPA® (glatiramer acetate injection), for subcutaneous useInitial U.S. Approval: 1996"
60f0aa03-ad25-4d48-80ce-7fcfa76f325f,10,tezepelumab,2587789,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240130_60f0aa03-ad25-4d48-80ce-7fcfa76f325f.json,"These highlights do not include all the information needed to use TEZSPIRE safely and effectively.  See full prescribing information for TEZSPIRE.
TEZSPIRE® (tezepelumab-ekko) injection, for subcutaneous useInitial U.S. Approval: 2021"
645c887c-8cd4-4623-8da9-ac223d71a8b9,8,avapritinib,2272107,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230528_645c887c-8cd4-4623-8da9-ac223d71a8b9.json,"These highlights do not include all the information needed to use AYVAKIT safely and effectively. See full prescribing information for AYVAKIT.
 AYVAKIT® (avapritinib) tablets, for oral use Initial U.S. Approval: 2020"
69301126-c901-4d0d-9acb-91ba1a87cd21,26,valacyclovir,73645,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240217_69301126-c901-4d0d-9acb-91ba1a87cd21.json,"HIGHLIGHTS OF PRESCRIBING INFORMATION
 

These highlights do not include all the information needed to use valacyclovir hydrochloride safely and effectively. See full prescribing information for valacyclovir hydrochloride.
 

Valacyclovir Tablets, USP
 

Initial U.S. Approval:1995"
6ee2265b-1da5-4215-848b-12aa5eb25eff,10,hydralazine,5470,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_6ee2265b-1da5-4215-848b-12aa5eb25eff.json,Rx only
73ccebc1-7412-2424-d62c-a5180ec52d81,1,trimethoprim,10829,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240130_73ccebc1-7412-2424-d62c-a5180ec52d81.json,"TRIMETHOPRIM TABLETS, USP
Rx only"
7652adc6-1aad-4422-b85c-0c6b11c23b73,7,gabapentin,25480,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_7652adc6-1aad-4422-b85c-0c6b11c23b73.json,"These highlights do not include all the information needed to use GABAPENTIN CAPSULES safely and effectively. See full prescribing information for GABAPENTIN CAPSULES.
 

GABAPENTIN capsules, for oral use
 

Initial U.S. Approval: 1993"
7663c49d-1b1d-755d-e053-2991aa0a4ee3,9,epinephrine,3992,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_7663c49d-1b1d-755d-e053-2991aa0a4ee3.json,"ADRENALIN® (EPINEPHRINE INJECTION, USP) 1mg/mL 1:1000 VIAL"
7d655d6d-01da-488c-bd4e-c7fbe0ace38c,5,testosterone,10379,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240215_7d655d6d-01da-488c-bd4e-c7fbe0ace38c.json,"These highlights do not include all the information needed to use TESTOSTERONE GEL, 1% safely and effectively.  See full prescribing information for TESTOSTERONE GEL, 1%.

 TESTOSTERONE gel 1%, for topical use, CIII Initial U.S. Approval: 1953"
7e9ab975-db2f-423c-a089-bc5a73313609,11,rivaroxaban,1114195,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/gold_xml/20231208_7e9ab975-db2f-423c-a089-bc5a73313609.json,"These highlights do not include all the information needed to use XARELTO safely and effectively. See full prescribing information for XARELTO.
 



XARELTO 
 ® (rivaroxaban) tablets, for oral use
 

XARELTO 
 ® (rivaroxaban) for oral suspension
 

Initial U.S. Approval: 2011"
829e744d-7bd4-43dc-9b58-ffb016cb8e67,1,didanosine,3364,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20120508_829e744d-7bd4-43dc-9b58-ffb016cb8e67.json,These highlights do not include all the information needed to use didanosine delayed-release capsules safely and effectively. See full prescribing information for didanosine delayed-release capsules. Initial U.S. Approval: 1991
84137882-e000-47da-bd5b-fa76ab3c76f9,20,axitinib,1242999,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/train_xml/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012"
860c799c-5199-4f0c-b21b-9910273474d9,6,pentamidine,7994,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240202_860c799c-5199-4f0c-b21b-9910273474d9.json,Pentamidine isethionate for injection
8983d6a0-f63f-4f8e-bba4-38223f39e29b,11,benznidazole,18994,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231111_8983d6a0-f63f-4f8e-bba4-38223f39e29b.json,"These highlights do not include all the information needed to use BENZNIDAZOLE TABLETS safely and effectively. See full prescribing information for BENZNIDAZOLE TABLETS.
 



BENZNIDAZOLE tablets, for oral use
 

Initial U.S. Approval: 2017"
8bdb47c5-9d19-4d59-94c8-62c117525e7f,1,zafirlukast,114970,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231204_8bdb47c5-9d19-4d59-94c8-62c117525e7f.json,Zafirlukast Tablets Rx only
8bf8e76c-27cb-42a4-aa9c-bdade68c463b,4,rasagiline,134748,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231227_8bf8e76c-27cb-42a4-aa9c-bdade68c463b.json,These highlights do not include all the information needed to use RASAGILINE TABLETS safely and effectively. See full prescribing information for RASAGILINE TABLETS. RASAGILINE tablets for oral use Initial U.S. Approval: 2006
8c065559-bd35-4dda-ac8f-624eea0641ae,9,zidovudine,11413,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_8c065559-bd35-4dda-ac8f-624eea0641ae.json,"These highlights do not include all the information needed to use ZIDOVUDINE TABLETS safely and effectively. See full prescribing information for ZIDOVUDINE TABLETS.
 



ZIDOVUDINE tablets, for oral use
 



Initial U.S. Approval: 1987"
8f7f73b8-586a-4df0-935f-fecd4696c16c,17,isavuconazonium,1608322,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240112_8f7f73b8-586a-4df0-935f-fecd4696c16c.json,"These highlights do not include all the information needed to use CRESEMBA® safely and effectively. See full prescribing information for CRESEMBA®.
CRESEMBA® (isavuconazonium sulfate) capsules, for oral useCRESEMBA® (isavuconazonium sulfate) for injection, for intravenous useInitial U.S. Approval: 2015"
9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f,6,ketoprofen,6142,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240206_9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f.json,KIPROFEN™ Capsules
9e79b42c-38a3-4b2c-a196-a5a1948250e2,57,lacosamide,623400,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/gold_xml/20231011_9e79b42c-38a3-4b2c-a196-a5a1948250e2.json,"These highlights do not include all the information needed to use VIMPAT® safely and effectively.  See full prescribing information for VIMPAT. 
VIMPAT® (lacosamide) film coated tablet, for oral use, CV VIMPAT® (lacosamide) injection, for intravenous use, CV VIMPAT® (lacosamide) oral solution, CV Initial U.S. Approval: 2008"
a09a25fc-a5a3-0c82-e053-2995a90a5d74,15,pasireotide,1364105,acute liver injury,10023126,jaundice,../data/2024_latest_labels/gold_xml/20230804_a09a25fc-a5a3-0c82-e053-2995a90a5d74.json,"These highlights do not include all the information needed to use SIGNIFOR safely and effectively. See full prescribing information for SIGNIFOR.




SIGNIFOR 
  ®(pasireotide) injection, for subcutaneous use 
 


Initial U.S. Approval: 2012"
a21006b7-6d6f-4f06-81b4-17978756452b,6,fostemsavir,2380373,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_a21006b7-6d6f-4f06-81b4-17978756452b.json,"These highlights do not include all the information needed to use RUKOBIA safely and effectively.  See full prescribing information for RUKOBIA.
RUKOBIA (fostemsavir) extended-release tablets, for oral useInitial U.S. Approval: 2020"
a23063c0-099a-4256-b95f-3a857bbf704b,18,alprazolam,596,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240209_a23063c0-099a-4256-b95f-3a857bbf704b.json,"These highlights do not include all the information needed to use ALPRAZOLAM TABLETS safely and effectively. See full prescribing information for ALPRAZOLAM TABLETS.


ALPRAZOLAM tablets, for oral use, CIV 


Initial U.S. Approval: 1981"
a64a50ba-e3da-4227-9bce-87101d60409e,2,sapropterin,753340,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231205_a64a50ba-e3da-4227-9bce-87101d60409e.json,"These highlights do not include all the information needed to use SAPROPTERIN DIHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for SAPROPTERIN DIHYDROCHLORIDE TABLETS.
 
SAPROPTERIN DIHYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 2007"
a865e0ef-8685-4f69-8838-648c4f3bab47,6,emapalumab,2104604,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230921_a865e0ef-8685-4f69-8838-648c4f3bab47.json,"These highlights do not include all the information needed to use GAMIFANT safely and effectively. See full prescribing information for GAMIFANT.
GAMIFANT® (emapalumab-lzsg) injection, for intravenous use Initial U.S. Approval: 2018"
b023a9f2-1a99-4b40-a953-edac7e3a79bf,15,anastrozole,84857,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240220_b023a9f2-1a99-4b40-a953-edac7e3a79bf.json,"These highlights do not include all the information needed to use anastrozole tablets safely and effectively. See full prescribing information for anastrozole tablets.
 

ANASTROZOLE tablet for oral use
 

Initial U.S. Approval: 1995"
b17679e8-88c8-4b8d-bfae-246fab6eead9,13,docetaxel,72962,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240201_b17679e8-88c8-4b8d-bfae-246fab6eead9.json,"These highlights do not include all the information needed to use DOCETAXEL INJECTION safely and effectively. See full prescribing information for DOCETAXEL INJECTION.DOCETAXEL injection, for intravenous use
Initial U.S. Approval: 1996"
b31ff20a-c363-4be0-9bc0-3081c163b63c,7,atovaquone,60212,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_b31ff20a-c363-4be0-9bc0-3081c163b63c.json,"These highlights do not include all the information needed to use ATOVAQUONE ORAL SUSPENSION safely and effectively. See full prescribing information for ATOVAQUONE ORAL SUSPENSION.


ATOVAQUONE oral suspension, for oral use


Initial U.S. Approval: 1992"
b4c2c9dc-a0bb-4d64-a667-a67ebe88392d,37,certolizumab pegol,709271,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/train_xml/20230105_b4c2c9dc-a0bb-4d64-a667-a67ebe88392d.json,"These highlights do not include all the information needed to use CIMZIA® safely and effectively. See full prescribing information for CIMZIA.
 



CIMZIA (certolizumab pegol) for injection, for subcutaneous use
 

CIMZIA (certolizumab pegol) injection, for subcutaneous use
 

Initial U.S. Approval: 2008"
b6b1d427-e19a-4fc1-b518-f58bacc46736,8,guanfacine,40114,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240217_b6b1d427-e19a-4fc1-b518-f58bacc46736.json,"Guanfacine Tablets, USP 


Rx only"
b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,ibuprofen,5640,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,"IBUPROFEN Tablets, USP"
b856bfaf-ec6b-4171-81c4-b9b07f780084,2,valganciclovir,275891,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240131_b856bfaf-ec6b-4171-81c4-b9b07f780084.json,"These highlights do not include all the information needed to use VALGANCICLOVIR HYDROCHLORIDE FOR ORAL SOLUTION safely and effectively. See full prescribing information for VALGANCICLOVIR HYDROCHLORIDE FOR ORAL SOLUTION. VALGANCICLOVIR HYDROCHLORIDE, for oral solution Initial U.S. Approval: 2001"
c3cca66e-348a-43e8-8f96-e995104dae3d,5,levamlodipine,2376944,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231115_c3cca66e-348a-43e8-8f96-e995104dae3d.json,"These highlights do not include all the information needed to use CONJUPRI® safely and effectively. See full prescribing information for CONJUPRI®. 
CONJUPRI® (levamlodipine) tablets, for oral use.Initial U.S. Approval: 2019"
c76f4b3b-9f93-349f-e053-2995a90a2d57,2,sodium tetradecyl sulfate,9913,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_c76f4b3b-9f93-349f-e053-2995a90a2d57.json,SOTRADECOL® 1% (SODIUM TETRADECYL SULFATE INJECTION) 20mg/2mL (10mg/mL)
d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f,8,mefenamate,257844,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240120_d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f.json,Mefenamic Acid Capsules USPRx Only
d1f64796-6ba0-415c-a6a0-5456b21a7ed6,5,fenofibrate,8703,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240221_d1f64796-6ba0-415c-a6a0-5456b21a7ed6.json,"These highlights do not include all the information needed to use FENOFIBRATE TABLETS safely and effectively. See full prescribing information for FENOFIBRATE TABLETS.
 
FENOFIBRATE tablets, for oral use
 
Initial U.S. Approval: 1993"
d267f492-43f6-45ba-8421-82ae2771788b,6,montelukast,88249,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_d267f492-43f6-45ba-8421-82ae2771788b.json,"These highlights do not include all the information needed to use MONTELUKAST SODIUM TABLETS and MONTELUKAST SODIUM CHEWABLE TABLETS safely and effectively. See full prescribing information for MONTELUKAST SODIUM TABLETS and MONTELUKAST SODIUM CHEWABLE TABLETS .


MONTELUKAST SODIUM tablets, for oral use
  
MONTELUKAST SODIUM chewable tablets, for oral use 
 

Initial U.S. Approval: 1998"
d3832a1a-a140-49c1-a7df-134fa81341e3,8,disulfiram,3554,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231227_d3832a1a-a140-49c1-a7df-134fa81341e3.json,"Disulfiram Tablets, USP
 
IN ALCOHOLISM
 

Rx only"
d5050d0e-81d1-4707-a38a-e80de2aebf09,2,cefditoren,83682,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20130606_d5050d0e-81d1-4707-a38a-e80de2aebf09.json,Cefditoren Pivoxil Tablets 200 mg and 400 mg
d7836711-b677-412d-bf2d-0f7c8444103a,3,epcoritamab,2637392,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230526_d7836711-b677-412d-bf2d-0f7c8444103a.json,"These highlights do not include all the information needed to use EPKINLY safely and effectively. See full prescribing information for EPKINLY.
 EPKINLY™ (epcoritamab-bysp) injection, for subcutaneous use Initial U.S. Approval: 2023"
de512e9b-444c-4ae4-8c6b-accd87a02021,5,chlorothiazide,2396,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231208_de512e9b-444c-4ae4-8c6b-accd87a02021.json,"Chlorothiazide Sodium for Injection, USP"
de77155c-ecf2-4f15-9758-21d271449d83,2,tivozanib,2534233,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20220826_de77155c-ecf2-4f15-9758-21d271449d83.json,"These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. 
FOTIVDA® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021"
e23dcfd0-071a-4458-a595-3562fabccbd4,3,dantrolene,3105,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240203_e23dcfd0-071a-4458-a595-3562fabccbd4.json,Dantrolene Sodium capsules
ed3039d8-3d27-4b71-a4b0-812943c9457f,10,trazodone,10737,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240221_ed3039d8-3d27-4b71-a4b0-812943c9457f.json,"These highlights do not include all the information needed to use TRAZODONE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for TRAZODONE HYDROCHLORIDE TABLETS.





TRAZODONE HYDROCHLORIDE tablets, for oral use




Initial U.S. Approval: 1981"
ed977166-7ac0-4a8c-a10c-4b19a69403c0,1,darunavir,460132,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240123_ed977166-7ac0-4a8c-a10c-4b19a69403c0.json,"These highlights do not include all the information needed to use DARUNAVIR TABLETS safely and effectively. See Full Prescribing Information for DARUNAVIR TABLETS.
DARUNAVIR tablets, for oral useInitial U.S. Approval: 2006"
eeb0fcfd-e4e8-4fb1-9635-901dc9446235,8,iloperidone,73178,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20221224_eeb0fcfd-e4e8-4fb1-9635-901dc9446235.json,"These highlights do not include all the information needed to use ILOPERIDONE TABLETS safely and effectively. See full prescribing information for ILOPERIDONE TABLETS.
ILOPERIDONE tablets, for oral use
Initial U.S. Approval: 2009"
f34c08e6-fe74-4de3-9e36-a82c3c1c183b,9,moxifloxacin,139462,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240214_f34c08e6-fe74-4de3-9e36-a82c3c1c183b.json,"These highlights do not include all the information needed to use MOXIFLOXACIN TABLETS safely and effectively. See full prescribing information for MOXIFLOXACIN TABLETS.
 MOXIFLOXACIN tablets, for oral use Initial U.S. Approval: 1999"
f5f56c59-04d5-4c5d-9441-5a93d3bdec82,6,felodipine,4316,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240222_f5f56c59-04d5-4c5d-9441-5a93d3bdec82.json,"Felodipine Extended-Release Tablets, USP
 Rx only"
fc38f1bb-f175-4a81-8ed9-c8701efdea35,102,fosinopril,50166,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231128_fc38f1bb-f175-4a81-8ed9-c8701efdea35.json,"FOSINOPRILSODIUM TABLETS, USP10mg, 20mg and 40mgRx Only"
fd427d2d-b78b-412a-9c80-606bc88ad112,10,eletriptan,231049,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231220_fd427d2d-b78b-412a-9c80-606bc88ad112.json,"These highlights do not include all the information needed to use ELETRIPTAN HYDROBROMIDE TABLETS safely and effectively. See full prescribing information for ELETRIPTAN HYDROBROMIDE TABLETS.


ELETRIPTAN hydrobromide tablets, for oral use 

Initial U.S. Approval: 2002"
0422fe47-c372-494f-bac2-612f550b44a4,12,cefazolin,2180,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240220_0422fe47-c372-494f-bac2-612f550b44a4.json,"Cefazolin for Injection, USP"
077a92f6-9f1b-479a-87c7-c92b5db6aa9c,10,relugolix,2472778,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240125_077a92f6-9f1b-479a-87c7-c92b5db6aa9c.json,"These highlights do not include all the information needed to use ORGOVYX safely and effectively. See full prescribing information for ORGOVYX.
 



ORGOVYX (relugolix) tablets, for oral use
 

Initial U.S. Approval: 2020"
08ce9fdd-1e84-4043-b085-91053f975b64,101,acitretin,16818,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240127_08ce9fdd-1e84-4043-b085-91053f975b64.json,"®

Tablets"
11344047-7ed4-61e7-e063-6394a90a332d,1,lansoprazole,17128,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240214_11344047-7ed4-61e7-e063-6394a90a332d.json,"These highlights do not include all the information needed to use 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULESsafely and effectively. See full prescribing information for 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULES.
 

LANSOPRAZOLE delayed-release capsules, for oral use
  
Initial U.S. Approval: 1995"
115a4125-07df-9f9b-e063-6394a90a3e49,1,prochlorperazine,8704,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240220_115a4125-07df-9f9b-e063-6394a90a3e49.json,"PROCHLORPERAZINE MALEATE TABLETS, USP
 

Rx Only"
17a8d11b-73b0-4833-a0b4-cf1ef85edefb,29,aripiprazole lauroxil,1673265,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231205_17a8d11b-73b0-4833-a0b4-cf1ef85edefb.json,"These highlights do not include all the information needed to use ARISTADA® safely and effectively. See full prescribing information for ARISTADA®.
ARISTADA® (aripiprazole lauroxil) extended-release injectable suspension, for intramuscular useInitial U.S. Approval: 2015"
1a2c0a9a-c637-4485-ad4b-0b6d0b05fa20,3,dipyridamole,3521,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20231014_1a2c0a9a-c637-4485-ad4b-0b6d0b05fa20.json,"Dipyridamole 5 mg/mL Injection, USP 10 mL Single Dose Vial"
1dbac120-d4e6-45a9-b950-3d82aa7a1271,10,labetalol,6185,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240215_1dbac120-d4e6-45a9-b950-3d82aa7a1271.json,"Labetalol Hydrochloride Tablets, USP
 

Rx only"
1e484a50-55db-4b85-8c57-6cd1b0353abd,32,macitentan,1442132,acute liver injury,10084058,congestive hepatopathy,../data/2024_latest_labels/gold_xml/20230615_1e484a50-55db-4b85-8c57-6cd1b0353abd.json,"These highlights do not include all the information needed to use OPSUMIT safely and effectively. See full prescribing information for OPSUMIT.
 



OPSUMIT 
 ® (macitentan) tablets, for oral use
 

Initial U.S. Approval: 2013"
1fd148fb-0fbc-4b6f-b790-23546fb46a71,20,doxorubicin,3639,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240124_1fd148fb-0fbc-4b6f-b790-23546fb46a71.json,"These highlights do not include all the information needed to use DOXORUBICIN HYDROCHLORIDE safely and effectively. See full prescribing information for DOXORUBICIN HYDROCHLORIDE. 
DOXORUBICIN HYDROCHLORIDE injection, for intravenous use DOXORUBICIN HYDROCHLORIDE for injection, for intravenous use Initial U.S. Approval: 1974"
22174520-4b78-4841-96f7-530ba12d2cf1,8,paroxetine,32937,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240217_22174520-4b78-4841-96f7-530ba12d2cf1.json,"Paroxetine Tablets USP, film coated for oral use"
23b1f2f5-2d84-4a1e-997f-6489204878b2,102,captopril,1998,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240112_23b1f2f5-2d84-4a1e-997f-6489204878b2.json,"Captopril Tablets, USP

for oral use

Rx only"
2421dc8f-a60d-4249-b093-c9e8e1d4bb82,10,glyburide,4815,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_2421dc8f-a60d-4249-b093-c9e8e1d4bb82.json,"Glyburide Tablets, USP
 

1.25, 2.5, and 5 mg"
2b34d62d-e02a-4af3-bc0d-1571dd4ee76d,7,lorlatinib,2103164,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230908_2b34d62d-e02a-4af3-bc0d-1571dd4ee76d.json,"These highlights do not include all the information needed to use LORBRENA safely and effectively. See full prescribing information for LORBRENA.
 LORBRENA® (lorlatinib) tablets, for oral use Initial U.S. Approval: 2018"
2b70cf0c-45be-428f-b396-5001ed4e30fc,6,amiloride,644,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20231130_2b70cf0c-45be-428f-b396-5001ed4e30fc.json,"Amiloride HCl Tablets, USP"
3e43c17f-7e7e-4ccd-b321-1dd5e62cdafd,8,levetiracetam,114477,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_3e43c17f-7e7e-4ccd-b321-1dd5e62cdafd.json,"These highlights do not include all the information needed to use LEVETIRACETAM INJECTION safely and effectively. See full prescribing information for LEVETIRACETAM INJECTION.
 LEVETIRACETAM injection, for intravenous use Initial U.S. Approval: 1999"
42f49299-7ae5-4d30-86eb-66b739c0e95d,5,lisinopril,29046,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_42f49299-7ae5-4d30-86eb-66b739c0e95d.json,"These highlights do not include all the information needed to use LISINOPRIL TABLETS safely and effectively. See full prescribing information for LISINOPRIL TABLETS
 



LISINOPRIL tablets, for oral use
 



Initial U.S. Approval: 1988"
454f092e-dcd0-47bd-a521-b07400403dad,5,mannitol,6628,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240123_454f092e-dcd0-47bd-a521-b07400403dad.json,"These highlights do not include all the information needed to use BRONCHITOL safely and effectively. See full prescribing information for BRONCHITOL.BRONCHITOL® (mannitol) inhalation powder, for oral inhalation useInitial U.S. Approval: 1964"
455892c3-d144-4ba8-9ab4-79cabff9876d,11,capmatinib,2362165,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240110_455892c3-d144-4ba8-9ab4-79cabff9876d.json,"These highlights do not include all the information needed to use TABRECTA safely and effectively. See full prescribing information for TABRECTA.
		
TABRECTA® (capmatinib) tablets, for oral use
		
		Initial U.S. Approval: 2020"
48aa32cb-047a-414a-822e-82a5f26d8817,17,diazepam,3322,acute liver injury,10019660,hepatic encephalopathy,../data/2024_latest_labels/latest_labels_ingredients/20240222_48aa32cb-047a-414a-822e-82a5f26d8817.json,"Diazepam Tablets, USP, CIV


Rx only"
48ffeac8-38e8-4007-903a-dbffce25d679,2,etravirine,475969,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240110_48ffeac8-38e8-4007-903a-dbffce25d679.json,"These highlights do not include all the information needed to use ETRAVIRINE TABLETS safely and effectively.See full prescribing information for ETRAVIRINE TABLETS.
ETRAVIRINE tablets, for oral useInitial U.S. Approval: 2008"
4a22e559-2dac-42d7-af8d-eb0ebbc2f76d,8,6-aminocaproic acid,99,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231229_4a22e559-2dac-42d7-af8d-eb0ebbc2f76d.json,"Aminocaproic Acid Tablets, USP

(500 mg)

Rx only"
4e338e89-3cf2-48eb-b6e2-a06c608c6513,36,abiraterone,1100072,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20211016_4e338e89-3cf2-48eb-b6e2-a06c608c6513.json,"These highlights do not include all the information needed to use ZYTIGA safely and effectively. See full prescribing information for ZYTIGA. 
ZYTIGA® (abiraterone acetate) tablets, for oral use Initial U.S. Approval: 2011"
5198b1c8-8dd6-4b8f-bd85-294ac468af53,10,fluvoxamine,42355,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_5198b1c8-8dd6-4b8f-bd85-294ac468af53.json,"These highlights do not include all the information needed to use FLUVOXAMINE MALEATE TABLETS safely and effectively. See full prescribing information for FLUVOXAMINE MALEATE TABLETS.
 

FLUVOXAMINE MALEATE tablets, for oral use
 
Initial U.S. Approval: 1994"
51ff7db5-aaf9-4c3c-86e6-958ebf16b60f,10,nefazodone,31565,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20220716_51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.json,"Nefazodone Hydrochloride Tablets, USP

Rx only

(Patient Information Included)"
56d64558-1fad-420e-8fcd-7103cd073127,1,celecoxib,140587,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240207_56d64558-1fad-420e-8fcd-7103cd073127.json,"These highlights do not include all the information needed to use CELECOXIB CAPSULES safely and effectively. See full prescribing information for CELECOXIB CAPSULES.
 

CELECOXIB capsules, for oral use
 

Initial U.S. Approval: 1998"
56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec,10,pramipexole,746741,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240222_56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec.json,"These highlights do not include all the information needed to use PRAMIPEXOLE DIHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for PRAMIPEXOLE DIHYDROCHLORIDE TABLETS.
 PRAMIPEXOLE DIHYDROCHLORIDE tablets, for oral use Initial U.S. Approval: 1997"
57f8aac6-3bd3-4ae1-aab2-759c8bc23292,4,trandolapril,38454,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20231111_57f8aac6-3bd3-4ae1-aab2-759c8bc23292.json,Trandolapril Tablets USP Rx only
58353438-3236-4596-9324-62fed9615cb7,12,dulaglutide,1551291,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231213_58353438-3236-4596-9324-62fed9615cb7.json,"These highlights do not include all the information needed to use TRULICITY safely and effectively. See full prescribing information for TRULICITY.
TRULICITY (dulaglutide) injection, for subcutaneous useInitial U.S. Approval: 2014"
5c40e41f-6401-4bda-975c-e1fac69867e9,12,isoniazid,6038,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240104_5c40e41f-6401-4bda-975c-e1fac69867e9.json,"Isoniazid Tablets, USP"
5c4841b4-fbc0-4163-8ee1-cb28629cbfbf,13,dihematoporphyrin ether,23066,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20230816_5c4841b4-fbc0-4163-8ee1-cb28629cbfbf.json,"These highlights do not include all the information needed to use PHOTOFRIN 
 ® safely and effectively. See full prescribing information for PHOTOFRIN.
 



PHOTOFRIN (porfimer sodium) for injection, for intravenous useInitial U.S. Approval: 1995"
5f01e40a-b6f6-40fb-b37c-3d06f1428e86,27,glatiramer,214582,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240123_5f01e40a-b6f6-40fb-b37c-3d06f1428e86.json,"These highlights do not include all the information needed to use GLATOPA safely and effectively. See full prescribing information for GLATOPA.
GLATOPA® (glatiramer acetate injection), for subcutaneous useInitial U.S. Approval: 1996"
645af8f4-0843-4afb-9ddc-f587f38adb68,8,demeclocycline,3154,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231221_645af8f4-0843-4afb-9ddc-f587f38adb68.json,"DEMECLOCYCLINE HYDROCHLORIDE TABLETS, USPRx only"
674e0e6d-46ed-4868-9196-04019d667716,24,pentostatin,8011,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20231222_674e0e6d-46ed-4868-9196-04019d667716.json,""
6b4040a2-a5c5-4ff0-ab45-935d7e49cf78,7,bevacizumab,253337,gi bleed,10030210,oesophageal varices haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20231224_6b4040a2-a5c5-4ff0-ab45-935d7e49cf78.json,"These highlights do not include all the information needed to use 
ALYMSYS
safely and effectively. See full prescribing information for
 ALYMSYS
. 
ALYMSYS
®
 (bevacizumab-maly) injection, for intravenous use 
Initial U.S. Approval: 2022 ALYMSYS (bevacizumab-maly) is biosimilar* to AVASTIN (bevacizumab)"
6d1c87df-b319-4c63-9f19-6584d7c4ff8e,8,rifampin,9384,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240119_6d1c87df-b319-4c63-9f19-6584d7c4ff8e.json,Rifampin Capsules USP
6fb99b0c-d937-f095-513b-b2c561047abf,4,lacosamide,623400,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240221_6fb99b0c-d937-f095-513b-b2c561047abf.json,"These highlights do not include all the information needed to use LACOSAMIDE ORAL SOLUTION safely and effectively. See full prescribing information for LACOSAMIDE ORAL SOLUTION.  LACOSAMIDE oral solution, CVInitial U.S. Approval: 2008"
726b1e63-437a-4b3b-b773-3ac47a5c0f38,8,ezetimibe,341248,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240218_726b1e63-437a-4b3b-b773-3ac47a5c0f38.json,"These highlights do not include all the information needed to use EZETIMIBE TABLETS safely and effectively. See full prescribing information for EZETIMIBE TABLETS.
 EZETIMIBE tablets, for oral use Initial U.S. Approval: 2002"
7652adc6-1aad-4422-b85c-0c6b11c23b73,7,gabapentin,25480,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_7652adc6-1aad-4422-b85c-0c6b11c23b73.json,"These highlights do not include all the information needed to use GABAPENTIN CAPSULES safely and effectively. See full prescribing information for GABAPENTIN CAPSULES.
 

GABAPENTIN capsules, for oral use
 

Initial U.S. Approval: 1993"
766b73e2-49bb-47f9-bbb1-44cfa1a3197e,4,bendamustine,134547,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240220_766b73e2-49bb-47f9-bbb1-44cfa1a3197e.json,"These highlights do not include all the information needed to use BENDAMUSTINE HYDROCHLORIDE INJECTION safely and effectively. See full prescribing information for BENDAMUSTINE HYDROCHLORIDE INJECTION. 
	BENDAMUSTINE HYDROCHLORIDE injection,	 for intravenous use. 	Initial U.S. Approval: 2008"
76e1839b-7462-4344-b319-001a5f57d67a,12,pantoprazole,40790,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240224_76e1839b-7462-4344-b319-001a5f57d67a.json,"These highlights do not include all the information needed to use PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS.
 

PANTOPRAZOLE SODIUM delayed-release tablets, for oral use
 
Initial U.S. approval: 2000"
7714a0ed-34bb-46e6-a0a5-b363908b22c2,25,eltrombopag,711942,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20240112_7714a0ed-34bb-46e6-a0a5-b363908b22c2.json,"These highlights do not include all the information needed to use PROMACTA safely and effectively. See full prescribing information for PROMACTA.
PROMACTA® (eltrombopag) tablets, for oral usePROMACTA® (eltrombopag) for oral suspensionInitial U.S. Approval: 2008"
7a7974c7-8b6c-41ae-9a48-a08a1439087a,100,tretinoin,10753,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240210_7a7974c7-8b6c-41ae-9a48-a08a1439087a.json,"These highlights do not include all the information needed to use TRETINOIN CAPSULES safely and effectively. See full prescribing information for TRETINOIN CAPSULES
.



TRETINOIN 
capsules, for oral use 

Initial U.S. Approval: 1995"
7fa848ba-a59c-4144-9f52-64d090f4d828,10,selpercatinib,2370147,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20231201_7fa848ba-a59c-4144-9f52-64d090f4d828.json,"These highlights do not include all the information needed to use RETEVMO safely and effectively. See full prescribing information for RETEVMO.RETEVMO® (selpercatinib) capsules, for oral useInitial U.S. Approval: 2020"
7fbea274-d6b5-4faa-bbf0-05fefab42114,6,atazanavir,343047,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240218_7fbea274-d6b5-4faa-bbf0-05fefab42114.json,"These highlights do not include all the information needed to use ATAZANAVIR CAPSULES safely and effectively. See full prescribing information for ATAZANAVIR CAPSULES.
 ATAZANAVIR capsules, for oral use Initial U.S. Approval: 2003"
83a504ef-cf92-467d-9ecf-d251194a3484,20,omacetaxine mepesuccinate,27100,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20231129_83a504ef-cf92-467d-9ecf-d251194a3484.json,"These highlights do not include all the information needed to use SYNRIBO safely and effectively.  See full prescribing information for SYNRIBO. 
SYNRIBO® (omacetaxine mepesuccinate) for injection, for subcutaneous useInitial U.S. Approval: 2012"
87768fbf-7c63-47da-8925-0316f343d6ef,16,perindopril,54552,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230221_87768fbf-7c63-47da-8925-0316f343d6ef.json,"These highlights do not include all the information needed to use PERINDOPRIL ERBUMINE TABLETS safely and effectively. See full prescribing information for PERINDOPRIL ERBUMINE TABLETS.
 PERINDOPRIL erbumine tablets, for oral use Initial U.S. Approval: 1993"
8c065559-bd35-4dda-ac8f-624eea0641ae,9,zidovudine,11413,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_8c065559-bd35-4dda-ac8f-624eea0641ae.json,"These highlights do not include all the information needed to use ZIDOVUDINE TABLETS safely and effectively. See full prescribing information for ZIDOVUDINE TABLETS.
 



ZIDOVUDINE tablets, for oral use
 



Initial U.S. Approval: 1987"
8ca926e0-4c3c-473f-9cd0-ff38032d6963,2,oseltamivir,260101,acute myocardial infarction,10002388,angina unstable,../data/2024_latest_labels/latest_labels_ingredients/20240117_8ca926e0-4c3c-473f-9cd0-ff38032d6963.json,"These highlights do not include all the information needed to use OSELTAMIVIR PHOSPHATE CAPSULES safely and effectively. See full prescribing information for OSELTAMIVIR PHOSPHATE CAPSULES. 
OSELTAMIVIR phosphate capsules, for oral useInitial U.S. Approval: 1999"
979205ee-b0b8-4483-ae61-f283f750bb7f,100,dapagliflozin,1488564,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240207_979205ee-b0b8-4483-ae61-f283f750bb7f.json,"These highlights do not include all the information needed to use DAPAGLIFLOZIN TABLETS  safely and effectively.  See full prescribing information for DAPAGLIFLOZIN TABLETS.
DAPAGLIFLOZIN tablets, for oral useInitial U.S. Approval: 2014"
9803db35-2600-4f42-80c1-43216fd1ba3d,4,acamprosate,82819,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20231107_9803db35-2600-4f42-80c1-43216fd1ba3d.json,"These highlights do not include all the information needed to use ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS.
ACAMPROSATE CALCIUM delayed-release tablets, for oral useInitial U.S. Approval: 2004"
9803db35-2600-4f42-80c1-43216fd1ba3d,4,acamprosate,82819,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231107_9803db35-2600-4f42-80c1-43216fd1ba3d.json,"These highlights do not include all the information needed to use ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS.
ACAMPROSATE CALCIUM delayed-release tablets, for oral useInitial U.S. Approval: 2004"
9929c166-8ba3-4159-a5f9-4618d5d227b0,102,flecainide,4441,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240113_9929c166-8ba3-4159-a5f9-4618d5d227b0.json,Flecainide Acetate Tablets USPRx only
99e9d85a-ec8e-48d2-acd0-5dda3b741838,6,ceftriaxone,2193,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240214_99e9d85a-ec8e-48d2-acd0-5dda3b741838.json,"Ceftriaxone for Injection, USP


Rx Only"
a1787fad-3612-43e1-98fa-ce62361e0b3c,13,imatinib,282388,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240203_a1787fad-3612-43e1-98fa-ce62361e0b3c.json,"These highlights do not include all the information needed to use IMATINIB MESYLATE TABLETS safely and effectively.  See full prescribing information for IMATINIB MESYLATE TABLETS. IMATINIB MESYLATE tablets, for oral useInitial U.S. Approval: 2001"
a3d68763-95e0-4ad6-89c2-c4b1c0b43948,1,torsemide,38413,gi bleed,10030172,oesophageal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240202_a3d68763-95e0-4ad6-89c2-c4b1c0b43948.json,"Torsemide Tablets, USP
 


These highlights do not include all the information needed to use TORSEMIDE TABLETS safely and effectively. See full prescribing information for TORSEMIDE TABLETS
 

TORSEMIDE tablets, for oral use
 
Initial U.S. Approval: 1993"
a3e4c8e5-bff0-4a8f-8401-e9866c846ee2,3,desflurane,27340,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231117_a3e4c8e5-bff0-4a8f-8401-e9866c846ee2.json,"These highlights do not include all the information needed to use Suprane (desflurane, USP) safely and effectively. See full prescribing information for Suprane (desflurane, USP).Suprane (desflurane, USP) Volatile Liquid for InhalationInitial U.S. Approval:  1992"
a3e4c8e5-bff0-4a8f-8401-e9866c846ee2,3,desflurane,27340,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231117_a3e4c8e5-bff0-4a8f-8401-e9866c846ee2.json,"These highlights do not include all the information needed to use Suprane (desflurane, USP) safely and effectively. See full prescribing information for Suprane (desflurane, USP).Suprane (desflurane, USP) Volatile Liquid for InhalationInitial U.S. Approval:  1992"
a68d1eff-5cbb-4a6e-98e7-0fb6590ce2a0,13,adenosine,296,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240130_a68d1eff-5cbb-4a6e-98e7-0fb6590ce2a0.json,"ADENOSINE INJECTION, USP"
a9b01bc6-95ac-46f9-befa-d845a74d53c1,16,estramustine,4089,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_a9b01bc6-95ac-46f9-befa-d845a74d53c1.json,"Emcyt®


 estramustine phosphate sodium

capsules"
adc84ad5-a04d-4fee-9ba8-91f7abd928e3,29,bosutinib,1307619,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240102_adc84ad5-a04d-4fee-9ba8-91f7abd928e3.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. 
BOSULIF® (bosutinib) tablets, for oral useBOSULIF® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012"
b118a40d-6b56-cee3-10f6-ded821a97018,275,venetoclax,1747556,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230318_b118a40d-6b56-cee3-10f6-ded821a97018.json,"These highlights do not include all the information needed to use VENCLEXTA safely and effectively. See full prescribing information for VENCLEXTA.


VENCLEXTA

®

 (venetoclax tablets), for oral use 

Initial U.S. Approval: 2016"
b1739aa5-69d8-4a69-be58-6d789ea2a516,10,clomipramine,2597,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231230_b1739aa5-69d8-4a69-be58-6d789ea2a516.json,"Clomipramine Hydrochloride Capsules, USP

(25 mg, 50 mg, and 75 mg)
 


Rx only"
b5631d3e-4604-4363-8f20-11dfc5a4a8ed,13,enfortumab,2268307,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231230_b5631d3e-4604-4363-8f20-11dfc5a4a8ed.json,"These highlights do not include all the information needed to use PADCEV safely and effectively. See full prescribing information for PADCEV.
PADCEV® (enfortumab vedotin-ejfv) for injection, for intravenous useInitial U.S. Approval: 2019"
b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,ibuprofen,5640,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,"IBUPROFEN Tablets, USP"
b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,ibuprofen,5640,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,"IBUPROFEN Tablets, USP"
b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,ibuprofen,5640,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,"IBUPROFEN Tablets, USP"
b8d657ac-dbda-4455-8bb5-3896951c3b67,4,zolmitriptan,135775,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240224_b8d657ac-dbda-4455-8bb5-3896951c3b67.json,"These highlights do not include all the information needed to use ZOLMITRIPTAN ORALLY DISINTEGRATING TABLETS safely and effectively. See full prescribing information for ZOLMITRIPTAN ORALLY DISINTEGRATING TABLETS.
 ZOLMITRIPTAN orally disintegrating tablets Initial U.S. Approval: 1997"
bbd8ab99-552e-4b81-aca4-6b0c7af8b9ae,16,"lymphocyte immune globulin, anti-thymocyte globulin",1011,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230407_bbd8ab99-552e-4b81-aca4-6b0c7af8b9ae.json,"These highlights do not include all the information needed to use THYMOGLOBULIN® safely and effectively.  See full prescribing information for THYMOGLOBULIN. 
THYMOGLOBULIN (anti-thymocyte globulin [rabbit]) for injection, for intravenous use Initial U.S. Approval: 1998"
c36132b2-3ec7-4c43-a25e-75cbdbe3d88d,5,cyclosporine,3008,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_c36132b2-3ec7-4c43-a25e-75cbdbe3d88d.json,"CYCLOSPORINE, MODIFIED - cyclosporine capsule, liquid filledRx only Prescribing Information"
c3658bc8-1524-43db-930e-66f9ac01b808,11,telmisartan,73494,acute liver injury,10024670,liver disorder,../data/2024_latest_labels/latest_labels_ingredients/20240124_c3658bc8-1524-43db-930e-66f9ac01b808.json,"These highlights do not include all the information needed to use TELMISARTAN TABLETS safely and effectively. See full prescribing information for TELMISARTAN TABLETS.  TELMISARTAN tablets, for oral useInitial U.S. Approval: 1998"
c488fb7c-0a5b-487c-b452-996809d1cb99,65,methylnaltrexone,29899,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231213_c488fb7c-0a5b-487c-b452-996809d1cb99.json,"These highlights do not include all the information needed to use RELISTOR safely and effectively. See full prescribing information for RELISTOR.
 

RELISTOR 
 ®(methylnaltrexone bromide) tablets, for oral use
 
RELISTOR 
 ®(methylnaltrexone bromide) injection, for subcutaneous use
 
Initial U.S. Approval: 2008"
c6c48eee-240b-4425-8691-35462523652e,1,propoxyphene,8785,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20100125_c6c48eee-240b-4425-8691-35462523652e.json,"DARVON-N  - propoxyphene napsylate tablet, film coated"
c82eb602-12e1-692b-d660-f8d5b5736b54,11,salmon calcitonin,36118,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20231214_c82eb602-12e1-692b-d660-f8d5b5736b54.json,"These highlights do not include all the information needed to use CALCITONIN SALMON NASAL SPRAY safely and effectively. See full prescribing information for CALCITONIN SALMON NASAL SPRAY. 

CALCITONIN SALMON nasal sprayInitial U.S. Approval: 1975"
c98fb504-76d0-4c25-9c0b-412885828a7a,7,lenalidomide,342369,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240213_c98fb504-76d0-4c25-9c0b-412885828a7a.json,"These highlights do not include all the information needed to use LENALIDOMIDE CAPSULES safely and effectively. See full prescribing information for LENALIDOMIDE CAPSULES.
LENALIDOMIDE capsules, for oral use
Initial U.S. Approval:2005"
cb4e6ba6-f216-4ed2-85d2-9f86f3b441ae,12,dabigatran etexilate,1037042,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20231216_cb4e6ba6-f216-4ed2-85d2-9f86f3b441ae.json,"These highlights do not include all the information needed to use PRADAXA Capsules safely and effectively.  See full prescribing information for PRADAXA Capsules. 
 PRADAXA® (dabigatran etexilate) capsules, for oral use Initial U.S. Approval: 2010"
cb960074-99c1-4a73-941f-f0644a7ec219,40,anagrelide,596724,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20231230_cb960074-99c1-4a73-941f-f0644a7ec219.json,"These highlights do not include all the information needed to use AGRYLIN safely and effectively. See full prescribing information for AGRYLIN.
AGRYLIN® (anagrelide) capsules, for oral useInitial U.S. Approval: 1997"
cb960074-99c1-4a73-941f-f0644a7ec219,40,anagrelide,596724,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231230_cb960074-99c1-4a73-941f-f0644a7ec219.json,"These highlights do not include all the information needed to use AGRYLIN safely and effectively. See full prescribing information for AGRYLIN.
AGRYLIN® (anagrelide) capsules, for oral useInitial U.S. Approval: 1997"
ccd95dfc-9236-4707-a715-6a12c91519ff,6,naproxen,7258,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_ccd95dfc-9236-4707-a715-6a12c91519ff.json,"These highlights do not include all the information needed to use NAPROXEN TABLETS safely and effectively. See full prescribing information for NAPROXEN TABLETS.
 

NAPROXEN tablets, for oral use
 

Initial U.S. Approval: 1976"
ccd95dfc-9236-4707-a715-6a12c91519ff,6,naproxen,7258,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_ccd95dfc-9236-4707-a715-6a12c91519ff.json,"These highlights do not include all the information needed to use NAPROXEN TABLETS safely and effectively. See full prescribing information for NAPROXEN TABLETS.
 

NAPROXEN tablets, for oral use
 

Initial U.S. Approval: 1976"
cf41a02d-c881-4b40-b99c-d5b79dbd645b,9,perphenazine,8076,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240215_cf41a02d-c881-4b40-b99c-d5b79dbd645b.json,"Perphenazine Tablets, USP"
d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f,8,mefenamate,257844,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240120_d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f.json,Mefenamic Acid Capsules USPRx Only
d1e41dcf-e82a-47c2-a0ad-6c6eef621834,16,neratinib,1940643,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231129_d1e41dcf-e82a-47c2-a0ad-6c6eef621834.json,"These highlights do not include all the information needed to use NERLYNX safely and effectively. See full prescribing information for NERLYNX.
 



NERLYNX 
 ®(neratinib) tablets, for oral use
 

Initial U.S. Approval: 2017"
d1f64796-6ba0-415c-a6a0-5456b21a7ed6,5,fenofibrate,8703,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240221_d1f64796-6ba0-415c-a6a0-5456b21a7ed6.json,"These highlights do not include all the information needed to use FENOFIBRATE TABLETS safely and effectively. See full prescribing information for FENOFIBRATE TABLETS.
 
FENOFIBRATE tablets, for oral use
 
Initial U.S. Approval: 1993"
d2af616e-673a-4fdd-ace8-db2d0f154604,15,alfuzosin,17300,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240120_d2af616e-673a-4fdd-ace8-db2d0f154604.json,"These highlights do not include all the information needed to use ALFUZOSIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for ALFUZOSIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS. ALFUZOSIN HYDROCHLORIDE extended-release tablets, for oral use Initial U.S. Approval: 2003"
d82aa06e-5a33-4844-99b7-4701313455a4,4,daprodustat,2628210,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230907_d82aa06e-5a33-4844-99b7-4701313455a4.json,"These highlights do not include all the information needed to use JESDUVROQ safely and effectively. See full prescribing information for JESDUVROQ.JESDUVROQ (daprodustat) tablets, for oral useInitial U.S. Approval: 2023"
da1ce22b-6a8e-40a2-afbb-011fa3ed3a8b,10,ropivacaine,35780,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240125_da1ce22b-6a8e-40a2-afbb-011fa3ed3a8b.json,"These highlights do not include all the information needed to use ROPIVACAINE HYDROCHLORIDE INJECTION safely and effectively. See full prescribing information for ROPIVACAINE HYDROCHLORIDE INJECTION.



ROPIVACAINE HYDROCHLORIDE injection, for epidural, perineural, or infiltration use 

Initial U.S. Approval: 1996"
da3c2935-817d-4331-83c3-ed68ba5d35fd,2,chlorpromazine,2403,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240214_da3c2935-817d-4331-83c3-ed68ba5d35fd.json,"ChlorproMAZINE Hydrochloride Tablets, USP 
Rx only"
dd367eec-359a-4065-b5c3-7c0107c823fe,7,tolcapone,72937,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20210106_dd367eec-359a-4065-b5c3-7c0107c823fe.json,"Tolcapone Tablets

100 mg"
df4cd207-c3b8-4008-5290-02f296c2b4a6,21,fenoldopam,24853,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20210812_df4cd207-c3b8-4008-5290-02f296c2b4a6.json,"These highlights do not include all the information needed to use CORLOPAM® safely and effectively.  See full prescribing information for CORLOPAM®. 
CORLOPAM® (fenoldopam mesylate) injection, for intravenous use Initial U.S. Approval: 1997"
e4dbaa72-7b3e-4aef-983b-90efb2b343cd,6,pravastatin,42463,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_e4dbaa72-7b3e-4aef-983b-90efb2b343cd.json,"These highlights do not include all the information needed to use PRAVASTATIN SODIUM TABLETS safely and effectively. See full prescribing information for PRAVASTATIN SODIUM TABLETS.
 

PRAVASTATIN SODIUM tablets, for oral use
 
Initial U.S. Approval: 1991"
e95b1ab8-0fd9-4399-897a-5ae73b36af45,2,carbidopa,2019,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240131_e95b1ab8-0fd9-4399-897a-5ae73b36af45.json,CARBIDOPA tablets
ec1bb0d1-f38a-4080-831a-68791d1d1fdb,7,roflumilast,1091836,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240209_ec1bb0d1-f38a-4080-831a-68791d1d1fdb.json,"These highlights do not include all the information needed to use ZORYVE cream safely and effectively. See full prescribing information for ZORYVE cream.
 ZORYVE® (roflumilast) cream, for topical use Initial U.S. Approval: 2011"
f2f090c2-3ee1-7689-e053-2995a90abe38,3,levofloxacin,82122,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240220_f2f090c2-3ee1-7689-e053-2995a90abe38.json,"These highlights do not include all the information needed to use LEVOFLOXACIN TABLETS 
  safely and effectively. See full prescribing information for LEVOFLOXACIN TABLETS. 
 




LEVOFLOXACIN tablets, for oral use






Initial U.S. Approval: 1996"
f2f090c2-3ee1-7689-e053-2995a90abe38,3,levofloxacin,82122,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240220_f2f090c2-3ee1-7689-e053-2995a90abe38.json,"These highlights do not include all the information needed to use LEVOFLOXACIN TABLETS 
  safely and effectively. See full prescribing information for LEVOFLOXACIN TABLETS. 
 




LEVOFLOXACIN tablets, for oral use






Initial U.S. Approval: 1996"
f3b50bbb-df03-4ed7-9d8d-180edc2abd54,9,betaxolol,1520,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240215_f3b50bbb-df03-4ed7-9d8d-180edc2abd54.json,"Betaxolol Tablets, USP"
f3bc9031-0620-4a50-b440-f661cadfeb1d,10,dinoprostone,3478,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230607_f3bc9031-0620-4a50-b440-f661cadfeb1d.json,"These highlights do not include all the information needed to use CERVIDIL safely and effectively. See full prescribing information for CERVIDIL. 
CERVIDIL® (dinoprostone) vaginal insert Initial U.S. Approval: 1977"
fa7d93e3-b69b-4e02-8146-89760cd8e9d6,6,avanafil,1291301,acute myocardial infarction,10002388,angina unstable,../data/2024_latest_labels/latest_labels_ingredients/20230910_fa7d93e3-b69b-4e02-8146-89760cd8e9d6.json,"These highlights do not include all the information needed to use 
STENDRA
 safely and effectively.  See full prescribing information for 
STENDRA
.



STENDRA

®

 (avanafil) 
tablets, for oral use

Initial U.S. Approval:  
2012"
fee3bd4a-ade3-41fa-839a-48e9af69bcf4,5,propofol,8782,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231201_fee3bd4a-ade3-41fa-839a-48e9af69bcf4.json,"Diprivan® (Propofol) Injectable Emulsion, USP"
00aa81c2-73c7-4bf8-94e9-f644381b631f,4,esomeprazole,283742,acute liver injury,10019660,hepatic encephalopathy,../data/2024_latest_labels/latest_labels_ingredients/20240119_00aa81c2-73c7-4bf8-94e9-f644381b631f.json,"These highlights do not include all the information needed to use ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES.
 

ESOMEPRAZOLE MAGNESIUM delayed-release capsules, for oral use
 

Initial U.S. Approval: 1989 (omeprazole)"
03cdbf5b-b572-448f-80e9-b3e812959901,2,estropipate,33747,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20120328_03cdbf5b-b572-448f-80e9-b3e812959901.json,DESCRIPTION
0653b873-b74b-4ec6-b112-675760703d91,3,nabumetone,31448,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240214_0653b873-b74b-4ec6-b112-675760703d91.json,"Nabumetone Tablets, USP

Rx only

8463021/1223F"
0772eb61-ca42-39de-e063-6294a90a6632,1,sunitinib,357977,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231012_0772eb61-ca42-39de-e063-6294a90a6632.json,"SUNITINIB MALATE
 

These highlights do not include all the information needed to use SUNITINIB MALATE CAPSULES safely and effectively. See full prescribing information for SUNITINIB MALATE CAPSULES.
 

Initial U.S. Approval: 2006"
0be243c6-de02-45dd-8210-cab1bbc8dfa7,28,clarithromycin,21212,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_0be243c6-de02-45dd-8210-cab1bbc8dfa7.json,"These highlights do not include all the information needed to use CLARITHROMYCIN TABLETS safely and effectively. See full prescribing information for CLARITHROMYCIN TABLETS.
 

CLARITHROMYCIN tablets, for oral use
 
Initial U.S. Approval: 1991"
0becbde8-6ec5-4830-a0d9-cfdb7b15eb84,11,minocycline,6980,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240217_0becbde8-6ec5-4830-a0d9-cfdb7b15eb84.json,"Minocycline Hydrochloride Capsules, USP
 

Rx only"
0c8ca614-58b2-4aa4-83d3-0387a8f782fd,9,larotrectinib,2105628,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231117_0c8ca614-58b2-4aa4-83d3-0387a8f782fd.json,"These highlights do not include all the information needed to use VITRAKVI safely and effectively.  See full prescribing information for VITRAKVI.
VITRAKVI® (larotrectinib) capsules, for oral use VITRAKVI® (larotrectinib) oral solutionInitial U.S. Approval: 2018"
0edeb103-5e94-4f42-828f-c7336486c784,3,cephalexin,2231,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240217_0edeb103-5e94-4f42-828f-c7336486c784.json,These highlights do not include all the information needed to use CEPHALEXIN FOR ORAL SUSPENSION safely and effectively. See full prescribing information for CEPHALEXIN FOR ORAL SUSPENSION CEPHALEXIN for oral suspension Initial U.S. Approval: 1971
0f672b76-f673-4cba-99d2-818a9e2e6d7f,7,losartan,52175,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_0f672b76-f673-4cba-99d2-818a9e2e6d7f.json,"These highlights do not include all the information needed to use LOSARTAN POTASSIUM TABLETS safely and effectively. see full prescribing information for LOSARTAN POTASSIUM TABLETS.
 



LOSARTAN POTASSIUM tablets, for oral use
 

Initial U.S. Approval: 1995"
0f672b76-f673-4cba-99d2-818a9e2e6d7f,7,losartan,52175,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_0f672b76-f673-4cba-99d2-818a9e2e6d7f.json,"These highlights do not include all the information needed to use LOSARTAN POTASSIUM TABLETS safely and effectively. see full prescribing information for LOSARTAN POTASSIUM TABLETS.
 



LOSARTAN POTASSIUM tablets, for oral use
 

Initial U.S. Approval: 1995"
106d9730-5938-8f27-e063-6294a90adc68,2,cyclobenzaprine,21949,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240221_106d9730-5938-8f27-e063-6294a90adc68.json,"Cyclobenzaprine hydrochloride Tablets, USP"
13abdafb-71a8-40a1-ba5a-7c2b2573e53e,12,amitriptyline,704,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240223_13abdafb-71a8-40a1-ba5a-7c2b2573e53e.json,"Amitriptyline Hydrochloride Tablets, USP"
1522921b-d6c2-420d-ba0d-39ac16ba8b37,13,phenazopyridine,8120,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240222_1522921b-d6c2-420d-ba0d-39ac16ba8b37.json,"PHENAZOPYRIDINE HYDROCHLORIDE TABLETS, USP



Rx Only"
17f85d17-ab71-4f5b-9fe3-0b8c822f69ff,19,pertuzumab,1298944,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20211121_17f85d17-ab71-4f5b-9fe3-0b8c822f69ff.json,"These highlights do not include all the information needed to use PERJETA safely and effectively.  See full prescribing information for PERJETA. 
PERJETA® (pertuzumab) injection, for intravenous use Initial U.S. Approval:  2012"
1d3e7aea-02a4-46b1-8a14-0324e4777cb4,5,ivermectin,6069,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240110_1d3e7aea-02a4-46b1-8a14-0324e4777cb4.json,"These highlights do not include all the information needed to use IVERMECTIN CREAM safely and effectively.  See full prescribing information for IVERMECTIN CREAM.IVERMECTIN cream, 1%, for topical useInitial U.S. Approval: 1996"
1e87a81a-7084-4436-918b-a50451534307,11,pilocarpine,8328,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231231_1e87a81a-7084-4436-918b-a50451534307.json,"These highlights do not include all the information needed to use PILOCARPINE HYDROCHLORIDE OPHTHALMIC SOLUTION safely and effectively. See full prescribing information for PILOCARPINE HYDROCHLORIDE OPHTHALMIC SOLUTION.  

PILOCARPINE
 hydrochloride ophthalmic solution 

Initial U.S. Approval: 1974"
1fffe88d-50c8-45cf-ac7c-a62b665c89a8,16,sulindac,10237,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240126_1fffe88d-50c8-45cf-ac7c-a62b665c89a8.json,SULINDAC TABLETS USP
21002702-422b-1402-73b8-670314d8e579,3,liothyronine,10814,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_21002702-422b-1402-73b8-670314d8e579.json,"These highlights do not include all the information needed to use LIOTHYRONINE SODIUM TABLETS safely and effectively. See full prescribing information for LIOTHYRONINE SODIUM TABLETS.
LIOTHYRONINE SODIUM tablets, for oral useInitial U.S. Approval: 1956"
22174520-4b78-4841-96f7-530ba12d2cf1,8,paroxetine,32937,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240217_22174520-4b78-4841-96f7-530ba12d2cf1.json,"Paroxetine Tablets USP, film coated for oral use"
222f77ff-d3f7-40f9-989c-e5902f44ef1e,10,rizatriptan,88014,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240222_222f77ff-d3f7-40f9-989c-e5902f44ef1e.json,"These highlights do not include all the information needed to use RIZATRIPTAN BENZOATE TABLETS safely and effectively. See full prescribing information for RIZATRIPTAN BENZOATE TABLETS.
 RIZATRIPTAN BENZOATE tablets, for oral use Initial U.S. Approval: 1998"
246e0ed0-f8ca-483b-a1ce-91052f3f35f0,9,enalapril,3827,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_246e0ed0-f8ca-483b-a1ce-91052f3f35f0.json,"Enalapril Maleate Tablets, USP"
24926986-7552-4f1a-8366-f035bbd07104,7,fluoxetine,4493,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240224_24926986-7552-4f1a-8366-f035bbd07104.json,"These highlights do not include all the information needed to use FLUOXETINE CAPSULES safely and effectively. See full prescribing information for FLUOXETINE CAPSULES.
 
FLUOXETINE capsules, for oral use
 
Initial U.S. Approval: 1987"
294b168b-6e5f-4db9-bf70-d599271458b3,6,goserelin,50610,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20230325_294b168b-6e5f-4db9-bf70-d599271458b3.json,These highlights do not include all the information needed to use ZOLADEX safely and effectively. See full prescribing information for ZOLADEX.ZOLADEX® (goserelin implant) 3.6 mgInitial U.S. Approval: 1989
2eda833b-1357-4ed4-a093-194524fcb061,25,thalidomide,10432,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230406_2eda833b-1357-4ed4-a093-194524fcb061.json,"These highlights do not include all the information needed to use THALOMID® safely and effectively. See full prescribing information for THALOMID. 
THALOMID (thalidomide) capsules, for oral use Initial U.S. Approval: 1998"
326ef804-8d3a-425e-8513-8c9811856aa0,100,trimipramine,10834,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230616_326ef804-8d3a-425e-8513-8c9811856aa0.json,"TRIMIPRAMINE MALEATE CAPSULES, 25 MG, 50 MG and 100 MG Rx Only"
37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,45,mycophenolate mofetil,68149,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240224_37241e87-4af4-4dc3-a1aa-ea6f20d8dc40.json,"These highlights do not include all the information needed to use CELLCEPT® safely and effectively. See full prescribing information for CELLCEPT® 
CELLCEPT® (mycophenolate mofetil) capsules, for oral use CELLCEPT® (mycophenolate mofetil) tablets, for oral use CELLCEPT®  Oral Suspension (mycophenolate mofetil), for oral suspension CELLCEPT®  Intravenous (mycophenolate mofetil) for injection, for intravenous use Initial U.S. Approval: 1995"
38f5341f-5ae3-46bf-8bfc-30dff2068477,102,alosetron,85248,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240112_38f5341f-5ae3-46bf-8bfc-30dff2068477.json,"These highlights do not include all the information needed to use ALOSETRON TABLETS safely and effectively. See full prescribing information for ALOSETRON TABLETS. 
ALOSETRON tablets, for oral use   Initial U.S. Approval: 2000"
3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac,9,mesalamine,52582,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240217_3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac.json,"Mesalamine Rectal Suspension Enema

4 grams/unit (60 mL)"
3d30eb8d-a62e-475f-926b-78ba63bee9c8,11,isoflurane,6026,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240130_3d30eb8d-a62e-475f-926b-78ba63bee9c8.json,"FORANE (isoflurane, USP) liquid for inhalation"
3d4ec829-7835-4d59-bc5b-6ce38811fba7,7,entacapone,60307,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240220_3d4ec829-7835-4d59-bc5b-6ce38811fba7.json,"Entacapone Tablets, USP

8418821/0821

Rx only

Prescribing Information"
3ecde48b-75a2-4beb-9999-369f3f61bb8a,37,ceftaroline fosamil,1040004,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/train_xml/20221118_3ecde48b-75a2-4beb-9999-369f3f61bb8a.json,"These highlights do not include all the information needed to use
 
T
EFLARO 
safely and effectively. See full prescribing information for 
TE
FLARO
.

    

TE
FLARO

®

 (ceftaroline fosamil) 
for 
injection
,
 for intravenous use

Initial U.S. Approval: 
2010"
42f49299-7ae5-4d30-86eb-66b739c0e95d,5,lisinopril,29046,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_42f49299-7ae5-4d30-86eb-66b739c0e95d.json,"These highlights do not include all the information needed to use LISINOPRIL TABLETS safely and effectively. See full prescribing information for LISINOPRIL TABLETS
 



LISINOPRIL tablets, for oral use
 



Initial U.S. Approval: 1988"
4911f343-68e6-71b0-e054-00144ff8d46c,5,meloxicam,41493,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240223_4911f343-68e6-71b0-e054-00144ff8d46c.json,"These highlights do not include all the information needed to use MELOXICAM TABLETS safely and effectively. See full prescribing information for MELOXICAM TABLETS.
 

Initial U.S. Approval: 2000"
49e5afe9-a0c7-40c4-af9f-f287a80c5c88,177,denosumab,993449,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/train_xml/20240203_49e5afe9-a0c7-40c4-af9f-f287a80c5c88.json,"These highlights do not include all the information needed to use PROLIA safely and effectively.  See full prescribing information for PROLIA.   
Prolia® (denosumab) Injection, for subcutaneous use Initial U.S. Approval: 2010"
4c9eb5d2-8d2c-4ce7-b45e-c92d3ce9532a,11,isosorbide,6057,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240222_4c9eb5d2-8d2c-4ce7-b45e-c92d3ce9532a.json,"Isosorbide Mononitrate Tablets, USP




Rx only"
51635427-fb13-45ee-813d-a40b0405d14f,7,diclofenac,3355,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_51635427-fb13-45ee-813d-a40b0405d14f.json,"Diclofenac Sodium Extended-Release Tablets, USP, Tablets of 100 mg
  

Rx only
  

Prescribing Information"
51cdb22b-035f-47d7-8048-38006e2589f2,20,nifedipine,7417,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240217_51cdb22b-035f-47d7-8048-38006e2589f2.json,Rx only
53486382-eee0-4cbe-bc4a-a57484e0d5a7,104,cilostazol,21107,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240113_53486382-eee0-4cbe-bc4a-a57484e0d5a7.json,"These highlights do not include all the information needed to use CILOSTAZOL TABLETS safely and effectively. See full prescribing information for CILOSTAZOL TABLETS.CILOSTAZOL tablets, for oral useInitial U.S. Approval: 1999"
5359b759-db7c-4672-9e8a-59c93869bd91,5,telavancin,473837,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231205_5359b759-db7c-4672-9e8a-59c93869bd91.json,"These highlights do not include all the information needed to use VIBATIV® (telavancin) safely and effectively. See full prescribing information for VIBATIV. 
VIBATIV® (telavancin) for injection, for intravenous use Initial U.S. Approval: 2009"
56370be6-42a2-4962-acdc-22b7c6e0e7fe,8,ziprasidone,115698,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_56370be6-42a2-4962-acdc-22b7c6e0e7fe.json,"These highlights do not include all the information needed to use ZIPRASIDONE CAPSULES safely and effectively. See full prescribing information for ZIPRASIDONE CAPSULES.


ZIPRASIDONE capsules, for oral use

Initial U.S. Approval: 2001"
575da603-b038-421f-9894-6796d9ac33cc,11,sertraline,36437,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_575da603-b038-421f-9894-6796d9ac33cc.json,"These highlights do not include all the information needed to use SERTRALINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for SERTRALINE HYDROCHLORIDE TABLETS.
 

SERTRALINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1991"
58d80bc6-bdfb-4908-93e7-aace447c8d1a,1,octreotide,7617,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240131_58d80bc6-bdfb-4908-93e7-aace447c8d1a.json,"These highlights do not include all the information needed to use MYCAPSSA® safely and effectively. See full prescribing information for MYCAPSSA.
 MYCAPSSA (octreotide) delayed-release capsules, for oral use Initial U.S. Approval: 1988"
6240792b-9224-2d10-e053-2a91aa0a2c3e,8,orlistat,37925,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231216_6240792b-9224-2d10-e053-2a91aa0a2c3e.json,"These highlights do not include all the information needed to use XENICAL safely and effectively. See full prescribing information for XENICAL.

 XENICAL (orlistat) Capsules for oral use Initial U.S. Approval: 1999"
64000394-1ef6-4e76-8ba8-11f25ba1b167,6,maralixibat,2571074,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20230329_64000394-1ef6-4e76-8ba8-11f25ba1b167.json,"These highlights do not include all the information needed to use LIVMARLI safely and effectively. See full prescribing information for LIVMARLI. 
 LIVMARLI® (maralixibat) oral solution  Initial U.S. Approval:  2021"
6fa380c4-c885-4743-85bf-88819ae68645,8,almotriptan,279645,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20230414_6fa380c4-c885-4743-85bf-88819ae68645.json,"These highlights do not include all the information needed to use ALMOTRIPTAN TABLETS safely and effectively. See full prescribing information for ALMOTRIPTAN TABLETS.   ALMOTRIPTAN tablets, for oral use Initial U.S. Approval: 2001"
746f3ab9-9e6e-4ce8-9384-0c7a57de8007,9,haloperidol,5093,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_746f3ab9-9e6e-4ce8-9384-0c7a57de8007.json,"Haloperidol Tablets, USP"
74d94dbf-0567-6c15-e053-2991aa0ac6e4,5,verapamil,11170,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240224_74d94dbf-0567-6c15-e053-2991aa0ac6e4.json,"VERAPAMIL HYDROCHLORIDE INJECTION, USP 10mg (2.5 mg/mL) 4mL ANSYR SYR"
7652adc6-1aad-4422-b85c-0c6b11c23b73,7,gabapentin,25480,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240224_7652adc6-1aad-4422-b85c-0c6b11c23b73.json,"These highlights do not include all the information needed to use GABAPENTIN CAPSULES safely and effectively. See full prescribing information for GABAPENTIN CAPSULES.
 

GABAPENTIN capsules, for oral use
 

Initial U.S. Approval: 1993"
76e1839b-7462-4344-b319-001a5f57d67a,12,pantoprazole,40790,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240224_76e1839b-7462-4344-b319-001a5f57d67a.json,"These highlights do not include all the information needed to use PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS.
 

PANTOPRAZOLE SODIUM delayed-release tablets, for oral use
 
Initial U.S. approval: 2000"
76e1839b-7462-4344-b319-001a5f57d67a,12,pantoprazole,40790,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_76e1839b-7462-4344-b319-001a5f57d67a.json,"These highlights do not include all the information needed to use PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS.
 

PANTOPRAZOLE SODIUM delayed-release tablets, for oral use
 
Initial U.S. approval: 2000"
7a7974c7-8b6c-41ae-9a48-a08a1439087a,100,tretinoin,10753,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240210_7a7974c7-8b6c-41ae-9a48-a08a1439087a.json,"These highlights do not include all the information needed to use TRETINOIN CAPSULES safely and effectively. See full prescribing information for TRETINOIN CAPSULES
.



TRETINOIN 
capsules, for oral use 

Initial U.S. Approval: 1995"
806b3e38-3b2a-4aaa-973c-e2d921bb353e,10,venlafaxine,39786,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240224_806b3e38-3b2a-4aaa-973c-e2d921bb353e.json,"Venlafaxine Tablets, USP
 
Rx only"
806b3e38-3b2a-4aaa-973c-e2d921bb353e,10,venlafaxine,39786,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_806b3e38-3b2a-4aaa-973c-e2d921bb353e.json,"Venlafaxine Tablets, USP
 
Rx only"
824f19c9-0546-4a8a-8d8f-c4055c04f7c7,33,regorafenib,1312397,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/gold_xml/20231202_824f19c9-0546-4a8a-8d8f-c4055c04f7c7.json,"These highlights do not include all the information needed to use STIVARGA safely and effectively.  See full prescribing information for STIVARGA.STIVARGA® (regorafenib) tablets, for oral useInitial U.S. Approval: 2012"
8345d55e-ad02-4726-a04b-1a46e3337a4b,13,capecitabine,194000,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240105_8345d55e-ad02-4726-a04b-1a46e3337a4b.json,"These highlights do not include all the information needed to use CAPECITABINE TABLETS safely and effectively. See full prescribing information for CAPECITABINE TABLETS.
 







CAPECITABINE tablets, for oral use
 







Initial U.S. Approval: 1998"
84137882-e000-47da-bd5b-fa76ab3c76f9,20,axitinib,1242999,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012"
84137882-e000-47da-bd5b-fa76ab3c76f9,20,axitinib,1242999,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012"
84428af5-ab7d-4822-a40e-3cf6e3fb9fee,9,hydrochlorothiazide,5487,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_84428af5-ab7d-4822-a40e-3cf6e3fb9fee.json,"Hydrochlorothiazide Capsules USP, 12.5 mg"
87768fbf-7c63-47da-8925-0316f343d6ef,16,perindopril,54552,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20230221_87768fbf-7c63-47da-8925-0316f343d6ef.json,"These highlights do not include all the information needed to use PERINDOPRIL ERBUMINE TABLETS safely and effectively. See full prescribing information for PERINDOPRIL ERBUMINE TABLETS.
 PERINDOPRIL erbumine tablets, for oral use Initial U.S. Approval: 1993"
90073508-6dca-4d27-aa5a-ed837737c35b,1,rezafungin,2639155,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230613_90073508-6dca-4d27-aa5a-ed837737c35b.json,"These highlights do not include all the information needed to use REZZAYO safely and effectively. See full prescribing information for REZZAYO.
 REZZAYO™ (rezafungin for injection), for intravenous useInitial U.S. Approval: 2023"
918d0e2a-3af3-46e8-ad06-528263e03ba0,11,fentanyl,4337,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240222_918d0e2a-3af3-46e8-ad06-528263e03ba0.json,"These highlights do not include all the information needed to use fentanyl buccal tablet safely and effectively.  See full prescribing information for fentanyl buccal tablet. 
 Fentanyl Buccal Tablet, CII    Initial U.S. Approval: 1968"
98ad5af1-bde6-4137-a599-b6354d664da4,1,methylergonovine,6883,acute myocardial infarction,10000891,acute myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240215_98ad5af1-bde6-4137-a599-b6354d664da4.json,"Methylergonovine Maleate Tablets, USP

Rx Only
  
8481394/0124F"
9f489295-1156-52c7-5fd0-5c4c52f9b813,8,voclosporin,2475166,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231215_9f489295-1156-52c7-5fd0-5c4c52f9b813.json,"These highlights do not include all the information needed to use LUPKYNIS™ safely and effectively. See full prescribing information for LUPKYNIS.








LUPKYNIS (voclosporin) capsules, for oral use




Initial U.S. Approval: 2021"
a32cb2e3-d4e5-4bbf-9d88-20b2b249e779,23,ritonavir,85762,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231221_a32cb2e3-d4e5-4bbf-9d88-20b2b249e779.json,"These highlights do not include all the information needed to use RITONAVIR TABLETS safely and effectively. See full prescribing information for RITONAVIR TABLETS.
 


RITONAVIR tablets, for oral use
 

Initial U.S. Approval: 1996"
a3b50576-cd40-4f7e-9506-bd0a61988424,3,famotidine,4278,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240220_a3b50576-cd40-4f7e-9506-bd0a61988424.json,"These highlights do not include all the information needed to use FAMOTIDINE TABLETS safely and effectively. See full prescribing information for FAMOTIDINE TABLETS.
 
FAMOTIDINE tablets, for oral use
 
Initial U.S. Approval: 1986"
ad750031-08ec-4d92-af2d-97a80c454e14,1,tiopronin,6765,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240207_ad750031-08ec-4d92-af2d-97a80c454e14.json,"These highlights do not include all the information needed to use TIOPRONIN DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for TIOPRONIN DELAYED-RELEASE TABLETS.
TIOPRONIN delayed-release tablets, for oral use Initial U.S. Approval: 1988"
b023a9f2-1a99-4b40-a953-edac7e3a79bf,15,anastrozole,84857,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240220_b023a9f2-1a99-4b40-a953-edac7e3a79bf.json,"These highlights do not include all the information needed to use anastrozole tablets safely and effectively. See full prescribing information for anastrozole tablets.
 

ANASTROZOLE tablet for oral use
 

Initial U.S. Approval: 1995"
b17679e8-88c8-4b8d-bfae-246fab6eead9,13,docetaxel,72962,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240201_b17679e8-88c8-4b8d-bfae-246fab6eead9.json,"These highlights do not include all the information needed to use DOCETAXEL INJECTION safely and effectively. See full prescribing information for DOCETAXEL INJECTION.DOCETAXEL injection, for intravenous use
Initial U.S. Approval: 1996"
b1bd0d02-eccb-4449-82b9-9b552835029e,10,warfarin,11289,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240222_b1bd0d02-eccb-4449-82b9-9b552835029e.json,"These highlights do not include all the information needed to use WARFARIN SODIUM TABLETS safely and effectively. See full prescribing information for WARFARIN SODIUM TABLETS.
 



WARFARIN SODIUM tablets, for oral use
 

Initial U.S. Approval: 1954"
b1bd0d02-eccb-4449-82b9-9b552835029e,10,warfarin,11289,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240222_b1bd0d02-eccb-4449-82b9-9b552835029e.json,"These highlights do not include all the information needed to use WARFARIN SODIUM TABLETS safely and effectively. See full prescribing information for WARFARIN SODIUM TABLETS.
 



WARFARIN SODIUM tablets, for oral use
 

Initial U.S. Approval: 1954"
b272ef9c-4d83-4ee2-b9cc-477440822cca,10,cefoxitin,2189,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240105_b272ef9c-4d83-4ee2-b9cc-477440822cca.json,"CEFOXITIN FOR INJECTION, USP(For Intravenous Use)"
bcb387ac-2e90-4f5e-94b2-d3635190678e,9,miltefosine,1494066,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231018_bcb387ac-2e90-4f5e-94b2-d3635190678e.json,"These highlights do not include all the information needed to use IMPAVIDO safely and effectively.  See full prescribing information for IMPAVIDO.
IMPAVIDO (miltefosine) capsules, for oral useInitial U.S. Approval: 2014"
bda70104-d84b-4d3f-9ca0-5f4f1ca816ad,13,voriconazole,121243,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240215_bda70104-d84b-4d3f-9ca0-5f4f1ca816ad.json,"These highlights do not include all the information needed to use VORICONAZOLE TABLETS safely and effectively. See full prescribing information for VORICONAZOLE TABLETS.VORICONAZOLE tablets, for oral useInitial U.S. Approval: 2002"
c23d89e9-b00b-4520-e053-2995a90a95af,9,pegcetacoplan,2557372,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240217_c23d89e9-b00b-4520-e053-2995a90a95af.json,"These highlights do not include all the information needed to use EMPAVELI safely and effectively. See full prescribing information for EMPAVELI. 
EMPAVELI® (pegcetacoplan) injection, for subcutaneous use Initial U.S. Approval: 2021"
c27f2d57-4b9d-4b78-8d85-3bac84f733b1,5,flurbiprofen,4502,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240128_c27f2d57-4b9d-4b78-8d85-3bac84f733b1.json,"Flurbiprofen Sodium Ophthalmic Solution, USP 0.03% 

(Sterile)"
c391fe11-fd47-4a35-af6d-c823ab7b8838,11,letrozole,72965,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240117_c391fe11-fd47-4a35-af6d-c823ab7b8838.json,"These highlights do not include all the information needed to use
letrozole tablets
safely and effectively. See full prescribing information for
letrozole tablets.








LETROZOLE tablets, for oral use








Initial U.S. Approval:
1997"
c391fe11-fd47-4a35-af6d-c823ab7b8838,11,letrozole,72965,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240117_c391fe11-fd47-4a35-af6d-c823ab7b8838.json,"These highlights do not include all the information needed to use
letrozole tablets
safely and effectively. See full prescribing information for
letrozole tablets.








LETROZOLE tablets, for oral use








Initial U.S. Approval:
1997"
c394914b-2334-418e-bf86-9f9100323717,6,ketoconazole,6135,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_c394914b-2334-418e-bf86-9f9100323717.json,KETOCONAZOLE CREAM 2%
c75fab51-c34f-4be2-b6fd-382e5e89b6a4,4,rabeprazole,114979,acute liver injury,10019660,hepatic encephalopathy,../data/2024_latest_labels/latest_labels_ingredients/20240209_c75fab51-c34f-4be2-b6fd-382e5e89b6a4.json,"These highlights do not include all the information needed to use RABEPRAZOLE SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for RABEPRAZOLE SODIUM DELAYED-RELEASE TABLETS.
 RABEPRAZOLE SODIUM delayed-release tablets, for oral use
 Initial U.S. Approval: 1999"
c8b58efa-1820-48a4-b70d-62918fc4abfc,6,irinotecan,51499,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240217_c8b58efa-1820-48a4-b70d-62918fc4abfc.json,"These highlights do not include all the information needed to use ONIVYDE® safely and effectively. See full prescribing information for ONIVYDE®
 ONIVYDE® (irinotecan liposome injection), for intravenous use Initial U.S. Approval: 1996"
c8b58efa-1820-48a4-b70d-62918fc4abfc,6,irinotecan,51499,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240217_c8b58efa-1820-48a4-b70d-62918fc4abfc.json,"These highlights do not include all the information needed to use ONIVYDE® safely and effectively. See full prescribing information for ONIVYDE®
 ONIVYDE® (irinotecan liposome injection), for intravenous use Initial U.S. Approval: 1996"
d1cda4f7-cb33-46ea-b9ac-431f6452b1a5,23,apalutamide,1999574,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240118_d1cda4f7-cb33-46ea-b9ac-431f6452b1a5.json,"These highlights do not include all the information needed to use ERLEADA safely and effectively. See full prescribing information for ERLEADA.
 



ERLEADA 
 ®(apalutamide) tablets, for oral use
 

Initial U.S. Approval – 2018"
d5929f91-6496-4c0e-97e8-0bd524e15763,3,bosutinib,1307619,acute liver injury,10024670,liver disorder,../data/2024_latest_labels/train_xml/20220817_d5929f91-6496-4c0e-97e8-0bd524e15763.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF.
 BOSULIF® (bosutinib) tablets, for oral use Initial U.S. Approval: 2012"
d79a4b28-ef2b-4f0f-baec-002df7d06dd4,10,cefaclor,2176,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240201_d79a4b28-ef2b-4f0f-baec-002df7d06dd4.json,Cefaclor Capsules USP
d79a4b28-ef2b-4f0f-baec-002df7d06dd4,10,cefaclor,2176,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240201_d79a4b28-ef2b-4f0f-baec-002df7d06dd4.json,Cefaclor Capsules USP
eb354221-c476-41cb-ad87-52423f81d698,3,cefdinir,25037,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_eb354221-c476-41cb-ad87-52423f81d698.json,"Cefdinir Capsules, USP
 
Rx only"
eed5e856-dd7b-4eaa-9dad-508f2bef9328,1,amoxapine,722,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230910_eed5e856-dd7b-4eaa-9dad-508f2bef9328.json,"Amoxapine Tablets, USP
 
Rx only"
f06d1bb3-83f1-4d84-8004-4c6681ad8a5a,4,paclitaxel,56946,acute liver injury,10019660,hepatic encephalopathy,../data/2024_latest_labels/latest_labels_ingredients/20240201_f06d1bb3-83f1-4d84-8004-4c6681ad8a5a.json,"These highlights do not include all the information needed to use PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND) safely and effectively. See full prescribing information for PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND).
PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND), for intravenous use Initial U.S. Approval: 2005"
f5f56c59-04d5-4c5d-9441-5a93d3bdec82,6,felodipine,4316,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240222_f5f56c59-04d5-4c5d-9441-5a93d3bdec82.json,"Felodipine Extended-Release Tablets, USP
 Rx only"
fa7d93e3-b69b-4e02-8146-89760cd8e9d6,6,avanafil,1291301,acute myocardial infarction,10002388,angina unstable,../data/2024_latest_labels/train_xml/20230910_fa7d93e3-b69b-4e02-8146-89760cd8e9d6.json,"These highlights do not include all the information needed to use 
STENDRA
 safely and effectively.  See full prescribing information for 
STENDRA
.



STENDRA

®

 (avanafil) 
tablets, for oral use

Initial U.S. Approval:  
2012"
fd427d2d-b78b-412a-9c80-606bc88ad112,10,eletriptan,231049,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20231220_fd427d2d-b78b-412a-9c80-606bc88ad112.json,"These highlights do not include all the information needed to use ELETRIPTAN HYDROBROMIDE TABLETS safely and effectively. See full prescribing information for ELETRIPTAN HYDROBROMIDE TABLETS.


ELETRIPTAN hydrobromide tablets, for oral use 

Initial U.S. Approval: 2002"
fedfd1db-7e32-44b2-89e9-7bb00ee6810d,24,sevoflurane,36453,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240131_fedfd1db-7e32-44b2-89e9-7bb00ee6810d.json,"Sojourn®
 
Sevoflurane, USP
 
Volatile Liquid for Inhalation"
0d976866-81b3-5db8-e063-6294a90a39f9,3,progesterone,8727,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240210_0d976866-81b3-5db8-e063-6294a90a39f9.json,""
0f15cb50-5917-c928-e063-6294a90ab284,2,cevimeline,44281,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240217_0f15cb50-5917-c928-e063-6294a90ab284.json,"Cevimeline Hydrochloride Capsules
 
Rx only"
144067b2-0532-476a-996e-e4a0a9d09b05,1,tenofovir disoproxil,300195,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/train_xml/20141007_144067b2-0532-476a-996e-e4a0a9d09b05.json,"These highlights do not include all the information needed to use STRIBILD safely and effectively. See full prescribing information for STRIBILD.
 STRIBILD® (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) tablets, for oral useInitial U.S. Approval: 2012"
14f80ad5-37cc-4672-9caa-2dd2f469af0a,2,febuxostat,73689,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240131_14f80ad5-37cc-4672-9caa-2dd2f469af0a.json,"These highlights do not include all the information needed to use FEBUXOSTAT TABLETS safely and effectively. See full prescribing information for FEBUXOSTAT TABLETS.
 
FEBUXOSTAT tablets, for oral use
 
Initial U.S. Approval: 2009"
14f80ad5-37cc-4672-9caa-2dd2f469af0a,2,febuxostat,73689,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240131_14f80ad5-37cc-4672-9caa-2dd2f469af0a.json,"These highlights do not include all the information needed to use FEBUXOSTAT TABLETS safely and effectively. See full prescribing information for FEBUXOSTAT TABLETS.
 
FEBUXOSTAT tablets, for oral use
 
Initial U.S. Approval: 2009"
16a4a314-f97e-4e91-95e9-576a3773d284,35,milnacipran,588250,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240207_16a4a314-f97e-4e91-95e9-576a3773d284.json,"These highlights do not include all the information needed to use 
SAVELLA
 
safely and effectively. See full prescribing information for 
SAVELLA
.  

   

SAVELLA
®
 (
milnacipran HCl
) 
t
ablets

Initial U.S. Approval: 2009"
18bbd246-5709-4477-b10a-f811f3801962,6,imipramine,5691,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_18bbd246-5709-4477-b10a-f811f3801962.json,"Imipramine Hydrochloride Tablets, USP
 
Rx Only"
1a2c0a9a-c637-4485-ad4b-0b6d0b05fa20,3,dipyridamole,3521,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231014_1a2c0a9a-c637-4485-ad4b-0b6d0b05fa20.json,"Dipyridamole 5 mg/mL Injection, USP 10 mL Single Dose Vial"
202d5142-6180-4d48-9a9f-1bd6992fc49b,2,nebivolol,31555,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240201_202d5142-6180-4d48-9a9f-1bd6992fc49b.json,"These highlights do not include all the information needed to use NEBIVOLOL TABLETS safely and effectively. See full prescribing information for NEBIVOLOL TABLETS.
 
NEBIVOLOL tablets, for oral use
 
Initial U.S. Approval: 2007"
20e5acf0-90b7-45c8-be78-91eaf77c9ac0,2,fludarabine,24698,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230620_20e5acf0-90b7-45c8-be78-91eaf77c9ac0.json,"These highlights do not include all the information needed to use FLUDARABINE phosphate injection safely and effectively. See full prescribing information for FLUDARABINE phosphate injection.
FLUDARABINE phosphate injection, for intravenous use onlyInitial U.S. Approval: 1991"
2265ef30-253e-11df-8a39-0800200c9a66,42,ipilimumab,1094833,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/train_xml/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011"
23b1f2f5-2d84-4a1e-997f-6489204878b2,102,captopril,1998,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240112_23b1f2f5-2d84-4a1e-997f-6489204878b2.json,"Captopril Tablets, USP

for oral use

Rx only"
246d42e5-5418-42ba-aff9-ae399b166c69,4,teriflunomide,1310520,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240216_246d42e5-5418-42ba-aff9-ae399b166c69.json,"These highlights do not include all the information needed to use TERIFLUNOMIDE TABLETS safely and effectively. See full prescribing information for TERIFLUNOMIDE TABLETS.
 







TERIFLUNOMIDE tablets, for oral use
 



Initial U.S. Approval: 2012"
24926986-7552-4f1a-8366-f035bbd07104,7,fluoxetine,4493,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_24926986-7552-4f1a-8366-f035bbd07104.json,"These highlights do not include all the information needed to use FLUOXETINE CAPSULES safely and effectively. See full prescribing information for FLUOXETINE CAPSULES.
 
FLUOXETINE capsules, for oral use
 
Initial U.S. Approval: 1987"
38955939-8d1e-4db2-9aed-3bab72ca5f8f,8,bleomycin,1622,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231224_38955939-8d1e-4db2-9aed-3bab72ca5f8f.json,"​ 
BLEO 15K

Bleomycin sulfate.  

Bleomycin sulfate powder for injection contains bleomycin sulfate 15,000 IU per vial"
3d30eb8d-a62e-475f-926b-78ba63bee9c8,11,isoflurane,6026,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240130_3d30eb8d-a62e-475f-926b-78ba63bee9c8.json,"FORANE (isoflurane, USP) liquid for inhalation"
4034fb6d-f55d-4df0-b500-d6a413591f6e,39,doxazosin,49276,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_4034fb6d-f55d-4df0-b500-d6a413591f6e.json,"These highlights do not include all the information needed to use DOXAZOSIN TABLETS safely and effectively. See full prescribing information for DOXAZOSIN TABLETS.




DOXAZOSIN tablets, for oral use 




Initial U.S. Approval: 1990"
41c095b6-acd9-4627-a813-bbca7ecafee5,10,donepezil,135447,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_41c095b6-acd9-4627-a813-bbca7ecafee5.json,"These highlights do not include all the information needed to use DONEPEZIL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for DONEPEZIL HYDROCHLORIDE TABLETS.
 

DONEPEZIL HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1996"
41c095b6-acd9-4627-a813-bbca7ecafee5,10,donepezil,135447,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_41c095b6-acd9-4627-a813-bbca7ecafee5.json,"These highlights do not include all the information needed to use DONEPEZIL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for DONEPEZIL HYDROCHLORIDE TABLETS.
 

DONEPEZIL HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1996"
42f49299-7ae5-4d30-86eb-66b739c0e95d,5,lisinopril,29046,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_42f49299-7ae5-4d30-86eb-66b739c0e95d.json,"These highlights do not include all the information needed to use LISINOPRIL TABLETS safely and effectively. See full prescribing information for LISINOPRIL TABLETS
 



LISINOPRIL tablets, for oral use
 



Initial U.S. Approval: 1988"
453a5759-2f0d-421d-be78-81ab97c8ce77,1,desvenlafaxine,734064,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240203_453a5759-2f0d-421d-be78-81ab97c8ce77.json,"These highlights do not include all the information needed to use DESVENLAFAXINE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for DESVENLAFAXINE EXTENDED-RELEASE TABLETS.DESVENLAFAXINE extended-release tablets, for oral useInitial U.S. Approval: 2008"
4764f37b-c9e6-4ede-bcc2-8a03b7c521df,46,dasatinib,475342,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230223_4764f37b-c9e6-4ede-bcc2-8a03b7c521df.json,"These highlights do not include all the information needed to use SPRYCEL® safely and effectively. See full prescribing information for SPRYCEL.

SPRYCEL (dasatinib) tablets, for oral useInitial U.S. Approval: 2006"
4911f343-68e6-71b0-e054-00144ff8d46c,5,meloxicam,41493,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240223_4911f343-68e6-71b0-e054-00144ff8d46c.json,"These highlights do not include all the information needed to use MELOXICAM TABLETS safely and effectively. See full prescribing information for MELOXICAM TABLETS.
 

Initial U.S. Approval: 2000"
499ab990-2b21-474f-aaba-d86388965f40,9,amikacin,641,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231005_499ab990-2b21-474f-aaba-d86388965f40.json,"These highlights do not include all the information needed to use ARIKAYCE safely and effectively. See full prescribing information for ARIKAYCE. 
ARIKAYCE® (amikacin liposome inhalation suspension), for oral inhalation use Initial U.S. Approval: 2018 LIMITED POPULATION"
4c486fc7-c8c4-4c6c-b30c-366dabaeaadd,14,gabapentin,25480,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/train_xml/20230830_4c486fc7-c8c4-4c6c-b30c-366dabaeaadd.json,"These highlights do not include all the information needed to use HORIZANT safely and effectively. See full prescribing information for HORIZANT. 
HORIZANT® (gabapentin enacarbil) Extended-Release Tablets for oral use Initial U.S. Approval: 2011"
5108ca9c-b307-4cb2-8ea1-6553764f375a,13,escitalopram,321988,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_5108ca9c-b307-4cb2-8ea1-6553764f375a.json,"These highlights do not include all the information needed to use ESCITALOPRAM TABLETS safely and effectively. See full prescribing information for ESCITALOPRAM TABLETS.
 



ESCITALOPRAM tablets, for oral use
 








Initial U.S. Approval: 2002"
513a41d0-37d4-4355-8a6d-a2c643bce6fa,10,phenelzine,8123,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20201210_513a41d0-37d4-4355-8a6d-a2c643bce6fa.json,"NARDIL®
 (Phenelzine Sulfate Tablets, USP)"
51635427-fb13-45ee-813d-a40b0405d14f,7,diclofenac,3355,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_51635427-fb13-45ee-813d-a40b0405d14f.json,"Diclofenac Sodium Extended-Release Tablets, USP, Tablets of 100 mg
  

Rx only
  

Prescribing Information"
51a88e8e-da02-4b97-9e7e-442fbffd908d,8,amiodarone,703,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_51a88e8e-da02-4b97-9e7e-442fbffd908d.json,"These highlights do not include all the information needed to use AMIODARONE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for AMIODARONE HYDROCHLORIDE TABLETS.
 

AMIODARONE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1985"
56370be6-42a2-4962-acdc-22b7c6e0e7fe,8,ziprasidone,115698,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240224_56370be6-42a2-4962-acdc-22b7c6e0e7fe.json,"These highlights do not include all the information needed to use ZIPRASIDONE CAPSULES safely and effectively. See full prescribing information for ZIPRASIDONE CAPSULES.


ZIPRASIDONE capsules, for oral use

Initial U.S. Approval: 2001"
56370be6-42a2-4962-acdc-22b7c6e0e7fe,8,ziprasidone,115698,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_56370be6-42a2-4962-acdc-22b7c6e0e7fe.json,"These highlights do not include all the information needed to use ZIPRASIDONE CAPSULES safely and effectively. See full prescribing information for ZIPRASIDONE CAPSULES.


ZIPRASIDONE capsules, for oral use

Initial U.S. Approval: 2001"
584abe73-8290-4484-ff8e-5890831c095e,21,sumatriptan,37418,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240222_584abe73-8290-4484-ff8e-5890831c095e.json,"These highlights do not include all the information needed to use IMITREX safely and effectively. See full prescribing information for IMITREX.IMITREX (sumatriptan) tablets, for oral useInitial U.S. Approval: 1992"
61c3d6c7-0d9c-4e46-b091-88d84893e14a,11,zolpidem,39993,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_61c3d6c7-0d9c-4e46-b091-88d84893e14a.json,"These highlights do not include all the information needed to use ZOLPIDEM TARTRATE TABLETS safely and effectively. See full prescribing information for ZOLPIDEM TARTRATE TABLETS.
 



ZOLPIDEM TARTRATE tablets, for oral use, C-IV
 

Initial U.S. Approval: 1992"
61e5108a-70eb-4d48-a742-defb2e918b63,100,prazosin,8629,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240223_61e5108a-70eb-4d48-a742-defb2e918b63.json,"Prazosin Hydrochloride Capsules, USP"
6c3408ac-d401-4925-8a03-26591afbc240,10,binimetinib,2049122,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231019_6c3408ac-d401-4925-8a03-26591afbc240.json,"These highlights do not include all the information needed to use MEKTOVI safely and effectively. See full prescribing information for MEKTOVI.
MEKTOVI® (binimetinib) tablets, for oral useInitial U.S. Approval: 2018"
6ee2265b-1da5-4215-848b-12aa5eb25eff,10,hydralazine,5470,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_6ee2265b-1da5-4215-848b-12aa5eb25eff.json,Rx only
6f4998ac-0714-4f5d-8944-9e6902b9f0a6,12,levothyroxine,10582,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240220_6f4998ac-0714-4f5d-8944-9e6902b9f0a6.json,"These highlights do not include all the information needed to use LEVOTHYROXINE SODIUM TABLETS safely and effectively. See full prescribing information for LEVOTHYROXINE SODIUM TABLETS.
 

LEVOTHYROXINE SODIUM tablets, for oral use
 

Initial U.S. Approval: 2002"
6fa682c9-a312-4932-9831-f286908660ee,34,atezolizumab,1792776,acute myocardial infarction,10000891,acute myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230523_6fa682c9-a312-4932-9831-f286908660ee.json,"These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. 
 TECENTRIQ® (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2016"
6fa682c9-a312-4932-9831-f286908660ee,34,atezolizumab,1792776,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230523_6fa682c9-a312-4932-9831-f286908660ee.json,"These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. 
 TECENTRIQ® (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2016"
6fc9c8e2-6f34-aa43-e053-2a91aa0ac377,10,quetiapine,51272,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240221_6fc9c8e2-6f34-aa43-e053-2a91aa0ac377.json,"QUETIAPINE TABLETS. These highlights do not include all the information needed to use QUETIAPINE TABLETS safely and effectively. See full prescribing information for QUETIAPINE TABLETS.
 

Quetiapine tablets, for oral use
 

Initial U.S. Approval: 1997"
71448ab0-e23e-4cf7-940e-7d67e7362fb4,1,cetirizine,20610,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240212_71448ab0-e23e-4cf7-940e-7d67e7362fb4.json,"CETIRIZINE HYDROCHLORIDE ORAL SOLUTION USP

1 mg/mL

Rx Only"
740a0f37-aa95-4558-b415-be516b8c40a3,2,tolmetin,10636,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230713_740a0f37-aa95-4558-b415-be516b8c40a3.json,"Tolmetin Sodium Capsules, USP 400 mg
 Rx only"
746f3ab9-9e6e-4ce8-9384-0c7a57de8007,9,haloperidol,5093,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_746f3ab9-9e6e-4ce8-9384-0c7a57de8007.json,"Haloperidol Tablets, USP"
766b73e2-49bb-47f9-bbb1-44cfa1a3197e,4,bendamustine,134547,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240220_766b73e2-49bb-47f9-bbb1-44cfa1a3197e.json,"These highlights do not include all the information needed to use BENDAMUSTINE HYDROCHLORIDE INJECTION safely and effectively. See full prescribing information for BENDAMUSTINE HYDROCHLORIDE INJECTION. 
	BENDAMUSTINE HYDROCHLORIDE injection,	 for intravenous use. 	Initial U.S. Approval: 2008"
7731e46a-2121-441b-b090-12dcefe240f0,9,tirofiban,73137,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240223_7731e46a-2121-441b-b090-12dcefe240f0.json,"These highlights do not include all the information needed to use TIROFIBAN HYDROCHLORIDE injection safely and effectively. See full prescribing information for TIROFIBAN HYDROCHLORIDE injection.
TIROFIBAN HYDROCHLORIDE injection, for intravenous use Initial U.S. Approval: 1998"
7e9ab975-db2f-423c-a089-bc5a73313609,11,rivaroxaban,1114195,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231208_7e9ab975-db2f-423c-a089-bc5a73313609.json,"These highlights do not include all the information needed to use XARELTO safely and effectively. See full prescribing information for XARELTO.
 



XARELTO 
 ® (rivaroxaban) tablets, for oral use
 

XARELTO 
 ® (rivaroxaban) for oral suspension
 

Initial U.S. Approval: 2011"
83aeddf8-6fed-487c-858b-2240f0a0e8af,1,indinavir,114289,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20120618_83aeddf8-6fed-487c-858b-2240f0a0e8af.json,"CRIXIVAN®
(INDINAVIR SULFATE)CAPSULES"
8a5fb6a2-9fae-4872-8c5c-0f1ba03a57cb,19,nisoldipine,7435,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231221_8a5fb6a2-9fae-4872-8c5c-0f1ba03a57cb.json,Nisoldipine
962b20df-88ff-4ab7-a900-135adb6c1d74,5,indapamide,5764,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231111_962b20df-88ff-4ab7-a900-135adb6c1d74.json,Indapamide Tablets USP Rx only
9e5e2ce4-7a57-4c61-a826-64c8d11d038e,8,papaverine,7895,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231118_9e5e2ce4-7a57-4c61-a826-64c8d11d038e.json,"PAPAVERINE HYDROCHLORIDE INJECTION, USP"
9f416ce0-012f-4194-9382-74ac71e4b2a9,6,ranitidine,9143,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231221_9f416ce0-012f-4194-9382-74ac71e4b2a9.json,"Ranitidine Tablets, USP

(150 mg and 300 mg)

Rx Only"
a6f42739-5bfc-4b76-8795-e93fa58f3d29,12,oxandrolone,7779,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20230707_a6f42739-5bfc-4b76-8795-e93fa58f3d29.json,"Oxandrolone Tablet, USP"
a8c46363-f739-4f6e-bca8-1ce5e8d3f78d,9,mebendazole,6672,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231217_a8c46363-f739-4f6e-bca8-1ce5e8d3f78d.json,"These highlights do not include all the information needed to use EMVERM® safely and effectively. See full prescribing information for EMVERM®.
EMVERM® (mebendazole) chewable tablets, for oral use Initial U.S. Approval: 1974"
ae77f00f-d43b-4b75-afd5-a2a9cb7138da,9,pemetrexed,68446,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240112_ae77f00f-d43b-4b75-afd5-a2a9cb7138da.json,"These highlights do not include all the information needed to use PEMETREXED FOR INJECTION safely and effectively. See full prescribing information for PEMETREXED FOR INJECTION.
PEMETREXED FOR INJECTION, for Intravenous Use Initial U.S. Approval: 2004"
b0c23a2c-b250-4c0d-9b2a-c1483faa2ca0,15,propylthiouracil,8794,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240213_b0c23a2c-b250-4c0d-9b2a-c1483faa2ca0.json,"Propylthiouracil Tablets, USP"
b1274d78-1096-4ae3-8299-a2e94eaa0ea5,16,itraconazole,28031,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240223_b1274d78-1096-4ae3-8299-a2e94eaa0ea5.json,Itraconazole Capsules
b7241707-7538-4d1a-91e7-3a25a91e0b9a,14,ifosfamide,5657,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20231116_b7241707-7538-4d1a-91e7-3a25a91e0b9a.json,"These highlights do not include all the information needed to use IFEX (ifosfamide) safely and effectively.  See full prescribing information for IFEX.
IFEX (ifosfamide) for injection, intravenous useInitial U.S. Approval: 1988"
b7241707-7538-4d1a-91e7-3a25a91e0b9a,14,ifosfamide,5657,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231116_b7241707-7538-4d1a-91e7-3a25a91e0b9a.json,"These highlights do not include all the information needed to use IFEX (ifosfamide) safely and effectively.  See full prescribing information for IFEX.
IFEX (ifosfamide) for injection, intravenous useInitial U.S. Approval: 1988"
b7f675e2-159c-490c-b6f4-3f16d9492b7d,3,niraparib,1918231,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240109_b7f675e2-159c-490c-b6f4-3f16d9492b7d.json,"These highlights do not include all the information needed to use ZEJULA safely and effectively.  See full prescribing information for ZEJULA.
ZEJULA (niraparib) tablets, for oral useInitial U.S. Approval: 2017"
ba02a95d-d82e-4a13-90b4-a219abc0249a,18,desipramine,3247,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240210_ba02a95d-d82e-4a13-90b4-a219abc0249a.json,"Desipramine Hydrochloride Tablets, USP"
ba02a95d-d82e-4a13-90b4-a219abc0249a,18,desipramine,3247,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240210_ba02a95d-d82e-4a13-90b4-a219abc0249a.json,"Desipramine Hydrochloride Tablets, USP"
bb9a3820-f31a-4dd9-bef4-97094c01a398,7,sargramostim,69634,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20230908_bb9a3820-f31a-4dd9-bef4-97094c01a398.json,"These highlights do not include all the information needed to use LEUKINE safely and effectively. See full prescribing information for LEUKINE.
		
LEUKINE® (sargramostim) for injection, for subcutaneous or intravenous use
		Initial U.S. Approval: 1991"
bda70104-d84b-4d3f-9ca0-5f4f1ca816ad,13,voriconazole,121243,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240215_bda70104-d84b-4d3f-9ca0-5f4f1ca816ad.json,"These highlights do not include all the information needed to use VORICONAZOLE TABLETS safely and effectively. See full prescribing information for VORICONAZOLE TABLETS.VORICONAZOLE tablets, for oral useInitial U.S. Approval: 2002"
c18073be-d52a-4347-a8d1-6be11bcb7824,5,trimethobenzamide,38685,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240131_c18073be-d52a-4347-a8d1-6be11bcb7824.json,These highlights do not include all the information needed to use TRIMETHOBENZAMIDE HYDROCHLODIRE CAPSULES safely and effectively. See full prescribing information for TRIMETHOBENZAMIDE HYDROCHLODIRE CAPSULES Initial U.S. Approval:1974
c27f2d57-4b9d-4b78-8d85-3bac84f733b1,5,flurbiprofen,4502,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240128_c27f2d57-4b9d-4b78-8d85-3bac84f733b1.json,"Flurbiprofen Sodium Ophthalmic Solution, USP 0.03% 

(Sterile)"
c3658bc8-1524-43db-930e-66f9ac01b808,11,telmisartan,73494,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240124_c3658bc8-1524-43db-930e-66f9ac01b808.json,"These highlights do not include all the information needed to use TELMISARTAN TABLETS safely and effectively. See full prescribing information for TELMISARTAN TABLETS.  TELMISARTAN tablets, for oral useInitial U.S. Approval: 1998"
c6080942-dee6-423e-b688-1272c2ae90d4,40,ramucirumab,1535922,acute liver injury,10019660,hepatic encephalopathy,../data/2024_latest_labels/gold_xml/20231129_c6080942-dee6-423e-b688-1272c2ae90d4.json,"These highlights do not include all the information needed to use CYRAMZA safely and effectively. See full prescribing information for CYRAMZA.
CYRAMZA (ramucirumab) injection, for intravenous useInitial U.S. Approval: 2014"
c75fab51-c34f-4be2-b6fd-382e5e89b6a4,4,rabeprazole,114979,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240209_c75fab51-c34f-4be2-b6fd-382e5e89b6a4.json,"These highlights do not include all the information needed to use RABEPRAZOLE SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for RABEPRAZOLE SODIUM DELAYED-RELEASE TABLETS.
 RABEPRAZOLE SODIUM delayed-release tablets, for oral use
 Initial U.S. Approval: 1999"
c7bb6ba1-9a7f-43f5-b058-ef26d4b59221,3,everolimus,141704,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240222_c7bb6ba1-9a7f-43f5-b058-ef26d4b59221.json,"These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS.
 EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009"
c8c50e03-5cb8-43f4-bdef-8edd12f1945f,10,pitavastatin,861634,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240223_c8c50e03-5cb8-43f4-bdef-8edd12f1945f.json,"These highlights do not include all the information needed to use ZYPITAMAG® safely and effectively. See full prescribing information for ZYPITAMAG. 
ZYPITAMAG (pitavastatin) tablets, for oral use 
 Initial U.S. Approval: 2009"
c98fb504-76d0-4c25-9c0b-412885828a7a,7,lenalidomide,342369,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240213_c98fb504-76d0-4c25-9c0b-412885828a7a.json,"These highlights do not include all the information needed to use LENALIDOMIDE CAPSULES safely and effectively. See full prescribing information for LENALIDOMIDE CAPSULES.
LENALIDOMIDE capsules, for oral use
Initial U.S. Approval:2005"
caad4ada-2cf9-4e12-99df-6ca4388cf0f6,100,dexlansoprazole,816346,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240130_caad4ada-2cf9-4e12-99df-6ca4388cf0f6.json,"These highlights do not include all the information needed to use DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES.


DEXLANSOPRAZOLE delayed-release capsules, for oral use 

Initial U.S. Approval: 1995 (lansoprazole)"
ccd95dfc-9236-4707-a715-6a12c91519ff,6,naproxen,7258,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240224_ccd95dfc-9236-4707-a715-6a12c91519ff.json,"These highlights do not include all the information needed to use NAPROXEN TABLETS safely and effectively. See full prescribing information for NAPROXEN TABLETS.
 

NAPROXEN tablets, for oral use
 

Initial U.S. Approval: 1976"
d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f,8,mefenamate,257844,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240120_d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f.json,Mefenamic Acid Capsules USPRx Only
d1f64796-6ba0-415c-a6a0-5456b21a7ed6,5,fenofibrate,8703,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240221_d1f64796-6ba0-415c-a6a0-5456b21a7ed6.json,"These highlights do not include all the information needed to use FENOFIBRATE TABLETS safely and effectively. See full prescribing information for FENOFIBRATE TABLETS.
 
FENOFIBRATE tablets, for oral use
 
Initial U.S. Approval: 1993"
d9db3882-a7b5-435b-9d5a-a5e4ef7c2537,2,fluphenazine,4496,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240214_d9db3882-a7b5-435b-9d5a-a5e4ef7c2537.json,"Fluphenazine Hydrochloride Tablets, USPRx only"
da3c2935-817d-4331-83c3-ed68ba5d35fd,2,chlorpromazine,2403,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240214_da3c2935-817d-4331-83c3-ed68ba5d35fd.json,"ChlorproMAZINE Hydrochloride Tablets, USP 
Rx only"
de77155c-ecf2-4f15-9758-21d271449d83,2,tivozanib,2534233,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20220826_de77155c-ecf2-4f15-9758-21d271449d83.json,"These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. 
FOTIVDA® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021"
e1114a58-9ab5-486e-85ed-360365b06396,1,methyldopa,6876,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230105_e1114a58-9ab5-486e-85ed-360365b06396.json,"Methyldopa Tablets, USP"
ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,54,carfilzomib,1302966,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20221029_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.json,"These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. 
KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012"
f06d1bb3-83f1-4d84-8004-4c6681ad8a5a,4,paclitaxel,56946,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240201_f06d1bb3-83f1-4d84-8004-4c6681ad8a5a.json,"These highlights do not include all the information needed to use PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND) safely and effectively. See full prescribing information for PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND).
PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND), for intravenous use Initial U.S. Approval: 2005"
f299b2d2-86ed-4fb8-822e-65455a0bb75a,6,oxaliplatin,32592,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_f299b2d2-86ed-4fb8-822e-65455a0bb75a.json,"These highlights do not include all the information needed to use OXALIPLATIN INJECTION safely and effectively. See full prescribing information for OXALIPLATIN INJECTION.OXALIPLATIN injection, for intravenous useInitial U.S. Approval: 2002"
f3c516ad-d405-4fbe-af6a-962080dbfa7d,3,aldesleukin,70223,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240208_f3c516ad-d405-4fbe-af6a-962080dbfa7d.json,"These highlights do not include all the information needed to use PROLEUKIN® safely and effectively. See full prescribing information for PROLEUKIN. 
 PROLEUKIN (aldesleukin) for injection, for intravenous use  Initial U.S. Approval: 1992"
f3c516ad-d405-4fbe-af6a-962080dbfa7d,3,aldesleukin,70223,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240208_f3c516ad-d405-4fbe-af6a-962080dbfa7d.json,"These highlights do not include all the information needed to use PROLEUKIN® safely and effectively. See full prescribing information for PROLEUKIN. 
 PROLEUKIN (aldesleukin) for injection, for intravenous use  Initial U.S. Approval: 1992"
f47d4365-40a8-445b-99cd-49edad6a8ffc,15,ketorolac,35827,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240206_f47d4365-40a8-445b-99cd-49edad6a8ffc.json,"Ketorolac Tromethamine Tablets USP, 10 mg 
 




Rx only"
f5e8d1da-8911-42db-9f90-cba04b28d011,102,fluvastatin,41127,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240113_f5e8d1da-8911-42db-9f90-cba04b28d011.json,"These highlights do not include all the information needed to use FLUVASTATIN CAPSULES safely and effectively.  See full prescribing information for FLUVASTATIN CAPSULES. 
FLUVASTATIN capsules, for oral useInitial U.S. Approval: 1993"
f9ab6b1c-98d0-4373-0e9b-b10cb4a67543,22,deferoxamine,3131,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231202_f9ab6b1c-98d0-4373-0e9b-b10cb4a67543.json,"These highlights do not include all the information needed to use DEFEROXAMINE MESYLATE safely and effectively. See full prescribing information for DEFEROXAMINE MESYLATE.

DEFEROXAMINE MESYLATE for injection, for intramuscular, intravenous, or subcutaneous use
Initial U.S. Approval: 1968"
fd638e5e-8032-e7ca-0179-95e96ab5d387,18,afatinib,1430438,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20220723_fd638e5e-8032-e7ca-0179-95e96ab5d387.json,"These highlights do not include all the information needed to use GILOTRIF safely and effectively.  See full prescribing information for GILOTRIF. 
GILOTRIF® (afatinib tablets), for oral use Initial U.S. Approval: 2013"
fe0ddd44-ef02-4827-b164-7fcbb45bcc1b,4,busulfan,1828,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240106_fe0ddd44-ef02-4827-b164-7fcbb45bcc1b.json,"These highlights do not include all the information needed to use BUSULFAN INJECTION safely and effectively. See full prescribing information for BUSULFAN INJECTION.
 



BUSULFAN Injection, for intravenous use
 

Initial U.S. Approval: 1999"
ff3b5265-f533-4332-a861-d8c9c1664ffd,15,lamivudine,68244,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240104_ff3b5265-f533-4332-a861-d8c9c1664ffd.json,"These highlights do not include all the information needed to use LAMIVUDINE TABLETS safely and effectively. See full prescribing information for LAMIVUDINE TABLETS.LAMIVUDINE tablets, for oral useInitial U.S. Approval: 1995"
fff5d805-4ffd-4e8e-8e63-6f129697563e,18,ceritinib,1535457,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20240123_fff5d805-4ffd-4e8e-8e63-6f129697563e.json,"These highlights do not include all the information needed to use ZYKADIA safely and effectively. See full prescribing information for ZYKADIA.


ZYKADIA® (ceritinib) capsules, for oral use

ZYKADIA® (ceritinib) tablets, for oral use

Initial U.S. Approval: 2014"
04a413fe-95f4-47a7-42ac-283a9e78297d,20,ethionamide,4127,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231010_04a413fe-95f4-47a7-42ac-283a9e78297d.json,"Trecator®


 (ethionamide tablets, USP) 

Tablets"
04fb6cd5-3c21-433e-a053-623b73218bd6,2,niacin,7393,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240126_04fb6cd5-3c21-433e-a053-623b73218bd6.json,"Niacin Tablets, USP 500 mg"
0919b927-c57c-40ae-88a8-39e9efe4f677,5,17-alpha-hydroxyprogesterone,5542,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230803_0919b927-c57c-40ae-88a8-39e9efe4f677.json,""
09c6c750-ae05-459f-83e8-4a9e4fd85212,28,atorvastatin,83367,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_09c6c750-ae05-459f-83e8-4a9e4fd85212.json,"These highlights do not include all the information needed to use ATORVASTATIN CALCIUM TABLETS safely and effectively. See full prescribing information for ATORVASTATIN CALCIUM TABLETS.
 

ATORVASTATIN CALCIUM tablets, for oral use
 

Initial U.S. Approval: 1996"
0d447b48-3f4b-430e-9e68-d8b9401c002e,4,desmopressin,3251,acute myocardial infarction,10000891,acute myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_0d447b48-3f4b-430e-9e68-d8b9401c002e.json,"Desmopressin Acetate Tablets
  
8472121/1222
  
Rx only"
0f672b76-f673-4cba-99d2-818a9e2e6d7f,7,losartan,52175,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240224_0f672b76-f673-4cba-99d2-818a9e2e6d7f.json,"These highlights do not include all the information needed to use LOSARTAN POTASSIUM TABLETS safely and effectively. see full prescribing information for LOSARTAN POTASSIUM TABLETS.
 



LOSARTAN POTASSIUM tablets, for oral use
 

Initial U.S. Approval: 1995"
116f655e-e32f-5030-e063-6394a90a64e5,1,amoxicillin,723,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_116f655e-e32f-5030-e063-6394a90a64e5.json,"These highlights do not include all the information needed to use AMOXICILLIN CAPSULES safely and effectively. See full prescribing information for AMOXICILLIN CAPSULES.
 

AMOXICILLIN capsules, for oral use
 
Initial U.S. Approval: 1974"
11fa3fc9-6776-49a6-b1c1-653f627c3e58,11,midostaurin,1919083,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230527_11fa3fc9-6776-49a6-b1c1-653f627c3e58.json,"These highlights do not include all the information needed to use RYDAPT safely and effectively. See full prescribing information for RYDAPT.
RYDAPT® (midostaurin) capsules, for oral useInitial U.S. Approval: 2017"
2150f73a-179b-4afc-b8ce-67c85cc72f04,60,everolimus,141704,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/train_xml/20230802_2150f73a-179b-4afc-b8ce-67c85cc72f04.json,"These highlights do not include all the information needed to use AFINITOR/AFINITOR DISPERZ safely and effectively. See full prescribing information for AFINITOR/AFINITOR DISPERZ.


AFINITOR® (everolimus) tablets, for oral use

AFINITOR DISPERZ® (everolimus tablets for oral suspension)

Initial U.S. Approval: 2009"
2265ef30-253e-11df-8a39-0800200c9a66,42,ipilimumab,1094833,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011"
241f0b1e-8b95-470d-876f-bf1804daaf18,11,ixabepilone,337523,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20230202_241f0b1e-8b95-470d-876f-bf1804daaf18.json,"These highlights do not include all the information needed to use IXEMPRA 
 ® safely and effectively. See full prescribing information for IXEMPRA 
 ®.
 



IXEMPRA 
 ® 
Kit (ixabepilone) for Injection, for intravenous infusion only
 



Initial U.S. Approval: 2007"
24ac0ee2-cd7b-4dda-a1bb-271e32331758,3,febuxostat,73689,acute liver injury,10024670,liver disorder,../data/2024_latest_labels/train_xml/20191219_24ac0ee2-cd7b-4dda-a1bb-271e32331758.json,"These HIGHLIGHTS do not include all the information needed to use ULORIC safely and effectively. See full prescribing information for ULORIC. 
 ULORIC (febuxostat) tablet for oral use  Initial U.S. Approval: 2009"
26eb95ba-1f77-4496-a6ea-92bd63a40a3e,100,oxaprozin,32613,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231207_26eb95ba-1f77-4496-a6ea-92bd63a40a3e.json,"These highlights do not include all the information needed to use OXAPROZIN TABLETS safely and effectively. See full prescribing information for OXAPROZIN TABLETS.
OXAPROZIN tablets, for oral useInitial U.S. Approval: 1992"
2b25ef01-5c9e-11e1-b86c-0800200c9a66,24,pomalidomide,1369713,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/gold_xml/20230411_2b25ef01-5c9e-11e1-b86c-0800200c9a66.json,"These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST.
 POMALYST® (pomalidomide) capsules, for oral use Initial U.S. Approval:  2013"
2cab8dd1-3a10-48e6-86ce-0e5275ed49e5,10,toremifene,38409,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230916_2cab8dd1-3a10-48e6-86ce-0e5275ed49e5.json,"These highlights do not include all the information needed to use FARESTON® safely and effectively. See full prescribing information for FARESTON®.


FARESTON® (toremifene citrate) 60 mg Tablets oral administration

Initial U.S. Approval: 1997"
2d9d90a6-63e6-46ef-96ff-dd6519ae7b6c,3,andexanet alfa,2045114,acute myocardial infarction,10000891,acute myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230629_2d9d90a6-63e6-46ef-96ff-dd6519ae7b6c.json,"These highlights do not include all the information needed to use ANDEXXA safely and effectively.  See Full Prescribing Information for ANDEXXA.
 ANDEXXA® (coagulation factor Xa (recombinant), inactivated-zhzo) Lyophilized powder for solution for intravenous injection Initial U.S. Approval:  2018"
2d9d90a6-63e6-46ef-96ff-dd6519ae7b6c,3,andexanet alfa,2045114,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230629_2d9d90a6-63e6-46ef-96ff-dd6519ae7b6c.json,"These highlights do not include all the information needed to use ANDEXXA safely and effectively.  See Full Prescribing Information for ANDEXXA.
 ANDEXXA® (coagulation factor Xa (recombinant), inactivated-zhzo) Lyophilized powder for solution for intravenous injection Initial U.S. Approval:  2018"
2eda833b-1357-4ed4-a093-194524fcb061,25,thalidomide,10432,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230406_2eda833b-1357-4ed4-a093-194524fcb061.json,"These highlights do not include all the information needed to use THALOMID® safely and effectively. See full prescribing information for THALOMID. 
THALOMID (thalidomide) capsules, for oral use Initial U.S. Approval: 1998"
2eda833b-1357-4ed4-a093-194524fcb061,25,thalidomide,10432,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230406_2eda833b-1357-4ed4-a093-194524fcb061.json,"These highlights do not include all the information needed to use THALOMID® safely and effectively. See full prescribing information for THALOMID. 
THALOMID (thalidomide) capsules, for oral use Initial U.S. Approval: 1998"
34de1806-d921-4d2f-8c7f-03625b717a70,25,methylphenidate,6901,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240221_34de1806-d921-4d2f-8c7f-03625b717a70.json,"These highlights do not include all the information needed to use METHYLPHENIDATE HCl EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for METHYLPHENIDATE HCl EXTENDED-RELEASE TABLETS.


METHYLPHENIDATE HCl extended-release tablets, for oral administration CII 

Initial U.S. Approval: 2000"
36377351-d208-4363-8826-0acfea3f0cc1,5,sodium ferric gluconate complex,261435,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230609_36377351-d208-4363-8826-0acfea3f0cc1.json,"These highlights do not include all the information needed to use sodium ferric gluconate complex in sucrose injection safely and effectively. See full prescribing information for sodium ferric gluconate complex in sucrose injection.
Sodium ferric gluconate complex in sucrose injection, for intravenous use 
Initial U.S. Approval: 1999"
39d53698-57fa-7c99-fc5b-f52a55684826,26,bendamustine,134547,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20221029_39d53698-57fa-7c99-fc5b-f52a55684826.json,"These highlights do not include all the information needed to use TREANDA safely and effectively. See full prescribing information for TREANDA.
TREANDA® (bendamustine hydrochloride) injection, for intravenous useTREANDA® (bendamustine hydrochloride) for injection, for intravenous useInitial U.S. Approval: 2008"
3a404db2-7a7d-476f-81cf-979a67d37f66,7,tadalafil,358263,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240223_3a404db2-7a7d-476f-81cf-979a67d37f66.json,"These highlights do not include all the information needed to use ALYQ™ safely and effectively.  See full prescribing information for ALYQ™. 


ALYQ™ (tadalafil) tablets for oral administration

Initial U.S. Approval: 2003"
3ecde48b-75a2-4beb-9999-369f3f61bb8a,37,ceftaroline fosamil,1040004,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20221118_3ecde48b-75a2-4beb-9999-369f3f61bb8a.json,"These highlights do not include all the information needed to use
 
T
EFLARO 
safely and effectively. See full prescribing information for 
TE
FLARO
.

    

TE
FLARO

®

 (ceftaroline fosamil) 
for 
injection
,
 for intravenous use

Initial U.S. Approval: 
2010"
44b0c461-47fb-4106-ba11-6ed85530235c,2,thioguanine,10485,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20230517_44b0c461-47fb-4106-ba11-6ed85530235c.json,"TABLOID®


brand 
Thioguanine

40-mg Scored Tablets"
458e043d-6584-4503-b398-2032d3cce2f1,22,clindamycin,2582,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240217_458e043d-6584-4503-b398-2032d3cce2f1.json,"Clindamycin Injection, USP"
48ffeac8-38e8-4007-903a-dbffce25d679,2,etravirine,475969,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240110_48ffeac8-38e8-4007-903a-dbffce25d679.json,"These highlights do not include all the information needed to use ETRAVIRINE TABLETS safely and effectively.See full prescribing information for ETRAVIRINE TABLETS.
ETRAVIRINE tablets, for oral useInitial U.S. Approval: 2008"
49aa3d6d-2270-4615-aafa-b440859ab870,4,naltrexone,7243,acute myocardial infarction,10002388,angina unstable,../data/2024_latest_labels/latest_labels_ingredients/20240216_49aa3d6d-2270-4615-aafa-b440859ab870.json,Naltrexone Hydrochloride Tablets USP 50 mg
49e5afe9-a0c7-40c4-af9f-f287a80c5c88,177,denosumab,993449,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240203_49e5afe9-a0c7-40c4-af9f-f287a80c5c88.json,"These highlights do not include all the information needed to use PROLIA safely and effectively.  See full prescribing information for PROLIA.   
Prolia® (denosumab) Injection, for subcutaneous use Initial U.S. Approval: 2010"
4afb20ee-eb3f-1937-ffa4-5d3228e82688,3,penicillamine,7975,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231205_4afb20ee-eb3f-1937-ffa4-5d3228e82688.json,Penicillamine Capsules
5359b759-db7c-4672-9e8a-59c93869bd91,5,telavancin,473837,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/gold_xml/20231205_5359b759-db7c-4672-9e8a-59c93869bd91.json,"These highlights do not include all the information needed to use VIBATIV® (telavancin) safely and effectively. See full prescribing information for VIBATIV. 
VIBATIV® (telavancin) for injection, for intravenous use Initial U.S. Approval: 2009"
58353438-3236-4596-9324-62fed9615cb7,12,dulaglutide,1551291,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20231213_58353438-3236-4596-9324-62fed9615cb7.json,"These highlights do not include all the information needed to use TRULICITY safely and effectively. See full prescribing information for TRULICITY.
TRULICITY (dulaglutide) injection, for subcutaneous useInitial U.S. Approval: 2014"
5c8cebcd-699f-4c4c-900b-94e0fe519345,100,propafenone,8754,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240208_5c8cebcd-699f-4c4c-900b-94e0fe519345.json,"These highlights do not include all the information needed to use PROPAFENONE HYDROCHLORIDE TABLETS safely and effectively.  See full prescribing information for PROPAFENONE HYDROCHLORIDE TABLETS.
PROPAFENONE HYDROCHLORIDE tablets, for oral useInitial U.S. Approval: 1989"
5cd725a1-2fa4-408a-a651-57a7b84b2118,18,avelumab,1875534,acute liver injury,10024670,liver disorder,../data/2024_latest_labels/latest_labels_ingredients/20240131_5cd725a1-2fa4-408a-a651-57a7b84b2118.json,"These highlights do not include all the information needed to use BAVENCIO safely and effectively. See full prescribing information for BAVENCIO.
 BAVENCIO® (avelumab) injection, for intravenous use Initial U.S. Approval: 2017"
6093952a-5248-45cb-ad17-33716a411146,37,nilotinib,662281,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240216_6093952a-5248-45cb-ad17-33716a411146.json,"These highlights do not include all the information needed to use TASIGNA safely and effectively. See full prescribing information for TASIGNA.
TASIGNA® (nilotinib) capsules, for oral use
		Initial U.S. Approval: 2007"
61492681-4be8-448b-b4c6-ef2261503d1a,12,metformin,6809,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_61492681-4be8-448b-b4c6-ef2261503d1a.json,"These highlights do not include all the information needed to use METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS.
 

METFORMIN HYDROCHLORIDE extended-release tablets, for oral use
 

Initial U.S. Approval: 1995"
63df5af3-b8ac-4e76-9830-2dbb340af922,27,dolutegravir,1433868,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231004_63df5af3-b8ac-4e76-9830-2dbb340af922.json,"These highlights do not include all the information needed to use TIVICAY safely and effectively. See full prescribing information for TIVICAY.TIVICAY (dolutegravir) tablets, for oral use TIVICAY PD (dolutegravir) tablets for oral suspensionInitial U.S. Approval: 2013"
67e3ba3c-77e1-43b5-a93c-5bf5e3855780,2,griseofulvin,5021,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231228_67e3ba3c-77e1-43b5-a93c-5bf5e3855780.json,"GRISEOFULVIN ORAL SUSPENSION, USP


Microsize


125 mg/5 mL




Rx only"
6fa682c9-a312-4932-9831-f286908660ee,34,atezolizumab,1792776,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230523_6fa682c9-a312-4932-9831-f286908660ee.json,"These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. 
 TECENTRIQ® (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2016"
722ce9eb-8f7b-4651-a287-d53dd7ab3707,21,acarbose,16681,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240207_722ce9eb-8f7b-4651-a287-d53dd7ab3707.json,"Acarbose Tablets, USP"
72d1a024-00b7-418a-b36e-b2cb48f2ab55,6,dotatate,1797118,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230315_72d1a024-00b7-418a-b36e-b2cb48f2ab55.json,"These highlights do not include all the information needed to use LUTATHERA safely and effectively. See full prescribing information for LUTATHERA.
		

		LUTATHERA® (lutetium Lu 177 dotatate) injection, for intravenous use
		
		Initial U.S. Approval: 2018"
75d68f19-4208-109e-e053-2991aa0ac857,19,riluzole,35623,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240210_75d68f19-4208-109e-e053-2991aa0ac857.json,"These highlights do not include all the information needed to use TIGLUTIK® safely and effectively. See full prescribing information for TIGLUTIK.
 



TIGLUTIK (riluzole) oral suspension
 

Initial U.S. Approval: 1995"
79eec27d-ac63-4996-8b1a-c2cd52ad2b2c,5,argatroban,15202,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240117_79eec27d-ac63-4996-8b1a-c2cd52ad2b2c.json,"These highlights do not include all the information needed to use ARGATROBAN INJECTION safely and effectively. See full prescribing information for ARGATROBAN INJECTION.


ARGATROBAN INJECTION, for intravenous infusion only 

Initial U.S. Approval: 2000"
7c295b64-ec39-42ec-9f02-da5b42e775e1,8,bicalutamide,83008,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240117_7c295b64-ec39-42ec-9f02-da5b42e775e1.json,"These highlights do not include all the information needed to use BICALUTAMIDE TABLETS safely and effectively. See full prescribing information for BICALUTAMIDE TABLETS.
 



BICALUTAMIDE TABLETS, for oral use
 



Initial U.S. Approval: 1995"
7ded2595-d661-48f4-a2e3-4aabfd744362,11,metaxalone,59078,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240214_7ded2595-d661-48f4-a2e3-4aabfd744362.json,"Metaxalone 
T
ablets
, USP"
7ed4d986-2aa9-43cd-9a8a-fbd11cb5ecef,5,daptomycin,22299,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240223_7ed4d986-2aa9-43cd-9a8a-fbd11cb5ecef.json,"These highlights do not include all the information needed to use DAPTOMYCIN IN SODIUM CHLORIDE INJECTION safely and effectively.  See full prescribing information for DAPTOMYCIN IN SODIUM CHLORIDE INJECTION.
DAPTOMYCIN IN SODIUM CHLORIDE injection, for intravenous use
Initial U.S. Approval: 2003"
7f0bc342-0a0a-1d28-e053-2991aa0a28b9,4,tenofovir disoproxil,300195,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240111_7f0bc342-0a0a-1d28-e053-2991aa0a28b9.json,"TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use
 
Rx only
 

These highlights do not include all the information needed to use TENOFOVIR DISOPROXIL FUMARATE TABLETS safely and effectively. See full prescribing information for TENOFOVIR DISOPROXIL FUMARATE TABLETS.
 

TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use
 

Initial U.S. Approval: 2001"
80a31286-a741-4440-b200-290c08925d06,9,atropine,1223,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240217_80a31286-a741-4440-b200-290c08925d06.json,"These highlights do not include all the information needed to use ATROPINE SULFATE INJECTION safely and effectively. See full prescribing information for ATROPINE SULFATE INJECTION.
ATROPINE SULFATE injection, for intravenous use
Initial U.S. Approval: 1960"
87768fbf-7c63-47da-8925-0316f343d6ef,16,perindopril,54552,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230221_87768fbf-7c63-47da-8925-0316f343d6ef.json,"These highlights do not include all the information needed to use PERINDOPRIL ERBUMINE TABLETS safely and effectively. See full prescribing information for PERINDOPRIL ERBUMINE TABLETS.
 PERINDOPRIL erbumine tablets, for oral use Initial U.S. Approval: 1993"
88f28338-9a64-42aa-a4e9-b1ad3fd073fe,9,betamethasone,1514,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240214_88f28338-9a64-42aa-a4e9-b1ad3fd073fe.json,"BETAMETHASONE VALERATE CREAM USP, 0.1%

BETAMETHASONE VALERATE OINTMENT USP, 0.1%

BETAMETHASONE VALERATE LOTION USP, 0.1%

(Potency expressed as betamethasone)"
8bc6397e-4bd8-4d37-a007-a327e4da34d9,56,cetuximab,318341,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20230628_8bc6397e-4bd8-4d37-a007-a327e4da34d9.json,"These highlights do not include all the information needed to use ERBITUX safely and effectively. See full prescribing information for ERBITUX.ERBITUX® (cetuximab) injection, for intravenous useInitial U.S. Approval: 2004"
8bc6397e-4bd8-4d37-a007-a327e4da34d9,56,cetuximab,318341,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230628_8bc6397e-4bd8-4d37-a007-a327e4da34d9.json,"These highlights do not include all the information needed to use ERBITUX safely and effectively. See full prescribing information for ERBITUX.ERBITUX® (cetuximab) injection, for intravenous useInitial U.S. Approval: 2004"
8bf8e76c-27cb-42a4-aa9c-bdade68c463b,4,rasagiline,134748,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231227_8bf8e76c-27cb-42a4-aa9c-bdade68c463b.json,These highlights do not include all the information needed to use RASAGILINE TABLETS safely and effectively. See full prescribing information for RASAGILINE TABLETS. RASAGILINE tablets for oral use Initial U.S. Approval: 2006
8c5d6067-16a1-43ab-9e52-a33c600a5c44,2,decitabine,15657,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240117_8c5d6067-16a1-43ab-9e52-a33c600a5c44.json,"These highlights do not include all the information needed to use DECITABINE FOR INJECTION safely and effectively. See full prescribing information for DECITABINE FOR INJECTION.
DECITABINE for injection, for intravenous useInitial U.S. Approval: 2006"
8d5ace90-983b-48c4-baf1-b44f6af146de,2,carbamazepine,2002,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240221_8d5ace90-983b-48c4-baf1-b44f6af146de.json,"Carbamazepine Oral Suspension, USP
 
Rx only
 
Prescribing Information"
8ded0773-3aec-4e89-9836-d22a5a84abf0,17,quinapril,35208,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231215_8ded0773-3aec-4e89-9836-d22a5a84abf0.json,Quinapril Tablets USP
907c965e-8faf-53db-e053-2995a90a8cd1,5,zonisamide,39998,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240111_907c965e-8faf-53db-e053-2995a90a8cd1.json,ZONISAMIDE
9678a98e-4aab-4d87-b5e1-37c3109e378e,16,tizanidine,57258,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240221_9678a98e-4aab-4d87-b5e1-37c3109e378e.json,"These highlights do not include all the information needed to use TIZANIDINE Tablets, USP safely and effectively. See full prescribing information for TIZANIDINE Tablets, USP.TIZANIDINE (tizanidine hydrochloride) Tablets USP, for oral useInitial U.S. Approval:1996"
a60c5173-6bc0-4c9d-9674-b3f4d68f79ba,4,cisplatin,2555,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240213_a60c5173-6bc0-4c9d-9674-b3f4d68f79ba.json,"These highlights do not include all the information needed to use CISPLATIN INJECTION, USP safely and effectively. See full prescribing information for CISPLATIN INJECTION, USP.
 



CISPLATIN injection USP, for intravenous use
 



Initial U.S. Approval: 1978"
a60c5173-6bc0-4c9d-9674-b3f4d68f79ba,4,cisplatin,2555,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240213_a60c5173-6bc0-4c9d-9674-b3f4d68f79ba.json,"These highlights do not include all the information needed to use CISPLATIN INJECTION, USP safely and effectively. See full prescribing information for CISPLATIN INJECTION, USP.
 



CISPLATIN injection USP, for intravenous use
 



Initial U.S. Approval: 1978"
ab8616a5-ea72-4df7-b095-54ea19ef6fba,10,valproate,40254,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240224_ab8616a5-ea72-4df7-b095-54ea19ef6fba.json,"These highlights do not include all the information needed to use DIVALPROEX SODIUM DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DIVALPROEX SODIUM DELAYED-RELEASE CAPSULES.
 



DIVALPROEX SODIUM delayed-release capsules, for oral use
 

Initial U.S. Approval: 1989"
b118a40d-6b56-cee3-10f6-ded821a97018,275,venetoclax,1747556,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20230318_b118a40d-6b56-cee3-10f6-ded821a97018.json,"These highlights do not include all the information needed to use VENCLEXTA safely and effectively. See full prescribing information for VENCLEXTA.


VENCLEXTA

®

 (venetoclax tablets), for oral use 

Initial U.S. Approval: 2016"
b4c2c9dc-a0bb-4d64-a667-a67ebe88392d,37,certolizumab pegol,709271,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230105_b4c2c9dc-a0bb-4d64-a667-a67ebe88392d.json,"These highlights do not include all the information needed to use CIMZIA® safely and effectively. See full prescribing information for CIMZIA.
 



CIMZIA (certolizumab pegol) for injection, for subcutaneous use
 

CIMZIA (certolizumab pegol) injection, for subcutaneous use
 

Initial U.S. Approval: 2008"
b6737b25-0c4f-4131-ba23-b0f2252a18ea,9,simvastatin,36567,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_b6737b25-0c4f-4131-ba23-b0f2252a18ea.json,"These highlights do not include all the information needed to use SIMVASTATIN TABLETS safely and effectively. See full prescribing information for SIMVASTATIN TABLETS.








SIMVASTATIN tablets, for oral use








Initial U.S. Approval:
1991"
bca1e4c6-4b2b-4876-8ab3-654629c4ff1b,10,prucalopride,2107310,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20221108_bca1e4c6-4b2b-4876-8ab3-654629c4ff1b.json,"These highlights do not include all the information needed to use MOTEGRITY safely and effectively. See full prescribing information for MOTEGRITY. 
 MOTEGRITY (prucalopride) tablets, for oral use Initial U.S. Approval: 2018"
c0781dae-3ef6-4cab-b084-01d2e45f3764,1,eptifibatide,75635,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240131_c0781dae-3ef6-4cab-b084-01d2e45f3764.json,"These highlights do not include all the information needed to use EPTIFIBATIDE INJECTION safely and effectively. See full prescribing information for EPTIFIBATIDE INJECTION.
EPTIFIBATIDE injection, for intravenous useInitial U.S. Approval: 1998"
c35e019d-ec34-4e61-9400-a7ae7913e025,3,erlotinib,337525,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231011_c35e019d-ec34-4e61-9400-a7ae7913e025.json,"These highlights do not include all the information needed to use ERLOTINIB TABLETS safely and effectively. See full prescribing information for ERLOTINIB TABLETS.
ERLOTINIB tablets, for oral use Initial U.S. Approval: 2004"
c35e019d-ec34-4e61-9400-a7ae7913e025,3,erlotinib,337525,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231011_c35e019d-ec34-4e61-9400-a7ae7913e025.json,"These highlights do not include all the information needed to use ERLOTINIB TABLETS safely and effectively. See full prescribing information for ERLOTINIB TABLETS.
ERLOTINIB tablets, for oral use Initial U.S. Approval: 2004"
c5116390-e0fe-4969-94cb-e9de5165fbab,23,saxagliptin,857974,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240207_c5116390-e0fe-4969-94cb-e9de5165fbab.json,"These highlights do not include all the information needed to use ONGLYZA safely and effectively. See full prescribing information for ONGLYZA.
ONGLYZA® (saxagliptin) tablets, for oral useInitial U.S. Approval: 2009"
ca70b23e-6f02-43a8-9c88-9550c0d230cf,100,apixaban,1364430,gi bleed,10018830,haematemesis,../data/2024_latest_labels/train_xml/20211231_ca70b23e-6f02-43a8-9c88-9550c0d230cf.json,"These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.
ELIQUIS® (apixaban) tablets, for oral useInitial U.S. Approval: 2012"
cac4f544-536c-4886-a379-99eed2d35240,8,sildenafil,136411,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240224_cac4f544-536c-4886-a379-99eed2d35240.json,"These highlights do not include all the information needed to use SILDENAFIL TABLETS safely and effectively. See full prescribing information for SILDENAFIL TABLETS.
 







SILDENAFIL tablets, for oral use
 







Initial U.S. Approval:1998"
cee4cdd0-58c5-4704-9fb6-d4bffb1764a8,2,midazolam,6960,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240207_cee4cdd0-58c5-4704-9fb6-d4bffb1764a8.json,"Midazolam Injection, USP

 CIV

 (For Intravenous or Intramuscular Use Only)

 Rx only

 NOT FOR USE IN NEONATES

 CONTAINS BENZYL ALCOHOL"
cf94c7fc-13a0-4ac9-bb85-9c38aa704d35,5,ferumoxytol,473387,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230803_cf94c7fc-13a0-4ac9-bb85-9c38aa704d35.json,"These highlights do not include all the information needed to use FERUMOXYTOL INJECTION safely and effectively. See full prescribing information for FERUMOXYTOL INJECTION. 
	FERUMOXYTOL injection, for intravenous use 	Initial U.S. Approval: 2009"
d35193e4-0b0e-4a0a-acd8-aa90cc075a2b,16,methotrexate,6851,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240217_d35193e4-0b0e-4a0a-acd8-aa90cc075a2b.json,"These highlights do not include all the information needed to use METHOTREXATE TABLETS safely and effectively. See full prescribing information for METHOTREXATE TABLETS.
 

METHOTREXATE tablets, for oral use
 
Initial U.S. Approval: 1953"
d5929f91-6496-4c0e-97e8-0bd524e15763,3,bosutinib,1307619,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20220817_d5929f91-6496-4c0e-97e8-0bd524e15763.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF.
 BOSULIF® (bosutinib) tablets, for oral use Initial U.S. Approval: 2012"
d66bdf0d-9d65-45de-ae5b-a58617c27492,9,dinutuximab,1606274,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20231216_d66bdf0d-9d65-45de-ae5b-a58617c27492.json,"These highlights do not include all the information needed to use UNITUXIN safely and effectively.  See Full Prescribing Information for UNITUXIN. 
UNITUXIN® (dinutuximab) injection, for intravenous use Initial U.S. Approval:  2015"
d72e0e10-4557-41b0-b65d-d395468cad19,11,aprepitant,358255,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240104_d72e0e10-4557-41b0-b65d-d395468cad19.json,"These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. 
APREPITANT capsules, for oral use Initial U.S. Approval: 2003"
d953457e-0aff-6c38-e053-2995a90a7d32,3,eplerenone,298869,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240110_d953457e-0aff-6c38-e053-2995a90a7d32.json,"Eplerenone Tablet
 
Rx Only
 

These highlights do not include all the information needed to use EPLERENONE TABLETS safely and effectively. See full prescribing information for EPLERENONE TABLETS.
 

Initial U.S. Approval: 2002"
e65d5108-22a2-4d87-a78d-15606f3cc9e2,3,nimodipine,7426,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231228_e65d5108-22a2-4d87-a78d-15606f3cc9e2.json,"Nimodipine Capsules


For Oral Use


Rx only"
eb354221-c476-41cb-ad87-52423f81d698,3,cefdinir,25037,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_eb354221-c476-41cb-ad87-52423f81d698.json,"Cefdinir Capsules, USP
 
Rx only"
f3b50bbb-df03-4ed7-9d8d-180edc2abd54,9,betaxolol,1520,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240215_f3b50bbb-df03-4ed7-9d8d-180edc2abd54.json,"Betaxolol Tablets, USP"
fabf55db-8b50-491f-b76d-a0fe5fb6c9b0,17,ciprofloxacin,2551,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_fabf55db-8b50-491f-b76d-a0fe5fb6c9b0.json,"These highlights do not include all the information needed to use CIPROFLOXACIN TABLETS safely and effectively. See full prescribing information for CIPROFLOXACIN TABLETS.
 

CIPROFLOXACIN tablet, for oral use
 
Initial U.S. Approval: 1987"
fabf55db-8b50-491f-b76d-a0fe5fb6c9b0,17,ciprofloxacin,2551,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240217_fabf55db-8b50-491f-b76d-a0fe5fb6c9b0.json,"These highlights do not include all the information needed to use CIPROFLOXACIN TABLETS safely and effectively. See full prescribing information for CIPROFLOXACIN TABLETS.
 

CIPROFLOXACIN tablet, for oral use
 
Initial U.S. Approval: 1987"
faf3dd6a-9cd0-39c2-0d2e-232cb3f67565,26,empagliflozin,1545653,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231122_faf3dd6a-9cd0-39c2-0d2e-232cb3f67565.json,"These highlights do not include all the information needed to use JARDIANCE safely and effectively.  See full prescribing information for JARDIANCE. 
JARDIANCE® (empagliflozin tablets), for oral useInitial U.S. Approval: 2014"
fc937c08-7bc0-4f97-80c9-e091e97f2f9a,1,metolazone,6916,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231228_fc937c08-7bc0-4f97-80c9-e091e97f2f9a.json,"Metolazone Tablets, USP"
fe0ddd44-ef02-4827-b164-7fcbb45bcc1b,4,busulfan,1828,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240106_fe0ddd44-ef02-4827-b164-7fcbb45bcc1b.json,"These highlights do not include all the information needed to use BUSULFAN INJECTION safely and effectively. See full prescribing information for BUSULFAN INJECTION.
 



BUSULFAN Injection, for intravenous use
 

Initial U.S. Approval: 1999"
fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea,26,dabrafenib,1424911,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20230910_fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea.json,"These highlights do not include all the information needed to use TAFINLAR safely and effectively. See full prescribing information for TAFINLAR.
TAFINLAR® (dabrafenib) capsules, for oral useTAFINLAR® (dabrafenib) tablets for oral suspensionInitial U.S. Approval: 2013"
00aa81c2-73c7-4bf8-94e9-f644381b631f,4,esomeprazole,283742,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240119_00aa81c2-73c7-4bf8-94e9-f644381b631f.json,"These highlights do not include all the information needed to use ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES.
 

ESOMEPRAZOLE MAGNESIUM delayed-release capsules, for oral use
 

Initial U.S. Approval: 1989 (omeprazole)"
01f90c94-71cb-4a1f-81ff-8004b850529b,15,dapagliflozin,1488564,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20231213_01f90c94-71cb-4a1f-81ff-8004b850529b.json,"These highlights do not include all the information needed to use FARXIGA safely and effectively.  See full prescribing information for FARXIGA.
FARXIGA® (dapagliflozin) tablets, for oral useInitial U.S. Approval: 2014"
029a90b6-0722-49be-8400-3ec29526aafd,6,irbesartan,83818,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_029a90b6-0722-49be-8400-3ec29526aafd.json,"These highlights do not include all the information needed to use IRBESARTAN TABLETS safely and effectively. See full prescribing information for IRBESARTAN TABLETS.
 



IRBESARTAN tablets, for oral use
 

Initial U.S. Approval: 1997"
0366164b-1846-443d-9564-dbe52d8d9b65,11,topiramate,38404,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_0366164b-1846-443d-9564-dbe52d8d9b65.json,"These highlights do not include all the information needed to use TOPIRAMATE safely and effectively. See full prescribing information for TOPIRAMATE.
 

TOPIRAMATE tablets, for oral use
 
TOPIRAMATE capsules, for oral use
 
Initial U.S. Approval-1996"
03b39d40-90fe-11df-9de6-0002a5d5c51b,21,romidepsin,877510,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/gold_xml/20230603_03b39d40-90fe-11df-9de6-0002a5d5c51b.json,"These highlights do not include all the information needed to use ISTODAX safely and effectively.  See full prescribing information for ISTODAX.
ISTODAX® (romidepsin) for injection, for intravenous useInitial U.S. Approval:  2009"
04a413fe-95f4-47a7-42ac-283a9e78297d,20,ethionamide,4127,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231010_04a413fe-95f4-47a7-42ac-283a9e78297d.json,"Trecator®


 (ethionamide tablets, USP) 

Tablets"
08b7ee65-53a5-ffbb-e063-6294a90ad4ee,9,chlorthalidone,2409,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240119_08b7ee65-53a5-ffbb-e063-6294a90ad4ee.json,Chlorthalidone Tablets USP 25mg and 50mg
0c721ba4-ae19-417f-aae1-221ed1a0866a,29,epoetin alfa,105694,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231102_0c721ba4-ae19-417f-aae1-221ed1a0866a.json,"These highlights do not include all the information needed to use PROCRIT safely and effectively. See full prescribing information for PROCRIT.
 

PROCRIT 
 ®(epoetin alfa) injection, for intravenous or subcutaneous use
 
Initial U.S. Approval: 1989"
0fd36cb9-c4f6-4167-93c9-8530865db3f9,155,darbepoetin alfa,283838,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230629_0fd36cb9-c4f6-4167-93c9-8530865db3f9.json,"These highlights do not include all the information needed to use 
ARANESP 
safely and effectively.  
See full prescribing information for 
ARANESP
.

   

ARANESP

®

 (darbepoetin alfa
)
 
i
njection, for intravenous or subcutaneous use

Initial U.S. Approval: 2001"
106b33e3-b199-e555-e063-6294a90a5af5,1,diltiazem,3443,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240220_106b33e3-b199-e555-e063-6294a90a5af5.json,"Diltiazem Hydrochloride Tablets, USP


Tablets"
113558e6-8b45-cdbd-e063-6394a90ac036,2,etodolac,24605,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240220_113558e6-8b45-cdbd-e063-6394a90ac036.json,"Etodolac Tablets, USP
  
(400 mg and 500 mg) 
 

Rx only"
113558e6-8b45-cdbd-e063-6394a90ac036,2,etodolac,24605,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240220_113558e6-8b45-cdbd-e063-6394a90ac036.json,"Etodolac Tablets, USP
  
(400 mg and 500 mg) 
 

Rx only"
1149f69d-65df-6a98-e063-6394a90aeaa4,1,phentermine,8152,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240223_1149f69d-65df-6a98-e063-6394a90aeaa4.json,"These highlights do not include all the information needed to use Phentermine Hydrochloride Capsules USP safely and effectively. See full prescribing information for Phentermine Hydrochloride Capsules USP.
PHENTERMINE Hydrochloride Capsules USP C IVInitial U.S. Approval: 1959"
11fa3fc9-6776-49a6-b1c1-653f627c3e58,11,midostaurin,1919083,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230527_11fa3fc9-6776-49a6-b1c1-653f627c3e58.json,"These highlights do not include all the information needed to use RYDAPT safely and effectively. See full prescribing information for RYDAPT.
RYDAPT® (midostaurin) capsules, for oral useInitial U.S. Approval: 2017"
1b8a4689-3916-4f4b-b54a-bbb4e322d79b,13,atenolol,1202,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_1b8a4689-3916-4f4b-b54a-bbb4e322d79b.json,"Atenolol Tablets, USP Rx only"
1c90aa68-cc12-41ef-aebc-2616ae45683a,11,candesartan,214354,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240221_1c90aa68-cc12-41ef-aebc-2616ae45683a.json,"These highlights do not include all the information needed to use 

candesartan cilexetil 

 safely and effectively.  See full prescribing information for 

candesartan cilexetil 

.

Candesartan cilexetil tablets, for oral use
Initial U.S. Approval: 1998"
1c90aa68-cc12-41ef-aebc-2616ae45683a,11,candesartan,214354,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240221_1c90aa68-cc12-41ef-aebc-2616ae45683a.json,"These highlights do not include all the information needed to use 

candesartan cilexetil 

 safely and effectively.  See full prescribing information for 

candesartan cilexetil 

.

Candesartan cilexetil tablets, for oral use
Initial U.S. Approval: 1998"
2150f73a-179b-4afc-b8ce-67c85cc72f04,60,everolimus,141704,gi bleed,10018830,haematemesis,../data/2024_latest_labels/train_xml/20230802_2150f73a-179b-4afc-b8ce-67c85cc72f04.json,"These highlights do not include all the information needed to use AFINITOR/AFINITOR DISPERZ safely and effectively. See full prescribing information for AFINITOR/AFINITOR DISPERZ.


AFINITOR® (everolimus) tablets, for oral use

AFINITOR DISPERZ® (everolimus tablets for oral suspension)

Initial U.S. Approval: 2009"
2150f73a-179b-4afc-b8ce-67c85cc72f04,60,everolimus,141704,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/train_xml/20230802_2150f73a-179b-4afc-b8ce-67c85cc72f04.json,"These highlights do not include all the information needed to use AFINITOR/AFINITOR DISPERZ safely and effectively. See full prescribing information for AFINITOR/AFINITOR DISPERZ.


AFINITOR® (everolimus) tablets, for oral use

AFINITOR DISPERZ® (everolimus tablets for oral suspension)

Initial U.S. Approval: 2009"
22174520-4b78-4841-96f7-530ba12d2cf1,8,paroxetine,32937,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240217_22174520-4b78-4841-96f7-530ba12d2cf1.json,"Paroxetine Tablets USP, film coated for oral use"
294b168b-6e5f-4db9-bf70-d599271458b3,6,goserelin,50610,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20230325_294b168b-6e5f-4db9-bf70-d599271458b3.json,These highlights do not include all the information needed to use ZOLADEX safely and effectively. See full prescribing information for ZOLADEX.ZOLADEX® (goserelin implant) 3.6 mgInitial U.S. Approval: 1989
2b25ef01-5c9e-11e1-b86c-0800200c9a66,24,pomalidomide,1369713,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20230411_2b25ef01-5c9e-11e1-b86c-0800200c9a66.json,"These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST.
 POMALYST® (pomalidomide) capsules, for oral use Initial U.S. Approval:  2013"
2b705cb6-cb75-4c2a-907a-4bd45d18bc2c,18,metoprolol,6918,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_2b705cb6-cb75-4c2a-907a-4bd45d18bc2c.json,"These highlights do not include all the information needed to use METOPROLOL TARTRATE TABLETS safely and effectively. See full prescribing information for METOPROLOL TARTRATE TABLETS.
 METOPROLOL TARTRATE tablets, for oral use Initial U.S. Approval: 1992"
2b705cb6-cb75-4c2a-907a-4bd45d18bc2c,18,metoprolol,6918,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_2b705cb6-cb75-4c2a-907a-4bd45d18bc2c.json,"These highlights do not include all the information needed to use METOPROLOL TARTRATE TABLETS safely and effectively. See full prescribing information for METOPROLOL TARTRATE TABLETS.
 METOPROLOL TARTRATE tablets, for oral use Initial U.S. Approval: 1992"
32d632f6-e7cc-455e-bd9a-3dcfc99a794f,1,desvenlafaxine,734064,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20121026_32d632f6-e7cc-455e-bd9a-3dcfc99a794f.json,"These highlights do not include all the information needed to use PRISTIQ safely and effectively. See full prescribing information for PRISTIQ.
PRISTIQ® (desvenlafaxine) Extended-Release Tablets, oralInitial U.S. Approval: 2008"
35addab5-09db-4f8a-9c69-6fbce33ecc37,5,ganciclovir,4678,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230115_35addab5-09db-4f8a-9c69-6fbce33ecc37.json,"These highlights do not include all the information needed to use GANCICLOVIR FOR INJECTION safely and effectively. See full prescribing information for GANCICLOVIR FOR INJECTION.GANCICLOVIR FOR INJECTION, for intravenous useInitial U.S. Approval: 1989Rx only"
3c52dddd-0457-41cd-99e0-d30d4fd00ec5,4,maraviroc,620216,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231111_3c52dddd-0457-41cd-99e0-d30d4fd00ec5.json,"These highlights do not include all the information needed to use SELZENTRY safely and effectively. See full prescribing information for SELZENTRY.
SELZENTRY (maraviroc) tablets, for oral useSELZENTRY (maraviroc) oral solutionInitial U.S. Approval: 2007"
4031017d-d768-46de-8081-476bcb883f5e,5,gemcitabine,12574,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230912_4031017d-d768-46de-8081-476bcb883f5e.json,"These highlights do not include all the information needed to use GEMCITABINE INJECTION safely and effectively. See full prescribing information for GEMCITABINE INJECTION.
 



GEMCITABINE injection, for intravenous use
 

Initial U.S. Approval: 1996"
42f49299-7ae5-4d30-86eb-66b739c0e95d,5,lisinopril,29046,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240224_42f49299-7ae5-4d30-86eb-66b739c0e95d.json,"These highlights do not include all the information needed to use LISINOPRIL TABLETS safely and effectively. See full prescribing information for LISINOPRIL TABLETS
 



LISINOPRIL tablets, for oral use
 



Initial U.S. Approval: 1988"
4442f029-dd5e-4834-9b01-eb8c638ce4b1,100,nortriptyline,7531,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240223_4442f029-dd5e-4834-9b01-eb8c638ce4b1.json,"Nortriptyline Hydrochloride Capsules, USP"
48ffeac8-38e8-4007-903a-dbffce25d679,2,etravirine,475969,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240110_48ffeac8-38e8-4007-903a-dbffce25d679.json,"These highlights do not include all the information needed to use ETRAVIRINE TABLETS safely and effectively.See full prescribing information for ETRAVIRINE TABLETS.
ETRAVIRINE tablets, for oral useInitial U.S. Approval: 2008"
4f9bd52a-99a7-4606-92b4-456a917aabef,13,ticagrelor,1116632,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240214_4f9bd52a-99a7-4606-92b4-456a917aabef.json,"These highlights do not include all the information needed to use BRILINTA safely and effectively. See full prescribing information for BRILINTA.
BRILINTA® (ticagrelor) tablets, for oral useInitial U.S. Approval: 2011"
53486382-eee0-4cbe-bc4a-a57484e0d5a7,104,cilostazol,21107,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240113_53486382-eee0-4cbe-bc4a-a57484e0d5a7.json,"These highlights do not include all the information needed to use CILOSTAZOL TABLETS safely and effectively. See full prescribing information for CILOSTAZOL TABLETS.CILOSTAZOL tablets, for oral useInitial U.S. Approval: 1999"
53486382-eee0-4cbe-bc4a-a57484e0d5a7,104,cilostazol,21107,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240113_53486382-eee0-4cbe-bc4a-a57484e0d5a7.json,"These highlights do not include all the information needed to use CILOSTAZOL TABLETS safely and effectively. See full prescribing information for CILOSTAZOL TABLETS.CILOSTAZOL tablets, for oral useInitial U.S. Approval: 1999"
56370be6-42a2-4962-acdc-22b7c6e0e7fe,8,ziprasidone,115698,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240224_56370be6-42a2-4962-acdc-22b7c6e0e7fe.json,"These highlights do not include all the information needed to use ZIPRASIDONE CAPSULES safely and effectively. See full prescribing information for ZIPRASIDONE CAPSULES.


ZIPRASIDONE capsules, for oral use

Initial U.S. Approval: 2001"
57f8aac6-3bd3-4ae1-aab2-759c8bc23292,4,trandolapril,38454,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231111_57f8aac6-3bd3-4ae1-aab2-759c8bc23292.json,Trandolapril Tablets USP Rx only
5c40e41f-6401-4bda-975c-e1fac69867e9,12,isoniazid,6038,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240104_5c40e41f-6401-4bda-975c-e1fac69867e9.json,"Isoniazid Tablets, USP"
5cd725a1-2fa4-408a-a651-57a7b84b2118,18,avelumab,1875534,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240131_5cd725a1-2fa4-408a-a651-57a7b84b2118.json,"These highlights do not include all the information needed to use BAVENCIO safely and effectively. See full prescribing information for BAVENCIO.
 BAVENCIO® (avelumab) injection, for intravenous use Initial U.S. Approval: 2017"
64b7df84-c990-49f7-bc04-0cccfd7d2019,14,tramadol,10689,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_64b7df84-c990-49f7-bc04-0cccfd7d2019.json,"These highlights do not include all the information needed to use TRAMADOL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for TRAMADOL HYDROCHLORIDE TABLETS.
 



TRAMADOL HYDROCHLORIDE tablets, for oral use, C-IV
 

Initial U.S. Approval: 1995"
6fa380c4-c885-4743-85bf-88819ae68645,8,almotriptan,279645,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230414_6fa380c4-c885-4743-85bf-88819ae68645.json,"These highlights do not include all the information needed to use ALMOTRIPTAN TABLETS safely and effectively. See full prescribing information for ALMOTRIPTAN TABLETS.   ALMOTRIPTAN tablets, for oral use Initial U.S. Approval: 2001"
722ce9eb-8f7b-4651-a287-d53dd7ab3707,21,acarbose,16681,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240207_722ce9eb-8f7b-4651-a287-d53dd7ab3707.json,"Acarbose Tablets, USP"
72d1a024-00b7-418a-b36e-b2cb48f2ab55,6,dotatate,1797118,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230315_72d1a024-00b7-418a-b36e-b2cb48f2ab55.json,"These highlights do not include all the information needed to use LUTATHERA safely and effectively. See full prescribing information for LUTATHERA.
		

		LUTATHERA® (lutetium Lu 177 dotatate) injection, for intravenous use
		
		Initial U.S. Approval: 2018"
76e1839b-7462-4344-b319-001a5f57d67a,12,pantoprazole,40790,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_76e1839b-7462-4344-b319-001a5f57d67a.json,"These highlights do not include all the information needed to use PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS.
 

PANTOPRAZOLE SODIUM delayed-release tablets, for oral use
 
Initial U.S. approval: 2000"
7714a0ed-34bb-46e6-a0a5-b363908b22c2,25,eltrombopag,711942,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240112_7714a0ed-34bb-46e6-a0a5-b363908b22c2.json,"These highlights do not include all the information needed to use PROMACTA safely and effectively. See full prescribing information for PROMACTA.
PROMACTA® (eltrombopag) tablets, for oral usePROMACTA® (eltrombopag) for oral suspensionInitial U.S. Approval: 2008"
7ee820e4-a479-4b7d-8730-101ac1f8015c,102,piroxicam,8356,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240113_7ee820e4-a479-4b7d-8730-101ac1f8015c.json,"These highlights do not include all the information needed to use PIROXICAM CAPSULES safely and effectively.  See full prescribing information for PIROXICAM CAPSULES.
PIROXICAM capsules, for oral useInitial U.S. Approval: 1982"
81d9e47e-ae81-4755-a5ee-546a038fadb4,7,mirtazapine,15996,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240224_81d9e47e-ae81-4755-a5ee-546a038fadb4.json,"These highlights do not include all the information needed to use MIRTAZAPINE TABLETS safely and effectively. See full prescribing information for MIRTAZAPINE TABLETS.
 

MIRTAZAPINE tablets, for oral use
 
Initial U.S. Approval: 1996"
83a504ef-cf92-467d-9ecf-d251194a3484,20,omacetaxine mepesuccinate,27100,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/gold_xml/20231129_83a504ef-cf92-467d-9ecf-d251194a3484.json,"These highlights do not include all the information needed to use SYNRIBO safely and effectively.  See full prescribing information for SYNRIBO. 
SYNRIBO® (omacetaxine mepesuccinate) for injection, for subcutaneous useInitial U.S. Approval: 2012"
8b365514-c859-ff93-e053-2a95a90ac698,4,leflunomide,27169,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240110_8b365514-c859-ff93-e053-2a95a90ac698.json,"LEFLUNOMIDE TABLETS
   

Rx Only
   

These highlights do not include all the information needed to use
   

See full prescribing information for
   

Initial U.S. Approval"
8baba4ea-2855-42fa-9bd9-5a7548d4cec3,24,durvalumab,1919503,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231223_8baba4ea-2855-42fa-9bd9-5a7548d4cec3.json,"These highlights do not include all the information needed to use IMFINZI safely and effectively.  See full prescribing information for IMFINZI.
IMFINZI® (durvalumab) injection, for intravenous useInitial U.S. Approval: 2017"
8d5f892b-e4f3-4a9e-9a91-95e2fca34144,9,canagliflozin,1373458,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20231216_8d5f892b-e4f3-4a9e-9a91-95e2fca34144.json,"These highlights do not include all the information needed to use INVOKANA safely and effectively. See full prescribing information for INVOKANA.
 

INVOKANA 
 ®(canagliflozin) tablets, for oral use
 
Initial U.S. Approval: 2013"
8d731e7e-3b04-49a2-a0f6-3779422174cc,11,tamoxifen,10324,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240201_8d731e7e-3b04-49a2-a0f6-3779422174cc.json,"Tamoxifen Citrate Tablets, USP


Rx 
O
nly"
9678a98e-4aab-4d87-b5e1-37c3109e378e,16,tizanidine,57258,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240221_9678a98e-4aab-4d87-b5e1-37c3109e378e.json,"These highlights do not include all the information needed to use TIZANIDINE Tablets, USP safely and effectively. See full prescribing information for TIZANIDINE Tablets, USP.TIZANIDINE (tizanidine hydrochloride) Tablets USP, for oral useInitial U.S. Approval:1996"
9678a98e-4aab-4d87-b5e1-37c3109e378e,16,tizanidine,57258,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240221_9678a98e-4aab-4d87-b5e1-37c3109e378e.json,"These highlights do not include all the information needed to use TIZANIDINE Tablets, USP safely and effectively. See full prescribing information for TIZANIDINE Tablets, USP.TIZANIDINE (tizanidine hydrochloride) Tablets USP, for oral useInitial U.S. Approval:1996"
9803db35-2600-4f42-80c1-43216fd1ba3d,4,acamprosate,82819,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20231107_9803db35-2600-4f42-80c1-43216fd1ba3d.json,"These highlights do not include all the information needed to use ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS.
ACAMPROSATE CALCIUM delayed-release tablets, for oral useInitial U.S. Approval: 2004"
9803db35-2600-4f42-80c1-43216fd1ba3d,4,acamprosate,82819,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231107_9803db35-2600-4f42-80c1-43216fd1ba3d.json,"These highlights do not include all the information needed to use ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS.
ACAMPROSATE CALCIUM delayed-release tablets, for oral useInitial U.S. Approval: 2004"
99e9d85a-ec8e-48d2-acd0-5dda3b741838,6,ceftriaxone,2193,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240214_99e9d85a-ec8e-48d2-acd0-5dda3b741838.json,"Ceftriaxone for Injection, USP


Rx Only"
9c44bd5b-4464-40a4-8933-8680950f00f2,29,adalimumab,327361,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240210_9c44bd5b-4464-40a4-8933-8680950f00f2.json,"These highlights do not include all the information needed to use AMJEVITA™ safely and effectively. See full prescribing information for AMJEVITA. 
 AMJEVITA (adalimumab-atto) injection, for subcutaneous use    Initial U.S. Approval: 2016 
 AMJEVITA (adalimumab-atto) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of AMJEVITA has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to HUMIRA® (adalimumab)."
9d88f915-13dd-5463-e053-2a95a90a09bf,3,enalaprilat,3829,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_9d88f915-13dd-5463-e053-2a95a90a09bf.json,ENALAPRILAT INJECTION 1.25mg/mL 1mL VIAL
a26cfa07-14a7-4468-8eed-3529f3d613f4,6,efavirenz,195085,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240105_a26cfa07-14a7-4468-8eed-3529f3d613f4.json,"These highlights do not include all the information needed to use EFAVIRENZ CAPSULES safely and effectively. See full prescribing information for EFAVIRENZ CAPSULES.
 EFAVIRENZ capsules for oral use Initial U.S. Approval: 1998"
a3087a39-f218-4f16-a1e7-17c39bb2eb69,5,hydroxocobalamin,5514,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240207_a3087a39-f218-4f16-a1e7-17c39bb2eb69.json,"HYDROXOCOBALAMIN INJECTION USP
Rx Only"
a586be28-96af-4fed-a13f-9b94fd4c7405,24,medroxyprogesterone,6691,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240227_a586be28-96af-4fed-a13f-9b94fd4c7405.json,"PROVERA®

 (medroxyprogesterone acetate tablets, USP)"
a6826aa3-fabb-4ff1-a7a3-cd4c34e3a330,4,clevidipine,233603,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20221118_a6826aa3-fabb-4ff1-a7a3-cd4c34e3a330.json,"These highlights do not include all the information needed to use Cleviprex safely and effectively. See full prescribing information for Cleviprex.
 



Cleviprex (clevidipine) injectable emulsion, for intravenous use
 

Initial U.S. Approval: 2008"
a99335d0-1e87-4180-bde3-cbb12bf91a52,1,dexmedetomidine,48937,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240215_a99335d0-1e87-4180-bde3-cbb12bf91a52.json,"These highlights do not include all the information needed to use DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION.
DEXMEDETOMIDINE HYDROCHLORIDE in 0.9% SODIUM CHLORIDE injection, for intravenous use
Initial U.S. Approval: 1999"
accf9569-4b57-4e83-a7db-4e890a75d1ba,23,mitoxantrone,7005,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20220420_accf9569-4b57-4e83-a7db-4e890a75d1ba.json,"MitoXANTRONE Injection, USP (concentrate)"
adc84ad5-a04d-4fee-9ba8-91f7abd928e3,29,bosutinib,1307619,acute liver injury,10024670,liver disorder,../data/2024_latest_labels/latest_labels_ingredients/20240102_adc84ad5-a04d-4fee-9ba8-91f7abd928e3.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. 
BOSULIF® (bosutinib) tablets, for oral useBOSULIF® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012"
adc84ad5-a04d-4fee-9ba8-91f7abd928e3,29,bosutinib,1307619,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240102_adc84ad5-a04d-4fee-9ba8-91f7abd928e3.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. 
BOSULIF® (bosutinib) tablets, for oral useBOSULIF® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012"
afad3051-9df2-4c54-9684-e8262a133af8,35,lurasidone,1040028,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/gold_xml/20230722_afad3051-9df2-4c54-9684-e8262a133af8.json,"These highlights do not include all the information needed to use LATUDA safely and effectively.  See full prescribing information for LATUDA.
LATUDA (lurasidone hydrochloride) tablets, for oral use Initial U.S. Approval: 2010"
b1274d78-1096-4ae3-8299-a2e94eaa0ea5,16,itraconazole,28031,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240223_b1274d78-1096-4ae3-8299-a2e94eaa0ea5.json,Itraconazole Capsules
b20b4e18-7a4b-4500-a08f-06c6dab0ee5b,10,alpelisib,2169285,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240124_b20b4e18-7a4b-4500-a08f-06c6dab0ee5b.json,"These highlights do not include all the information needed to use PIQRAY safely and effectively. See full prescribing information for PIQRAY.


PIQRAY® (alpelisib) tablets, for oral use

Initial U.S. Approval: 2019"
b6737b25-0c4f-4131-ba23-b0f2252a18ea,9,simvastatin,36567,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_b6737b25-0c4f-4131-ba23-b0f2252a18ea.json,"These highlights do not include all the information needed to use SIMVASTATIN TABLETS safely and effectively. See full prescribing information for SIMVASTATIN TABLETS.








SIMVASTATIN tablets, for oral use








Initial U.S. Approval:
1991"
be4bc0de-0fdc-4d46-8d25-be43c79e6a06,22,abemaciclib,1946825,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240104_be4bc0de-0fdc-4d46-8d25-be43c79e6a06.json,"These highlights do not include all the information needed to use VERZENIO safely and effectively. See full prescribing information for VERZENIO.
VERZENIO® (abemaciclib) tablets, for oral useInitial U.S. Approval: 2017"
bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac,4,deferasirox,614373,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240223_bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac.json,"These highlights do not include all the information needed to use DEFERASIROX TABLETS FOR ORAL SUSPENSION safely and effectively. See full prescribing information for DEFERASIROX TABLETS FOR ORAL SUSPENSION. 
DEFERASIROX tablets, for oral suspensionInitial U.S. Approval: 2005"
c2b21ad5-fa83-1fb6-e053-2a95a90a3d0f,3,famciclovir,68099,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240110_c2b21ad5-fa83-1fb6-e053-2a95a90a3d0f.json,"Famciclovir Tablets
 
Rx only
 

These highlights do not include all the information needed to use FAMCICLOVIR TABLETS safely and effectively. See full prescribing information for FAMCICLOVIR TABLETS.
 

Initial U.S. Approval: 1994"
c35e019d-ec34-4e61-9400-a7ae7913e025,3,erlotinib,337525,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20231011_c35e019d-ec34-4e61-9400-a7ae7913e025.json,"These highlights do not include all the information needed to use ERLOTINIB TABLETS safely and effectively. See full prescribing information for ERLOTINIB TABLETS.
ERLOTINIB tablets, for oral use Initial U.S. Approval: 2004"
c36132b2-3ec7-4c43-a25e-75cbdbe3d88d,5,cyclosporine,3008,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_c36132b2-3ec7-4c43-a25e-75cbdbe3d88d.json,"CYCLOSPORINE, MODIFIED - cyclosporine capsule, liquid filledRx only Prescribing Information"
c387579e-cee0-4334-bd1e-73f93ac1bde6,18,cobimetinib,1722365,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230613_c387579e-cee0-4334-bd1e-73f93ac1bde6.json,"These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information for COTELLIC.
COTELLIC®  (cobimetinib) tablets, for oral useInitial U.S. Approval: 2015"
c488fb7c-0a5b-487c-b452-996809d1cb99,65,methylnaltrexone,29899,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/gold_xml/20231213_c488fb7c-0a5b-487c-b452-996809d1cb99.json,"These highlights do not include all the information needed to use RELISTOR safely and effectively. See full prescribing information for RELISTOR.
 

RELISTOR 
 ®(methylnaltrexone bromide) tablets, for oral use
 
RELISTOR 
 ®(methylnaltrexone bromide) injection, for subcutaneous use
 
Initial U.S. Approval: 2008"
c82eb602-12e1-692b-d660-f8d5b5736b54,11,salmon calcitonin,36118,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231214_c82eb602-12e1-692b-d660-f8d5b5736b54.json,"These highlights do not include all the information needed to use CALCITONIN SALMON NASAL SPRAY safely and effectively. See full prescribing information for CALCITONIN SALMON NASAL SPRAY. 

CALCITONIN SALMON nasal sprayInitial U.S. Approval: 1975"
c94e51d9-beef-4b06-e053-2a95a90a754a,3,talc,10323,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230115_c94e51d9-beef-4b06-e053-2a95a90a754a.json,Steritalc
c9a1d0a8-581f-4f91-a2b8-f419192d0ebf,12,roflumilast,1091836,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/gold_xml/20220916_c9a1d0a8-581f-4f91-a2b8-f419192d0ebf.json,"These highlights do not include all the information needed to use DALIRESP safely and effectively. See full prescribing information for DALIRESP.
DALIRESP® (roflumilast) tabletsInitial U.S. Approval: 2011"
cdfbe0cd-eb15-45a1-ac17-531bcda21aec,11,obeticholic acid,1798288,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20221021_cdfbe0cd-eb15-45a1-ac17-531bcda21aec.json,"These highlights do not include all the information needed to use OCALIVA® safely and effectively.  See full prescribing information for OCALIVA. 
OCALIVA® (obeticholic acid) tablets, for oral use Initial U.S. Approval: 2016"
d77d40db-7f38-88eb-fd5d-4282f0642028,4,teriparatide,32915,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240131_d77d40db-7f38-88eb-fd5d-4282f0642028.json,"These highlights do not include all the information needed to use TERIPARATIDE INJECTION safely and effectively. See full prescribing information for TERIPARATIDE INJECTION.
TERIPARATIDE injection for subcutaneous useInitial U.S. Approval: 1987"
dbf738c4-3fac-4422-a9d8-51d9c83a8789,3,infliximab,191831,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240110_dbf738c4-3fac-4422-a9d8-51d9c83a8789.json,"These highlights do not include all the information needed to use RENFLEXIS® safely and effectively. See full prescribing information for RENFLEXIS. 
RENFLEXIS (infliximab-abda) for injection, for intravenous use Initial U.S. Approval: 2017 RENFLEXIS (infliximab-abda) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of RENFLEXIS has been demonstrated for the condition(s) of use (e.g. indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to REMICADE (infliximab)."
de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa,24,cabazitaxel,996051,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20230720_de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa.json,"These highlights do not include all the information needed to use JEVTANA safely and effectively. See full prescribing information for JEVTANA.
 JEVTANA® (cabazitaxel) injection, for intravenous use Initial U.S. Approval: 2010"
e0022c28-8cda-4f1e-bcf1-1f440d37ec4a,6,allogeneic processed thymus tissue,2626460,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231208_e0022c28-8cda-4f1e-bcf1-1f440d37ec4a.json,"These highlights do not include all the information needed to use RETHYMIC safely and effectively. See full prescribing information for RETHYMIC.


RETHYMIC (Allogeneic processed thymus tissue–agdc)
For surgical implantation
Initial U.S. Approval: 2021"
e55f3dc2-c754-4550-a2c0-c304471a8791,2,nitrofurantoin,7454,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240223_e55f3dc2-c754-4550-a2c0-c304471a8791.json,"Nitrofurantoin Capsules, USP (monohydrate/macrocrystals)

Rx Only"
ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,54,carfilzomib,1302966,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20221029_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.json,"These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. 
KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012"
f1a91500-a944-4cb8-b4a8-ae278bcf728d,4,mobocertinib,2570736,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230930_f1a91500-a944-4cb8-b4a8-ae278bcf728d.json,"These highlights do not include all the information needed to use EXKIVITY safely and effectively. See full prescribing information for EXKIVITY.
 EXKIVITY® (mobocertinib) capsules, for oral use Initial U.S. Approval: 2021"
f2feda53-54b9-4e40-8a01-9e7b45cb3d8c,9,arformoterol,304962,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240110_f2feda53-54b9-4e40-8a01-9e7b45cb3d8c.json,"These highlights do not include all the information needed to use ARFORMOTEROL TARTRATE INHALATION SOLUTION safely and effectively. See full prescribing information for ARFORMOTEROL TARTRATE INHALATION SOLUTION.
 ARFORMOTEROL TARTRATE inhalation solution Initial U.S. Approval: 2006"
02c91fba-9c47-43ef-ac78-e82369798834,16,estradiol,4083,acute liver injury,10023126,jaundice,../data/2024_latest_labels/train_xml/20231130_02c91fba-9c47-43ef-ac78-e82369798834.json,These highlights do not include all the information needed to use NATAZIA safely and effectively.  See full prescribing information for NATAZIA.NATAZIA (estradiol valerate and estradiol valerate/dienogest) tablets for oral useInitial U.S. Approval: 2010
03151cb5-d32b-4484-8f2a-8c5d24c7f6f1,10,glipizide,4821,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_03151cb5-d32b-4484-8f2a-8c5d24c7f6f1.json,"These highlights do not include all the information needed to use GLIPIZIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for GLIPIZIDE EXTENDED-RELEASE TABLETS.
 



GLIPIZIDE extended-release tablets, for oral use
 

Initial U.S. Approval: 1994"
068e6edd-a5fe-40d8-8dcf-ac82b78dced4,9,cefixime,25033,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240216_068e6edd-a5fe-40d8-8dcf-ac82b78dced4.json,"These highlights do not include all the information needed to use CEFIXIME FOR ORAL SUSPENSION safely and effectively. See full prescribing information for CEFIXIME FOR ORAL SUSPENSION.
 CEFIXIME for oral suspension Initial U.S. Approval: 1986"
068e6edd-a5fe-40d8-8dcf-ac82b78dced4,9,cefixime,25033,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240216_068e6edd-a5fe-40d8-8dcf-ac82b78dced4.json,"These highlights do not include all the information needed to use CEFIXIME FOR ORAL SUSPENSION safely and effectively. See full prescribing information for CEFIXIME FOR ORAL SUSPENSION.
 CEFIXIME for oral suspension Initial U.S. Approval: 1986"
06f442d6-071e-4081-b7f7-40f3b803ab3f,4,sorafenib,495881,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240219_06f442d6-071e-4081-b7f7-40f3b803ab3f.json,"These highlights do not include all the information needed to use SORAFENIB TABLETS safely and effectively.
 
See full prescribing information for SORAFENIB TABLETS.
 
Sorafenib tablets, for oral use
 
Initial U.S. Approval: 2005"
083a3282-254f-4042-b0eb-70f76a279f10,100,vardenafil,306674,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240127_083a3282-254f-4042-b0eb-70f76a279f10.json,"These highlights do not include all the information needed to use VARDENAFIL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for VARDENAFIL HYDROCHLORIDE TABLETS.
 



VARDENAFIL HYDROCHLORIDE tablets, for oral use
 

Initial U.S. Approval: 2003"
116f4f0d-66c5-49dd-e063-6394a90ab2b5,1,acyclovir,281,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_116f4f0d-66c5-49dd-e063-6394a90ab2b5.json,"Acyclovir Tablets, USP"
11fa3fc9-6776-49a6-b1c1-653f627c3e58,11,midostaurin,1919083,acute myocardial infarction,10000891,acute myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230527_11fa3fc9-6776-49a6-b1c1-653f627c3e58.json,"These highlights do not include all the information needed to use RYDAPT safely and effectively. See full prescribing information for RYDAPT.
RYDAPT® (midostaurin) capsules, for oral useInitial U.S. Approval: 2017"
14f80ad5-37cc-4672-9caa-2dd2f469af0a,2,febuxostat,73689,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240131_14f80ad5-37cc-4672-9caa-2dd2f469af0a.json,"These highlights do not include all the information needed to use FEBUXOSTAT TABLETS safely and effectively. See full prescribing information for FEBUXOSTAT TABLETS.
 
FEBUXOSTAT tablets, for oral use
 
Initial U.S. Approval: 2009"
1e87a81a-7084-4436-918b-a50451534307,11,pilocarpine,8328,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20231231_1e87a81a-7084-4436-918b-a50451534307.json,"These highlights do not include all the information needed to use PILOCARPINE HYDROCHLORIDE OPHTHALMIC SOLUTION safely and effectively. See full prescribing information for PILOCARPINE HYDROCHLORIDE OPHTHALMIC SOLUTION.  

PILOCARPINE
 hydrochloride ophthalmic solution 

Initial U.S. Approval: 1974"
201b0eb8-4a1e-4e22-ab4b-addb642710d6,6,dolasetron,68091,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231215_201b0eb8-4a1e-4e22-ab4b-addb642710d6.json,Anzemet
220a9b3c-c583-49e3-8bf0-d0c97dc9b829,102,lovastatin,6472,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240207_220a9b3c-c583-49e3-8bf0-d0c97dc9b829.json,"Lovastatin Tablet USP
 


Revision M"
222f77ff-d3f7-40f9-989c-e5902f44ef1e,10,rizatriptan,88014,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240222_222f77ff-d3f7-40f9-989c-e5902f44ef1e.json,"These highlights do not include all the information needed to use RIZATRIPTAN BENZOATE TABLETS safely and effectively. See full prescribing information for RIZATRIPTAN BENZOATE TABLETS.
 RIZATRIPTAN BENZOATE tablets, for oral use Initial U.S. Approval: 1998"
241f0b1e-8b95-470d-876f-bf1804daaf18,11,ixabepilone,337523,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230202_241f0b1e-8b95-470d-876f-bf1804daaf18.json,"These highlights do not include all the information needed to use IXEMPRA 
 ® safely and effectively. See full prescribing information for IXEMPRA 
 ®.
 



IXEMPRA 
 ® 
Kit (ixabepilone) for Injection, for intravenous infusion only
 



Initial U.S. Approval: 2007"
24815546-658b-4b01-ac11-de7fbd0ebd16,2,salsalate,36108,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240209_24815546-658b-4b01-ac11-de7fbd0ebd16.json,"Salsalate Tablets, USP 500 mg and 750 mg"
24ac0ee2-cd7b-4dda-a1bb-271e32331758,3,febuxostat,73689,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/train_xml/20191219_24ac0ee2-cd7b-4dda-a1bb-271e32331758.json,"These HIGHLIGHTS do not include all the information needed to use ULORIC safely and effectively. See full prescribing information for ULORIC. 
 ULORIC (febuxostat) tablet for oral use  Initial U.S. Approval: 2009"
24ac0ee2-cd7b-4dda-a1bb-271e32331758,3,febuxostat,73689,acute liver injury,10023126,jaundice,../data/2024_latest_labels/train_xml/20191219_24ac0ee2-cd7b-4dda-a1bb-271e32331758.json,"These HIGHLIGHTS do not include all the information needed to use ULORIC safely and effectively. See full prescribing information for ULORIC. 
 ULORIC (febuxostat) tablet for oral use  Initial U.S. Approval: 2009"
2b25ef01-5c9e-11e1-b86c-0800200c9a66,24,pomalidomide,1369713,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/gold_xml/20230411_2b25ef01-5c9e-11e1-b86c-0800200c9a66.json,"These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST.
 POMALYST® (pomalidomide) capsules, for oral use Initial U.S. Approval:  2013"
2b705cb6-cb75-4c2a-907a-4bd45d18bc2c,18,metoprolol,6918,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_2b705cb6-cb75-4c2a-907a-4bd45d18bc2c.json,"These highlights do not include all the information needed to use METOPROLOL TARTRATE TABLETS safely and effectively. See full prescribing information for METOPROLOL TARTRATE TABLETS.
 METOPROLOL TARTRATE tablets, for oral use Initial U.S. Approval: 1992"
2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,46,tocilizumab,612865,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230101_2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13.json,"These highlights do not include all the information needed to use ACTEMRA safely and effectively. See full prescribing information for ACTEMRA. 
 ACTEMRA® (tocilizumab) injection, for intravenous or subcutaneous use  Initial U.S. Approval: 2010"
3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac,9,mesalamine,52582,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240217_3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac.json,"Mesalamine Rectal Suspension Enema

4 grams/unit (60 mL)"
3fc03452-cbfb-48a2-a747-45b03399741c,8,canagliflozin,1373458,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231216_3fc03452-cbfb-48a2-a747-45b03399741c.json,"These highlights do not include all the information needed to use INVOKANA safely and effectively. See full prescribing information for INVOKANA.
 

INVOKANA 
 ®(canagliflozin) tablets, for oral use
 
Initial U.S. Approval: 2013"
4442f029-dd5e-4834-9b01-eb8c638ce4b1,100,nortriptyline,7531,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240223_4442f029-dd5e-4834-9b01-eb8c638ce4b1.json,"Nortriptyline Hydrochloride Capsules, USP"
48ffeac8-38e8-4007-903a-dbffce25d679,2,etravirine,475969,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240110_48ffeac8-38e8-4007-903a-dbffce25d679.json,"These highlights do not include all the information needed to use ETRAVIRINE TABLETS safely and effectively.See full prescribing information for ETRAVIRINE TABLETS.
ETRAVIRINE tablets, for oral useInitial U.S. Approval: 2008"
4be9cc3f-0016-4426-a700-574b45ce245b,10,rifabutin,55672,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231108_4be9cc3f-0016-4426-a700-574b45ce245b.json,"Rifabutin Capsules USP, 150 mg
Rx only"
5198b1c8-8dd6-4b8f-bd85-294ac468af53,10,fluvoxamine,42355,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_5198b1c8-8dd6-4b8f-bd85-294ac468af53.json,"These highlights do not include all the information needed to use FLUVOXAMINE MALEATE TABLETS safely and effectively. See full prescribing information for FLUVOXAMINE MALEATE TABLETS.
 

FLUVOXAMINE MALEATE tablets, for oral use
 
Initial U.S. Approval: 1994"
53bdb79c-c4cf-4818-b1f0-225e67a14536,24,clozapine,2626,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240209_53bdb79c-c4cf-4818-b1f0-225e67a14536.json,"These highlights do not include all the information needed to use CLOZAPINE TABLETS safely and effectively. See full prescribing information for CLOZAPINE TABLETS.
 
CLOZAPINE tablets, for oral use
 
Initial U.S. Approval: 1989"
57f8aac6-3bd3-4ae1-aab2-759c8bc23292,4,trandolapril,38454,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231111_57f8aac6-3bd3-4ae1-aab2-759c8bc23292.json,Trandolapril Tablets USP Rx only
58c4261e-e98f-4280-9562-2800956dff14,16,glimepiride,25789,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_58c4261e-e98f-4280-9562-2800956dff14.json,"These highlights do not include all the information needed to use GLIMEPIRIDE TABLETS safely and effectively. See full prescribing information for GLIMEPIRIDE TABLETS.
 

GLIMEPIRIDE tablets for oral use
 

Initial U.S. Approval: 1995"
6296e2ed-334c-b9af-e053-2991aa0aae0c,5,erythromycin,4053,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240214_6296e2ed-334c-b9af-e053-2991aa0aae0c.json,"Erythromycin Ophthalmic Ointment, USP 0.5% (Sterile)"
6370e342-16a5-4339-a13f-ba275fd5de09,103,clomiphene,2596,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240111_6370e342-16a5-4339-a13f-ba275fd5de09.json,Clomiphene Citrate Tablets
64b7df84-c990-49f7-bc04-0cccfd7d2019,14,tramadol,10689,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240217_64b7df84-c990-49f7-bc04-0cccfd7d2019.json,"These highlights do not include all the information needed to use TRAMADOL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for TRAMADOL HYDROCHLORIDE TABLETS.
 



TRAMADOL HYDROCHLORIDE tablets, for oral use, C-IV
 

Initial U.S. Approval: 1995"
6a9cbc29-9f15-4b24-8d86-206b82887f3d,24,etravirine,475969,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20230816_6a9cbc29-9f15-4b24-8d86-206b82887f3d.json,"These highlights do not include all the information needed to use INTELENCE safely and effectively. See full prescribing information for INTELENCE.
 





INTELENCE 
 ®(etravirine) tablets, for oral use
 

Initial U.S. Approval: 2008"
6fc9c8e2-6f34-aa43-e053-2a91aa0ac377,10,quetiapine,51272,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240221_6fc9c8e2-6f34-aa43-e053-2a91aa0ac377.json,"QUETIAPINE TABLETS. These highlights do not include all the information needed to use QUETIAPINE TABLETS safely and effectively. See full prescribing information for QUETIAPINE TABLETS.
 

Quetiapine tablets, for oral use
 

Initial U.S. Approval: 1997"
7036c6df-6527-4701-b484-6b962914b52a,7,tiagabine,31914,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240102_7036c6df-6527-4701-b484-6b962914b52a.json,Tiagabine Hydrochloride Tablets
7c295b64-ec39-42ec-9f02-da5b42e775e1,8,bicalutamide,83008,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240117_7c295b64-ec39-42ec-9f02-da5b42e775e1.json,"These highlights do not include all the information needed to use BICALUTAMIDE TABLETS safely and effectively. See full prescribing information for BICALUTAMIDE TABLETS.
 



BICALUTAMIDE TABLETS, for oral use
 



Initial U.S. Approval: 1995"
7df922bc-5750-4259-906f-64f960c38d5f,9,eszopiclone,461016,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_7df922bc-5750-4259-906f-64f960c38d5f.json,"These highlights do not include all the information needed to use ESZOPICLONE TABLETS safely and effectively. See full prescribing information for ESZOPICLONE TABLETS.
 



ESZOPICLONE tablets, for oral use, CIV
 

Initial U.S. Approval: 2004"
7ed4d986-2aa9-43cd-9a8a-fbd11cb5ecef,5,daptomycin,22299,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240223_7ed4d986-2aa9-43cd-9a8a-fbd11cb5ecef.json,"These highlights do not include all the information needed to use DAPTOMYCIN IN SODIUM CHLORIDE INJECTION safely and effectively.  See full prescribing information for DAPTOMYCIN IN SODIUM CHLORIDE INJECTION.
DAPTOMYCIN IN SODIUM CHLORIDE injection, for intravenous use
Initial U.S. Approval: 2003"
81a33cfa-262f-4432-a05d-7dd260928437,7,isopropyl alcohol,797541,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240130_81a33cfa-262f-4432-a05d-7dd260928437.json,"These highlights do not include all the information needed to use ABRILADA safely and effectively. See full prescribing information for ABRILADA.
ABRILADA™ (adalimumab-afzb) injection, for subcutaneous useInitial U.S. Approval: 2019
ABRILADA (adalimumab-afzb) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of ABRILADA has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to HUMIRA (adalimumab)."
84137882-e000-47da-bd5b-fa76ab3c76f9,20,axitinib,1242999,acute liver injury,10024670,liver disorder,../data/2024_latest_labels/train_xml/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012"
88441a9f-b4f9-455d-a355-46fb30699a7b,10,sulfasalazine,9524,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_88441a9f-b4f9-455d-a355-46fb30699a7b.json,"Sulfasalazine Tablets, USP"
8b365514-c859-ff93-e053-2a95a90ac698,4,leflunomide,27169,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240110_8b365514-c859-ff93-e053-2a95a90ac698.json,"LEFLUNOMIDE TABLETS
   

Rx Only
   

These highlights do not include all the information needed to use
   

See full prescribing information for
   

Initial U.S. Approval"
9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f,6,ketoprofen,6142,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240206_9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f.json,KIPROFEN™ Capsules
9c9d9f5c-bfd1-4e2a-be4a-697344ca6833,11,citalopram,2556,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_9c9d9f5c-bfd1-4e2a-be4a-697344ca6833.json,"These highlights do not include all the information needed to use citalopram tablets safely and effectively. See full prescribing information for citalopram tablets.
 


CITALOPRAM (Citalopram) tablets, for oral use
 


Initial U.S. Approval: 1998"
9e1f2222-1d89-4e63-989c-ccebe2ab1eb4,11,pemigatinib,2359268,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230615_9e1f2222-1d89-4e63-989c-ccebe2ab1eb4.json,"These highlights do not include all the information needed to use PEMAZYRE safely and effectively. See full prescribing information for PEMAZYRE.


PEMAZYRE® (pemigatinib) tablets, for oral use

Initial U.S. Approval: 
2020"
a0478684-e477-4b52-97a9-04a76e794c87,5,romidepsin,877510,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230627_a0478684-e477-4b52-97a9-04a76e794c87.json,"These highlights do not include all the information needed to use ROMIDEPSIN INJECTION safely and effectively. See full prescribing information for ROMIDEPSIN INJECTION.




ROMIDEPSIN injection, for intravenous use

Initial U.S. Approval: 2009"
a6826aa3-fabb-4ff1-a7a3-cd4c34e3a330,4,clevidipine,233603,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20221118_a6826aa3-fabb-4ff1-a7a3-cd4c34e3a330.json,"These highlights do not include all the information needed to use Cleviprex safely and effectively. See full prescribing information for Cleviprex.
 



Cleviprex (clevidipine) injectable emulsion, for intravenous use
 

Initial U.S. Approval: 2008"
b023a9f2-1a99-4b40-a953-edac7e3a79bf,15,anastrozole,84857,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240220_b023a9f2-1a99-4b40-a953-edac7e3a79bf.json,"These highlights do not include all the information needed to use anastrozole tablets safely and effectively. See full prescribing information for anastrozole tablets.
 

ANASTROZOLE tablet for oral use
 

Initial U.S. Approval: 1995"
b4c2c9dc-a0bb-4d64-a667-a67ebe88392d,37,certolizumab pegol,709271,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/train_xml/20230105_b4c2c9dc-a0bb-4d64-a667-a67ebe88392d.json,"These highlights do not include all the information needed to use CIMZIA® safely and effectively. See full prescribing information for CIMZIA.
 



CIMZIA (certolizumab pegol) for injection, for subcutaneous use
 

CIMZIA (certolizumab pegol) injection, for subcutaneous use
 

Initial U.S. Approval: 2008"
bcb387ac-2e90-4f5e-94b2-d3635190678e,9,miltefosine,1494066,acute liver injury,10023126,jaundice,../data/2024_latest_labels/gold_xml/20231018_bcb387ac-2e90-4f5e-94b2-d3635190678e.json,"These highlights do not include all the information needed to use IMPAVIDO safely and effectively.  See full prescribing information for IMPAVIDO.
IMPAVIDO (miltefosine) capsules, for oral useInitial U.S. Approval: 2014"
bda70104-d84b-4d3f-9ca0-5f4f1ca816ad,13,voriconazole,121243,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240215_bda70104-d84b-4d3f-9ca0-5f4f1ca816ad.json,"These highlights do not include all the information needed to use VORICONAZOLE TABLETS safely and effectively. See full prescribing information for VORICONAZOLE TABLETS.VORICONAZOLE tablets, for oral useInitial U.S. Approval: 2002"
c00d1607-ac36-457b-a34b-75ad74f9cf0a,32,saquinavir,83395,acute liver injury,10024670,liver disorder,../data/2024_latest_labels/latest_labels_ingredients/20210630_c00d1607-ac36-457b-a34b-75ad74f9cf0a.json,"These highlights do not include all the information needed to use INVIRASE safely and effectively. See full prescribing information for INVIRASE. 
INVIRASE® (saquinavir mesylate) tablets, for oral use
 Initial U.S. Approval: 1995"
c01906fa-2c73-4c13-9765-2fd06628d263,26,lincomycin,6398,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231108_c01906fa-2c73-4c13-9765-2fd06628d263.json,"Lincocin®


 lincomycin injection, USP"
c16ac648-d5d2-9f7d-8637-e2328572754e,15,belatacept,1112973,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20230125_c16ac648-d5d2-9f7d-8637-e2328572754e.json,"These highlights do not include all the information needed to use NULOJIX safely and effectively. See full prescribing information for NULOJIX.
NULOJIX (belatacept) for injection, for intravenous useInitial U.S. Approval: 2011"
c732b415-e1f9-478f-896d-1dc8b6362da4,9,ethambutol,4110,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240124_c732b415-e1f9-478f-896d-1dc8b6362da4.json,ETHAMBUTOL HYDROCHLORIDE TABLETS USP
c8b58efa-1820-48a4-b70d-62918fc4abfc,6,irinotecan,51499,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240217_c8b58efa-1820-48a4-b70d-62918fc4abfc.json,"These highlights do not include all the information needed to use ONIVYDE® safely and effectively. See full prescribing information for ONIVYDE®
 ONIVYDE® (irinotecan liposome injection), for intravenous use Initial U.S. Approval: 1996"
cd86ee78-2781-468b-930c-3c4677bcc092,25,vorinostat,194337,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231129_cd86ee78-2781-468b-930c-3c4677bcc092.json,"These highlights do not include all the information needed to use ZOLINZA safely and effectively. See full prescribing information for ZOLINZA. 
ZOLINZA® (vorinostat capsules, for oral use) Initial U.S. Approval: 2006"
ce9f0ea6-69f9-6b68-2811-3b51e34acea6,5,carboprost,2051,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240112_ce9f0ea6-69f9-6b68-2811-3b51e34acea6.json,""
cee5b232-0464-4697-93ef-77e044c83776,8,clopidogrel,32968,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240222_cee5b232-0464-4697-93ef-77e044c83776.json,"These highlights do not include all the information needed to use CLOPIDOGREL TABLETS safely and effectively. See full prescribing information for CLOPIDOGREL TABLETS.
 



CLOPIDOGREL tablets, for oral use
 



Initial U.S. Approval: 1997"
cf94c7fc-13a0-4ac9-bb85-9c38aa704d35,5,ferumoxytol,473387,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20230803_cf94c7fc-13a0-4ac9-bb85-9c38aa704d35.json,"These highlights do not include all the information needed to use FERUMOXYTOL INJECTION safely and effectively. See full prescribing information for FERUMOXYTOL INJECTION. 
	FERUMOXYTOL injection, for intravenous use 	Initial U.S. Approval: 2009"
d1cda4f7-cb33-46ea-b9ac-431f6452b1a5,23,apalutamide,1999574,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240118_d1cda4f7-cb33-46ea-b9ac-431f6452b1a5.json,"These highlights do not include all the information needed to use ERLEADA safely and effectively. See full prescribing information for ERLEADA.
 



ERLEADA 
 ®(apalutamide) tablets, for oral use
 

Initial U.S. Approval – 2018"
d1f64796-6ba0-415c-a6a0-5456b21a7ed6,5,fenofibrate,8703,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240221_d1f64796-6ba0-415c-a6a0-5456b21a7ed6.json,"These highlights do not include all the information needed to use FENOFIBRATE TABLETS safely and effectively. See full prescribing information for FENOFIBRATE TABLETS.
 
FENOFIBRATE tablets, for oral use
 
Initial U.S. Approval: 1993"
da1c9f37-779e-4682-816f-93d0faa4cfc9,16,nintedanib,1592737,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20221103_da1c9f37-779e-4682-816f-93d0faa4cfc9.json,"These highlights do not include all the information needed to use OFEV safely and effectively. See full prescribing information for OFEV. 
OFEV® (nintedanib capsules), for oral use Initial U.S. Approval: 2014"
dd47a015-ff90-d7a7-8dcb-4e6e31a68071,1,dabigatran etexilate,1037042,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240214_dd47a015-ff90-d7a7-8dcb-4e6e31a68071.json,"These highlights do not include all the information needed to use DABIGATRAN 
ETEXILATE CAPSULES
 safely and effectively. See full prescribing information for 
DABIGATRAN
 ETEXILATE CAPSULES.


DABIGATRAN E
TEXILATE capsules, for oral use 

Initial U.S. Approval: 2010"
e2e576e6-6181-4178-b989-61d0e795e559,13,sitagliptin,593411,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240202_e2e576e6-6181-4178-b989-61d0e795e559.json,"These highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA. 
JANUVIA® (sitagliptin) tablets, for oral useInitial U.S. Approval: 2006"
ed23b6bc-32c7-4c50-a53d-313ae78e5623,13,cefotaxime,2186,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20210804_ed23b6bc-32c7-4c50-a53d-313ae78e5623.json,"CEFOTAXIME FOR INJECTION, USP"
f057cf4d-b06f-4fbd-aa2e-68c5e4d8a846,3,deferiprone,11645,acute liver injury,10023126,jaundice,../data/2024_latest_labels/train_xml/20211210_f057cf4d-b06f-4fbd-aa2e-68c5e4d8a846.json,"These highlights do not include all the information needed to use FERRIPROX Oral Solution safely and effectively. See full prescribing information for FERRIPROX Oral Solution.FERRIPROX® (deferiprone) oral solution, for oral useInitial U.S. Approval: 2011"
f0cd76e9-460c-450e-b094-172e636f340a,7,mitotane,7004,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240123_f0cd76e9-460c-450e-b094-172e636f340a.json,"These highlights do not include all the information needed to use LYSODREN safely and effectively. See full prescribing information for LYSODREN.
 LYSODREN® (mitotane) tablets, for oral use Initial U.S. Approval: 1970"
fea50328-b3d5-4300-8c67-82cda0a975b7,6,triamterene,10763,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231208_fea50328-b3d5-4300-8c67-82cda0a975b7.json,"Triamterene Capsule, USP Potassium-Sparing Diuretic"
fedfd1db-7e32-44b2-89e9-7bb00ee6810d,24,sevoflurane,36453,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240131_fedfd1db-7e32-44b2-89e9-7bb00ee6810d.json,"Sojourn®
 
Sevoflurane, USP
 
Volatile Liquid for Inhalation"
03a58215-dba7-4f63-8b98-d74d054a574a,6,frovatriptan,228783,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240104_03a58215-dba7-4f63-8b98-d74d054a574a.json,"These highlights do not include all the information needed to use FROVATRIPTAN SUCCINATE TABLETS safely and effectively. See full prescribing information for FROVATRIPTAN SUCCINATE TABLETS.
FROVATRIPTAN SUCCINATE tablets, for oral useInitial U.S. Approval:  2001"
0653b873-b74b-4ec6-b112-675760703d91,3,nabumetone,31448,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240214_0653b873-b74b-4ec6-b112-675760703d91.json,"Nabumetone Tablets, USP

Rx only

8463021/1223F"
068e6edd-a5fe-40d8-8dcf-ac82b78dced4,9,cefixime,25033,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240216_068e6edd-a5fe-40d8-8dcf-ac82b78dced4.json,"These highlights do not include all the information needed to use CEFIXIME FOR ORAL SUSPENSION safely and effectively. See full prescribing information for CEFIXIME FOR ORAL SUSPENSION.
 CEFIXIME for oral suspension Initial U.S. Approval: 1986"
077a92f6-9f1b-479a-87c7-c92b5db6aa9c,10,relugolix,2472778,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240125_077a92f6-9f1b-479a-87c7-c92b5db6aa9c.json,"These highlights do not include all the information needed to use ORGOVYX safely and effectively. See full prescribing information for ORGOVYX.
 



ORGOVYX (relugolix) tablets, for oral use
 

Initial U.S. Approval: 2020"
09c6c750-ae05-459f-83e8-4a9e4fd85212,28,atorvastatin,83367,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_09c6c750-ae05-459f-83e8-4a9e4fd85212.json,"These highlights do not include all the information needed to use ATORVASTATIN CALCIUM TABLETS safely and effectively. See full prescribing information for ATORVASTATIN CALCIUM TABLETS.
 

ATORVASTATIN CALCIUM tablets, for oral use
 

Initial U.S. Approval: 1996"
10a3fbc9-00c6-ad83-e063-6294a90ae1ad,1,omeprazole,7646,acute liver injury,10019660,hepatic encephalopathy,../data/2024_latest_labels/latest_labels_ingredients/20240220_10a3fbc9-00c6-ad83-e063-6294a90ae1ad.json,"These highlights do not include all the information needed to use OMEPRAZOLE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for OMEPRAZOLE DELAYED-RELEASE CAPSULES.
 

OMEPRAZOLE delayed-release capsules, for oral use
 
Initial U.S. Approval: 1989"
14f80ad5-37cc-4672-9caa-2dd2f469af0a,2,febuxostat,73689,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240131_14f80ad5-37cc-4672-9caa-2dd2f469af0a.json,"These highlights do not include all the information needed to use FEBUXOSTAT TABLETS safely and effectively. See full prescribing information for FEBUXOSTAT TABLETS.
 
FEBUXOSTAT tablets, for oral use
 
Initial U.S. Approval: 2009"
14f80ad5-37cc-4672-9caa-2dd2f469af0a,2,febuxostat,73689,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240131_14f80ad5-37cc-4672-9caa-2dd2f469af0a.json,"These highlights do not include all the information needed to use FEBUXOSTAT TABLETS safely and effectively. See full prescribing information for FEBUXOSTAT TABLETS.
 
FEBUXOSTAT tablets, for oral use
 
Initial U.S. Approval: 2009"
14f80ad5-37cc-4672-9caa-2dd2f469af0a,2,febuxostat,73689,acute liver injury,10024670,liver disorder,../data/2024_latest_labels/latest_labels_ingredients/20240131_14f80ad5-37cc-4672-9caa-2dd2f469af0a.json,"These highlights do not include all the information needed to use FEBUXOSTAT TABLETS safely and effectively. See full prescribing information for FEBUXOSTAT TABLETS.
 
FEBUXOSTAT tablets, for oral use
 
Initial U.S. Approval: 2009"
220a9b3c-c583-49e3-8bf0-d0c97dc9b829,102,lovastatin,6472,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240207_220a9b3c-c583-49e3-8bf0-d0c97dc9b829.json,"Lovastatin Tablet USP
 


Revision M"
246e0ed0-f8ca-483b-a1ce-91052f3f35f0,9,enalapril,3827,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240224_246e0ed0-f8ca-483b-a1ce-91052f3f35f0.json,"Enalapril Maleate Tablets, USP"
246e0ed0-f8ca-483b-a1ce-91052f3f35f0,9,enalapril,3827,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_246e0ed0-f8ca-483b-a1ce-91052f3f35f0.json,"Enalapril Maleate Tablets, USP"
27f15fac-7d98-4114-a2ec-92494a91da98,8,semaglutide,1991302,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240208_27f15fac-7d98-4114-a2ec-92494a91da98.json,"These highlights do not include all the information needed to use RYBELSUS®
 safely and effectively.  See full prescribing information for RYBELSUS.
RYBELSUS (semaglutide) tablets, for oral use
Initial U.S. Approval: 2017"
2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,46,tocilizumab,612865,acute liver injury,10023126,jaundice,../data/2024_latest_labels/gold_xml/20230101_2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13.json,"These highlights do not include all the information needed to use ACTEMRA safely and effectively. See full prescribing information for ACTEMRA. 
 ACTEMRA® (tocilizumab) injection, for intravenous or subcutaneous use  Initial U.S. Approval: 2010"
304a3059-4f7f-4ec4-839d-86492bb5e07b,6,memantine,6719,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240221_304a3059-4f7f-4ec4-839d-86492bb5e07b.json,"These highlights do not include all the information needed to use MEMANTINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for MEMANTINE HYDROCHLORIDE TABLETS.
 
MEMANTINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 2003"
36377351-d208-4363-8826-0acfea3f0cc1,5,sodium ferric gluconate complex,261435,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20230609_36377351-d208-4363-8826-0acfea3f0cc1.json,"These highlights do not include all the information needed to use sodium ferric gluconate complex in sucrose injection safely and effectively. See full prescribing information for sodium ferric gluconate complex in sucrose injection.
Sodium ferric gluconate complex in sucrose injection, for intravenous use 
Initial U.S. Approval: 1999"
37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,45,mycophenolate mofetil,68149,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240224_37241e87-4af4-4dc3-a1aa-ea6f20d8dc40.json,"These highlights do not include all the information needed to use CELLCEPT® safely and effectively. See full prescribing information for CELLCEPT® 
CELLCEPT® (mycophenolate mofetil) capsules, for oral use CELLCEPT® (mycophenolate mofetil) tablets, for oral use CELLCEPT®  Oral Suspension (mycophenolate mofetil), for oral suspension CELLCEPT®  Intravenous (mycophenolate mofetil) for injection, for intravenous use Initial U.S. Approval: 1995"
38f5341f-5ae3-46bf-8bfc-30dff2068477,102,alosetron,85248,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240112_38f5341f-5ae3-46bf-8bfc-30dff2068477.json,"These highlights do not include all the information needed to use ALOSETRON TABLETS safely and effectively. See full prescribing information for ALOSETRON TABLETS. 
ALOSETRON tablets, for oral use   Initial U.S. Approval: 2000"
458e043d-6584-4503-b398-2032d3cce2f1,22,clindamycin,2582,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240217_458e043d-6584-4503-b398-2032d3cce2f1.json,"Clindamycin Injection, USP"
4c486fc7-c8c4-4c6c-b30c-366dabaeaadd,14,gabapentin,25480,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20230830_4c486fc7-c8c4-4c6c-b30c-366dabaeaadd.json,"These highlights do not include all the information needed to use HORIZANT safely and effectively. See full prescribing information for HORIZANT. 
HORIZANT® (gabapentin enacarbil) Extended-Release Tablets for oral use Initial U.S. Approval: 2011"
4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213,6,cyclophosphamide,3002,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240113_4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213.json,"""These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE CAPSULES safely and effectively"". ""See full prescribing information for CYCLOPHOSPHAMIDE CAPSULES.""
 



""CYCLOPHOSPHAMIDE capsules""
 

""Initial U.S. Approval: 1959"""
51cdb22b-035f-47d7-8048-38006e2589f2,20,nifedipine,7417,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240217_51cdb22b-035f-47d7-8048-38006e2589f2.json,Rx only
52fea941-0b47-41c1-b00d-f88150e8ab93,13,thioridazine,10502,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20211217_52fea941-0b47-41c1-b00d-f88150e8ab93.json,WARNING
5451bcaa-0aca-4581-bcea-2f9c2a33b260,20,oxycodone,7804,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_5451bcaa-0aca-4581-bcea-2f9c2a33b260.json,"These highlights do not include all the information needed to use OXYCODONE HYDROCHLORIDE ORAL SOLUTION safely and effectively. See full prescribing information for OXYCODONE HYDROCHLORIDE ORAL SOLUTION.
OXYCODONE HYDROCHLORIDE oral solution, CIIInitial U.S. Approval: 1950"
55ae23ff-60f5-4de6-bd1b-472243b8636b,8,pioglitazone,33738,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_55ae23ff-60f5-4de6-bd1b-472243b8636b.json,"These highlights do not include all the information needed to use PIOGLITAZONE TABLETS safely and effectively. See full prescribing information for PIOGLITAZONE TABLETS
 







PIOGLITAZONE tablets, for oral use
 



Initial U.S. Approval: 1999"
56b6ba36-9b49-4422-a2a4-7bfa0d941a5d,2,flutamide,4508,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20220115_56b6ba36-9b49-4422-a2a4-7bfa0d941a5d.json,EULEXINTM (flutamide) CAPSULES USP
56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec,10,pramipexole,746741,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240222_56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec.json,"These highlights do not include all the information needed to use PRAMIPEXOLE DIHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for PRAMIPEXOLE DIHYDROCHLORIDE TABLETS.
 PRAMIPEXOLE DIHYDROCHLORIDE tablets, for oral use Initial U.S. Approval: 1997"
68aaacbe-98c5-450b-9bf4-4809d7ad2ca0,18,latanoprost,43611,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240113_68aaacbe-98c5-450b-9bf4-4809d7ad2ca0.json,"These highlights do not include all the information needed to use LATANOPROST OPHTHALMIC SOLUTION safely and effectively.  See full prescribing information for LATANOPROST OPHTHALMIC SOLUTION.
LATANOPROST ophthalmic solution 0.005%, for topical ophthalmic useInitial U.S. Approval: 1996"
69301126-c901-4d0d-9acb-91ba1a87cd21,26,valacyclovir,73645,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_69301126-c901-4d0d-9acb-91ba1a87cd21.json,"HIGHLIGHTS OF PRESCRIBING INFORMATION
 

These highlights do not include all the information needed to use valacyclovir hydrochloride safely and effectively. See full prescribing information for valacyclovir hydrochloride.
 

Valacyclovir Tablets, USP
 

Initial U.S. Approval:1995"
6c5c47ab-28ee-11e1-bfc2-0800200c9a66,19,estradiol,4083,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_6c5c47ab-28ee-11e1-bfc2-0800200c9a66.json,"These highlights do not include all the information needed to use MINIVELLE safely and effectively. See full prescribing information for MINIVELLE.
         

MINIVELLE® (estradiol transdermal system) 
Initial U.S. Approval: 1975"
6d1c87df-b319-4c63-9f19-6584d7c4ff8e,8,rifampin,9384,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240119_6d1c87df-b319-4c63-9f19-6584d7c4ff8e.json,Rifampin Capsules USP
7663c49d-1b1d-755d-e053-2991aa0a4ee3,9,epinephrine,3992,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240224_7663c49d-1b1d-755d-e053-2991aa0a4ee3.json,"ADRENALIN® (EPINEPHRINE INJECTION, USP) 1mg/mL 1:1000 VIAL"
80686b7e-f6f4-4154-b5c0-c846425e2d91,12,elotuzumab,1726104,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230125_80686b7e-f6f4-4154-b5c0-c846425e2d91.json,"These highlights do not include all the information needed to use EMPLICITI safely and effectively. See full prescribing information for EMPLICITI.
EMPLICITI
®
 (elotuzumab) for injection, for intravenous useInitial U.S. Approval: 2015"
829e744d-7bd4-43dc-9b58-ffb016cb8e67,1,didanosine,3364,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20120508_829e744d-7bd4-43dc-9b58-ffb016cb8e67.json,These highlights do not include all the information needed to use didanosine delayed-release capsules safely and effectively. See full prescribing information for didanosine delayed-release capsules. Initial U.S. Approval: 1991
8345d55e-ad02-4726-a04b-1a46e3337a4b,13,capecitabine,194000,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240105_8345d55e-ad02-4726-a04b-1a46e3337a4b.json,"These highlights do not include all the information needed to use CAPECITABINE TABLETS safely and effectively. See full prescribing information for CAPECITABINE TABLETS.
 







CAPECITABINE tablets, for oral use
 







Initial U.S. Approval: 1998"
83aeddf8-6fed-487c-858b-2240f0a0e8af,1,indinavir,114289,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20120618_83aeddf8-6fed-487c-858b-2240f0a0e8af.json,"CRIXIVAN®
(INDINAVIR SULFATE)CAPSULES"
8b4c8696-e23e-4c51-a4d2-babab5bd945a,3,remifentanil,73032,acute liver injury,10061008,biliary tract disorder,../data/2024_latest_labels/latest_labels_ingredients/20231223_8b4c8696-e23e-4c51-a4d2-babab5bd945a.json,"These highlights do not include all the information needed to use ULTIVA safely and effectively.  See full prescribing information for ULTIVA. 
ULTIVA® (remifentanil hydrochloride), for injection, for intravenous use, CII
Initial U.S. Approval: 1996"
8ded0773-3aec-4e89-9836-d22a5a84abf0,17,quinapril,35208,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20231215_8ded0773-3aec-4e89-9836-d22a5a84abf0.json,Quinapril Tablets USP
8edd78a9-d762-4578-a610-28d6595f4bf3,1,melphalan,6718,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231218_8edd78a9-d762-4578-a610-28d6595f4bf3.json,Melphalan Hydrochloride for Injection(For Intravenous Infusion)
8f7f73b8-586a-4df0-935f-fecd4696c16c,17,isavuconazonium,1608322,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240112_8f7f73b8-586a-4df0-935f-fecd4696c16c.json,"These highlights do not include all the information needed to use CRESEMBA® safely and effectively. See full prescribing information for CRESEMBA®.
CRESEMBA® (isavuconazonium sulfate) capsules, for oral useCRESEMBA® (isavuconazonium sulfate) for injection, for intravenous useInitial U.S. Approval: 2015"
90717878-64cb-4ffc-90bc-7b4e81e3d1cd,12,nafcillin,7233,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240207_90717878-64cb-4ffc-90bc-7b4e81e3d1cd.json,"Nafcillin for Injection, USP Rx only"
918d0e2a-3af3-46e8-ad06-528263e03ba0,11,fentanyl,4337,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240222_918d0e2a-3af3-46e8-ad06-528263e03ba0.json,"These highlights do not include all the information needed to use fentanyl buccal tablet safely and effectively.  See full prescribing information for fentanyl buccal tablet. 
 Fentanyl Buccal Tablet, CII    Initial U.S. Approval: 1968"
9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f,6,ketoprofen,6142,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240206_9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f.json,KIPROFEN™ Capsules
a23063c0-099a-4256-b95f-3a857bbf704b,18,alprazolam,596,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240209_a23063c0-099a-4256-b95f-3a857bbf704b.json,"These highlights do not include all the information needed to use ALPRAZOLAM TABLETS safely and effectively. See full prescribing information for ALPRAZOLAM TABLETS.


ALPRAZOLAM tablets, for oral use, CIV 


Initial U.S. Approval: 1981"
a4978a54-1799-43d6-85dd-05fa9de0a5d7,8,ambrisentan,358274,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240131_a4978a54-1799-43d6-85dd-05fa9de0a5d7.json,"These highlights do not include all the information needed to use AMBRISENTAN TABLETS safely and effectively. See full prescribing information for AMBRISENTAN TABLETS.  AMBRISENTAN tablets, for oral use  Initial U.S. Approval: 2007"
a4978a54-1799-43d6-85dd-05fa9de0a5d7,8,ambrisentan,358274,acute liver injury,10084058,congestive hepatopathy,../data/2024_latest_labels/latest_labels_ingredients/20240131_a4978a54-1799-43d6-85dd-05fa9de0a5d7.json,"These highlights do not include all the information needed to use AMBRISENTAN TABLETS safely and effectively. See full prescribing information for AMBRISENTAN TABLETS.  AMBRISENTAN tablets, for oral use  Initial U.S. Approval: 2007"
b0075b72-c3cc-f844-e053-2a95a90a417f,5,meropenem,29561,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240104_b0075b72-c3cc-f844-e053-2a95a90a417f.json,"These highlights do not include all the information needed to use MEROPENEM FOR INJECTION safely and effectively. See full prescribing information for MEROPENEM FOR INJECTION
 







MEROPENEM for injection, for intravenous use
 







Initial U.S. Approval: 1996"
b17679e8-88c8-4b8d-bfae-246fab6eead9,13,docetaxel,72962,acute myocardial infarction,10002388,angina unstable,../data/2024_latest_labels/latest_labels_ingredients/20240201_b17679e8-88c8-4b8d-bfae-246fab6eead9.json,"These highlights do not include all the information needed to use DOCETAXEL INJECTION safely and effectively. See full prescribing information for DOCETAXEL INJECTION.DOCETAXEL injection, for intravenous use
Initial U.S. Approval: 1996"
b605b541-4bfd-db3e-9710-11c27f6dee6c,2,bortezomib,358258,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240105_b605b541-4bfd-db3e-9710-11c27f6dee6c.json,"These highlights do not include all the information needed to use BORTEZOMIB FOR INJECTION safely and effectively. See full prescribing information for BORTEZOMIB FOR INJECTION.
 BORTEZOMIB for injection, for subcutaneous or intravenous useInitial U.S. Approval: 2003"
b7241707-7538-4d1a-91e7-3a25a91e0b9a,14,ifosfamide,5657,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231116_b7241707-7538-4d1a-91e7-3a25a91e0b9a.json,"These highlights do not include all the information needed to use IFEX (ifosfamide) safely and effectively.  See full prescribing information for IFEX.
IFEX (ifosfamide) for injection, intravenous useInitial U.S. Approval: 1988"
b848e6f3-63c0-4d2e-bda5-c9e961472092,1,lurasidone,1040028,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240208_b848e6f3-63c0-4d2e-bda5-c9e961472092.json,"These highlights do not include all the information needed to use LURASIDONE HYDROCHLORIDE TABLETS safely and effectively.  See full prescribing information for LURASIDONE HYDROCHLORIDE TABLETS.LURASIDONE HYDROCHLORIDE tablets, for oral useInitial U.S. Approval: 2010"
bcbc5d92-e022-4a0d-ab4d-2b0d7aa68c58,5,levomilnacipran,1433212,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20231228_bcbc5d92-e022-4a0d-ab4d-2b0d7aa68c58.json,"These highlights do not include all the information needed to use LEVOMILNACIPRAN EXTENDED-RELEASE CAPSULES safely and effectively. See full prescribing information for LEVOMILNACIPRAN EXTENDED-RELEASE CAPSULES.
 


LEVOMILNACIPRAN extended-release capsules, for oral use 

Initial U.S. Approval: 2009 (milnacipran)"
be4bc0de-0fdc-4d46-8d25-be43c79e6a06,22,abemaciclib,1946825,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240104_be4bc0de-0fdc-4d46-8d25-be43c79e6a06.json,"These highlights do not include all the information needed to use VERZENIO safely and effectively. See full prescribing information for VERZENIO.
VERZENIO® (abemaciclib) tablets, for oral useInitial U.S. Approval: 2017"
c09c4cde-9f6c-4c4f-9d96-18beb5377564,1,methyltestosterone,6904,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20220223_c09c4cde-9f6c-4c4f-9d96-18beb5377564.json,"Methyltestosterone Capsules, USP, CIII (10 mg) Rx only"
c27f2d57-4b9d-4b78-8d85-3bac84f733b1,5,flurbiprofen,4502,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240128_c27f2d57-4b9d-4b78-8d85-3bac84f733b1.json,"Flurbiprofen Sodium Ophthalmic Solution, USP 0.03% 

(Sterile)"
c2b21ad5-fa83-1fb6-e053-2a95a90a3d0f,3,famciclovir,68099,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240110_c2b21ad5-fa83-1fb6-e053-2a95a90a3d0f.json,"Famciclovir Tablets
 
Rx only
 

These highlights do not include all the information needed to use FAMCICLOVIR TABLETS safely and effectively. See full prescribing information for FAMCICLOVIR TABLETS.
 

Initial U.S. Approval: 1994"
c79d3668-5243-4627-ad2b-cc7c045df120,100,levocetirizine,356887,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240207_c79d3668-5243-4627-ad2b-cc7c045df120.json,"These highlights do not include all the information needed to use LEVOCETIRIZINE DIHYDROCHLORIDE tablets safely and effectively. See full prescribing information for LEVOCETIRIZINE DIHYDROCHLORIDE tablets.
LEVOCETIRIZINE DIHYDROCHLORIDE tablets, for oral useInitial U.S. Approval: 1995"
c7bb6ba1-9a7f-43f5-b058-ef26d4b59221,3,everolimus,141704,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240222_c7bb6ba1-9a7f-43f5-b058-ef26d4b59221.json,"These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS.
 EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009"
c8b58efa-1820-48a4-b70d-62918fc4abfc,6,irinotecan,51499,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240217_c8b58efa-1820-48a4-b70d-62918fc4abfc.json,"These highlights do not include all the information needed to use ONIVYDE® safely and effectively. See full prescribing information for ONIVYDE®
 ONIVYDE® (irinotecan liposome injection), for intravenous use Initial U.S. Approval: 1996"
c98fb504-76d0-4c25-9c0b-412885828a7a,7,lenalidomide,342369,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240213_c98fb504-76d0-4c25-9c0b-412885828a7a.json,"These highlights do not include all the information needed to use LENALIDOMIDE CAPSULES safely and effectively. See full prescribing information for LENALIDOMIDE CAPSULES.
LENALIDOMIDE capsules, for oral use
Initial U.S. Approval:2005"
c98fb504-76d0-4c25-9c0b-412885828a7a,7,lenalidomide,342369,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240213_c98fb504-76d0-4c25-9c0b-412885828a7a.json,"These highlights do not include all the information needed to use LENALIDOMIDE CAPSULES safely and effectively. See full prescribing information for LENALIDOMIDE CAPSULES.
LENALIDOMIDE capsules, for oral use
Initial U.S. Approval:2005"
cc7014b1-c775-411d-b374-8113248b4077,4,inotuzumab ozogamicin,1942950,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20200922_cc7014b1-c775-411d-b374-8113248b4077.json,"These highlights do not include all the information needed to use BESPONSA™ safely and effectively. See full prescribing information for BESPONSA.
BESPONSA (inotuzumab ozogamicin) for injection, for intravenous useInitial U.S. Approval: 2017"
cdfbe0cd-eb15-45a1-ac17-531bcda21aec,11,obeticholic acid,1798288,acute liver injury,10019660,hepatic encephalopathy,../data/2024_latest_labels/latest_labels_ingredients/20221021_cdfbe0cd-eb15-45a1-ac17-531bcda21aec.json,"These highlights do not include all the information needed to use OCALIVA® safely and effectively.  See full prescribing information for OCALIVA. 
OCALIVA® (obeticholic acid) tablets, for oral use Initial U.S. Approval: 2016"
d7354af1-f304-f4d9-e053-2995a90ab219,2,sparsentan,2630535,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230225_d7354af1-f304-f4d9-e053-2995a90ab219.json,"These highlights do not include all the information needed to use FILSPARITM safely and effectively. See full prescribing information for FILSPARITM.
FILSPARITM (sparsentan) tablets, for oral useInitial U.S. Approval: 2023"
d9d74915-6606-4570-9c52-c4001d3177de,20,anakinra,72435,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20201230_d9d74915-6606-4570-9c52-c4001d3177de.json,"These highlights do not include all the information needed to use KINERET safely and effectively.  See full prescribing information for KINERET.  
KINERET® (anakinra) injection, for subcutaneous useInitial U.S. Approval: 2001"
e72c2bc6-9462-4a2e-8e1d-b97592376cbd,32,nelfinavir,134527,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20230921_e72c2bc6-9462-4a2e-8e1d-b97592376cbd.json,"These highlights do not include all the information needed to use VIRACEPT safely and effectively. See full prescribing information for VIRACEPT.
 VIRACEPT® (nelfinavir mesylate) Tablets, for oral use  VIRACEPT®  (nelfinavir mesylate) Oral Powder, for oral use Initial U.S. Approval: 1997"
ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,54,carfilzomib,1302966,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20221029_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.json,"These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. 
KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012"
ed23b6bc-32c7-4c50-a53d-313ae78e5623,13,cefotaxime,2186,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20210804_ed23b6bc-32c7-4c50-a53d-313ae78e5623.json,"CEFOTAXIME FOR INJECTION, USP"
f5e8d1da-8911-42db-9f90-cba04b28d011,102,fluvastatin,41127,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240113_f5e8d1da-8911-42db-9f90-cba04b28d011.json,"These highlights do not include all the information needed to use FLUVASTATIN CAPSULES safely and effectively.  See full prescribing information for FLUVASTATIN CAPSULES. 
FLUVASTATIN capsules, for oral useInitial U.S. Approval: 1993"
f89f2933-0743-45e7-9a91-086f9b2e56da,10,pentoxifylline,8013,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240202_f89f2933-0743-45e7-9a91-086f9b2e56da.json,"PENTOXIFYLLINE EXTENDED-RELEASE TABLETS, USP 400 mg


Rx Only"
fc38f1bb-f175-4a81-8ed9-c8701efdea35,102,fosinopril,50166,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231128_fc38f1bb-f175-4a81-8ed9-c8701efdea35.json,"FOSINOPRILSODIUM TABLETS, USP10mg, 20mg and 40mgRx Only"
0366164b-1846-443d-9564-dbe52d8d9b65,11,topiramate,38404,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240224_0366164b-1846-443d-9564-dbe52d8d9b65.json,"These highlights do not include all the information needed to use TOPIRAMATE safely and effectively. See full prescribing information for TOPIRAMATE.
 

TOPIRAMATE tablets, for oral use
 
TOPIRAMATE capsules, for oral use
 
Initial U.S. Approval-1996"
08a44bdd-028d-41af-9d4e-70971b0bcc4e,2,furosemide,4603,acute liver injury,10019660,hepatic encephalopathy,../data/2024_latest_labels/latest_labels_ingredients/20240224_08a44bdd-028d-41af-9d4e-70971b0bcc4e.json,"Furosemide Injection, USP"
0a273a2d-a1ff-412a-925e-696648730dae,5,clofarabine,44151,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231224_0a273a2d-a1ff-412a-925e-696648730dae.json,"These highlights do not include all the information needed to use CLOFARABINE INJECTION safely and effectively. See full prescribing information for CLOFARABINE INJECTION.


CLOFARABINE injection, for intravenous use

Initial U.S. Approval: 2004"
0c717ae4-ec27-47db-ac1b-e504dbb379be,11,dexmethylphenidate,352372,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240221_0c717ae4-ec27-47db-ac1b-e504dbb379be.json,"These highlights do not include all the information needed to use DEXMETHYLPHENIDATE hydrochloride tablets safely and effectively. See full prescribing information for DEXMETHYLPHENIDATE hydrochloride tablets.
  



DEXMETHYLPHENIDATE HYDROCHLORIDE TABLETS, for oral use, CII
  

Initial U.S. Approval: 2001"
0d976866-81b3-5db8-e063-6294a90a39f9,3,progesterone,8727,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240210_0d976866-81b3-5db8-e063-6294a90a39f9.json,""
10a3fbc9-00c6-ad83-e063-6294a90ae1ad,1,omeprazole,7646,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240220_10a3fbc9-00c6-ad83-e063-6294a90ae1ad.json,"These highlights do not include all the information needed to use OMEPRAZOLE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for OMEPRAZOLE DELAYED-RELEASE CAPSULES.
 

OMEPRAZOLE delayed-release capsules, for oral use
 
Initial U.S. Approval: 1989"
113558e6-8b45-cdbd-e063-6394a90ac036,2,etodolac,24605,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240220_113558e6-8b45-cdbd-e063-6394a90ac036.json,"Etodolac Tablets, USP
  
(400 mg and 500 mg) 
 

Rx only"
116f4f0d-66c5-49dd-e063-6394a90ab2b5,1,acyclovir,281,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240217_116f4f0d-66c5-49dd-e063-6394a90ab2b5.json,"Acyclovir Tablets, USP"
11fad602-16c2-4c1f-bdf1-867d95f063ca,10,rosuvastatin,301542,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_11fad602-16c2-4c1f-bdf1-867d95f063ca.json,"These highlights do not include all the information needed to use ROSUVASTATIN TABLETS safely and effectively. See full prescribing information for ROSUVASTATIN TABLETS.
 

ROSUVASTATIN tablets, for oral use
 
Initial U.S. Approval: 2003"
13abdafb-71a8-40a1-ba5a-7c2b2573e53e,12,amitriptyline,704,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240223_13abdafb-71a8-40a1-ba5a-7c2b2573e53e.json,"Amitriptyline Hydrochloride Tablets, USP"
16a4a314-f97e-4e91-95e9-576a3773d284,35,milnacipran,588250,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240207_16a4a314-f97e-4e91-95e9-576a3773d284.json,"These highlights do not include all the information needed to use 
SAVELLA
 
safely and effectively. See full prescribing information for 
SAVELLA
.  

   

SAVELLA
®
 (
milnacipran HCl
) 
t
ablets

Initial U.S. Approval: 2009"
17a8d11b-73b0-4833-a0b4-cf1ef85edefb,29,aripiprazole lauroxil,1673265,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20231205_17a8d11b-73b0-4833-a0b4-cf1ef85edefb.json,"These highlights do not include all the information needed to use ARISTADA® safely and effectively. See full prescribing information for ARISTADA®.
ARISTADA® (aripiprazole lauroxil) extended-release injectable suspension, for intramuscular useInitial U.S. Approval: 2015"
1a0c3bea-c87b-4d25-bb44-5f0174da6b34,14,cabozantinib,1363268,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/train_xml/20230907_1a0c3bea-c87b-4d25-bb44-5f0174da6b34.json,"These highlights do not include all the information needed to use COMETRIQ safely and effectively. See full prescribing information for COMETRIQ.
COMETRIQ® (cabozantinib) capsules, for oral useInitial U.S. Approval: 2012"
1aa40de5-c02d-49d6-8722-ed88c40c3ba6,2,felbamate,24812,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240101_1aa40de5-c02d-49d6-8722-ed88c40c3ba6.json,"Felbamate Tablets, USP

(400 mg and 600 mg)


Rx only"
1b8a4689-3916-4f4b-b54a-bbb4e322d79b,13,atenolol,1202,acute myocardial infarction,10000891,acute myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_1b8a4689-3916-4f4b-b54a-bbb4e322d79b.json,"Atenolol Tablets, USP Rx only"
1b8a4689-3916-4f4b-b54a-bbb4e322d79b,13,atenolol,1202,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_1b8a4689-3916-4f4b-b54a-bbb4e322d79b.json,"Atenolol Tablets, USP Rx only"
1b8a4689-3916-4f4b-b54a-bbb4e322d79b,13,atenolol,1202,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240224_1b8a4689-3916-4f4b-b54a-bbb4e322d79b.json,"Atenolol Tablets, USP Rx only"
1b8a4689-3916-4f4b-b54a-bbb4e322d79b,13,atenolol,1202,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_1b8a4689-3916-4f4b-b54a-bbb4e322d79b.json,"Atenolol Tablets, USP Rx only"
1dbac120-d4e6-45a9-b950-3d82aa7a1271,10,labetalol,6185,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240215_1dbac120-d4e6-45a9-b950-3d82aa7a1271.json,"Labetalol Hydrochloride Tablets, USP
 

Rx only"
1e87a81a-7084-4436-918b-a50451534307,11,pilocarpine,8328,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231231_1e87a81a-7084-4436-918b-a50451534307.json,"These highlights do not include all the information needed to use PILOCARPINE HYDROCHLORIDE OPHTHALMIC SOLUTION safely and effectively. See full prescribing information for PILOCARPINE HYDROCHLORIDE OPHTHALMIC SOLUTION.  

PILOCARPINE
 hydrochloride ophthalmic solution 

Initial U.S. Approval: 1974"
2150f73a-179b-4afc-b8ce-67c85cc72f04,60,everolimus,141704,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20230802_2150f73a-179b-4afc-b8ce-67c85cc72f04.json,"These highlights do not include all the information needed to use AFINITOR/AFINITOR DISPERZ safely and effectively. See full prescribing information for AFINITOR/AFINITOR DISPERZ.


AFINITOR® (everolimus) tablets, for oral use

AFINITOR DISPERZ® (everolimus tablets for oral suspension)

Initial U.S. Approval: 2009"
22d67228-6c24-47ca-afc7-52ef279520a0,5,nalmefene,31479,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240110_22d67228-6c24-47ca-afc7-52ef279520a0.json,""
241f0b1e-8b95-470d-876f-bf1804daaf18,11,ixabepilone,337523,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20230202_241f0b1e-8b95-470d-876f-bf1804daaf18.json,"These highlights do not include all the information needed to use IXEMPRA 
 ® safely and effectively. See full prescribing information for IXEMPRA 
 ®.
 



IXEMPRA 
 ® 
Kit (ixabepilone) for Injection, for intravenous infusion only
 



Initial U.S. Approval: 2007"
2c631ce7-ea15-4b51-b5bc-4962e3c315cd,3,fluorouracil,4492,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231202_2c631ce7-ea15-4b51-b5bc-4962e3c315cd.json,"FLUOROURACIL TOPICAL SOLUTION Rx only  FOR TOPICAL USE ONLY  NOT FOR OPHTHALMIC, ORAL, OR INTRAVAGINAL USE"
2cab8dd1-3a10-48e6-86ce-0e5275ed49e5,10,toremifene,38409,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230916_2cab8dd1-3a10-48e6-86ce-0e5275ed49e5.json,"These highlights do not include all the information needed to use FARESTON® safely and effectively. See full prescribing information for FARESTON®.


FARESTON® (toremifene citrate) 60 mg Tablets oral administration

Initial U.S. Approval: 1997"
2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,46,tocilizumab,612865,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/gold_xml/20230101_2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13.json,"These highlights do not include all the information needed to use ACTEMRA safely and effectively. See full prescribing information for ACTEMRA. 
 ACTEMRA® (tocilizumab) injection, for intravenous or subcutaneous use  Initial U.S. Approval: 2010"
304a3059-4f7f-4ec4-839d-86492bb5e07b,6,memantine,6719,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240221_304a3059-4f7f-4ec4-839d-86492bb5e07b.json,"These highlights do not include all the information needed to use MEMANTINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for MEMANTINE HYDROCHLORIDE TABLETS.
 
MEMANTINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 2003"
35d0074e-212b-4a1f-9cd7-974ca08d2c95,21,ropinirole,72302,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240206_35d0074e-212b-4a1f-9cd7-974ca08d2c95.json,"These highlights do not include all the information needed to use ROPINIROLE TABLETS safely and effectively. See full prescribing information for ROPINIROLE TABLETS.
ROPINIROLE tablets, for oral use Initial U.S. Approval: 1997"
37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,45,mycophenolate mofetil,68149,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_37241e87-4af4-4dc3-a1aa-ea6f20d8dc40.json,"These highlights do not include all the information needed to use CELLCEPT® safely and effectively. See full prescribing information for CELLCEPT® 
CELLCEPT® (mycophenolate mofetil) capsules, for oral use CELLCEPT® (mycophenolate mofetil) tablets, for oral use CELLCEPT®  Oral Suspension (mycophenolate mofetil), for oral suspension CELLCEPT®  Intravenous (mycophenolate mofetil) for injection, for intravenous use Initial U.S. Approval: 1995"
37767123-8b72-4e1f-b00d-ff3305e9923f,14,methocarbamol,6845,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_37767123-8b72-4e1f-b00d-ff3305e9923f.json,"Methocarbamol Tablets
 



Rx Only"
39e62997-8781-449a-e054-00144ff88e88,7,nizatidine,42319,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20221228_39e62997-8781-449a-e054-00144ff88e88.json,"Nizatidine Oral Solution 

15 mg/mL 

 
Rx only"
3bad23a6-09a6-4194-9182-093ed61bc71c,39,caspofungin,140108,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231128_3bad23a6-09a6-4194-9182-093ed61bc71c.json,"These highlights do not include all the information needed to use CANCIDAS safely and effectively. See full prescribing information for CANCIDAS.
CANCIDAS® (caspofungin acetate) for injection, for intravenous useInitial U.S. Approval: 2001"
3e43c17f-7e7e-4ccd-b321-1dd5e62cdafd,8,levetiracetam,114477,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_3e43c17f-7e7e-4ccd-b321-1dd5e62cdafd.json,"These highlights do not include all the information needed to use LEVETIRACETAM INJECTION safely and effectively. See full prescribing information for LEVETIRACETAM INJECTION.
 LEVETIRACETAM injection, for intravenous use Initial U.S. Approval: 1999"
4034fb6d-f55d-4df0-b500-d6a413591f6e,39,doxazosin,49276,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_4034fb6d-f55d-4df0-b500-d6a413591f6e.json,"These highlights do not include all the information needed to use DOXAZOSIN TABLETS safely and effectively. See full prescribing information for DOXAZOSIN TABLETS.




DOXAZOSIN tablets, for oral use 




Initial U.S. Approval: 1990"
41c095b6-acd9-4627-a813-bbca7ecafee5,10,donepezil,135447,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240224_41c095b6-acd9-4627-a813-bbca7ecafee5.json,"These highlights do not include all the information needed to use DONEPEZIL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for DONEPEZIL HYDROCHLORIDE TABLETS.
 

DONEPEZIL HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1996"
42f49299-7ae5-4d30-86eb-66b739c0e95d,5,lisinopril,29046,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_42f49299-7ae5-4d30-86eb-66b739c0e95d.json,"These highlights do not include all the information needed to use LISINOPRIL TABLETS safely and effectively. See full prescribing information for LISINOPRIL TABLETS
 



LISINOPRIL tablets, for oral use
 



Initial U.S. Approval: 1988"
44966a7e-d777-40fb-956f-d0f31f737848,17,cidofovir,83171,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231026_44966a7e-d777-40fb-956f-d0f31f737848.json,"Cidofovir Injection, USP Rx onlyFOR INTRAVENOUS INFUSION ONLY.NOT FOR INTRAOCULAR INJECTION."
44966a7e-d777-40fb-956f-d0f31f737848,17,cidofovir,83171,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231026_44966a7e-d777-40fb-956f-d0f31f737848.json,"Cidofovir Injection, USP Rx onlyFOR INTRAVENOUS INFUSION ONLY.NOT FOR INTRAOCULAR INJECTION."
487cd7e7-434c-4925-99fa-aa80b1cc776b,3,tirzepatide,2601723,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231116_487cd7e7-434c-4925-99fa-aa80b1cc776b.json,"These highlights do not include all the information needed to use ZEPBOUND safely and effectively. See full prescribing information for ZEPBOUND.ZEPBOUND™ (tirzepatide) Injection, for subcutaneous useInitial U.S. Approval: 2022"
4911f343-68e6-71b0-e054-00144ff8d46c,5,meloxicam,41493,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240223_4911f343-68e6-71b0-e054-00144ff8d46c.json,"These highlights do not include all the information needed to use MELOXICAM TABLETS safely and effectively. See full prescribing information for MELOXICAM TABLETS.
 

Initial U.S. Approval: 2000"
5108ca9c-b307-4cb2-8ea1-6553764f375a,13,escitalopram,321988,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_5108ca9c-b307-4cb2-8ea1-6553764f375a.json,"These highlights do not include all the information needed to use ESCITALOPRAM TABLETS safely and effectively. See full prescribing information for ESCITALOPRAM TABLETS.
 



ESCITALOPRAM tablets, for oral use
 








Initial U.S. Approval: 2002"
5198b1c8-8dd6-4b8f-bd85-294ac468af53,10,fluvoxamine,42355,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240224_5198b1c8-8dd6-4b8f-bd85-294ac468af53.json,"These highlights do not include all the information needed to use FLUVOXAMINE MALEATE TABLETS safely and effectively. See full prescribing information for FLUVOXAMINE MALEATE TABLETS.
 

FLUVOXAMINE MALEATE tablets, for oral use
 
Initial U.S. Approval: 1994"
51a88e8e-da02-4b97-9e7e-442fbffd908d,8,amiodarone,703,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_51a88e8e-da02-4b97-9e7e-442fbffd908d.json,"These highlights do not include all the information needed to use AMIODARONE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for AMIODARONE HYDROCHLORIDE TABLETS.
 

AMIODARONE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1985"
53103d2f-4453-49a8-9e36-888d919879f6,1,zaleplon,74667,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240217_53103d2f-4453-49a8-9e36-888d919879f6.json,"Zaleplon Capsules, USP

CIV"
53486382-eee0-4cbe-bc4a-a57484e0d5a7,104,cilostazol,21107,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240113_53486382-eee0-4cbe-bc4a-a57484e0d5a7.json,"These highlights do not include all the information needed to use CILOSTAZOL TABLETS safely and effectively. See full prescribing information for CILOSTAZOL TABLETS.CILOSTAZOL tablets, for oral useInitial U.S. Approval: 1999"
5721b46a-4a9f-46c2-8804-a9bad4d5f80a,5,flucytosine,4451,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240131_5721b46a-4a9f-46c2-8804-a9bad4d5f80a.json,FLUCYTOSINE Capsules USPRx only
58d80bc6-bdfb-4908-93e7-aace447c8d1a,1,octreotide,7617,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240131_58d80bc6-bdfb-4908-93e7-aace447c8d1a.json,"These highlights do not include all the information needed to use MYCAPSSA® safely and effectively. See full prescribing information for MYCAPSSA.
 MYCAPSSA (octreotide) delayed-release capsules, for oral use Initial U.S. Approval: 1988"
5cf989d5-36f5-4561-a30b-9fcb9deb6b6a,10,tafenoquine,2054023,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20230811_5cf989d5-36f5-4561-a30b-9fcb9deb6b6a.json,"These highlights do not include all the information needed to use KRINTAFEL safely and effectively. See full prescribing information for KRINTAFEL.
KRINTAFEL (tafenoquine) tablets, for oral useInitial U.S. Approval: 2018"
5fccc31d-32c9-49e7-91a9-664cc726872b,102,triazolam,10767,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231129_5fccc31d-32c9-49e7-91a9-664cc726872b.json,"These highlights do not include all the information needed to use TRIAZOLAM TABLETS safely and effectively. See full prescribing information for TRIAZOLAM TABLETS. 

TRIAZOLAM tablets, for oral use, CIV

Initial U.S. Approval: 1982"
61c3d6c7-0d9c-4e46-b091-88d84893e14a,11,zolpidem,39993,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_61c3d6c7-0d9c-4e46-b091-88d84893e14a.json,"These highlights do not include all the information needed to use ZOLPIDEM TARTRATE TABLETS safely and effectively. See full prescribing information for ZOLPIDEM TARTRATE TABLETS.
 



ZOLPIDEM TARTRATE tablets, for oral use, C-IV
 

Initial U.S. Approval: 1992"
626dc9e5-c6b4-4f9c-9bf4-774fd3ae619a,43,iron sucrose,24909,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230107_626dc9e5-c6b4-4f9c-9bf4-774fd3ae619a.json,"These highlights do not include all the information needed to use VENOFER ® safely and effectively. See full prescribing information for VENOFER.Venofer (iron sucrose) injection, for intravenous useInitial U.S. Approval:  2000"
63df5af3-b8ac-4e76-9830-2dbb340af922,27,dolutegravir,1433868,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/train_xml/20231004_63df5af3-b8ac-4e76-9830-2dbb340af922.json,"These highlights do not include all the information needed to use TIVICAY safely and effectively. See full prescribing information for TIVICAY.TIVICAY (dolutegravir) tablets, for oral use TIVICAY PD (dolutegravir) tablets for oral suspensionInitial U.S. Approval: 2013"
65d254c0-67ad-42c4-b972-ad463b755b2d,8,ivosidenib,2049873,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20231108_65d254c0-67ad-42c4-b972-ad463b755b2d.json,"These highlights do not include all the information needed to use TIBSOVO safely and effectively. See full prescribing information for TIBSOVO.
 TIBSOVO® (ivosidenib tablets), for oral use Initial U.S. Approval: 2018"
6a9cbc29-9f15-4b24-8d86-206b82887f3d,24,etravirine,475969,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/train_xml/20230816_6a9cbc29-9f15-4b24-8d86-206b82887f3d.json,"These highlights do not include all the information needed to use INTELENCE safely and effectively. See full prescribing information for INTELENCE.
 





INTELENCE 
 ®(etravirine) tablets, for oral use
 

Initial U.S. Approval: 2008"
6fa682c9-a312-4932-9831-f286908660ee,34,atezolizumab,1792776,gi bleed,10030210,oesophageal varices haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230523_6fa682c9-a312-4932-9831-f286908660ee.json,"These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. 
 TECENTRIQ® (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2016"
6fa682c9-a312-4932-9831-f286908660ee,34,atezolizumab,1792776,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230523_6fa682c9-a312-4932-9831-f286908660ee.json,"These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. 
 TECENTRIQ® (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2016"
72e6b33c-0351-4070-9172-eeaa186c01d2,14,tenofovir alafenamide,1721603,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240215_72e6b33c-0351-4070-9172-eeaa186c01d2.json,"These highlights do not include all the information needed to use VEMLIDY safely and effectively. See full prescribing information for VEMLIDY. 
 VEMLIDY® (tenofovir alafenamide) tablets, for oral use  Initial U.S. Approval: 2015"
73a1e6c0-71d0-4ba1-bbca-c067479e487d,101,isosorbide dinitrate,6058,acute myocardial infarction,10002388,angina unstable,../data/2024_latest_labels/latest_labels_ingredients/20240114_73a1e6c0-71d0-4ba1-bbca-c067479e487d.json,"Isosorbide Dinitrate Tablets, USP

Rx only"
77a67dc6-35d3-48ff-9d18-292d4d442f70,15,alvimopan,480639,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20231214_77a67dc6-35d3-48ff-9d18-292d4d442f70.json,"These highlights do not include all the information needed to use ENTEREG safely and effectively. See full prescribing information for ENTEREG.
 ENTEREG® (alvimopan) capsules, for oral use Initial U.S. Approval: 2008"
79eec27d-ac63-4996-8b1a-c2cd52ad2b2c,5,argatroban,15202,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240117_79eec27d-ac63-4996-8b1a-c2cd52ad2b2c.json,"These highlights do not include all the information needed to use ARGATROBAN INJECTION safely and effectively. See full prescribing information for ARGATROBAN INJECTION.


ARGATROBAN INJECTION, for intravenous infusion only 

Initial U.S. Approval: 2000"
7b11f6ac-4c27-4748-9e65-22d4cf3adfb4,6,liraglutide,475968,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240131_7b11f6ac-4c27-4748-9e65-22d4cf3adfb4.json,"These highlights do not include all the information needed to use SAXENDA® safely and effectively.  See full prescribing information for SAXENDA.SAXENDA (liraglutide) injection, for subcutaneous useInitial U.S. Approval: 2010"
7f0bc342-0a0a-1d28-e053-2991aa0a28b9,4,tenofovir disoproxil,300195,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240111_7f0bc342-0a0a-1d28-e053-2991aa0a28b9.json,"TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use
 
Rx only
 

These highlights do not include all the information needed to use TENOFOVIR DISOPROXIL FUMARATE TABLETS safely and effectively. See full prescribing information for TENOFOVIR DISOPROXIL FUMARATE TABLETS.
 

TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use
 

Initial U.S. Approval: 2001"
8345d55e-ad02-4726-a04b-1a46e3337a4b,13,capecitabine,194000,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240105_8345d55e-ad02-4726-a04b-1a46e3337a4b.json,"These highlights do not include all the information needed to use CAPECITABINE TABLETS safely and effectively. See full prescribing information for CAPECITABINE TABLETS.
 







CAPECITABINE tablets, for oral use
 







Initial U.S. Approval: 1998"
83aeddf8-6fed-487c-858b-2240f0a0e8af,1,indinavir,114289,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20120618_83aeddf8-6fed-487c-858b-2240f0a0e8af.json,"CRIXIVAN®
(INDINAVIR SULFATE)CAPSULES"
86c0b4ae-5e38-4efe-88af-50ac560e294f,8,ibandronate,115264,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240202_86c0b4ae-5e38-4efe-88af-50ac560e294f.json,"These highlights do not include all the information needed to use IBANDRONATE SODIUM TABLETS safely and effectively. See full prescribing information for IBANDRONATE SODIUM TABLETS.
 IBANDRONATE SODIUM tablets, for oral use Initial U.S. Approval: 2003"
8ea61d0d-4403-4d9f-a946-85a459cc0aa0,5,fondaparinux,321208,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240206_8ea61d0d-4403-4d9f-a946-85a459cc0aa0.json,"These highlights do not include all the information needed to use FONDAPARINUX SODIUM INJECTION safely and effectively. See full prescribing information for FONDAPARINUX SODIUM INJECTION.
 FONDAPARINUX SODIUM injection, for subcutaneous use Initial U.S. Approval: 2001"
962b20df-88ff-4ab7-a900-135adb6c1d74,5,indapamide,5764,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231111_962b20df-88ff-4ab7-a900-135adb6c1d74.json,Indapamide Tablets USP Rx only
973ed458-f46b-4f61-a329-816c4db79a2c,5,amifostine,4126,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240217_973ed458-f46b-4f61-a329-816c4db79a2c.json,"These highlights do not include all the information needed to use ETHYOL safely and effectively. See full prescribing information for ETHYOL.
ETHYOL® (amifostine) for injection, for intravenous useInitial U.S. Approval: 1995"
9c9d9f5c-bfd1-4e2a-be4a-697344ca6833,11,citalopram,2556,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_9c9d9f5c-bfd1-4e2a-be4a-697344ca6833.json,"These highlights do not include all the information needed to use citalopram tablets safely and effectively. See full prescribing information for citalopram tablets.
 


CITALOPRAM (Citalopram) tablets, for oral use
 


Initial U.S. Approval: 1998"
a1787fad-3612-43e1-98fa-ce62361e0b3c,13,imatinib,282388,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240203_a1787fad-3612-43e1-98fa-ce62361e0b3c.json,"These highlights do not include all the information needed to use IMATINIB MESYLATE TABLETS safely and effectively.  See full prescribing information for IMATINIB MESYLATE TABLETS. IMATINIB MESYLATE tablets, for oral useInitial U.S. Approval: 2001"
a1787fad-3612-43e1-98fa-ce62361e0b3c,13,imatinib,282388,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240203_a1787fad-3612-43e1-98fa-ce62361e0b3c.json,"These highlights do not include all the information needed to use IMATINIB MESYLATE TABLETS safely and effectively.  See full prescribing information for IMATINIB MESYLATE TABLETS. IMATINIB MESYLATE tablets, for oral useInitial U.S. Approval: 2001"
a1787fad-3612-43e1-98fa-ce62361e0b3c,13,imatinib,282388,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240203_a1787fad-3612-43e1-98fa-ce62361e0b3c.json,"These highlights do not include all the information needed to use IMATINIB MESYLATE TABLETS safely and effectively.  See full prescribing information for IMATINIB MESYLATE TABLETS. IMATINIB MESYLATE tablets, for oral useInitial U.S. Approval: 2001"
a586be28-96af-4fed-a13f-9b94fd4c7405,24,medroxyprogesterone,6691,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240227_a586be28-96af-4fed-a13f-9b94fd4c7405.json,"PROVERA®

 (medroxyprogesterone acetate tablets, USP)"
accf9569-4b57-4e83-a7db-4e890a75d1ba,23,mitoxantrone,7005,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20220420_accf9569-4b57-4e83-a7db-4e890a75d1ba.json,"MitoXANTRONE Injection, USP (concentrate)"
adfc2b23-00a5-4f05-a08b-83087e1e4843,1,enoxaparin,67108,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240206_adfc2b23-00a5-4f05-a08b-83087e1e4843.json,"These highlights do not include all the information needed to use ENOXAPARIN SODIUM INJECTION safely and effectively. See full prescribing information for ENOXAPARIN SODIUM INJECTION.ENOXAPARIN SODIUM injection, for subcutaneous and intravenous useInitial U.S. Approval: 1993"
b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1,5,ziconotide,68503,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231201_b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1.json,"These highlights do not include all the information needed to use PRIALT safely and effectively.  See full prescribing information for PRIALT.PRIALT (ziconotide) solution, intrathecal infusion Initial U.S. Approval: 2004"
b272ef9c-4d83-4ee2-b9cc-477440822cca,10,cefoxitin,2189,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240105_b272ef9c-4d83-4ee2-b9cc-477440822cca.json,"CEFOXITIN FOR INJECTION, USP(For Intravenous Use)"
b4c2c9dc-a0bb-4d64-a667-a67ebe88392d,37,certolizumab pegol,709271,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20230105_b4c2c9dc-a0bb-4d64-a667-a67ebe88392d.json,"These highlights do not include all the information needed to use CIMZIA® safely and effectively. See full prescribing information for CIMZIA.
 



CIMZIA (certolizumab pegol) for injection, for subcutaneous use
 

CIMZIA (certolizumab pegol) injection, for subcutaneous use
 

Initial U.S. Approval: 2008"
b6737b25-0c4f-4131-ba23-b0f2252a18ea,9,simvastatin,36567,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_b6737b25-0c4f-4131-ba23-b0f2252a18ea.json,"These highlights do not include all the information needed to use SIMVASTATIN TABLETS safely and effectively. See full prescribing information for SIMVASTATIN TABLETS.








SIMVASTATIN tablets, for oral use








Initial U.S. Approval:
1991"
b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,ibuprofen,5640,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,"IBUPROFEN Tablets, USP"
bcc81df2-20e3-4738-bfcf-301da883c1d9,10,ceftazidime,2191,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240201_bcc81df2-20e3-4738-bfcf-301da883c1d9.json,Ceftazidime for Injection
bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac,4,deferasirox,614373,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240223_bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac.json,"These highlights do not include all the information needed to use DEFERASIROX TABLETS FOR ORAL SUSPENSION safely and effectively. See full prescribing information for DEFERASIROX TABLETS FOR ORAL SUSPENSION. 
DEFERASIROX tablets, for oral suspensionInitial U.S. Approval: 2005"
c387579e-cee0-4334-bd1e-73f93ac1bde6,18,cobimetinib,1722365,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20230613_c387579e-cee0-4334-bd1e-73f93ac1bde6.json,"These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information for COTELLIC.
COTELLIC®  (cobimetinib) tablets, for oral useInitial U.S. Approval: 2015"
c6080942-dee6-423e-b688-1272c2ae90d4,40,ramucirumab,1535922,acute liver injury,10019660,hepatic encephalopathy,../data/2024_latest_labels/latest_labels_ingredients/20231129_c6080942-dee6-423e-b688-1272c2ae90d4.json,"These highlights do not include all the information needed to use CYRAMZA safely and effectively. See full prescribing information for CYRAMZA.
CYRAMZA (ramucirumab) injection, for intravenous useInitial U.S. Approval: 2014"
c669f77c-fa48-478b-a14b-80b20a0139c2,12,alteplase,8410,acute myocardial infarction,10000891,acute myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20220916_c669f77c-fa48-478b-a14b-80b20a0139c2.json,"These highlights do not include all the information needed to use ACTIVASE safely and effectively. See full prescribing information for ACTIVASE. 
Activase (alteplase) for injection, for intravenous use Initial U.S. Approval: 1987"
c669f77c-fa48-478b-a14b-80b20a0139c2,12,alteplase,8410,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20220916_c669f77c-fa48-478b-a14b-80b20a0139c2.json,"These highlights do not include all the information needed to use ACTIVASE safely and effectively. See full prescribing information for ACTIVASE. 
Activase (alteplase) for injection, for intravenous use Initial U.S. Approval: 1987"
c75fab51-c34f-4be2-b6fd-382e5e89b6a4,4,rabeprazole,114979,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240209_c75fab51-c34f-4be2-b6fd-382e5e89b6a4.json,"These highlights do not include all the information needed to use RABEPRAZOLE SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for RABEPRAZOLE SODIUM DELAYED-RELEASE TABLETS.
 RABEPRAZOLE SODIUM delayed-release tablets, for oral use
 Initial U.S. Approval: 1999"
c7bb6ba1-9a7f-43f5-b058-ef26d4b59221,3,everolimus,141704,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240222_c7bb6ba1-9a7f-43f5-b058-ef26d4b59221.json,"These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS.
 EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009"
ccd95dfc-9236-4707-a715-6a12c91519ff,6,naproxen,7258,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_ccd95dfc-9236-4707-a715-6a12c91519ff.json,"These highlights do not include all the information needed to use NAPROXEN TABLETS safely and effectively. See full prescribing information for NAPROXEN TABLETS.
 

NAPROXEN tablets, for oral use
 

Initial U.S. Approval: 1976"
d2af616e-673a-4fdd-ace8-db2d0f154604,15,alfuzosin,17300,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240120_d2af616e-673a-4fdd-ace8-db2d0f154604.json,"These highlights do not include all the information needed to use ALFUZOSIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for ALFUZOSIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS. ALFUZOSIN HYDROCHLORIDE extended-release tablets, for oral use Initial U.S. Approval: 2003"
d4500795-3b07-4a7d-b432-73cafbb3dbc6,2,aztreonam,1272,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240110_d4500795-3b07-4a7d-b432-73cafbb3dbc6.json,"Aztreonam for Injection, USP"
d9db3882-a7b5-435b-9d5a-a5e4ef7c2537,2,fluphenazine,4496,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240214_d9db3882-a7b5-435b-9d5a-a5e4ef7c2537.json,"Fluphenazine Hydrochloride Tablets, USPRx only"
de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa,24,cabazitaxel,996051,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20230720_de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa.json,"These highlights do not include all the information needed to use JEVTANA safely and effectively. See full prescribing information for JEVTANA.
 JEVTANA® (cabazitaxel) injection, for intravenous use Initial U.S. Approval: 2010"
df4cd207-c3b8-4008-5290-02f296c2b4a6,21,fenoldopam,24853,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20210812_df4cd207-c3b8-4008-5290-02f296c2b4a6.json,"These highlights do not include all the information needed to use CORLOPAM® safely and effectively.  See full prescribing information for CORLOPAM®. 
CORLOPAM® (fenoldopam mesylate) injection, for intravenous use Initial U.S. Approval: 1997"
e03d32dd-878f-43ee-b8c2-3adad98bf66c,100,methimazole,6835,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240223_e03d32dd-878f-43ee-b8c2-3adad98bf66c.json,"Methimazole Tablets, USP

 Rx only"
e4dbaa72-7b3e-4aef-983b-90efb2b343cd,6,pravastatin,42463,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_e4dbaa72-7b3e-4aef-983b-90efb2b343cd.json,"These highlights do not include all the information needed to use PRAVASTATIN SODIUM TABLETS safely and effectively. See full prescribing information for PRAVASTATIN SODIUM TABLETS.
 

PRAVASTATIN SODIUM tablets, for oral use
 
Initial U.S. Approval: 1991"
e72c2bc6-9462-4a2e-8e1d-b97592376cbd,32,nelfinavir,134527,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230921_e72c2bc6-9462-4a2e-8e1d-b97592376cbd.json,"These highlights do not include all the information needed to use VIRACEPT safely and effectively. See full prescribing information for VIRACEPT.
 VIRACEPT® (nelfinavir mesylate) Tablets, for oral use  VIRACEPT®  (nelfinavir mesylate) Oral Powder, for oral use Initial U.S. Approval: 1997"
f3c516ad-d405-4fbe-af6a-962080dbfa7d,3,aldesleukin,70223,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240208_f3c516ad-d405-4fbe-af6a-962080dbfa7d.json,"These highlights do not include all the information needed to use PROLEUKIN® safely and effectively. See full prescribing information for PROLEUKIN. 
 PROLEUKIN (aldesleukin) for injection, for intravenous use  Initial U.S. Approval: 1992"
f47d4365-40a8-445b-99cd-49edad6a8ffc,15,ketorolac,35827,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240206_f47d4365-40a8-445b-99cd-49edad6a8ffc.json,"Ketorolac Tromethamine Tablets USP, 10 mg 
 




Rx only"
f47d4365-40a8-445b-99cd-49edad6a8ffc,15,ketorolac,35827,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240206_f47d4365-40a8-445b-99cd-49edad6a8ffc.json,"Ketorolac Tromethamine Tablets USP, 10 mg 
 




Rx only"
f5a010cf-5954-4e6d-acfa-fb414efdf471,1,mitomycin,632,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20231101_f5a010cf-5954-4e6d-acfa-fb414efdf471.json,"Mitomycin for Injection, USP Rx only"
f5a010cf-5954-4e6d-acfa-fb414efdf471,1,mitomycin,632,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231101_f5a010cf-5954-4e6d-acfa-fb414efdf471.json,"Mitomycin for Injection, USP Rx only"
f5e8d1da-8911-42db-9f90-cba04b28d011,102,fluvastatin,41127,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240113_f5e8d1da-8911-42db-9f90-cba04b28d011.json,"These highlights do not include all the information needed to use FLUVASTATIN CAPSULES safely and effectively.  See full prescribing information for FLUVASTATIN CAPSULES. 
FLUVASTATIN capsules, for oral useInitial U.S. Approval: 1993"
f7e9a4b3-a2ee-4f0a-becd-6ef90867332b,37,morphine,7052,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240215_f7e9a4b3-a2ee-4f0a-becd-6ef90867332b.json,"These highlights do not include all the information needed to use MORPHINE SULFATE EXTENDED-RELEASE CAPSULES safely and effectively. See full prescribing information for MORPHINE SULFATE EXTENDED-RELEASE CAPSULES.


MORPHINE SULFATE extended-release capsules, for oral use, CIIInitial U.S. Approval: 1941"
f87dc257-c131-47ca-acc3-55ab79f9107b,9,benazepril,18867,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240224_f87dc257-c131-47ca-acc3-55ab79f9107b.json,"These highlights do not include all the information needed to use BENAZEPRIL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for use BENAZEPRIL HYDROCHLORIDE TABLETS.
 



BENAZEPRIL HYDROCHLORIDE tablets, film coated for oral use
 

Initial U.S. Approval: 1991"
fdbcc274-c343-4461-9db9-6ff1be15d727,10,bupropion,42347,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_fdbcc274-c343-4461-9db9-6ff1be15d727.json,"These highlights do not include all the information needed to use 
  BUPROPIONHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for 
  BUPROPIONHYDROCHLORIDE TABLETS. 
 


BUPROPION HYDROCHLORIDE tablets, for oral use
  
Initial U.S. Approval: 1985"
fff5d805-4ffd-4e8e-8e63-6f129697563e,18,ceritinib,1535457,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240123_fff5d805-4ffd-4e8e-8e63-6f129697563e.json,"These highlights do not include all the information needed to use ZYKADIA safely and effectively. See full prescribing information for ZYKADIA.


ZYKADIA® (ceritinib) capsules, for oral use

ZYKADIA® (ceritinib) tablets, for oral use

Initial U.S. Approval: 2014"
029a90b6-0722-49be-8400-3ec29526aafd,6,irbesartan,83818,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_029a90b6-0722-49be-8400-3ec29526aafd.json,"These highlights do not include all the information needed to use IRBESARTAN TABLETS safely and effectively. See full prescribing information for IRBESARTAN TABLETS.
 



IRBESARTAN tablets, for oral use
 

Initial U.S. Approval: 1997"
02c91fba-9c47-43ef-ac78-e82369798834,16,estradiol,4083,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20231130_02c91fba-9c47-43ef-ac78-e82369798834.json,These highlights do not include all the information needed to use NATAZIA safely and effectively.  See full prescribing information for NATAZIA.NATAZIA (estradiol valerate and estradiol valerate/dienogest) tablets for oral useInitial U.S. Approval: 2010
06f442d6-071e-4081-b7f7-40f3b803ab3f,4,sorafenib,495881,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240219_06f442d6-071e-4081-b7f7-40f3b803ab3f.json,"These highlights do not include all the information needed to use SORAFENIB TABLETS safely and effectively.
 
See full prescribing information for SORAFENIB TABLETS.
 
Sorafenib tablets, for oral use
 
Initial U.S. Approval: 2005"
08982e49-d2eb-4b25-b01a-1be52fd669ef,16,tipranavir,190548,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20220623_08982e49-d2eb-4b25-b01a-1be52fd669ef.json,"These highlights do not include all the information needed to use APTIVUS safely and effectively.  See full prescribing information for APTIVUS. 
APTIVUS® (tipranavir) capsules, for oral use APTIVUS® (tipranavir) oral solution Initial U.S. Approval: 2005"
0b1332a1-0581-4707-9bf6-1eccfa39bef4,2,futibatinib,2628190,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20230203_0b1332a1-0581-4707-9bf6-1eccfa39bef4.json,"These highlights do not include all the information needed to use LYTGOBI safely and effectively. See full prescribing information for LYTGOBI.
LYTGOBI® (futibatinib) tablets, for oral use
Initial U.S. Approval: 2022"
0edeb103-5e94-4f42-828f-c7336486c784,3,cephalexin,2231,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_0edeb103-5e94-4f42-828f-c7336486c784.json,These highlights do not include all the information needed to use CEPHALEXIN FOR ORAL SUSPENSION safely and effectively. See full prescribing information for CEPHALEXIN FOR ORAL SUSPENSION CEPHALEXIN for oral suspension Initial U.S. Approval: 1971
106b33e3-b199-e555-e063-6294a90a5af5,1,diltiazem,3443,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240220_106b33e3-b199-e555-e063-6294a90a5af5.json,"Diltiazem Hydrochloride Tablets, USP


Tablets"
113558e6-8b45-cdbd-e063-6394a90ac036,2,etodolac,24605,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240220_113558e6-8b45-cdbd-e063-6394a90ac036.json,"Etodolac Tablets, USP
  
(400 mg and 500 mg) 
 

Rx only"
144067b2-0532-476a-996e-e4a0a9d09b05,1,tenofovir disoproxil,300195,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20141007_144067b2-0532-476a-996e-e4a0a9d09b05.json,"These highlights do not include all the information needed to use STRIBILD safely and effectively. See full prescribing information for STRIBILD.
 STRIBILD® (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) tablets, for oral useInitial U.S. Approval: 2012"
1a0c3bea-c87b-4d25-bb44-5f0174da6b34,14,cabozantinib,1363268,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20230907_1a0c3bea-c87b-4d25-bb44-5f0174da6b34.json,"These highlights do not include all the information needed to use COMETRIQ safely and effectively. See full prescribing information for COMETRIQ.
COMETRIQ® (cabozantinib) capsules, for oral useInitial U.S. Approval: 2012"
1aa75a3a-18c9-49e1-91a6-293d0b7da756,8,procarbazine,8702,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20231121_1aa75a3a-18c9-49e1-91a6-293d0b7da756.json,"MATULANE 
  ®(procarbazine hydrochloride) Capsules"
1b5646a9-4724-44b8-8cd0-9c14f5e87f86,12,lamotrigine,28439,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_1b5646a9-4724-44b8-8cd0-9c14f5e87f86.json,"These highlights do not include all the information needed to use LAMOTRIGINE TABLETS safely and effectively. See full prescribing information for LAMOTRIGINE TABLETS.
 



LAMOTRIGINE Tablets, for oral use
 



Initial U.S. Approval: 1994"
2265ef30-253e-11df-8a39-0800200c9a66,42,ipilimumab,1094833,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011"
23b1f2f5-2d84-4a1e-997f-6489204878b2,102,captopril,1998,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240112_23b1f2f5-2d84-4a1e-997f-6489204878b2.json,"Captopril Tablets, USP

for oral use

Rx only"
26eb95ba-1f77-4496-a6ea-92bd63a40a3e,100,oxaprozin,32613,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231207_26eb95ba-1f77-4496-a6ea-92bd63a40a3e.json,"These highlights do not include all the information needed to use OXAPROZIN TABLETS safely and effectively. See full prescribing information for OXAPROZIN TABLETS.
OXAPROZIN tablets, for oral useInitial U.S. Approval: 1992"
26eb95ba-1f77-4496-a6ea-92bd63a40a3e,100,oxaprozin,32613,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231207_26eb95ba-1f77-4496-a6ea-92bd63a40a3e.json,"These highlights do not include all the information needed to use OXAPROZIN TABLETS safely and effectively. See full prescribing information for OXAPROZIN TABLETS.
OXAPROZIN tablets, for oral useInitial U.S. Approval: 1992"
2cab8dd1-3a10-48e6-86ce-0e5275ed49e5,10,toremifene,38409,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20230916_2cab8dd1-3a10-48e6-86ce-0e5275ed49e5.json,"These highlights do not include all the information needed to use FARESTON® safely and effectively. See full prescribing information for FARESTON®.


FARESTON® (toremifene citrate) 60 mg Tablets oral administration

Initial U.S. Approval: 1997"
2d45dd3c-71c3-4cc1-92ac-6dcecb195dd2,7,loxapine,6475,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_2d45dd3c-71c3-4cc1-92ac-6dcecb195dd2.json,"Loxapine Capsules, USP"
2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,46,tocilizumab,612865,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20230101_2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13.json,"These highlights do not include all the information needed to use ACTEMRA safely and effectively. See full prescribing information for ACTEMRA. 
 ACTEMRA® (tocilizumab) injection, for intravenous or subcutaneous use  Initial U.S. Approval: 2010"
38b482a8-960b-4591-9857-5031ecb830aa,35,blinatumomab,1597258,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240220_38b482a8-960b-4591-9857-5031ecb830aa.json,"These highlights do not include all the information needed to use BLINCYTO® safely and effectively. See full prescribing information for BLINCYTO.  
BLINCYTO® (blinatumomab) for injection, for intravenous use Initial U.S. Approval: 2014"
3f22c14f-3148-4037-9df0-5d910bc241f5,7,clonidine,2599,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_3f22c14f-3148-4037-9df0-5d910bc241f5.json,"CLONIDINE HYDROCHLORIDE TABLETS, USP"
41c095b6-acd9-4627-a813-bbca7ecafee5,10,donepezil,135447,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_41c095b6-acd9-4627-a813-bbca7ecafee5.json,"These highlights do not include all the information needed to use DONEPEZIL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for DONEPEZIL HYDROCHLORIDE TABLETS.
 

DONEPEZIL HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1996"
42f49299-7ae5-4d30-86eb-66b739c0e95d,5,lisinopril,29046,acute myocardial infarction,10000891,acute myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_42f49299-7ae5-4d30-86eb-66b739c0e95d.json,"These highlights do not include all the information needed to use LISINOPRIL TABLETS safely and effectively. See full prescribing information for LISINOPRIL TABLETS
 



LISINOPRIL tablets, for oral use
 



Initial U.S. Approval: 1988"
48ffeac8-38e8-4007-903a-dbffce25d679,2,etravirine,475969,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240110_48ffeac8-38e8-4007-903a-dbffce25d679.json,"These highlights do not include all the information needed to use ETRAVIRINE TABLETS safely and effectively.See full prescribing information for ETRAVIRINE TABLETS.
ETRAVIRINE tablets, for oral useInitial U.S. Approval: 2008"
49aa3d6d-2270-4615-aafa-b440859ab870,4,naltrexone,7243,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240216_49aa3d6d-2270-4615-aafa-b440859ab870.json,Naltrexone Hydrochloride Tablets USP 50 mg
4c486fc7-c8c4-4c6c-b30c-366dabaeaadd,14,gabapentin,25480,gi bleed,10018830,haematemesis,../data/2024_latest_labels/train_xml/20230830_4c486fc7-c8c4-4c6c-b30c-366dabaeaadd.json,"These highlights do not include all the information needed to use HORIZANT safely and effectively. See full prescribing information for HORIZANT. 
HORIZANT® (gabapentin enacarbil) Extended-Release Tablets for oral use Initial U.S. Approval: 2011"
51ff7db5-aaf9-4c3c-86e6-958ebf16b60f,10,nefazodone,31565,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20220716_51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.json,"Nefazodone Hydrochloride Tablets, USP

Rx only

(Patient Information Included)"
53bdb79c-c4cf-4818-b1f0-225e67a14536,24,clozapine,2626,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240209_53bdb79c-c4cf-4818-b1f0-225e67a14536.json,"These highlights do not include all the information needed to use CLOZAPINE TABLETS safely and effectively. See full prescribing information for CLOZAPINE TABLETS.
 
CLOZAPINE tablets, for oral use
 
Initial U.S. Approval: 1989"
5552884e-10ea-450c-9658-d3d4f33c946e,8,triclabendazole,2118525,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240123_5552884e-10ea-450c-9658-d3d4f33c946e.json,"These highlights do not include all the information needed to use EGATEN safely and effectively. See full prescribing information for EGATEN.EGATEN® (triclabendazole) tablets, for oral useInitial U.S. Approval: 2019"
56d64558-1fad-420e-8fcd-7103cd073127,1,celecoxib,140587,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240207_56d64558-1fad-420e-8fcd-7103cd073127.json,"These highlights do not include all the information needed to use CELECOXIB CAPSULES safely and effectively. See full prescribing information for CELECOXIB CAPSULES.
 

CELECOXIB capsules, for oral use
 

Initial U.S. Approval: 1998"
56d64558-1fad-420e-8fcd-7103cd073127,1,celecoxib,140587,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240207_56d64558-1fad-420e-8fcd-7103cd073127.json,"These highlights do not include all the information needed to use CELECOXIB CAPSULES safely and effectively. See full prescribing information for CELECOXIB CAPSULES.
 

CELECOXIB capsules, for oral use
 

Initial U.S. Approval: 1998"
575da603-b038-421f-9894-6796d9ac33cc,11,sertraline,36437,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_575da603-b038-421f-9894-6796d9ac33cc.json,"These highlights do not include all the information needed to use SERTRALINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for SERTRALINE HYDROCHLORIDE TABLETS.
 

SERTRALINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1991"
6093952a-5248-45cb-ad17-33716a411146,37,nilotinib,662281,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240216_6093952a-5248-45cb-ad17-33716a411146.json,"These highlights do not include all the information needed to use TASIGNA safely and effectively. See full prescribing information for TASIGNA.
TASIGNA® (nilotinib) capsules, for oral use
		Initial U.S. Approval: 2007"
6093952a-5248-45cb-ad17-33716a411146,37,nilotinib,662281,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240216_6093952a-5248-45cb-ad17-33716a411146.json,"These highlights do not include all the information needed to use TASIGNA safely and effectively. See full prescribing information for TASIGNA.
TASIGNA® (nilotinib) capsules, for oral use
		Initial U.S. Approval: 2007"
6093952a-5248-45cb-ad17-33716a411146,37,nilotinib,662281,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240216_6093952a-5248-45cb-ad17-33716a411146.json,"These highlights do not include all the information needed to use TASIGNA safely and effectively. See full prescribing information for TASIGNA.
TASIGNA® (nilotinib) capsules, for oral use
		Initial U.S. Approval: 2007"
61a0be9d-ee58-43e0-b5cb-141011835081,23,lomitapide,1364479,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240221_61a0be9d-ee58-43e0-b5cb-141011835081.json,"These highlights do not include all the information needed to use JUXTAPID safely and effectively. See full prescribing information for JUXTAPID. 
JUXTAPID® (lomitapide) capsules, for oral use Initial U.S. Approval: 2012"
64b7df84-c990-49f7-bc04-0cccfd7d2019,14,tramadol,10689,acute liver injury,10061008,biliary tract disorder,../data/2024_latest_labels/latest_labels_ingredients/20240217_64b7df84-c990-49f7-bc04-0cccfd7d2019.json,"These highlights do not include all the information needed to use TRAMADOL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for TRAMADOL HYDROCHLORIDE TABLETS.
 



TRAMADOL HYDROCHLORIDE tablets, for oral use, C-IV
 

Initial U.S. Approval: 1995"
66311f74-0472-4fa3-848a-06002ca0def5,22,interferon beta-1b,72257,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230812_66311f74-0472-4fa3-848a-06002ca0def5.json,"These highlights do not include all the information needed to use BETASERON safely and effectively.  See full prescribing information for BETASERON.
BETASERON (interferon beta-1b) for injection, for subcutaneous useInitial U.S. Approval: 1993"
6690679c-be2f-4588-a2e4-89fff74dd6be,9,tremelimumab,2619313,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240206_6690679c-be2f-4588-a2e4-89fff74dd6be.json,"These highlights do not include all the information needed to use IMJUDO safely and effectively. See full prescribing information for IMJUDO.IMJUDO® (tremelimumab-actl) injection, for intravenous useInitial U.S. Approval: 2022"
6690679c-be2f-4588-a2e4-89fff74dd6be,9,tremelimumab,2619313,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240206_6690679c-be2f-4588-a2e4-89fff74dd6be.json,"These highlights do not include all the information needed to use IMJUDO safely and effectively. See full prescribing information for IMJUDO.IMJUDO® (tremelimumab-actl) injection, for intravenous useInitial U.S. Approval: 2022"
68aaacbe-98c5-450b-9bf4-4809d7ad2ca0,18,latanoprost,43611,acute myocardial infarction,10002388,angina unstable,../data/2024_latest_labels/latest_labels_ingredients/20240113_68aaacbe-98c5-450b-9bf4-4809d7ad2ca0.json,"These highlights do not include all the information needed to use LATANOPROST OPHTHALMIC SOLUTION safely and effectively.  See full prescribing information for LATANOPROST OPHTHALMIC SOLUTION.
LATANOPROST ophthalmic solution 0.005%, for topical ophthalmic useInitial U.S. Approval: 1996"
6935e846-d5a1-49e5-89a2-f8ebe4d5590d,22,enfuvirtide,139896,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20221122_6935e846-d5a1-49e5-89a2-f8ebe4d5590d.json,"These highlights do not include all the information needed to use FUZEON safely and effectively. See full prescribing information for FUZEON. 
 FUZEON® (enfuvirtide) for Injection  Initial U.S. Approval: 2003"
6b4040a2-a5c5-4ff0-ab45-935d7e49cf78,7,bevacizumab,253337,acute myocardial infarction,10002388,angina unstable,../data/2024_latest_labels/latest_labels_ingredients/20231224_6b4040a2-a5c5-4ff0-ab45-935d7e49cf78.json,"These highlights do not include all the information needed to use 
ALYMSYS
safely and effectively. See full prescribing information for
 ALYMSYS
. 
ALYMSYS
®
 (bevacizumab-maly) injection, for intravenous use 
Initial U.S. Approval: 2022 ALYMSYS (bevacizumab-maly) is biosimilar* to AVASTIN (bevacizumab)"
6fa380c4-c885-4743-85bf-88819ae68645,8,almotriptan,279645,acute myocardial infarction,10000891,acute myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230414_6fa380c4-c885-4743-85bf-88819ae68645.json,"These highlights do not include all the information needed to use ALMOTRIPTAN TABLETS safely and effectively. See full prescribing information for ALMOTRIPTAN TABLETS.   ALMOTRIPTAN tablets, for oral use Initial U.S. Approval: 2001"
7447e8c6-c198-cd2d-e053-2a91aa0a3895,7,promethazine,8745,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_7447e8c6-c198-cd2d-e053-2a91aa0a3895.json,"PROMETHAZINE HCI INJECTION, USP 25mg/mL 1mL VIAL"
74e5060c-8426-1b77-e053-2a91aa0a1f13,8,methylprednisolone,6902,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_74e5060c-8426-1b77-e053-2a91aa0a1f13.json,SOLU-MEDROL® 40MG PER VIAL 1mL ACT-O-VIAL®
75c0c785-38e0-4049-a6fb-b77581f5b35c,6,cefiderocol,2265702,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20211124_75c0c785-38e0-4049-a6fb-b77581f5b35c.json,"These highlights do not include all the information needed to use FETROJA® safely and effectively. See full prescribing information for FETROJA. 
 FETROJA (cefiderocol) for injection, for intravenous use  Initial U.S. Approval: 2019"
7d655d6d-01da-488c-bd4e-c7fbe0ace38c,5,testosterone,10379,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240215_7d655d6d-01da-488c-bd4e-c7fbe0ace38c.json,"These highlights do not include all the information needed to use TESTOSTERONE GEL, 1% safely and effectively.  See full prescribing information for TESTOSTERONE GEL, 1%.

 TESTOSTERONE gel 1%, for topical use, CIII Initial U.S. Approval: 1953"
7e659505-c902-4906-9461-1cc83e2236d2,25,raltegravir,719872,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231210_7e659505-c902-4906-9461-1cc83e2236d2.json,"These highlights do not include all the information needed to use ISENTRESS safely and effectively. See full prescribing information for ISENTRESS. 
ISENTRESS® (raltegravir) film-coated tablets, for oral useISENTRESS® HD (raltegravir) film-coated tablets, for oral useISENTRESS® (raltegravir) chewable tablets, for oral useISENTRESS® (raltegravir) for oral suspensionInitial U.S. Approval: 2007"
7ee820e4-a479-4b7d-8730-101ac1f8015c,102,piroxicam,8356,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240113_7ee820e4-a479-4b7d-8730-101ac1f8015c.json,"These highlights do not include all the information needed to use PIROXICAM CAPSULES safely and effectively.  See full prescribing information for PIROXICAM CAPSULES.
PIROXICAM capsules, for oral useInitial U.S. Approval: 1982"
806b3e38-3b2a-4aaa-973c-e2d921bb353e,10,venlafaxine,39786,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240224_806b3e38-3b2a-4aaa-973c-e2d921bb353e.json,"Venlafaxine Tablets, USP
 
Rx only"
81a33cfa-262f-4432-a05d-7dd260928437,7,isopropyl alcohol,797541,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240130_81a33cfa-262f-4432-a05d-7dd260928437.json,"These highlights do not include all the information needed to use ABRILADA safely and effectively. See full prescribing information for ABRILADA.
ABRILADA™ (adalimumab-afzb) injection, for subcutaneous useInitial U.S. Approval: 2019
ABRILADA (adalimumab-afzb) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of ABRILADA has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to HUMIRA (adalimumab)."
824f19c9-0546-4a8a-8d8f-c4055c04f7c7,33,regorafenib,1312397,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231202_824f19c9-0546-4a8a-8d8f-c4055c04f7c7.json,"These highlights do not include all the information needed to use STIVARGA safely and effectively.  See full prescribing information for STIVARGA.STIVARGA® (regorafenib) tablets, for oral useInitial U.S. Approval: 2012"
84137882-e000-47da-bd5b-fa76ab3c76f9,20,axitinib,1242999,acute liver injury,10024670,liver disorder,../data/2024_latest_labels/latest_labels_ingredients/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012"
857e53aa-1098-4dad-b654-0276cdd43e03,4,asparaginase,1156,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20221201_857e53aa-1098-4dad-b654-0276cdd43e03.json,"These highlights do not include all the information needed to use RYLAZE safely and effectively. See full prescribing information for RYLAZE.
RYLAZE® (asparaginase erwinia chrysanthemi (recombinant)-rywn) injection, for intramuscular useInitial U.S. Approval: 2021"
904899f2-9c54-44d2-901e-47e894571500,2,norethindrone,7514,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240112_904899f2-9c54-44d2-901e-47e894571500.json,"ERRIN® (NORETHINDRONE TABLETS USP, 0.35 MG)"
96f19af4-de8f-4fd7-90d8-55fe6ebdd81d,15,meclofenamate,588003,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20211014_96f19af4-de8f-4fd7-90d8-55fe6ebdd81d.json,""
99fb821a-fe33-4468-9026-9729a8deff08,5,cyproheptadine,3013,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240118_99fb821a-fe33-4468-9026-9729a8deff08.json,CYPROHEPTADINE HYDROCHLORIDE TABLETS USPRx only
9aba3135-00ff-47ba-b926-55eb16b361bf,7,chlordiazepoxide,2356,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_9aba3135-00ff-47ba-b926-55eb16b361bf.json,"Chlordiazepoxide Hydrochloride Capsules, USP CIV
 

Rx only"
9c9d9f5c-bfd1-4e2a-be4a-697344ca6833,11,citalopram,2556,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_9c9d9f5c-bfd1-4e2a-be4a-697344ca6833.json,"These highlights do not include all the information needed to use citalopram tablets safely and effectively. See full prescribing information for citalopram tablets.
 


CITALOPRAM (Citalopram) tablets, for oral use
 


Initial U.S. Approval: 1998"
9c9d9f5c-bfd1-4e2a-be4a-697344ca6833,11,citalopram,2556,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_9c9d9f5c-bfd1-4e2a-be4a-697344ca6833.json,"These highlights do not include all the information needed to use citalopram tablets safely and effectively. See full prescribing information for citalopram tablets.
 


CITALOPRAM (Citalopram) tablets, for oral use
 


Initial U.S. Approval: 1998"
9d88f915-13dd-5463-e053-2a95a90a09bf,3,enalaprilat,3829,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_9d88f915-13dd-5463-e053-2a95a90a09bf.json,ENALAPRILAT INJECTION 1.25mg/mL 1mL VIAL
9e5c0ef3-3179-4d7b-bc76-901473c73ce8,20,varenicline,591622,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240220_9e5c0ef3-3179-4d7b-bc76-901473c73ce8.json,"These highlights do not include all the information needed to use VARENICLINE TABLETS safely and effectively. See full prescribing information for VARENICLINE TABLETS.



VARENICLINE tablets, for oral use 

Initial U.S. Approval: 2006"
9e5c0ef3-3179-4d7b-bc76-901473c73ce8,20,varenicline,591622,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240220_9e5c0ef3-3179-4d7b-bc76-901473c73ce8.json,"These highlights do not include all the information needed to use VARENICLINE TABLETS safely and effectively. See full prescribing information for VARENICLINE TABLETS.



VARENICLINE tablets, for oral use 

Initial U.S. Approval: 2006"
a1787fad-3612-43e1-98fa-ce62361e0b3c,13,imatinib,282388,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240203_a1787fad-3612-43e1-98fa-ce62361e0b3c.json,"These highlights do not include all the information needed to use IMATINIB MESYLATE TABLETS safely and effectively.  See full prescribing information for IMATINIB MESYLATE TABLETS. IMATINIB MESYLATE tablets, for oral useInitial U.S. Approval: 2001"
a3b50576-cd40-4f7e-9506-bd0a61988424,3,famotidine,4278,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240220_a3b50576-cd40-4f7e-9506-bd0a61988424.json,"These highlights do not include all the information needed to use FAMOTIDINE TABLETS safely and effectively. See full prescribing information for FAMOTIDINE TABLETS.
 
FAMOTIDINE tablets, for oral use
 
Initial U.S. Approval: 1986"
a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811,1,lisdexamfetamine,700810,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240220_a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811.json,"These highlights do not include all the information needed to use LISDEXAMFETAMINE DIMESYLATE CHEWABLE TABLETS safely and effectively. See full prescribing information for LISDEXAMFETAMINE DIMESYLATE CHEWABLE TABLETS. LISDEXAMFETAMINE DIMESYLATE chewable tablets, for oral use, CII Initial U.S. Approval: 2007"
a99335d0-1e87-4180-bde3-cbb12bf91a52,1,dexmedetomidine,48937,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240215_a99335d0-1e87-4180-bde3-cbb12bf91a52.json,"These highlights do not include all the information needed to use DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION.
DEXMEDETOMIDINE HYDROCHLORIDE in 0.9% SODIUM CHLORIDE injection, for intravenous use
Initial U.S. Approval: 1999"
accf9569-4b57-4e83-a7db-4e890a75d1ba,23,mitoxantrone,7005,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20220420_accf9569-4b57-4e83-a7db-4e890a75d1ba.json,"MitoXANTRONE Injection, USP (concentrate)"
b023a9f2-1a99-4b40-a953-edac7e3a79bf,15,anastrozole,84857,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240220_b023a9f2-1a99-4b40-a953-edac7e3a79bf.json,"These highlights do not include all the information needed to use anastrozole tablets safely and effectively. See full prescribing information for anastrozole tablets.
 

ANASTROZOLE tablet for oral use
 

Initial U.S. Approval: 1995"
b0c23a2c-b250-4c0d-9b2a-c1483faa2ca0,15,propylthiouracil,8794,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240213_b0c23a2c-b250-4c0d-9b2a-c1483faa2ca0.json,"Propylthiouracil Tablets, USP"
b605b541-4bfd-db3e-9710-11c27f6dee6c,2,bortezomib,358258,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240105_b605b541-4bfd-db3e-9710-11c27f6dee6c.json,"These highlights do not include all the information needed to use BORTEZOMIB FOR INJECTION safely and effectively. See full prescribing information for BORTEZOMIB FOR INJECTION.
 BORTEZOMIB for injection, for subcutaneous or intravenous useInitial U.S. Approval: 2003"
b605b541-4bfd-db3e-9710-11c27f6dee6c,2,bortezomib,358258,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240105_b605b541-4bfd-db3e-9710-11c27f6dee6c.json,"These highlights do not include all the information needed to use BORTEZOMIB FOR INJECTION safely and effectively. See full prescribing information for BORTEZOMIB FOR INJECTION.
 BORTEZOMIB for injection, for subcutaneous or intravenous useInitial U.S. Approval: 2003"
b6465b44-a6dd-f99c-d009-6851cf05169c,11,trastuzumab,224905,gi bleed,10030172,oesophageal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240125_b6465b44-a6dd-f99c-d009-6851cf05169c.json,"These highlights do not include all the information needed to use OGIVRI safely and effectively.  See full prescribing information for OGIVRI. 
OGIVRI® (trastuzumab-dkst) for injection, for intravenous use
Initial U.S. Approval: 2017
 

OGIVRI® (trastuzumab-dkst) is biosimilar* to HERCEPTIN (trastuzumab)."
b7241707-7538-4d1a-91e7-3a25a91e0b9a,14,ifosfamide,5657,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231116_b7241707-7538-4d1a-91e7-3a25a91e0b9a.json,"These highlights do not include all the information needed to use IFEX (ifosfamide) safely and effectively.  See full prescribing information for IFEX.
IFEX (ifosfamide) for injection, intravenous useInitial U.S. Approval: 1988"
b9bc3907-bfa7-4d9f-90d9-c2097230f7e4,5,ethacrynate,62349,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231231_b9bc3907-bfa7-4d9f-90d9-c2097230f7e4.json,"Ethacrynic Acid Tablets, USP 

(25 mg)


Rx Only"
ba1cca98-f350-4655-88e3-6ef990779fb9,1,telithromycin,274786,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20120511_ba1cca98-f350-4655-88e3-6ef990779fb9.json,"KETEK®
(telithromycin) Tablets"
bc737938-ae36-460b-a2a8-609f3fe59156,2,vancomycin,11124,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240216_bc737938-ae36-460b-a2a8-609f3fe59156.json,"These highlights do not include all the information needed to use VANCOMYCIN HYDROCHLORIDE CAPSULES safely and effectively. See full prescribing information for VANCOMYCIN HYDROCHLORIDE CAPSULES.  VANCOMYCIN HYDROCHLORIDE capsules, for oral use Initial U.S. Approval: 1986 To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin hydrochloride capsules and other antibacterial drugs, vancomycin hydrochloride capsules should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria."
c00d1607-ac36-457b-a34b-75ad74f9cf0a,32,saquinavir,83395,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20210630_c00d1607-ac36-457b-a34b-75ad74f9cf0a.json,"These highlights do not include all the information needed to use INVIRASE safely and effectively. See full prescribing information for INVIRASE. 
INVIRASE® (saquinavir mesylate) tablets, for oral use
 Initial U.S. Approval: 1995"
c16ac648-d5d2-9f7d-8637-e2328572754e,15,belatacept,1112973,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230125_c16ac648-d5d2-9f7d-8637-e2328572754e.json,"These highlights do not include all the information needed to use NULOJIX safely and effectively. See full prescribing information for NULOJIX.
NULOJIX (belatacept) for injection, for intravenous useInitial U.S. Approval: 2011"
c2575a86-19e5-44df-8603-ff066bb9c9c5,12,trifluoperazine,10800,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240214_c2575a86-19e5-44df-8603-ff066bb9c9c5.json,""
c3658bc8-1524-43db-930e-66f9ac01b808,11,telmisartan,73494,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240124_c3658bc8-1524-43db-930e-66f9ac01b808.json,"These highlights do not include all the information needed to use TELMISARTAN TABLETS safely and effectively. See full prescribing information for TELMISARTAN TABLETS.  TELMISARTAN tablets, for oral useInitial U.S. Approval: 1998"
c7bb6ba1-9a7f-43f5-b058-ef26d4b59221,3,everolimus,141704,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240222_c7bb6ba1-9a7f-43f5-b058-ef26d4b59221.json,"These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS.
 EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009"
d2daba09-f1c2-4764-a567-1291be4892b9,100,posaconazole,282446,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240124_d2daba09-f1c2-4764-a567-1291be4892b9.json,"These highlights do not include all the information needed to use
POSACONAZOLE DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for

POSACONAZOLE

DELAYED-RELEASE TABLETS
.



POSACONAZOLE

delayed-release tablets, for oral use

Initial U.S. Approval: 2006"
d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,1,tinzaparin,69646,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20080508_d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee.json,INNOHEP®(tinzaparin sodium injection)
d4737be8-7c17-4548-b380-808c5b4ad7ac,8,oxcarbazepine,32624,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240224_d4737be8-7c17-4548-b380-808c5b4ad7ac.json,"These highlights do not include all the information needed to use OXCARBAZEPINE TABLETS safely and effectively. See full prescribing information for OXCARBAZEPINE TABLETS.
 



OXCARBAZEPINE tablets, for oral use
 

Initial U.S. Approval: 2000"
e4c45bb5-15f4-437e-ab98-a649b3676d14,22,lomitapide,1364479,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/gold_xml/20220430_e4c45bb5-15f4-437e-ab98-a649b3676d14.json,"These highlights do not include all the information needed to use JUXTAPID safely and effectively. See full prescribing information for JUXTAPID. 
JUXTAPID® (lomitapide) capsules, for oral use Initial U.S. Approval: 2012"
ed23b6bc-32c7-4c50-a53d-313ae78e5623,13,cefotaxime,2186,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20210804_ed23b6bc-32c7-4c50-a53d-313ae78e5623.json,"CEFOTAXIME FOR INJECTION, USP"
f0ba651e-3d8a-11df-8fbe-119855d89593,14,pentosan polysulfate,155046,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20221111_f0ba651e-3d8a-11df-8fbe-119855d89593.json,"ELMIRON 
 ®-100 MG
 

(PENTOSAN POLYSULFATE SODIUM)
 

CAPSULES"
f34c08e6-fe74-4de3-9e36-a82c3c1c183b,9,moxifloxacin,139462,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240214_f34c08e6-fe74-4de3-9e36-a82c3c1c183b.json,"These highlights do not include all the information needed to use MOXIFLOXACIN TABLETS safely and effectively. See full prescribing information for MOXIFLOXACIN TABLETS.
 MOXIFLOXACIN tablets, for oral use Initial U.S. Approval: 1999"
f3c516ad-d405-4fbe-af6a-962080dbfa7d,3,aldesleukin,70223,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240208_f3c516ad-d405-4fbe-af6a-962080dbfa7d.json,"These highlights do not include all the information needed to use PROLEUKIN® safely and effectively. See full prescribing information for PROLEUKIN. 
 PROLEUKIN (aldesleukin) for injection, for intravenous use  Initial U.S. Approval: 1992"
fa7d93e3-b69b-4e02-8146-89760cd8e9d6,6,avanafil,1291301,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230910_fa7d93e3-b69b-4e02-8146-89760cd8e9d6.json,"These highlights do not include all the information needed to use 
STENDRA
 safely and effectively.  See full prescribing information for 
STENDRA
.



STENDRA

®

 (avanafil) 
tablets, for oral use

Initial U.S. Approval:  
2012"
fabf55db-8b50-491f-b76d-a0fe5fb6c9b0,17,ciprofloxacin,2551,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240217_fabf55db-8b50-491f-b76d-a0fe5fb6c9b0.json,"These highlights do not include all the information needed to use CIPROFLOXACIN TABLETS safely and effectively. See full prescribing information for CIPROFLOXACIN TABLETS.
 

CIPROFLOXACIN tablet, for oral use
 
Initial U.S. Approval: 1987"
ff3b5265-f533-4332-a861-d8c9c1664ffd,15,lamivudine,68244,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240104_ff3b5265-f533-4332-a861-d8c9c1664ffd.json,"These highlights do not include all the information needed to use LAMIVUDINE TABLETS safely and effectively. See full prescribing information for LAMIVUDINE TABLETS.LAMIVUDINE tablets, for oral useInitial U.S. Approval: 1995"
00aa81c2-73c7-4bf8-94e9-f644381b631f,4,esomeprazole,283742,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240119_00aa81c2-73c7-4bf8-94e9-f644381b631f.json,"These highlights do not include all the information needed to use ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES.
 

ESOMEPRAZOLE MAGNESIUM delayed-release capsules, for oral use
 

Initial U.S. Approval: 1989 (omeprazole)"
02c91fba-9c47-43ef-ac78-e82369798834,16,estradiol,4083,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/train_xml/20231130_02c91fba-9c47-43ef-ac78-e82369798834.json,These highlights do not include all the information needed to use NATAZIA safely and effectively.  See full prescribing information for NATAZIA.NATAZIA (estradiol valerate and estradiol valerate/dienogest) tablets for oral useInitial U.S. Approval: 2010
03af7d09-314a-fe85-e063-6294a90afa25,1,valsartan,69749,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240127_03af7d09-314a-fe85-e063-6294a90afa25.json,"These highlights do not include all the information needed to use VALSARTAN TABLETS safely and effectively. See full prescribing information for VALSARTAN TABLETS.
 

VALSARTAN tablets, for ORAL use
 
Initial U.S. Approval: 1996"
0b8bf078-34c2-4f45-9012-38a8ac082b01,6,adagrasib,2625882,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240223_0b8bf078-34c2-4f45-9012-38a8ac082b01.json,"These highlights do not include all the information needed to use KRAZATI safely and effectively. See full prescribing information for KRAZATI. 
 KRAZATI® (adagrasib) tablets, for oral use  Initial U.S. Approval: 2022"
0f15cb50-5917-c928-e063-6294a90ab284,2,cevimeline,44281,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240217_0f15cb50-5917-c928-e063-6294a90ab284.json,"Cevimeline Hydrochloride Capsules
 
Rx only"
0fd36cb9-c4f6-4167-93c9-8530865db3f9,155,darbepoetin alfa,283838,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20230629_0fd36cb9-c4f6-4167-93c9-8530865db3f9.json,"These highlights do not include all the information needed to use 
ARANESP 
safely and effectively.  
See full prescribing information for 
ARANESP
.

   

ARANESP

®

 (darbepoetin alfa
)
 
i
njection, for intravenous or subcutaneous use

Initial U.S. Approval: 2001"
10a3fbc9-00c6-ad83-e063-6294a90ae1ad,1,omeprazole,7646,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240220_10a3fbc9-00c6-ad83-e063-6294a90ae1ad.json,"These highlights do not include all the information needed to use OMEPRAZOLE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for OMEPRAZOLE DELAYED-RELEASE CAPSULES.
 

OMEPRAZOLE delayed-release capsules, for oral use
 
Initial U.S. Approval: 1989"
1276283e-21b0-4932-864f-547c62bd49e5,5,ursodeoxycholate,62427,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240217_1276283e-21b0-4932-864f-547c62bd49e5.json,"Ursodiol Capsules, USP
 

Rx Only
 

Prescribing Information"
144067b2-0532-476a-996e-e4a0a9d09b05,1,cobicistat,1306284,acute liver injury,10023126,jaundice,../data/2024_latest_labels/train_xml/20141007_144067b2-0532-476a-996e-e4a0a9d09b05.json,"These highlights do not include all the information needed to use STRIBILD safely and effectively. See full prescribing information for STRIBILD.
 STRIBILD® (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) tablets, for oral useInitial U.S. Approval: 2012"
18bbd246-5709-4477-b10a-f811f3801962,6,imipramine,5691,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_18bbd246-5709-4477-b10a-f811f3801962.json,"Imipramine Hydrochloride Tablets, USP
 
Rx Only"
1b5646a9-4724-44b8-8cd0-9c14f5e87f86,12,lamotrigine,28439,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240224_1b5646a9-4724-44b8-8cd0-9c14f5e87f86.json,"These highlights do not include all the information needed to use LAMOTRIGINE TABLETS safely and effectively. See full prescribing information for LAMOTRIGINE TABLETS.
 



LAMOTRIGINE Tablets, for oral use
 



Initial U.S. Approval: 1994"
1b5646a9-4724-44b8-8cd0-9c14f5e87f86,12,lamotrigine,28439,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_1b5646a9-4724-44b8-8cd0-9c14f5e87f86.json,"These highlights do not include all the information needed to use LAMOTRIGINE TABLETS safely and effectively. See full prescribing information for LAMOTRIGINE TABLETS.
 



LAMOTRIGINE Tablets, for oral use
 



Initial U.S. Approval: 1994"
1b8a4689-3916-4f4b-b54a-bbb4e322d79b,13,atenolol,1202,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_1b8a4689-3916-4f4b-b54a-bbb4e322d79b.json,"Atenolol Tablets, USP Rx only"
2265ef30-253e-11df-8a39-0800200c9a66,42,ipilimumab,1094833,gi bleed,10030210,oesophageal varices haemorrhage,../data/2024_latest_labels/train_xml/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011"
24ac0ee2-cd7b-4dda-a1bb-271e32331758,3,febuxostat,73689,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/train_xml/20191219_24ac0ee2-cd7b-4dda-a1bb-271e32331758.json,"These HIGHLIGHTS do not include all the information needed to use ULORIC safely and effectively. See full prescribing information for ULORIC. 
 ULORIC (febuxostat) tablet for oral use  Initial U.S. Approval: 2009"
24ac0ee2-cd7b-4dda-a1bb-271e32331758,3,febuxostat,73689,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20191219_24ac0ee2-cd7b-4dda-a1bb-271e32331758.json,"These HIGHLIGHTS do not include all the information needed to use ULORIC safely and effectively. See full prescribing information for ULORIC. 
 ULORIC (febuxostat) tablet for oral use  Initial U.S. Approval: 2009"
304a3059-4f7f-4ec4-839d-86492bb5e07b,6,memantine,6719,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240221_304a3059-4f7f-4ec4-839d-86492bb5e07b.json,"These highlights do not include all the information needed to use MEMANTINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for MEMANTINE HYDROCHLORIDE TABLETS.
 
MEMANTINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 2003"
37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,45,mycophenolate mofetil,68149,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_37241e87-4af4-4dc3-a1aa-ea6f20d8dc40.json,"These highlights do not include all the information needed to use CELLCEPT® safely and effectively. See full prescribing information for CELLCEPT® 
CELLCEPT® (mycophenolate mofetil) capsules, for oral use CELLCEPT® (mycophenolate mofetil) tablets, for oral use CELLCEPT®  Oral Suspension (mycophenolate mofetil), for oral suspension CELLCEPT®  Intravenous (mycophenolate mofetil) for injection, for intravenous use Initial U.S. Approval: 1995"
3a404db2-7a7d-476f-81cf-979a67d37f66,7,tadalafil,358263,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240223_3a404db2-7a7d-476f-81cf-979a67d37f66.json,"These highlights do not include all the information needed to use ALYQ™ safely and effectively.  See full prescribing information for ALYQ™. 


ALYQ™ (tadalafil) tablets for oral administration

Initial U.S. Approval: 2003"
3c52dddd-0457-41cd-99e0-d30d4fd00ec5,4,maraviroc,620216,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231111_3c52dddd-0457-41cd-99e0-d30d4fd00ec5.json,"These highlights do not include all the information needed to use SELZENTRY safely and effectively. See full prescribing information for SELZENTRY.
SELZENTRY (maraviroc) tablets, for oral useSELZENTRY (maraviroc) oral solutionInitial U.S. Approval: 2007"
4034fb6d-f55d-4df0-b500-d6a413591f6e,39,doxazosin,49276,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240224_4034fb6d-f55d-4df0-b500-d6a413591f6e.json,"These highlights do not include all the information needed to use DOXAZOSIN TABLETS safely and effectively. See full prescribing information for DOXAZOSIN TABLETS.




DOXAZOSIN tablets, for oral use 




Initial U.S. Approval: 1990"
4238a064-1bfd-4ce3-b9d9-12c96eee8af0,2,olmesartan,321064,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240217_4238a064-1bfd-4ce3-b9d9-12c96eee8af0.json,"These highlights do not include all the information needed to use OLMESARTAN MEDOXOMIL TABLETS safely and effectively. See full prescribing information for OLMESARTAN MEDOXOMIL TABLETS.  OLMESARTAN MEDOXOMIL tablets, for oral use   Initial U.S. Approval: 2002"
42c49deb-713b-427a-9670-08af08adcffb,22,alectinib,1727455,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20220618_42c49deb-713b-427a-9670-08af08adcffb.json,"These highlights do not include all the information needed to use ALECENSA safely and effectively. See full prescribing information for ALECENSA. 
ALECENSA® (alectinib) capsules, for oral useInitial U.S. Approval: 2015"
43ba3de1-ab2e-06f6-e054-00144ff8d46c,3,auranofin,1227,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20181215_43ba3de1-ab2e-06f6-e054-00144ff8d46c.json,"PRESCRIBING INFORMATION
 



RIDAURA 
 ®




Auranofin
 



Capsules"
49596de6-ab18-49d1-9e5b-30968fc21c36,26,vincristine,11202,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230202_49596de6-ab18-49d1-9e5b-30968fc21c36.json,"VinCRIStine Sulfate 

Injection, USP"
49aa3d6d-2270-4615-aafa-b440859ab870,4,naltrexone,7243,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240216_49aa3d6d-2270-4615-aafa-b440859ab870.json,Naltrexone Hydrochloride Tablets USP 50 mg
4b5f7c65-aa2d-452a-b3db-bc85c06ff12f,20,cariprazine,1667655,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_4b5f7c65-aa2d-452a-b3db-bc85c06ff12f.json,"These highlights do not include all the information needed to use 
VRAYLAR
 safely and effectively.  
See full prescribing information for 
VRAYLAR
.  

   

VRAYLAR

®

 (
cariprazine
)
 
c
apsules
,
 
for 
o
ral 
u
se

Initial U.S. Approval: 
2015"
4dd14728-02b4-4e75-b9c6-227be7816d5b,9,abacavir,190521,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240217_4dd14728-02b4-4e75-b9c6-227be7816d5b.json,"These highlights do not include all the information needed to use ABACAVIR TABLETS safely and effectively. See full prescribing information for ABACAVIR TABLETS.
 



ABACAVIR tablets, for oral use
 

Initial U.S. Approval: 1998"
4e338e89-3cf2-48eb-b6e2-a06c608c6513,36,abiraterone,1100072,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/train_xml/20211016_4e338e89-3cf2-48eb-b6e2-a06c608c6513.json,"These highlights do not include all the information needed to use ZYTIGA safely and effectively. See full prescribing information for ZYTIGA. 
ZYTIGA® (abiraterone acetate) tablets, for oral use Initial U.S. Approval: 2011"
4e338e89-3cf2-48eb-b6e2-a06c608c6513,36,abiraterone,1100072,acute myocardial infarction,10002388,angina unstable,../data/2024_latest_labels/train_xml/20211016_4e338e89-3cf2-48eb-b6e2-a06c608c6513.json,"These highlights do not include all the information needed to use ZYTIGA safely and effectively. See full prescribing information for ZYTIGA. 
ZYTIGA® (abiraterone acetate) tablets, for oral use Initial U.S. Approval: 2011"
4ffd02a3-86b8-4af7-b539-aa32e38c6b12,14,colesevelam,141626,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240209_4ffd02a3-86b8-4af7-b539-aa32e38c6b12.json,"These highlights do not include all the information needed to use COLESEVELAM HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for COLESEVELAM HYDROCHLORIDE TABLETS.
 COLESEVELAM HYDROCHLORIDE tablets, for oral use
 Initial U.S. Approval: 2000"
51635427-fb13-45ee-813d-a40b0405d14f,7,diclofenac,3355,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240224_51635427-fb13-45ee-813d-a40b0405d14f.json,"Diclofenac Sodium Extended-Release Tablets, USP, Tablets of 100 mg
  

Rx only
  

Prescribing Information"
51a88e8e-da02-4b97-9e7e-442fbffd908d,8,amiodarone,703,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_51a88e8e-da02-4b97-9e7e-442fbffd908d.json,"These highlights do not include all the information needed to use AMIODARONE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for AMIODARONE HYDROCHLORIDE TABLETS.
 

AMIODARONE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1985"
56b6ba36-9b49-4422-a2a4-7bfa0d941a5d,2,flutamide,4508,acute liver injury,10019660,hepatic encephalopathy,../data/2024_latest_labels/latest_labels_ingredients/20220115_56b6ba36-9b49-4422-a2a4-7bfa0d941a5d.json,EULEXINTM (flutamide) CAPSULES USP
56d64558-1fad-420e-8fcd-7103cd073127,1,celecoxib,140587,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240207_56d64558-1fad-420e-8fcd-7103cd073127.json,"These highlights do not include all the information needed to use CELECOXIB CAPSULES safely and effectively. See full prescribing information for CELECOXIB CAPSULES.
 

CELECOXIB capsules, for oral use
 

Initial U.S. Approval: 1998"
575da603-b038-421f-9894-6796d9ac33cc,11,sertraline,36437,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_575da603-b038-421f-9894-6796d9ac33cc.json,"These highlights do not include all the information needed to use SERTRALINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for SERTRALINE HYDROCHLORIDE TABLETS.
 

SERTRALINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1991"
58c4261e-e98f-4280-9562-2800956dff14,16,glimepiride,25789,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_58c4261e-e98f-4280-9562-2800956dff14.json,"These highlights do not include all the information needed to use GLIMEPIRIDE TABLETS safely and effectively. See full prescribing information for GLIMEPIRIDE TABLETS.
 

GLIMEPIRIDE tablets for oral use
 

Initial U.S. Approval: 1995"
5a1cbf7e-0352-aa3b-080c-222a6423ecd8,11,entecavir,306266,acute liver injury,10019660,hepatic encephalopathy,../data/2024_latest_labels/latest_labels_ingredients/20240110_5a1cbf7e-0352-aa3b-080c-222a6423ecd8.json,"Entecavir Tablets, USP
 
Rx Only
 

These highlights do not include all the information needed to use ENTECAVIR TABLETS safely and effectively. See full prescribing information for ENTECAVIR TABLETS.
 

Initial U.S. Approval: 2005"
5a9ef4ea-c76a-4d34-a604-27c5b505f5a4,27,liraglutide,475968,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/gold_xml/20230715_5a9ef4ea-c76a-4d34-a604-27c5b505f5a4.json,"These highlights do not include all the information needed to use VICTOZA safely and effectively. See full prescribing information for VICTOZA.VICTOZA® (liraglutide) injection, for subcutaneous useInitial U.S. Approval: 2010"
5a9ef4ea-c76a-4d34-a604-27c5b505f5a4,27,liraglutide,475968,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/gold_xml/20230715_5a9ef4ea-c76a-4d34-a604-27c5b505f5a4.json,"These highlights do not include all the information needed to use VICTOZA safely and effectively. See full prescribing information for VICTOZA.VICTOZA® (liraglutide) injection, for subcutaneous useInitial U.S. Approval: 2010"
6093952a-5248-45cb-ad17-33716a411146,37,nilotinib,662281,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240216_6093952a-5248-45cb-ad17-33716a411146.json,"These highlights do not include all the information needed to use TASIGNA safely and effectively. See full prescribing information for TASIGNA.
TASIGNA® (nilotinib) capsules, for oral use
		Initial U.S. Approval: 2007"
645af8f4-0843-4afb-9ddc-f587f38adb68,8,demeclocycline,3154,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231221_645af8f4-0843-4afb-9ddc-f587f38adb68.json,"DEMECLOCYCLINE HYDROCHLORIDE TABLETS, USPRx only"
6c3408ac-d401-4925-8a03-26591afbc240,10,binimetinib,2049122,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231019_6c3408ac-d401-4925-8a03-26591afbc240.json,"These highlights do not include all the information needed to use MEKTOVI safely and effectively. See full prescribing information for MEKTOVI.
MEKTOVI® (binimetinib) tablets, for oral useInitial U.S. Approval: 2018"
6c5c47ab-28ee-11e1-bfc2-0800200c9a66,19,estradiol,4083,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_6c5c47ab-28ee-11e1-bfc2-0800200c9a66.json,"These highlights do not include all the information needed to use MINIVELLE safely and effectively. See full prescribing information for MINIVELLE.
         

MINIVELLE® (estradiol transdermal system) 
Initial U.S. Approval: 1975"
6c5c47ab-28ee-11e1-bfc2-0800200c9a66,19,estradiol,4083,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_6c5c47ab-28ee-11e1-bfc2-0800200c9a66.json,"These highlights do not include all the information needed to use MINIVELLE safely and effectively. See full prescribing information for MINIVELLE.
         

MINIVELLE® (estradiol transdermal system) 
Initial U.S. Approval: 1975"
6d1c87df-b319-4c63-9f19-6584d7c4ff8e,8,rifampin,9384,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240119_6d1c87df-b319-4c63-9f19-6584d7c4ff8e.json,Rifampin Capsules USP
6fc9c8e2-6f34-aa43-e053-2a91aa0ac377,10,quetiapine,51272,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240221_6fc9c8e2-6f34-aa43-e053-2a91aa0ac377.json,"QUETIAPINE TABLETS. These highlights do not include all the information needed to use QUETIAPINE TABLETS safely and effectively. See full prescribing information for QUETIAPINE TABLETS.
 

Quetiapine tablets, for oral use
 

Initial U.S. Approval: 1997"
7602fb73-3ce3-5978-e053-2991aa0abea3,8,phenylephrine,8163,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_7602fb73-3ce3-5978-e053-2991aa0abea3.json,"PHENYLEPHRINE HCI INJECTION, USP 10mg/mL 1mL VIAL"
793062e5-5a0c-40f9-8d8b-ca0862cd8a37,11,aripiprazole,89013,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240217_793062e5-5a0c-40f9-8d8b-ca0862cd8a37.json,"These highlights do not include all the information needed to use ARIPIPRAZOLE TABLETS safely and effectively. See full prescribing information for ARIPIPRAZOLE TABLETS.
 



ARIPIPRAZOLE tablets, for oral use
 

Initial U.S. Approval: 2002"
79eec27d-ac63-4996-8b1a-c2cd52ad2b2c,5,argatroban,15202,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240117_79eec27d-ac63-4996-8b1a-c2cd52ad2b2c.json,"These highlights do not include all the information needed to use ARGATROBAN INJECTION safely and effectively. See full prescribing information for ARGATROBAN INJECTION.


ARGATROBAN INJECTION, for intravenous infusion only 

Initial U.S. Approval: 2000"
7e9ab975-db2f-423c-a089-bc5a73313609,11,rivaroxaban,1114195,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231208_7e9ab975-db2f-423c-a089-bc5a73313609.json,"These highlights do not include all the information needed to use XARELTO safely and effectively. See full prescribing information for XARELTO.
 



XARELTO 
 ® (rivaroxaban) tablets, for oral use
 

XARELTO 
 ® (rivaroxaban) for oral suspension
 

Initial U.S. Approval: 2011"
84137882-e000-47da-bd5b-fa76ab3c76f9,20,axitinib,1242999,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012"
8ca926e0-4c3c-473f-9cd0-ff38032d6963,2,oseltamivir,260101,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240117_8ca926e0-4c3c-473f-9cd0-ff38032d6963.json,"These highlights do not include all the information needed to use OSELTAMIVIR PHOSPHATE CAPSULES safely and effectively. See full prescribing information for OSELTAMIVIR PHOSPHATE CAPSULES. 
OSELTAMIVIR phosphate capsules, for oral useInitial U.S. Approval: 1999"
8d5ace90-983b-48c4-baf1-b44f6af146de,2,carbamazepine,2002,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240221_8d5ace90-983b-48c4-baf1-b44f6af146de.json,"Carbamazepine Oral Suspension, USP
 
Rx only
 
Prescribing Information"
8ded0773-3aec-4e89-9836-d22a5a84abf0,17,quinapril,35208,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231215_8ded0773-3aec-4e89-9836-d22a5a84abf0.json,Quinapril Tablets USP
8ded0773-3aec-4e89-9836-d22a5a84abf0,17,quinapril,35208,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231215_8ded0773-3aec-4e89-9836-d22a5a84abf0.json,Quinapril Tablets USP
918d0e2a-3af3-46e8-ad06-528263e03ba0,11,fentanyl,4337,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240222_918d0e2a-3af3-46e8-ad06-528263e03ba0.json,"These highlights do not include all the information needed to use fentanyl buccal tablet safely and effectively.  See full prescribing information for fentanyl buccal tablet. 
 Fentanyl Buccal Tablet, CII    Initial U.S. Approval: 1968"
93b7e6c2-e6a7-4f6b-9ecd-62d6bb0a6dda,3,naratriptan,141366,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231219_93b7e6c2-e6a7-4f6b-9ecd-62d6bb0a6dda.json,"These highlights do not include all the information needed to use NARATRIPTAN TABLETS safely and effectively. See full prescribing information for NARATRIPTAN TABLETS.


NARATRIPTAN tablets, for oral use


Initial U.S. Approval: 1998"
98ad5af1-bde6-4137-a599-b6354d664da4,1,methylergonovine,6883,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240215_98ad5af1-bde6-4137-a599-b6354d664da4.json,"Methylergonovine Maleate Tablets, USP

Rx Only
  
8481394/0124F"
a0d5a4c1-ec79-42e6-8e8f-ae4d144edb43,19,oxazepam,7781,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240123_a0d5a4c1-ec79-42e6-8e8f-ae4d144edb43.json,"Oxazepam Capsules, USP"
a74239bf-4684-424c-ba4e-6087e363265b,14,amlodipine,17767,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_a74239bf-4684-424c-ba4e-6087e363265b.json,"These highlights do not include all the information needed to use amlodipine besylate tablets safely and effectively. See full prescribing information for amlodipine besylate tablets. 
AMLODIPINE besylate tablets, USP for oral administration
Initial U.S. Approval: 1987"
af9d68b3-c43e-44e5-bf7d-80dbc2edc53a,11,hydroxyurea,5552,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240215_af9d68b3-c43e-44e5-bf7d-80dbc2edc53a.json,"These highlights do not include all the information needed to use HYDROXYUREA Capsules safely and effectively. See full prescribing information for HYDROXYUREA Capsules. HYDROXYUREA capsules, USP, for oral use
 

Initial U.S. Approval: 1967
 



---------------------RECENT MAJOR CHANGES--------------


Warnings and Precautions, Pulmonary Toxicity (5.9) 7/2019"
b1ac4c92-e1fd-4015-b172-0932790ae019,2,prednisone,8640,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240227_b1ac4c92-e1fd-4015-b172-0932790ae019.json,"Prednisone Tablets, USP   Rx only"
b471eb51-488e-5312-e053-2a95a90a8116,5,fulvestrant,282357,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240118_b471eb51-488e-5312-e053-2a95a90a8116.json,"These highlights do not include all the information needed to use FULVESTRANT INJECTION safely and effectively. See full prescribing information for FULVESTRANT INJECTION.
 
FULVESTRANT injection, for intramuscular use
 
Initial U.S. Approval: 2002"
b7b679a9-6823-4ef8-8d31-3ab5058ffcfc,11,leuprolide,42375,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240210_b7b679a9-6823-4ef8-8d31-3ab5058ffcfc.json,"These highlights do not include all the information needed to use ELIGARD
®
 safely and effectively. See full prescribing information for ELIGARD.
ELIGARD (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 2002"
ba02a95d-d82e-4a13-90b4-a219abc0249a,18,desipramine,3247,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240210_ba02a95d-d82e-4a13-90b4-a219abc0249a.json,"Desipramine Hydrochloride Tablets, USP"
baac91ad-f8ee-4694-89f8-5c47a8eda39a,10,moexipril,30131,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240104_baac91ad-f8ee-4694-89f8-5c47a8eda39a.json,"Moexipril Hydrochloride Tablets USP

7.5 mg and 15 mg"
bf3425e0-428d-4bdb-ac9a-3b9d483df83a,9,isradipine,33910,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240105_bf3425e0-428d-4bdb-ac9a-3b9d483df83a.json,"Isradipine Capsules, USP

Rx only"
c27f2d57-4b9d-4b78-8d85-3bac84f733b1,5,flurbiprofen,4502,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240128_c27f2d57-4b9d-4b78-8d85-3bac84f733b1.json,"Flurbiprofen Sodium Ophthalmic Solution, USP 0.03% 

(Sterile)"
c82eb602-12e1-692b-d660-f8d5b5736b54,11,salmon calcitonin,36118,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231214_c82eb602-12e1-692b-d660-f8d5b5736b54.json,"These highlights do not include all the information needed to use CALCITONIN SALMON NASAL SPRAY safely and effectively. See full prescribing information for CALCITONIN SALMON NASAL SPRAY. 

CALCITONIN SALMON nasal sprayInitial U.S. Approval: 1975"
c89e8f4d-96c0-44c6-906a-b803141920b1,27,cefuroxime,2194,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240215_c89e8f4d-96c0-44c6-906a-b803141920b1.json,"These highlights do not include all the information needed to use CEFUROXIME AXETIL TABLETS safely and effectively. See full prescribing information for CEFUROXIME AXETIL TABLETS.  CEFUROXIME AXETIL tablets, for oral use  Initial U.S. Approval: 1987"
cac4f544-536c-4886-a379-99eed2d35240,8,sildenafil,136411,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_cac4f544-536c-4886-a379-99eed2d35240.json,"These highlights do not include all the information needed to use SILDENAFIL TABLETS safely and effectively. See full prescribing information for SILDENAFIL TABLETS.
 







SILDENAFIL tablets, for oral use
 







Initial U.S. Approval:1998"
cf94c7fc-13a0-4ac9-bb85-9c38aa704d35,5,ferumoxytol,473387,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230803_cf94c7fc-13a0-4ac9-bb85-9c38aa704d35.json,"These highlights do not include all the information needed to use FERUMOXYTOL INJECTION safely and effectively. See full prescribing information for FERUMOXYTOL INJECTION. 
	FERUMOXYTOL injection, for intravenous use 	Initial U.S. Approval: 2009"
d953457e-0aff-6c38-e053-2995a90a7d32,3,eplerenone,298869,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240110_d953457e-0aff-6c38-e053-2995a90a7d32.json,"Eplerenone Tablet
 
Rx Only
 

These highlights do not include all the information needed to use EPLERENONE TABLETS safely and effectively. See full prescribing information for EPLERENONE TABLETS.
 

Initial U.S. Approval: 2002"
de5bad69-a014-4e25-b1b9-214373ca57a5,1,triamcinolone,10759,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240223_de5bad69-a014-4e25-b1b9-214373ca57a5.json,"Triamcinolone Acetonide

 Cream USP, 0.1%"
de77155c-ecf2-4f15-9758-21d271449d83,2,tivozanib,2534233,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20220826_de77155c-ecf2-4f15-9758-21d271449d83.json,"These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. 
FOTIVDA® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021"
e1114a58-9ab5-486e-85ed-360365b06396,1,methyldopa,6876,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20230105_e1114a58-9ab5-486e-85ed-360365b06396.json,"Methyldopa Tablets, USP"
e16c33fd-aa86-49ad-a767-c79ade4a62c7,14,timolol,10600,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240209_e16c33fd-aa86-49ad-a767-c79ade4a62c7.json,"TIMOLOL MALEATE

ophthalmic solution
, USP 0.25% and 0.5%

sterile"
e4dbaa72-7b3e-4aef-983b-90efb2b343cd,6,pravastatin,42463,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240224_e4dbaa72-7b3e-4aef-983b-90efb2b343cd.json,"These highlights do not include all the information needed to use PRAVASTATIN SODIUM TABLETS safely and effectively. See full prescribing information for PRAVASTATIN SODIUM TABLETS.
 

PRAVASTATIN SODIUM tablets, for oral use
 
Initial U.S. Approval: 1991"
eed5e856-dd7b-4eaa-9dad-508f2bef9328,1,amoxapine,722,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20230910_eed5e856-dd7b-4eaa-9dad-508f2bef9328.json,"Amoxapine Tablets, USP
 
Rx only"
eed5e856-dd7b-4eaa-9dad-508f2bef9328,1,amoxapine,722,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230910_eed5e856-dd7b-4eaa-9dad-508f2bef9328.json,"Amoxapine Tablets, USP
 
Rx only"
f073b58e-56d6-4c8d-a2ce-b37719402d77,3,vinblastine,11198,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20200101_f073b58e-56d6-4c8d-a2ce-b37719402d77.json,Vinblastine Sulfate Injection
f2f090c2-3ee1-7689-e053-2995a90abe38,3,levofloxacin,82122,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240220_f2f090c2-3ee1-7689-e053-2995a90abe38.json,"These highlights do not include all the information needed to use LEVOFLOXACIN TABLETS 
  safely and effectively. See full prescribing information for LEVOFLOXACIN TABLETS. 
 




LEVOFLOXACIN tablets, for oral use






Initial U.S. Approval: 1996"
fc38f1bb-f175-4a81-8ed9-c8701efdea35,102,fosinopril,50166,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231128_fc38f1bb-f175-4a81-8ed9-c8701efdea35.json,"FOSINOPRILSODIUM TABLETS, USP10mg, 20mg and 40mgRx Only"
0002ad27-779d-42ab-83b5-bc65453412a1,22,trametinib,1425099,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20230912_0002ad27-779d-42ab-83b5-bc65453412a1.json,"These highlights do not include all the information needed to use MEKINIST safely and effectively. See full prescribing information for MEKINIST.
MEKINIST® (trametinib) tablets, for oral useMEKINIST® (trametinib) for oral solutionInitial U.S. Approval: 2013"
02c91fba-9c47-43ef-ac78-e82369798834,16,estradiol,4083,acute myocardial infarction,10002388,angina unstable,../data/2024_latest_labels/train_xml/20231130_02c91fba-9c47-43ef-ac78-e82369798834.json,These highlights do not include all the information needed to use NATAZIA safely and effectively.  See full prescribing information for NATAZIA.NATAZIA (estradiol valerate and estradiol valerate/dienogest) tablets for oral useInitial U.S. Approval: 2010
0d976866-81b3-5db8-e063-6294a90a39f9,3,progesterone,8727,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240210_0d976866-81b3-5db8-e063-6294a90a39f9.json,""
1502544d-1b3a-46bd-84f5-af92cab72ce8,9,rifapentine,35617,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240110_1502544d-1b3a-46bd-84f5-af92cab72ce8.json,"These highlights do not include all the information needed to use PRIFTIN® safely and effectively. See full prescribing information for PRIFTIN.
 PRIFTIN (rifapentine) tablets, for oral use Initial U.S. Approval: 1998"
202d5142-6180-4d48-9a9f-1bd6992fc49b,2,nebivolol,31555,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240201_202d5142-6180-4d48-9a9f-1bd6992fc49b.json,"These highlights do not include all the information needed to use NEBIVOLOL TABLETS safely and effectively. See full prescribing information for NEBIVOLOL TABLETS.
 
NEBIVOLOL tablets, for oral use
 
Initial U.S. Approval: 2007"
2150f73a-179b-4afc-b8ce-67c85cc72f04,60,everolimus,141704,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20230802_2150f73a-179b-4afc-b8ce-67c85cc72f04.json,"These highlights do not include all the information needed to use AFINITOR/AFINITOR DISPERZ safely and effectively. See full prescribing information for AFINITOR/AFINITOR DISPERZ.


AFINITOR® (everolimus) tablets, for oral use

AFINITOR DISPERZ® (everolimus tablets for oral suspension)

Initial U.S. Approval: 2009"
246d42e5-5418-42ba-aff9-ae399b166c69,4,teriflunomide,1310520,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240216_246d42e5-5418-42ba-aff9-ae399b166c69.json,"These highlights do not include all the information needed to use TERIFLUNOMIDE TABLETS safely and effectively. See full prescribing information for TERIFLUNOMIDE TABLETS.
 







TERIFLUNOMIDE tablets, for oral use
 



Initial U.S. Approval: 2012"
294b168b-6e5f-4db9-bf70-d599271458b3,6,goserelin,50610,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230325_294b168b-6e5f-4db9-bf70-d599271458b3.json,These highlights do not include all the information needed to use ZOLADEX safely and effectively. See full prescribing information for ZOLADEX.ZOLADEX® (goserelin implant) 3.6 mgInitial U.S. Approval: 1989
2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee,11,erdafitinib,2123125,acute myocardial infarction,10000891,acute myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240202_2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee.json,"These highlights do not include all the information needed to use BALVERSA safely and effectively. See full prescribing information for BALVERSA.
 

BALVERSA 
 ®(erdafitinib) tablets, for oral use
 
Initial U.S. Approval: 2019"
2b25ef01-5c9e-11e1-b86c-0800200c9a66,24,pomalidomide,1369713,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230411_2b25ef01-5c9e-11e1-b86c-0800200c9a66.json,"These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST.
 POMALYST® (pomalidomide) capsules, for oral use Initial U.S. Approval:  2013"
2d45dd3c-71c3-4cc1-92ac-6dcecb195dd2,7,loxapine,6475,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_2d45dd3c-71c3-4cc1-92ac-6dcecb195dd2.json,"Loxapine Capsules, USP"
2d599ccf-8e63-4ff1-aa52-4809744ea97a,9,temozolomide,37776,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240216_2d599ccf-8e63-4ff1-aa52-4809744ea97a.json,"These highlights do not include all the information needed to use TEMOZOLOMIDE CAPSULES safely and effectively. See full prescribing information for TEMOZOLOMIDE CAPSULES.
 



TEMOZOLOMIDE capsules, for oral use
 



Initial U.S. Approval: 1999"
2eda833b-1357-4ed4-a093-194524fcb061,25,thalidomide,10432,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20230406_2eda833b-1357-4ed4-a093-194524fcb061.json,"These highlights do not include all the information needed to use THALOMID® safely and effectively. See full prescribing information for THALOMID. 
THALOMID (thalidomide) capsules, for oral use Initial U.S. Approval: 1998"
3376536b-043d-478a-b129-7ce11ec94e3e,2,doxercalciferol,11516,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240222_3376536b-043d-478a-b129-7ce11ec94e3e.json,"These highlights do not include all the information needed to use DOXERCALCIFEROL INJECTION safely and effectively. See full prescribing information for DOXERCALCIFEROL INJECTION.
 DOXERCALCIFEROL injection, for intravenous use Initial U.S. Approval: 1999"
3784c35c-e87f-410c-900b-8fd6313c6010,13,cobicistat,1306284,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20210923_3784c35c-e87f-410c-900b-8fd6313c6010.json,"These highlights do not include all the information needed to use TYBOST safely and effectively. See full prescribing information for TYBOST. 
TYBOST® (cobicistat) tablets, for oral use Initial U.S. Approval: 2012"
3850cce2-6137-42e5-a792-d318c4a4b3b5,14,cabozantinib,1363268,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231003_3850cce2-6137-42e5-a792-d318c4a4b3b5.json,"These highlights do not include all the information needed to use CABOMETYX safely and effectively.  See full prescribing information for CABOMETYX.CABOMETYX® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012"
3bad23a6-09a6-4194-9182-093ed61bc71c,39,caspofungin,140108,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231128_3bad23a6-09a6-4194-9182-093ed61bc71c.json,"These highlights do not include all the information needed to use CANCIDAS safely and effectively. See full prescribing information for CANCIDAS.
CANCIDAS® (caspofungin acetate) for injection, for intravenous useInitial U.S. Approval: 2001"
471baba2-7154-4488-9891-0db2f46791e7,9,romosozumab,2123126,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20220623_471baba2-7154-4488-9891-0db2f46791e7.json,"These highlights do not include all the information needed to use EVENITY safely and effectively. See full prescribing information for EVENITY.  

   

EVENITY

®

 
(
romosozumab-aqqg
) 
injection, 
for
 
subcutaneous
 use

Initial U.S. Approval: 2019"
4764f37b-c9e6-4ede-bcc2-8a03b7c521df,46,dasatinib,475342,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20230223_4764f37b-c9e6-4ede-bcc2-8a03b7c521df.json,"These highlights do not include all the information needed to use SPRYCEL® safely and effectively. See full prescribing information for SPRYCEL.

SPRYCEL (dasatinib) tablets, for oral useInitial U.S. Approval: 2006"
4911f343-68e6-71b0-e054-00144ff8d46c,5,meloxicam,41493,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240223_4911f343-68e6-71b0-e054-00144ff8d46c.json,"These highlights do not include all the information needed to use MELOXICAM TABLETS safely and effectively. See full prescribing information for MELOXICAM TABLETS.
 

Initial U.S. Approval: 2000"
49873158-5c0a-41da-86a2-369ef6b0cbc8,2,ranolazine,35829,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240216_49873158-5c0a-41da-86a2-369ef6b0cbc8.json,"These highlights do not include all the information needed to use RANOLAZINE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for RANOLAZINE EXTENDED-RELEASE TABLETS.
 RANOLAZINE extended-release tablets, for oral use Initial U.S. Approval: 2006"
4c2a1403-3862-1efd-0a91-444989222b37,6,aspirin,1191,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20151015_4c2a1403-3862-1efd-0a91-444989222b37.json,"These highlights do not include all the information needed to use DURLAZA™ safely and effectively.  See full prescribing information for DURLAZA.
DURLAZA (aspirin) Extended Release Capsules, for oral useInitial U.S. Approval:2015"
4e338e89-3cf2-48eb-b6e2-a06c608c6513,36,abiraterone,1100072,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/train_xml/20211016_4e338e89-3cf2-48eb-b6e2-a06c608c6513.json,"These highlights do not include all the information needed to use ZYTIGA safely and effectively. See full prescribing information for ZYTIGA. 
ZYTIGA® (abiraterone acetate) tablets, for oral use Initial U.S. Approval: 2011"
4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213,6,cyclophosphamide,3002,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240113_4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213.json,"""These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE CAPSULES safely and effectively"". ""See full prescribing information for CYCLOPHOSPHAMIDE CAPSULES.""
 



""CYCLOPHOSPHAMIDE capsules""
 

""Initial U.S. Approval: 1959"""
5198b1c8-8dd6-4b8f-bd85-294ac468af53,10,fluvoxamine,42355,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_5198b1c8-8dd6-4b8f-bd85-294ac468af53.json,"These highlights do not include all the information needed to use FLUVOXAMINE MALEATE TABLETS safely and effectively. See full prescribing information for FLUVOXAMINE MALEATE TABLETS.
 

FLUVOXAMINE MALEATE tablets, for oral use
 
Initial U.S. Approval: 1994"
53486382-eee0-4cbe-bc4a-a57484e0d5a7,104,cilostazol,21107,gi bleed,10030172,oesophageal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240113_53486382-eee0-4cbe-bc4a-a57484e0d5a7.json,"These highlights do not include all the information needed to use CILOSTAZOL TABLETS safely and effectively. See full prescribing information for CILOSTAZOL TABLETS.CILOSTAZOL tablets, for oral useInitial U.S. Approval: 1999"
55ad6325-16f6-4f0c-a1dc-734847052d0b,2,danazol,3102,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240126_55ad6325-16f6-4f0c-a1dc-734847052d0b.json,"Danazol Capsules, USP
 

Rx only"
56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec,10,pramipexole,746741,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240222_56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec.json,"These highlights do not include all the information needed to use PRAMIPEXOLE DIHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for PRAMIPEXOLE DIHYDROCHLORIDE TABLETS.
 PRAMIPEXOLE DIHYDROCHLORIDE tablets, for oral use Initial U.S. Approval: 1997"
5c4841b4-fbc0-4163-8ee1-cb28629cbfbf,13,dihematoporphyrin ether,23066,gi bleed,10030172,oesophageal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230816_5c4841b4-fbc0-4163-8ee1-cb28629cbfbf.json,"These highlights do not include all the information needed to use PHOTOFRIN 
 ® safely and effectively. See full prescribing information for PHOTOFRIN.
 



PHOTOFRIN (porfimer sodium) for injection, for intravenous useInitial U.S. Approval: 1995"
61c3d6c7-0d9c-4e46-b091-88d84893e14a,11,zolpidem,39993,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_61c3d6c7-0d9c-4e46-b091-88d84893e14a.json,"These highlights do not include all the information needed to use ZOLPIDEM TARTRATE TABLETS safely and effectively. See full prescribing information for ZOLPIDEM TARTRATE TABLETS.
 



ZOLPIDEM TARTRATE tablets, for oral use, C-IV
 

Initial U.S. Approval: 1992"
6935e846-d5a1-49e5-89a2-f8ebe4d5590d,22,enfuvirtide,139896,acute myocardial infarction,10002388,angina unstable,../data/2024_latest_labels/latest_labels_ingredients/20221122_6935e846-d5a1-49e5-89a2-f8ebe4d5590d.json,"These highlights do not include all the information needed to use FUZEON safely and effectively. See full prescribing information for FUZEON. 
 FUZEON® (enfuvirtide) for Injection  Initial U.S. Approval: 2003"
6a9cbc29-9f15-4b24-8d86-206b82887f3d,24,etravirine,475969,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20230816_6a9cbc29-9f15-4b24-8d86-206b82887f3d.json,"These highlights do not include all the information needed to use INTELENCE safely and effectively. See full prescribing information for INTELENCE.
 





INTELENCE 
 ®(etravirine) tablets, for oral use
 

Initial U.S. Approval: 2008"
6c5c47ab-28ee-11e1-bfc2-0800200c9a66,19,estradiol,4083,acute myocardial infarction,10002388,angina unstable,../data/2024_latest_labels/latest_labels_ingredients/20240224_6c5c47ab-28ee-11e1-bfc2-0800200c9a66.json,"These highlights do not include all the information needed to use MINIVELLE safely and effectively. See full prescribing information for MINIVELLE.
         

MINIVELLE® (estradiol transdermal system) 
Initial U.S. Approval: 1975"
6ee2265b-1da5-4215-848b-12aa5eb25eff,10,hydralazine,5470,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240224_6ee2265b-1da5-4215-848b-12aa5eb25eff.json,Rx only
726daf35-4c03-464f-a814-cc0a715d6031,1,fluconazole,4450,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240223_726daf35-4c03-464f-a814-cc0a715d6031.json,"Fluconazole Tablets USP
 
Rx only"
726daf35-4c03-464f-a814-cc0a715d6031,1,fluconazole,4450,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240223_726daf35-4c03-464f-a814-cc0a715d6031.json,"Fluconazole Tablets USP
 
Rx only"
749e42fb-2fe0-45dd-9268-b43bb3f4081c,32,bosentan,75207,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240223_749e42fb-2fe0-45dd-9268-b43bb3f4081c.json,"These highlights do not include all the information needed to use TRACLEER safely and effectively. See full prescribing information for TRACLEER.
 



TRACLEER 
 ®(bosentan) tablets, for oral use
 

TRACLEER 
 ®(bosentan) tablets for oral suspension
 

Initial U.S. Approval: 2001"
74e5060c-8426-1b77-e053-2a91aa0a1f13,8,methylprednisolone,6902,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_74e5060c-8426-1b77-e053-2a91aa0a1f13.json,SOLU-MEDROL® 40MG PER VIAL 1mL ACT-O-VIAL®
793062e5-5a0c-40f9-8d8b-ca0862cd8a37,11,aripiprazole,89013,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240217_793062e5-5a0c-40f9-8d8b-ca0862cd8a37.json,"These highlights do not include all the information needed to use ARIPIPRAZOLE TABLETS safely and effectively. See full prescribing information for ARIPIPRAZOLE TABLETS.
 



ARIPIPRAZOLE tablets, for oral use
 

Initial U.S. Approval: 2002"
7f10bf63-06c8-477d-a13e-fb88e287617a,103,repaglinide,73044,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240116_7f10bf63-06c8-477d-a13e-fb88e287617a.json,"These highlights do not include all the information needed to use REPAGLINIDE TABLETS safely and effectively.  See full prescribing information for REPAGLINIDE TABLETS.REPAGLINIDE tablets, for oral useInitial U.S. Approval: 1997"
7fbea274-d6b5-4faa-bbf0-05fefab42114,6,atazanavir,343047,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240218_7fbea274-d6b5-4faa-bbf0-05fefab42114.json,"These highlights do not include all the information needed to use ATAZANAVIR CAPSULES safely and effectively. See full prescribing information for ATAZANAVIR CAPSULES.
 ATAZANAVIR capsules, for oral use Initial U.S. Approval: 2003"
81c40311-7dc4-4332-8920-a39a8466aea6,8,thiothixene,10510,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231229_81c40311-7dc4-4332-8920-a39a8466aea6.json,"Thiothixene Capsules, USP

(1 mg, 2 mg, 5 mg and 10 mg)

Rx Only"
8450bd15-2b06-4fc7-b302-9021312e3f0d,18,tigecycline,384455,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231228_8450bd15-2b06-4fc7-b302-9021312e3f0d.json,"These highlights do not include all the information needed to use TIGECYCLINE FOR INJECTION safely and effectively. See full prescribing information for TIGECYCLINE FOR INJECTION. 


TIGECYCLINE for injection, for intravenous use 

Initial U.S. Approval: 2005"
852f013f-6759-4438-83c1-8ff48133dc85,4,albendazole,430,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240117_852f013f-6759-4438-83c1-8ff48133dc85.json,"HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ALBENDAZOLE TABLETS safely and effectively. See full prescribing information for ALBENDAZOLE TABLETS.  ALBENDAZOLE tablets, for oral use  Initial U.S. Approval: 1996"
88441a9f-b4f9-455d-a355-46fb30699a7b,10,sulfasalazine,9524,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_88441a9f-b4f9-455d-a355-46fb30699a7b.json,"Sulfasalazine Tablets, USP"
88698921-cd8f-4d41-96e6-ff671913c5c3,7,nateglinide,274332,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231110_88698921-cd8f-4d41-96e6-ff671913c5c3.json,"These highlights do not include all the information needed to use NATEGLINIDE TABELTS safely and effectively. See full prescribing information for NATEGLINIDE TABELTS.
NATEGLINIDE tablets, for oral useInitial U.S. Approval: 2000"
907c965e-8faf-53db-e053-2995a90a8cd1,5,zonisamide,39998,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240111_907c965e-8faf-53db-e053-2995a90a8cd1.json,ZONISAMIDE
9929c166-8ba3-4159-a5f9-4618d5d227b0,102,flecainide,4441,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240113_9929c166-8ba3-4159-a5f9-4618d5d227b0.json,Flecainide Acetate Tablets USPRx only
9d88f915-13dd-5463-e053-2a95a90a09bf,3,enalaprilat,3829,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240224_9d88f915-13dd-5463-e053-2a95a90a09bf.json,ENALAPRILAT INJECTION 1.25mg/mL 1mL VIAL
9d88f915-13dd-5463-e053-2a95a90a09bf,3,enalaprilat,3829,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_9d88f915-13dd-5463-e053-2a95a90a09bf.json,ENALAPRILAT INJECTION 1.25mg/mL 1mL VIAL
a0dc1a93-b7b8-4179-8ea7-ceecbe1ef243,9,galantamine,4637,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240214_a0dc1a93-b7b8-4179-8ea7-ceecbe1ef243.json,"These highlights do not include all the information needed to use GALANTAMINE TABLETS safely and effectively. See full prescribing information for GALANTAMINE TABLETS.
 GALANTAMINE tablets, for oral use Initial U.S. Approval: 2001"
a32cb2e3-d4e5-4bbf-9d88-20b2b249e779,23,ritonavir,85762,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231221_a32cb2e3-d4e5-4bbf-9d88-20b2b249e779.json,"These highlights do not include all the information needed to use RITONAVIR TABLETS safely and effectively. See full prescribing information for RITONAVIR TABLETS.
 


RITONAVIR tablets, for oral use
 

Initial U.S. Approval: 1996"
a74239bf-4684-424c-ba4e-6087e363265b,14,amlodipine,17767,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_a74239bf-4684-424c-ba4e-6087e363265b.json,"These highlights do not include all the information needed to use amlodipine besylate tablets safely and effectively. See full prescribing information for amlodipine besylate tablets. 
AMLODIPINE besylate tablets, USP for oral administration
Initial U.S. Approval: 1987"
adc84ad5-a04d-4fee-9ba8-91f7abd928e3,29,bosutinib,1307619,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240102_adc84ad5-a04d-4fee-9ba8-91f7abd928e3.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. 
BOSULIF® (bosutinib) tablets, for oral useBOSULIF® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012"
b1bd0d02-eccb-4449-82b9-9b552835029e,10,warfarin,11289,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240222_b1bd0d02-eccb-4449-82b9-9b552835029e.json,"These highlights do not include all the information needed to use WARFARIN SODIUM TABLETS safely and effectively. See full prescribing information for WARFARIN SODIUM TABLETS.
 



WARFARIN SODIUM tablets, for oral use
 

Initial U.S. Approval: 1954"
b3ecc533-dd55-4a2f-84c4-ecd454aae766,14,balsalazide,18747,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240209_b3ecc533-dd55-4a2f-84c4-ecd454aae766.json,"These highlights do not include all the information needed to use BALSALAZIDE DISODIUM CAPSULES safely and effectively. See full prescribing information for BALSALAZIDE DISODIUM CAPSULES.
 

BALSALAZIDE DISODIUM capsules, for oral use
 
Initial U.S. Approval: 2000"
bda70104-d84b-4d3f-9ca0-5f4f1ca816ad,13,voriconazole,121243,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240215_bda70104-d84b-4d3f-9ca0-5f4f1ca816ad.json,"These highlights do not include all the information needed to use VORICONAZOLE TABLETS safely and effectively. See full prescribing information for VORICONAZOLE TABLETS.VORICONAZOLE tablets, for oral useInitial U.S. Approval: 2002"
bf514e99-4958-44a0-a87a-02a950f87e60,7,acetazolamide,167,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_bf514e99-4958-44a0-a87a-02a950f87e60.json,"Acetazolamide Extended-release Capsules, USP
Rx only"
c0946de1-2a2d-47ff-8071-50c1d3ad7982,8,phenytoin,8183,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_c0946de1-2a2d-47ff-8071-50c1d3ad7982.json,"These highlights do not include all the information needed to use EXTENDED PHENYTOIN SODIUM CAPSULES safely and effectively. See full prescribing information for EXTENDED PHENYTOIN SODIUM CAPSULES.
 

EXTENDED PHENYTOIN SODIUM capsules, for oral use
 
Initial U.S. Approval: 1953"
c09c4cde-9f6c-4c4f-9d96-18beb5377564,1,methyltestosterone,6904,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20220223_c09c4cde-9f6c-4c4f-9d96-18beb5377564.json,"Methyltestosterone Capsules, USP, CIII (10 mg) Rx only"
c27f2d57-4b9d-4b78-8d85-3bac84f733b1,5,flurbiprofen,4502,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240128_c27f2d57-4b9d-4b78-8d85-3bac84f733b1.json,"Flurbiprofen Sodium Ophthalmic Solution, USP 0.03% 

(Sterile)"
c394914b-2334-418e-bf86-9f9100323717,6,ketoconazole,6135,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_c394914b-2334-418e-bf86-9f9100323717.json,KETOCONAZOLE CREAM 2%
c5d0b74b-e5bc-4e81-91e8-4bfc587bf54c,6,misoprostol,42331,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240110_c5d0b74b-e5bc-4e81-91e8-4bfc587bf54c.json,"Misoprostol
 

Tablets"
c8c50e03-5cb8-43f4-bdef-8edd12f1945f,10,pitavastatin,861634,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240223_c8c50e03-5cb8-43f4-bdef-8edd12f1945f.json,"These highlights do not include all the information needed to use ZYPITAMAG® safely and effectively. See full prescribing information for ZYPITAMAG. 
ZYPITAMAG (pitavastatin) tablets, for oral use 
 Initial U.S. Approval: 2009"
cee5b232-0464-4697-93ef-77e044c83776,8,clopidogrel,32968,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240222_cee5b232-0464-4697-93ef-77e044c83776.json,"These highlights do not include all the information needed to use CLOPIDOGREL TABLETS safely and effectively. See full prescribing information for CLOPIDOGREL TABLETS.
 



CLOPIDOGREL tablets, for oral use
 



Initial U.S. Approval: 1997"
d0aa57cb-d2f4-46d7-af43-7c8b06aa81a6,21,nafarelin,28656,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230301_d0aa57cb-d2f4-46d7-af43-7c8b06aa81a6.json,"Synarel®


(nafarelin acetate)

nasal solution"
d2daba09-f1c2-4764-a567-1291be4892b9,100,posaconazole,282446,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240124_d2daba09-f1c2-4764-a567-1291be4892b9.json,"These highlights do not include all the information needed to use
POSACONAZOLE DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for

POSACONAZOLE

DELAYED-RELEASE TABLETS
.



POSACONAZOLE

delayed-release tablets, for oral use

Initial U.S. Approval: 2006"
da1c9f37-779e-4682-816f-93d0faa4cfc9,16,nintedanib,1592737,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/gold_xml/20221103_da1c9f37-779e-4682-816f-93d0faa4cfc9.json,"These highlights do not include all the information needed to use OFEV safely and effectively. See full prescribing information for OFEV. 
OFEV® (nintedanib capsules), for oral use Initial U.S. Approval: 2014"
da1ce22b-6a8e-40a2-afbb-011fa3ed3a8b,10,ropivacaine,35780,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240125_da1ce22b-6a8e-40a2-afbb-011fa3ed3a8b.json,"These highlights do not include all the information needed to use ROPIVACAINE HYDROCHLORIDE INJECTION safely and effectively. See full prescribing information for ROPIVACAINE HYDROCHLORIDE INJECTION.



ROPIVACAINE HYDROCHLORIDE injection, for epidural, perineural, or infiltration use 

Initial U.S. Approval: 1996"
e4f2a84f-5117-4738-b769-aba8debbddb0,11,saxagliptin,857974,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/gold_xml/20230219_e4f2a84f-5117-4738-b769-aba8debbddb0.json,"These highlights do not include all the information needed to use ONGLYZA safely and effectively. See full prescribing information for ONGLYZA.
ONGLYZA® (saxagliptin) tablets, for oral useInitial U.S. Approval: 2009"
f1be363d-6fc5-4b08-9b96-976933db19e1,9,apixaban,1364430,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240224_f1be363d-6fc5-4b08-9b96-976933db19e1.json,"These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.
 



ELIQUIS 
 ® (apixaban) tablets, for oral use
 

Initial U.S. Approval: 2012"
f89f2933-0743-45e7-9a91-086f9b2e56da,10,pentoxifylline,8013,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240202_f89f2933-0743-45e7-9a91-086f9b2e56da.json,"PENTOXIFYLLINE EXTENDED-RELEASE TABLETS, USP 400 mg


Rx Only"
fabf55db-8b50-491f-b76d-a0fe5fb6c9b0,17,ciprofloxacin,2551,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240217_fabf55db-8b50-491f-b76d-a0fe5fb6c9b0.json,"These highlights do not include all the information needed to use CIPROFLOXACIN TABLETS safely and effectively. See full prescribing information for CIPROFLOXACIN TABLETS.
 

CIPROFLOXACIN tablet, for oral use
 
Initial U.S. Approval: 1987"
fc38f1bb-f175-4a81-8ed9-c8701efdea35,102,fosinopril,50166,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20231128_fc38f1bb-f175-4a81-8ed9-c8701efdea35.json,"FOSINOPRILSODIUM TABLETS, USP10mg, 20mg and 40mgRx Only"
fdbcc274-c343-4461-9db9-6ff1be15d727,10,bupropion,42347,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_fdbcc274-c343-4461-9db9-6ff1be15d727.json,"These highlights do not include all the information needed to use 
  BUPROPIONHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for 
  BUPROPIONHYDROCHLORIDE TABLETS. 
 


BUPROPION HYDROCHLORIDE tablets, for oral use
  
Initial U.S. Approval: 1985"
0002ad27-779d-42ab-83b5-bc65453412a1,22,trametinib,1425099,gi bleed,10018830,haematemesis,../data/2024_latest_labels/gold_xml/20230912_0002ad27-779d-42ab-83b5-bc65453412a1.json,"These highlights do not include all the information needed to use MEKINIST safely and effectively. See full prescribing information for MEKINIST.
MEKINIST® (trametinib) tablets, for oral useMEKINIST® (trametinib) for oral solutionInitial U.S. Approval: 2013"
04fb6cd5-3c21-433e-a053-623b73218bd6,2,niacin,7393,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240126_04fb6cd5-3c21-433e-a053-623b73218bd6.json,"Niacin Tablets, USP 500 mg"
08f0ea03-4e6d-195d-aef4-886e32befa95,27,peginterferon beta-1a,1546168,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230808_08f0ea03-4e6d-195d-aef4-886e32befa95.json,"These highlights do not include all the information needed to use PLEGRIDY® safely and effectively.  See full prescribing information for PLEGRIDY.
PLEGRIDY (peginterferon beta-1a) injection, for subcutaneous or intramuscular useInitial U.S. Approval:  2014"
0be243c6-de02-45dd-8210-cab1bbc8dfa7,28,clarithromycin,21212,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_0be243c6-de02-45dd-8210-cab1bbc8dfa7.json,"These highlights do not include all the information needed to use CLARITHROMYCIN TABLETS safely and effectively. See full prescribing information for CLARITHROMYCIN TABLETS.
 

CLARITHROMYCIN tablets, for oral use
 
Initial U.S. Approval: 1991"
0be26591-e0dd-429d-a4c7-b2e39aab13dd,9,terbinafine,37801,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_0be26591-e0dd-429d-a4c7-b2e39aab13dd.json,"These highlights do not include all the information needed to use TERBINAFINE TABLETS safely and effectively. See full prescribing information for TERBINAFINE TABLETS
 

TERBINAFINE tablets, for oral use
 
Initial U.S. Approval: 1992"
0c717ae4-ec27-47db-ac1b-e504dbb379be,11,dexmethylphenidate,352372,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240221_0c717ae4-ec27-47db-ac1b-e504dbb379be.json,"These highlights do not include all the information needed to use DEXMETHYLPHENIDATE hydrochloride tablets safely and effectively. See full prescribing information for DEXMETHYLPHENIDATE hydrochloride tablets.
  



DEXMETHYLPHENIDATE HYDROCHLORIDE TABLETS, for oral use, CII
  

Initial U.S. Approval: 2001"
0e98593a-8424-48c8-acc0-671f4b566aee,9,carvedilol,20352,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240224_0e98593a-8424-48c8-acc0-671f4b566aee.json,"These highlights do not include all the information needed to use CARVEDILOL TABLETS safely and effectively. See full prescribing information for CARVEDILOL TABLETS.
 

CARVEDILOL tablets, for oral use
 
Initial U.S. Approval: 1995"
106d9730-5938-8f27-e063-6294a90adc68,2,cyclobenzaprine,21949,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240221_106d9730-5938-8f27-e063-6294a90adc68.json,"Cyclobenzaprine hydrochloride Tablets, USP"
11344047-7ed4-61e7-e063-6394a90a332d,1,lansoprazole,17128,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240214_11344047-7ed4-61e7-e063-6394a90a332d.json,"These highlights do not include all the information needed to use 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULESsafely and effectively. See full prescribing information for 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULES.
 

LANSOPRAZOLE delayed-release capsules, for oral use
  
Initial U.S. Approval: 1995"
11d5a86e-7861-43f1-ae04-84daa0de7888,13,exemestane,258494,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231220_11d5a86e-7861-43f1-ae04-84daa0de7888.json,"These highlights do not include all the information needed to use EXEMESTANE TABLETS safely and effectively. See full prescribing information for EXEMESTANE TABLETS. 


EXEMESTANE tablets, for oral use 

Initial U.S. Approval: 1999"
11d5a86e-7861-43f1-ae04-84daa0de7888,13,exemestane,258494,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231220_11d5a86e-7861-43f1-ae04-84daa0de7888.json,"These highlights do not include all the information needed to use EXEMESTANE TABLETS safely and effectively. See full prescribing information for EXEMESTANE TABLETS. 


EXEMESTANE tablets, for oral use 

Initial U.S. Approval: 1999"
11fad602-16c2-4c1f-bdf1-867d95f063ca,10,rosuvastatin,301542,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_11fad602-16c2-4c1f-bdf1-867d95f063ca.json,"These highlights do not include all the information needed to use ROSUVASTATIN TABLETS safely and effectively. See full prescribing information for ROSUVASTATIN TABLETS.
 

ROSUVASTATIN tablets, for oral use
 
Initial U.S. Approval: 2003"
14f3f9ba-7a4a-45d5-a25e-efe5cdff117d,8,pregabalin,187832,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240223_14f3f9ba-7a4a-45d5-a25e-efe5cdff117d.json,"These highlights do not include all the information needed to use PREGABALIN CAPSULES safely and effectively. See full prescribing information for PREGABALIN CAPSULES.
 



PREGABALIN capsules, for oral use CV
 



Initial U.S. Approval: 2004"
1502544d-1b3a-46bd-84f5-af92cab72ce8,9,rifapentine,35617,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240110_1502544d-1b3a-46bd-84f5-af92cab72ce8.json,"These highlights do not include all the information needed to use PRIFTIN® safely and effectively. See full prescribing information for PRIFTIN.
 PRIFTIN (rifapentine) tablets, for oral use Initial U.S. Approval: 1998"
160b85ac-d964-463b-9f1e-1429f14ed318,1,nitroglycerin,4917,acute myocardial infarction,10002388,angina unstable,../data/2024_latest_labels/latest_labels_ingredients/20240223_160b85ac-d964-463b-9f1e-1429f14ed318.json,"These highlights do not include all the information needed to use NITROGLYCERIN SUBLINGUAL TABLETS safely and effectively. See full prescribing information for NITROGLYCERIN SUBLINGUAL TABLETS. NITROGLYCERIN sublingual tablets, for oral use  Initial U.S. Approval: 1981"
1738a682-5903-b675-3a7a-61d299a6f248,19,zoledronic acid,77655,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240113_1738a682-5903-b675-3a7a-61d299a6f248.json,"These highlights do not include all the information needed to use ZOLEDRONIC ACID INJECTION safely and effectively. See full prescribing information for ZOLEDRONIC ACID INJECTION. ZOLEDRONIC ACID injection, for intravenous use 
Initial U.S. Approval: 2001"
17a8d11b-73b0-4833-a0b4-cf1ef85edefb,29,aripiprazole lauroxil,1673265,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231205_17a8d11b-73b0-4833-a0b4-cf1ef85edefb.json,"These highlights do not include all the information needed to use ARISTADA® safely and effectively. See full prescribing information for ARISTADA®.
ARISTADA® (aripiprazole lauroxil) extended-release injectable suspension, for intramuscular useInitial U.S. Approval: 2015"
18fb1c2b-0c1e-436c-a5b6-d4840b5da228,12,nicardipine,7396,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240214_18fb1c2b-0c1e-436c-a5b6-d4840b5da228.json,"These highlights do not include all the information needed to use NICARDIPINE HYDROCHLORIDE safely and effectively. See full prescribing information for NICARDIPINE HYDROCHLORIDE.
 NICARDIPINE 
HYDROCHLORIDE injection, for intravenous use

Initial U.S. Approval: 1988"
18fb1c2b-0c1e-436c-a5b6-d4840b5da228,12,nicardipine,7396,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240214_18fb1c2b-0c1e-436c-a5b6-d4840b5da228.json,"These highlights do not include all the information needed to use NICARDIPINE HYDROCHLORIDE safely and effectively. See full prescribing information for NICARDIPINE HYDROCHLORIDE.
 NICARDIPINE 
HYDROCHLORIDE injection, for intravenous use

Initial U.S. Approval: 1988"
19880f51-badb-4846-a02a-592a210690ab,10,sirolimus,35302,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240209_19880f51-badb-4846-a02a-592a210690ab.json,"These highlights do not include all the information needed to use SIROLIMUS ORAL SOLUTION safely and effectively. See full prescribing information for SIROLIMUS ORAL SOLUTION.


SIROLIMUS oral solutionInitial U.S. Approval: 1999"
1aa40de5-c02d-49d6-8722-ed88c40c3ba6,2,felbamate,24812,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240101_1aa40de5-c02d-49d6-8722-ed88c40c3ba6.json,"Felbamate Tablets, USP

(400 mg and 600 mg)


Rx only"
1d3a45f3-3854-4d0c-9241-770aa24063fd,5,duloxetine,72625,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_1d3a45f3-3854-4d0c-9241-770aa24063fd.json,"These highlights do not include all the information needed to use DULOXETINE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DULOXETINE DELAYED-RELEASE CAPSULES.
 
DULOXETINE delayed-release capsules for oral use.
 
Initial U.S. Approval: 2004"
22174520-4b78-4841-96f7-530ba12d2cf1,8,paroxetine,32937,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240217_22174520-4b78-4841-96f7-530ba12d2cf1.json,"Paroxetine Tablets USP, film coated for oral use"
23f3c1f4-0fc8-4804-a9e3-04cf25dd302e,26,trastuzumab,224905,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/gold_xml/20230902_23f3c1f4-0fc8-4804-a9e3-04cf25dd302e.json,"These highlights do not include all the information needed to use KADCYLA safely and effectively.  See full prescribing information for KADCYLA. 
KADCYLA® (ado-trastuzumab emtansine) for injection, for intravenous use Initial U.S. Approval:  2013"
2421dc8f-a60d-4249-b093-c9e8e1d4bb82,10,glyburide,4815,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_2421dc8f-a60d-4249-b093-c9e8e1d4bb82.json,"Glyburide Tablets, USP
 

1.25, 2.5, and 5 mg"
26eb95ba-1f77-4496-a6ea-92bd63a40a3e,100,oxaprozin,32613,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20231207_26eb95ba-1f77-4496-a6ea-92bd63a40a3e.json,"These highlights do not include all the information needed to use OXAPROZIN TABLETS safely and effectively. See full prescribing information for OXAPROZIN TABLETS.
OXAPROZIN tablets, for oral useInitial U.S. Approval: 1992"
2cab8dd1-3a10-48e6-86ce-0e5275ed49e5,10,toremifene,38409,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20230916_2cab8dd1-3a10-48e6-86ce-0e5275ed49e5.json,"These highlights do not include all the information needed to use FARESTON® safely and effectively. See full prescribing information for FARESTON®.


FARESTON® (toremifene citrate) 60 mg Tablets oral administration

Initial U.S. Approval: 1997"
326ef804-8d3a-425e-8513-8c9811856aa0,100,trimipramine,10834,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20230616_326ef804-8d3a-425e-8513-8c9811856aa0.json,"TRIMIPRAMINE MALEATE CAPSULES, 25 MG, 50 MG and 100 MG Rx Only"
34de1806-d921-4d2f-8c7f-03625b717a70,25,methylphenidate,6901,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240221_34de1806-d921-4d2f-8c7f-03625b717a70.json,"These highlights do not include all the information needed to use METHYLPHENIDATE HCl EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for METHYLPHENIDATE HCl EXTENDED-RELEASE TABLETS.


METHYLPHENIDATE HCl extended-release tablets, for oral administration CII 

Initial U.S. Approval: 2000"
3850cce2-6137-42e5-a792-d318c4a4b3b5,14,cabozantinib,1363268,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231003_3850cce2-6137-42e5-a792-d318c4a4b3b5.json,"These highlights do not include all the information needed to use CABOMETYX safely and effectively.  See full prescribing information for CABOMETYX.CABOMETYX® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012"
38b482a8-960b-4591-9857-5031ecb830aa,35,blinatumomab,1597258,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20240220_38b482a8-960b-4591-9857-5031ecb830aa.json,"These highlights do not include all the information needed to use BLINCYTO® safely and effectively. See full prescribing information for BLINCYTO.  
BLINCYTO® (blinatumomab) for injection, for intravenous use Initial U.S. Approval: 2014"
3bc8668e-8ec3-4c54-b46b-5ca0dac87c1b,13,micafungin,325887,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231201_3bc8668e-8ec3-4c54-b46b-5ca0dac87c1b.json,"These highlights do not include all the information needed to use MICAFUNGIN FOR INJECTION safely and effectively. See full prescribing information for MICAFUNGIN FOR INJECTION.
 MICAFUNGIN for Injection, for intravenous infusion only Initial U.S. Approval: 2005"
3d30eb8d-a62e-475f-926b-78ba63bee9c8,11,isoflurane,6026,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240130_3d30eb8d-a62e-475f-926b-78ba63bee9c8.json,"FORANE (isoflurane, USP) liquid for inhalation"
4034fb6d-f55d-4df0-b500-d6a413591f6e,39,doxazosin,49276,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_4034fb6d-f55d-4df0-b500-d6a413591f6e.json,"These highlights do not include all the information needed to use DOXAZOSIN TABLETS safely and effectively. See full prescribing information for DOXAZOSIN TABLETS.




DOXAZOSIN tablets, for oral use 




Initial U.S. Approval: 1990"
406883ea-7f97-4eff-8d43-0bab004654f1,9,insulin glargine,274783,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240104_406883ea-7f97-4eff-8d43-0bab004654f1.json,"These highlights do not include all the information needed to use INSULIN GLARGINE safely and effectively. See full prescribing information for INSULIN GLARGINE. 
INSULIN GLARGINE injection, for subcutaneous use Initial U.S. Approval: 2000 
This product is LANTUS® (insulin glargine)."
413c645e-074d-4276-b39a-d83521077602,14,abiraterone,1100072,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_413c645e-074d-4276-b39a-d83521077602.json,"These highlights do not include all the information needed to use ABIRATERONE ACETATE TABLETS safely and effectively. See full prescribing information for ABIRATERONE ACETATE TABLETS.
  

ABIRATERONE ACETATE tablets,
 
for oral use 

Initial U.S. Approval: 2011"
413c645e-074d-4276-b39a-d83521077602,14,abiraterone,1100072,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240217_413c645e-074d-4276-b39a-d83521077602.json,"These highlights do not include all the information needed to use ABIRATERONE ACETATE TABLETS safely and effectively. See full prescribing information for ABIRATERONE ACETATE TABLETS.
  

ABIRATERONE ACETATE tablets,
 
for oral use 

Initial U.S. Approval: 2011"
4314da8a-40e5-4aba-a32b-57b4166ade30,12,azithromycin,18631,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_4314da8a-40e5-4aba-a32b-57b4166ade30.json,"These highlights do not include all the information needed to use AZITHROMYCIN TABLETS safely and effectively. See full prescribing information for AZITHROMYCIN TABLETS.  AZITHROMYCIN tablets, for oral use Initial U.S. Approval: 1991"
4442f029-dd5e-4834-9b01-eb8c638ce4b1,100,nortriptyline,7531,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240223_4442f029-dd5e-4834-9b01-eb8c638ce4b1.json,"Nortriptyline Hydrochloride Capsules, USP"
4764f37b-c9e6-4ede-bcc2-8a03b7c521df,46,dasatinib,475342,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230223_4764f37b-c9e6-4ede-bcc2-8a03b7c521df.json,"These highlights do not include all the information needed to use SPRYCEL® safely and effectively. See full prescribing information for SPRYCEL.

SPRYCEL (dasatinib) tablets, for oral useInitial U.S. Approval: 2006"
48aa32cb-047a-414a-822e-82a5f26d8817,17,diazepam,3322,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240222_48aa32cb-047a-414a-822e-82a5f26d8817.json,"Diazepam Tablets, USP, CIV


Rx only"
4a0c7c8b-b95f-455d-9600-b7351e4397fe,2,olutasidenib,2623641,acute liver injury,10061008,biliary tract disorder,../data/2024_latest_labels/latest_labels_ingredients/20230331_4a0c7c8b-b95f-455d-9600-b7351e4397fe.json,"These highlights do not include all the information needed to use REZLIDHIA safely and effectively. See full prescribing information for REZLIDHIA.
REZLIDHIA™ (olutasidenib) capsules, for oral useInitial U.S. Approval: 2022"
4e8516dc-a3c6-4d8f-aa14-2c37c6c8f6e6,1,isotretinoin,6064,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240207_4e8516dc-a3c6-4d8f-aa14-2c37c6c8f6e6.json,"These highlights do not include all the information needed to use ISOTRETINOIN CAPSULES safely and effectively. See full prescribing information for ISOTRETINOIN CAPSULES.
 ISOTRETINOIN capsules, for oral use Initial U.S. Approval: 1982"
4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213,6,cyclophosphamide,3002,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240113_4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213.json,"""These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE CAPSULES safely and effectively"". ""See full prescribing information for CYCLOPHOSPHAMIDE CAPSULES.""
 



""CYCLOPHOSPHAMIDE capsules""
 

""Initial U.S. Approval: 1959"""
51635427-fb13-45ee-813d-a40b0405d14f,7,diclofenac,3355,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_51635427-fb13-45ee-813d-a40b0405d14f.json,"Diclofenac Sodium Extended-Release Tablets, USP, Tablets of 100 mg
  

Rx only
  

Prescribing Information"
52781229-ee82-43f9-a113-4419a611978d,1,rivastigmine,183379,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240111_52781229-ee82-43f9-a113-4419a611978d.json,"These highlights do not include all the information needed to use RIVASTIGMINE TARTRATE CAPSULES safely and effectively. See full prescribing information for RIVASTIGMINE TARTRATE CAPSULES.
 
RIVASTIGMINE TARTRATE capsules, for oral use
 
Initial U.S. Approval: 2000"
58353438-3236-4596-9324-62fed9615cb7,12,dulaglutide,1551291,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231213_58353438-3236-4596-9324-62fed9615cb7.json,"These highlights do not include all the information needed to use TRULICITY safely and effectively. See full prescribing information for TRULICITY.
TRULICITY (dulaglutide) injection, for subcutaneous useInitial U.S. Approval: 2014"
584abe73-8290-4484-ff8e-5890831c095e,21,sumatriptan,37418,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240222_584abe73-8290-4484-ff8e-5890831c095e.json,"These highlights do not include all the information needed to use IMITREX safely and effectively. See full prescribing information for IMITREX.IMITREX (sumatriptan) tablets, for oral useInitial U.S. Approval: 1992"
58a3c995-5ad6-465d-8437-5970c9088213,1,chlorambucil,2346,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20230517_58a3c995-5ad6-465d-8437-5970c9088213.json,"LEUKERAN®
(chlorambucil) Tablets"
5cd725a1-2fa4-408a-a651-57a7b84b2118,18,avelumab,1875534,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240131_5cd725a1-2fa4-408a-a651-57a7b84b2118.json,"These highlights do not include all the information needed to use BAVENCIO safely and effectively. See full prescribing information for BAVENCIO.
 BAVENCIO® (avelumab) injection, for intravenous use Initial U.S. Approval: 2017"
5f01e40a-b6f6-40fb-b37c-3d06f1428e86,27,glatiramer,214582,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240123_5f01e40a-b6f6-40fb-b37c-3d06f1428e86.json,"These highlights do not include all the information needed to use GLATOPA safely and effectively. See full prescribing information for GLATOPA.
GLATOPA® (glatiramer acetate injection), for subcutaneous useInitial U.S. Approval: 1996"
666f89b4-fd81-420a-a390-eb1cd4014f61,10,diflunisal,3393,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240210_666f89b4-fd81-420a-a390-eb1cd4014f61.json,Rx only
6a9cbc29-9f15-4b24-8d86-206b82887f3d,24,etravirine,475969,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/train_xml/20230816_6a9cbc29-9f15-4b24-8d86-206b82887f3d.json,"These highlights do not include all the information needed to use INTELENCE safely and effectively. See full prescribing information for INTELENCE.
 





INTELENCE 
 ®(etravirine) tablets, for oral use
 

Initial U.S. Approval: 2008"
6a9cbc29-9f15-4b24-8d86-206b82887f3d,24,etravirine,475969,gi bleed,10018830,haematemesis,../data/2024_latest_labels/train_xml/20230816_6a9cbc29-9f15-4b24-8d86-206b82887f3d.json,"These highlights do not include all the information needed to use INTELENCE safely and effectively. See full prescribing information for INTELENCE.
 





INTELENCE 
 ®(etravirine) tablets, for oral use
 

Initial U.S. Approval: 2008"
6e22050f-95ee-410a-b770-0c32fb8b321b,100,doxepin,3638,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240127_6e22050f-95ee-410a-b770-0c32fb8b321b.json,"Doxepin Hydrochloride Capsules, USP 10 mg, 25 mg, 50 mg, 75 mg and 100 mg"
76e1839b-7462-4344-b319-001a5f57d67a,12,pantoprazole,40790,gi bleed,10030172,oesophageal haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20240224_76e1839b-7462-4344-b319-001a5f57d67a.json,"These highlights do not include all the information needed to use PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS.
 

PANTOPRAZOLE SODIUM delayed-release tablets, for oral use
 
Initial U.S. approval: 2000"
77d619f8-05a3-408a-a6f8-1511694b6a24,3,ticlopidine,10594,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20160806_77d619f8-05a3-408a-a6f8-1511694b6a24.json,TICLOPIDINE HYDROCHLORIDE TABLETS USP 0154 Rx only
77d619f8-05a3-408a-a6f8-1511694b6a24,3,ticlopidine,10594,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20160806_77d619f8-05a3-408a-a6f8-1511694b6a24.json,TICLOPIDINE HYDROCHLORIDE TABLETS USP 0154 Rx only
7974d4ad-c419-4c7f-bbd6-f631d53e30de,3,tranylcypromine,10734,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230527_7974d4ad-c419-4c7f-bbd6-f631d53e30de.json,"These highlights do not include all the information needed to use TRANYLCYPROMINE SULFATE TABLETS safely and effectively. See full prescribing information for TRANYLCYPROMINE SULFATE TABLETS.TRANYLCYPROMINE SULFATE USP tablets, for oral useInitial U.S. Approval: 1961"
7e9ab975-db2f-423c-a089-bc5a73313609,11,rivaroxaban,1114195,acute liver injury,10023126,jaundice,../data/2024_latest_labels/gold_xml/20231208_7e9ab975-db2f-423c-a089-bc5a73313609.json,"These highlights do not include all the information needed to use XARELTO safely and effectively. See full prescribing information for XARELTO.
 



XARELTO 
 ® (rivaroxaban) tablets, for oral use
 

XARELTO 
 ® (rivaroxaban) for oral suspension
 

Initial U.S. Approval: 2011"
7ee820e4-a479-4b7d-8730-101ac1f8015c,102,piroxicam,8356,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240113_7ee820e4-a479-4b7d-8730-101ac1f8015c.json,"These highlights do not include all the information needed to use PIROXICAM CAPSULES safely and effectively.  See full prescribing information for PIROXICAM CAPSULES.
PIROXICAM capsules, for oral useInitial U.S. Approval: 1982"
806b3e38-3b2a-4aaa-973c-e2d921bb353e,10,venlafaxine,39786,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_806b3e38-3b2a-4aaa-973c-e2d921bb353e.json,"Venlafaxine Tablets, USP
 
Rx only"
852f013f-6759-4438-83c1-8ff48133dc85,4,albendazole,430,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240117_852f013f-6759-4438-83c1-8ff48133dc85.json,"HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ALBENDAZOLE TABLETS safely and effectively. See full prescribing information for ALBENDAZOLE TABLETS.  ALBENDAZOLE tablets, for oral use  Initial U.S. Approval: 1996"
8d731e7e-3b04-49a2-a0f6-3779422174cc,11,tamoxifen,10324,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240201_8d731e7e-3b04-49a2-a0f6-3779422174cc.json,"Tamoxifen Citrate Tablets, USP


Rx 
O
nly"
8e292a8d-9fd6-45fb-8fb5-d8cb25a4b46d,4,cefprozil,19552,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240131_8e292a8d-9fd6-45fb-8fb5-d8cb25a4b46d.json,""
904899f2-9c54-44d2-901e-47e894571500,2,norethindrone,7514,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240112_904899f2-9c54-44d2-901e-47e894571500.json,"ERRIN® (NORETHINDRONE TABLETS USP, 0.35 MG)"
9803db35-2600-4f42-80c1-43216fd1ba3d,4,acamprosate,82819,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231107_9803db35-2600-4f42-80c1-43216fd1ba3d.json,"These highlights do not include all the information needed to use ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS.
ACAMPROSATE CALCIUM delayed-release tablets, for oral useInitial U.S. Approval: 2004"
9929c166-8ba3-4159-a5f9-4618d5d227b0,102,flecainide,4441,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240113_9929c166-8ba3-4159-a5f9-4618d5d227b0.json,Flecainide Acetate Tablets USPRx only
9f416ce0-012f-4194-9382-74ac71e4b2a9,6,ranitidine,9143,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231221_9f416ce0-012f-4194-9382-74ac71e4b2a9.json,"Ranitidine Tablets, USP

(150 mg and 300 mg)

Rx Only"
a74239bf-4684-424c-ba4e-6087e363265b,14,amlodipine,17767,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_a74239bf-4684-424c-ba4e-6087e363265b.json,"These highlights do not include all the information needed to use amlodipine besylate tablets safely and effectively. See full prescribing information for amlodipine besylate tablets. 
AMLODIPINE besylate tablets, USP for oral administration
Initial U.S. Approval: 1987"
b1739aa5-69d8-4a69-be58-6d789ea2a516,10,clomipramine,2597,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231230_b1739aa5-69d8-4a69-be58-6d789ea2a516.json,"Clomipramine Hydrochloride Capsules, USP

(25 mg, 50 mg, and 75 mg)
 


Rx only"
b471eb51-488e-5312-e053-2a95a90a8116,5,fulvestrant,282357,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240118_b471eb51-488e-5312-e053-2a95a90a8116.json,"These highlights do not include all the information needed to use FULVESTRANT INJECTION safely and effectively. See full prescribing information for FULVESTRANT INJECTION.
 
FULVESTRANT injection, for intramuscular use
 
Initial U.S. Approval: 2002"
b4c2c9dc-a0bb-4d64-a667-a67ebe88392d,37,certolizumab pegol,709271,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230105_b4c2c9dc-a0bb-4d64-a667-a67ebe88392d.json,"These highlights do not include all the information needed to use CIMZIA® safely and effectively. See full prescribing information for CIMZIA.
 



CIMZIA (certolizumab pegol) for injection, for subcutaneous use
 

CIMZIA (certolizumab pegol) injection, for subcutaneous use
 

Initial U.S. Approval: 2008"
b6465b44-a6dd-f99c-d009-6851cf05169c,11,trastuzumab,224905,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240125_b6465b44-a6dd-f99c-d009-6851cf05169c.json,"These highlights do not include all the information needed to use OGIVRI safely and effectively.  See full prescribing information for OGIVRI. 
OGIVRI® (trastuzumab-dkst) for injection, for intravenous use
Initial U.S. Approval: 2017
 

OGIVRI® (trastuzumab-dkst) is biosimilar* to HERCEPTIN (trastuzumab)."
b8d657ac-dbda-4455-8bb5-3896951c3b67,4,zolmitriptan,135775,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_b8d657ac-dbda-4455-8bb5-3896951c3b67.json,"These highlights do not include all the information needed to use ZOLMITRIPTAN ORALLY DISINTEGRATING TABLETS safely and effectively. See full prescribing information for ZOLMITRIPTAN ORALLY DISINTEGRATING TABLETS.
 ZOLMITRIPTAN orally disintegrating tablets Initial U.S. Approval: 1997"
bf93022c-a965-49c5-a852-c59e580d7d91,14,indomethacin,5781,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240222_bf93022c-a965-49c5-a852-c59e580d7d91.json,"These highlights do not include all the information needed to use INDOMETHACIN CAPSULES safely and effectively. See full prescribing information for INDOMETHACIN CAPSULES.
 



INDOMETHACIN capsules, for oral use
 

Initial U.S. Approval: 1965"
c5e8e2fd-7087-4b78-9181-cc259c0be2f1,46,rifaximin,35619,acute liver injury,10019660,hepatic encephalopathy,../data/2024_latest_labels/latest_labels_ingredients/20231116_c5e8e2fd-7087-4b78-9181-cc259c0be2f1.json,"These highlights do not include all the information needed to use XIFAXAN safely and effectively. See full prescribing information for XIFAXAN.
 
XIFAXAN 
 ®(rifaximin) tablets, for oral use
 
Initial U.S. Approval: 2004
 
To reduce the development of drug-resistant bacteria and maintain the effectiveness of XIFAXAN and other antibacterial drugs, XIFAXAN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria."
c6c48eee-240b-4425-8691-35462523652e,1,propoxyphene,8785,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20100125_c6c48eee-240b-4425-8691-35462523652e.json,"DARVON-N  - propoxyphene napsylate tablet, film coated"
c7bb6ba1-9a7f-43f5-b058-ef26d4b59221,3,everolimus,141704,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240222_c7bb6ba1-9a7f-43f5-b058-ef26d4b59221.json,"These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS.
 EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009"
caad4ada-2cf9-4e12-99df-6ca4388cf0f6,100,dexlansoprazole,816346,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240130_caad4ada-2cf9-4e12-99df-6ca4388cf0f6.json,"These highlights do not include all the information needed to use DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES.


DEXLANSOPRAZOLE delayed-release capsules, for oral use 

Initial U.S. Approval: 1995 (lansoprazole)"
ccd95dfc-9236-4707-a715-6a12c91519ff,6,naproxen,7258,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240224_ccd95dfc-9236-4707-a715-6a12c91519ff.json,"These highlights do not include all the information needed to use NAPROXEN TABLETS safely and effectively. See full prescribing information for NAPROXEN TABLETS.
 

NAPROXEN tablets, for oral use
 

Initial U.S. Approval: 1976"
cfeab9e3-58b9-4890-9185-11b62904e2af,13,metronidazole,6922,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240223_cfeab9e3-58b9-4890-9185-11b62904e2af.json,Metronidazole Tablets USP
d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,1,tinzaparin,69646,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20080508_d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee.json,INNOHEP®(tinzaparin sodium injection)
d6364be4-056b-4ebe-83bc-3fc85e8f488c,7,lorazepam,6470,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_d6364be4-056b-4ebe-83bc-3fc85e8f488c.json,"Lorazepam Tablets, USP CIV
 
Rx only"
e4dbaa72-7b3e-4aef-983b-90efb2b343cd,6,pravastatin,42463,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_e4dbaa72-7b3e-4aef-983b-90efb2b343cd.json,"These highlights do not include all the information needed to use PRAVASTATIN SODIUM TABLETS safely and effectively. See full prescribing information for PRAVASTATIN SODIUM TABLETS.
 

PRAVASTATIN SODIUM tablets, for oral use
 
Initial U.S. Approval: 1991"
e55f3dc2-c754-4550-a2c0-c304471a8791,2,nitrofurantoin,7454,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240223_e55f3dc2-c754-4550-a2c0-c304471a8791.json,"Nitrofurantoin Capsules, USP (monohydrate/macrocrystals)

Rx Only"
eb354221-c476-41cb-ad87-52423f81d698,3,cefdinir,25037,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_eb354221-c476-41cb-ad87-52423f81d698.json,"Cefdinir Capsules, USP
 
Rx only"
ed3039d8-3d27-4b71-a4b0-812943c9457f,10,trazodone,10737,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240221_ed3039d8-3d27-4b71-a4b0-812943c9457f.json,"These highlights do not include all the information needed to use TRAZODONE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for TRAZODONE HYDROCHLORIDE TABLETS.





TRAZODONE HYDROCHLORIDE tablets, for oral use




Initial U.S. Approval: 1981"
f34c08e6-fe74-4de3-9e36-a82c3c1c183b,9,moxifloxacin,139462,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240214_f34c08e6-fe74-4de3-9e36-a82c3c1c183b.json,"These highlights do not include all the information needed to use MOXIFLOXACIN TABLETS safely and effectively. See full prescribing information for MOXIFLOXACIN TABLETS.
 MOXIFLOXACIN tablets, for oral use Initial U.S. Approval: 1999"
f567d5c7-ea5d-49a7-a035-b47208135f73,9,quinine,9071,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231221_f567d5c7-ea5d-49a7-a035-b47208135f73.json,"These highlights do not include all the information needed to use 
QUININE SULFATE CAPSULES safely and effectively. See full prescribing information for
 QUININE SULFATE CAPSULES.


QUININE sulfate capsules, for oral use

Initial U.S. Approval: 2005"
f941fc61-f7a3-4e4a-ab7c-87c1667fa05b,5,rituximab,121191,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240104_f941fc61-f7a3-4e4a-ab7c-87c1667fa05b.json,"These highlights do not include all the information needed to use RUXIENCE safely and effectively. See full prescribing information for RUXIENCE. 
RUXIENCE® (rituximab-pvvr) injection, for intravenous use Initial U.S. Approval: 2019 
RUXIENCE (rituximab-pvvr) is biosimilar
Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of RUXIENCE has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information.
 to RITUXAN (rituximab)"
fb973a8d-7fea-4a7a-963f-2a8e67a46e55,6,vipivotide tetraxetan,2597054,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240123_fb973a8d-7fea-4a7a-963f-2a8e67a46e55.json,"These highlights do not include all the information needed to use PLUVICTO safely and effectively. See full prescribing information for PLUVICTO.
		

		PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous use
		
		Initial U.S. Approval: 2022"
fbac3b4f-dc23-4359-ac3f-2b3fdde41af2,32,allopurinol,519,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_fbac3b4f-dc23-4359-ac3f-2b3fdde41af2.json,"These highlights do not include all the information needed to use ALLOPURINOL TABLETS safely and effectively. See full prescribing information for ALLOPURINOL TABLETS.


ALLOPURINOL tablets for oral use 

Initial U.S. Approval:1966"
fea50328-b3d5-4300-8c67-82cda0a975b7,6,triamterene,10763,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231208_fea50328-b3d5-4300-8c67-82cda0a975b7.json,"Triamterene Capsule, USP Potassium-Sparing Diuretic"
0836c6ac-ee37-5640-2fed-a3185a0b16eb,32,abatacept,614391,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240201_0836c6ac-ee37-5640-2fed-a3185a0b16eb.json,"These highlights do not include all the information needed to use ORENCIA safely and effectively. See full prescribing information for ORENCIA.
ORENCIA (abatacept) for injection, for intravenous useORENCIA (abatacept) injection, for subcutaneous useInitial U.S. Approval: 2005"
08a44bdd-028d-41af-9d4e-70971b0bcc4e,2,furosemide,4603,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_08a44bdd-028d-41af-9d4e-70971b0bcc4e.json,"Furosemide Injection, USP"
08ce9fdd-1e84-4043-b085-91053f975b64,101,acitretin,16818,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240127_08ce9fdd-1e84-4043-b085-91053f975b64.json,"®

Tablets"
08ce9fdd-1e84-4043-b085-91053f975b64,101,acitretin,16818,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240127_08ce9fdd-1e84-4043-b085-91053f975b64.json,"®

Tablets"
0a2a1310-0a57-4fb0-a2e6-6fdb21cda9c7,7,buspirone,1827,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_0a2a1310-0a57-4fb0-a2e6-6fdb21cda9c7.json,"Buspirone Hydrochloride Tablets, USP"
106d9730-5938-8f27-e063-6294a90adc68,2,cyclobenzaprine,21949,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240221_106d9730-5938-8f27-e063-6294a90adc68.json,"Cyclobenzaprine hydrochloride Tablets, USP"
11fa3fc9-6776-49a6-b1c1-653f627c3e58,11,midostaurin,1919083,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20230527_11fa3fc9-6776-49a6-b1c1-653f627c3e58.json,"These highlights do not include all the information needed to use RYDAPT safely and effectively. See full prescribing information for RYDAPT.
RYDAPT® (midostaurin) capsules, for oral useInitial U.S. Approval: 2017"
11fad602-16c2-4c1f-bdf1-867d95f063ca,10,rosuvastatin,301542,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_11fad602-16c2-4c1f-bdf1-867d95f063ca.json,"These highlights do not include all the information needed to use ROSUVASTATIN TABLETS safely and effectively. See full prescribing information for ROSUVASTATIN TABLETS.
 

ROSUVASTATIN tablets, for oral use
 
Initial U.S. Approval: 2003"
13839d4f-6acf-4ffb-a128-79df59319273,7,talazoparib,2099704,acute liver injury,10024670,liver disorder,../data/2024_latest_labels/latest_labels_ingredients/20240223_13839d4f-6acf-4ffb-a128-79df59319273.json,"These highlights do not include all the information needed to use TALZENNA safely and effectively. See full prescribing information for TALZENNA.
TALZENNA® (talazoparib) capsules, for oral use Initial U.S. Approval: 2018"
13abdafb-71a8-40a1-ba5a-7c2b2573e53e,12,amitriptyline,704,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240223_13abdafb-71a8-40a1-ba5a-7c2b2573e53e.json,"Amitriptyline Hydrochloride Tablets, USP"
1793e218-7b49-497d-879f-1020de6e6d68,8,prednisolone,8638,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240215_1793e218-7b49-497d-879f-1020de6e6d68.json,Prednisolone Sodium Phosphate Oral Solution
17f85d17-ab71-4f5b-9fe3-0b8c822f69ff,19,pertuzumab,1298944,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/gold_xml/20211121_17f85d17-ab71-4f5b-9fe3-0b8c822f69ff.json,"These highlights do not include all the information needed to use PERJETA safely and effectively.  See full prescribing information for PERJETA. 
PERJETA® (pertuzumab) injection, for intravenous use Initial U.S. Approval:  2012"
1aa75a3a-18c9-49e1-91a6-293d0b7da756,8,procarbazine,8702,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231121_1aa75a3a-18c9-49e1-91a6-293d0b7da756.json,"MATULANE 
  ®(procarbazine hydrochloride) Capsules"
1ecb2311-eee3-4230-a019-a3496308cff1,9,dihydroergotamine,3418,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240131_1ecb2311-eee3-4230-a019-a3496308cff1.json,"Dihydroertotamine Mesylate Nasal Spray, 4 mg/mL"
22174520-4b78-4841-96f7-530ba12d2cf1,8,paroxetine,32937,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240217_22174520-4b78-4841-96f7-530ba12d2cf1.json,"Paroxetine Tablets USP, film coated for oral use"
235dfc38-0f0b-4037-b501-7a9f4294740c,16,encorafenib,2049106,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231019_235dfc38-0f0b-4037-b501-7a9f4294740c.json,"These highlights do not include all the information needed to use BRAFTOVI safely and effectively. See full prescribing information for BRAFTOVI.
BRAFTOVI® (encorafenib) capsules, for oral useInitial U.S. Approval: 2018"
2a90b899-7746-43dc-ac8a-e754428eb30c,13,desloratadine,275635,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240124_2a90b899-7746-43dc-ac8a-e754428eb30c.json,"These highlights do not include all the information needed to use DESLORATADINE TABLETS safely and effectively. See full prescribing information for DESLORATADINE TABLETS.
DESLORATADINE tablets for oral use Initial U.S. Approval: 2001"
2b70cf0c-45be-428f-b396-5001ed4e30fc,6,amiloride,644,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231130_2b70cf0c-45be-428f-b396-5001ed4e30fc.json,"Amiloride HCl Tablets, USP"
2eda833b-1357-4ed4-a093-194524fcb061,25,thalidomide,10432,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20230406_2eda833b-1357-4ed4-a093-194524fcb061.json,"These highlights do not include all the information needed to use THALOMID® safely and effectively. See full prescribing information for THALOMID. 
THALOMID (thalidomide) capsules, for oral use Initial U.S. Approval: 1998"
36d50a08-60bd-40eb-807c-778d69bf2d2e,1,velmanase alfa,2630725,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230301_36d50a08-60bd-40eb-807c-778d69bf2d2e.json,"These highlights do not include all the information needed to use 
LAMZEDE

®

 
safely and effectively. 
See full prescribing information for 
LAMZEDE
.

  

LAMZEDE
 (
velmanase alfa
-
tycv
) 
for 
injection
, 
for intravenous use

Initial U.S. Approval: 
2023"
3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac,9,mesalamine,52582,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac.json,"Mesalamine Rectal Suspension Enema

4 grams/unit (60 mL)"
413c645e-074d-4276-b39a-d83521077602,14,abiraterone,1100072,acute myocardial infarction,10002388,angina unstable,../data/2024_latest_labels/latest_labels_ingredients/20240217_413c645e-074d-4276-b39a-d83521077602.json,"These highlights do not include all the information needed to use ABIRATERONE ACETATE TABLETS safely and effectively. See full prescribing information for ABIRATERONE ACETATE TABLETS.
  

ABIRATERONE ACETATE tablets,
 
for oral use 

Initial U.S. Approval: 2011"
4be9cc3f-0016-4426-a700-574b45ce245b,10,rifabutin,55672,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231108_4be9cc3f-0016-4426-a700-574b45ce245b.json,"Rifabutin Capsules USP, 150 mg
Rx only"
4c486fc7-c8c4-4c6c-b30c-366dabaeaadd,14,gabapentin,25480,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/train_xml/20230830_4c486fc7-c8c4-4c6c-b30c-366dabaeaadd.json,"These highlights do not include all the information needed to use HORIZANT safely and effectively. See full prescribing information for HORIZANT. 
HORIZANT® (gabapentin enacarbil) Extended-Release Tablets for oral use Initial U.S. Approval: 2011"
51635427-fb13-45ee-813d-a40b0405d14f,7,diclofenac,3355,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_51635427-fb13-45ee-813d-a40b0405d14f.json,"Diclofenac Sodium Extended-Release Tablets, USP, Tablets of 100 mg
  

Rx only
  

Prescribing Information"
56d64558-1fad-420e-8fcd-7103cd073127,1,celecoxib,140587,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240207_56d64558-1fad-420e-8fcd-7103cd073127.json,"These highlights do not include all the information needed to use CELECOXIB CAPSULES safely and effectively. See full prescribing information for CELECOXIB CAPSULES.
 

CELECOXIB capsules, for oral use
 

Initial U.S. Approval: 1998"
5c4841b4-fbc0-4163-8ee1-cb28629cbfbf,13,dihematoporphyrin ether,23066,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20230816_5c4841b4-fbc0-4163-8ee1-cb28629cbfbf.json,"These highlights do not include all the information needed to use PHOTOFRIN 
 ® safely and effectively. See full prescribing information for PHOTOFRIN.
 



PHOTOFRIN (porfimer sodium) for injection, for intravenous useInitial U.S. Approval: 1995"
5c4841b4-fbc0-4163-8ee1-cb28629cbfbf,13,dihematoporphyrin ether,23066,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230816_5c4841b4-fbc0-4163-8ee1-cb28629cbfbf.json,"These highlights do not include all the information needed to use PHOTOFRIN 
 ® safely and effectively. See full prescribing information for PHOTOFRIN.
 



PHOTOFRIN (porfimer sodium) for injection, for intravenous useInitial U.S. Approval: 1995"
5c8cebcd-699f-4c4c-900b-94e0fe519345,100,propafenone,8754,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240208_5c8cebcd-699f-4c4c-900b-94e0fe519345.json,"These highlights do not include all the information needed to use PROPAFENONE HYDROCHLORIDE TABLETS safely and effectively.  See full prescribing information for PROPAFENONE HYDROCHLORIDE TABLETS.
PROPAFENONE HYDROCHLORIDE tablets, for oral useInitial U.S. Approval: 1989"
5f01e40a-b6f6-40fb-b37c-3d06f1428e86,27,glatiramer,214582,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240123_5f01e40a-b6f6-40fb-b37c-3d06f1428e86.json,"These highlights do not include all the information needed to use GLATOPA safely and effectively. See full prescribing information for GLATOPA.
GLATOPA® (glatiramer acetate injection), for subcutaneous useInitial U.S. Approval: 1996"
6a44eefe-fbe8-431c-a418-2571b26aa42e,4,tegaserod,139778,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20200605_6a44eefe-fbe8-431c-a418-2571b26aa42e.json,"These highlights do not include all the information needed to use ZELNORM

™

 safely and effectively. See full prescribing information for ZELNORM

™

.  

ZELNORM

™

 (tegaserod) tablets, for oral use

Initial U.S. Approval: 2002"
74205252-3949-57fa-e053-2991aa0aee4d,7,dopamine,3628,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240224_74205252-3949-57fa-e053-2991aa0aee4d.json,"DOPAMINE HCI INJ., USP 400mg (40mg/mL) 10mL VIAL"
74d94dbf-0567-6c15-e053-2991aa0ac6e4,5,verapamil,11170,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_74d94dbf-0567-6c15-e053-2991aa0ac6e4.json,"VERAPAMIL HYDROCHLORIDE INJECTION, USP 10mg (2.5 mg/mL) 4mL ANSYR SYR"
74f84173-a43f-7788-e053-2991aa0a8fb2,6,hydrocortisone,5492,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_74f84173-a43f-7788-e053-2991aa0a8fb2.json,SOLU-CORTEF® 100mg 2mL ACT-O-VIAL®
7652adc6-1aad-4422-b85c-0c6b11c23b73,7,gabapentin,25480,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240224_7652adc6-1aad-4422-b85c-0c6b11c23b73.json,"These highlights do not include all the information needed to use GABAPENTIN CAPSULES safely and effectively. See full prescribing information for GABAPENTIN CAPSULES.
 

GABAPENTIN capsules, for oral use
 

Initial U.S. Approval: 1993"
76e1839b-7462-4344-b319-001a5f57d67a,12,pantoprazole,40790,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_76e1839b-7462-4344-b319-001a5f57d67a.json,"These highlights do not include all the information needed to use PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS.
 

PANTOPRAZOLE SODIUM delayed-release tablets, for oral use
 
Initial U.S. approval: 2000"
793062e5-5a0c-40f9-8d8b-ca0862cd8a37,11,aripiprazole,89013,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_793062e5-5a0c-40f9-8d8b-ca0862cd8a37.json,"These highlights do not include all the information needed to use ARIPIPRAZOLE TABLETS safely and effectively. See full prescribing information for ARIPIPRAZOLE TABLETS.
 



ARIPIPRAZOLE tablets, for oral use
 

Initial U.S. Approval: 2002"
7a7974c7-8b6c-41ae-9a48-a08a1439087a,100,tretinoin,10753,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240210_7a7974c7-8b6c-41ae-9a48-a08a1439087a.json,"These highlights do not include all the information needed to use TRETINOIN CAPSULES safely and effectively. See full prescribing information for TRETINOIN CAPSULES
.



TRETINOIN 
capsules, for oral use 

Initial U.S. Approval: 1995"
7b11f6ac-4c27-4748-9e65-22d4cf3adfb4,6,liraglutide,475968,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240131_7b11f6ac-4c27-4748-9e65-22d4cf3adfb4.json,"These highlights do not include all the information needed to use SAXENDA® safely and effectively.  See full prescribing information for SAXENDA.SAXENDA (liraglutide) injection, for subcutaneous useInitial U.S. Approval: 2010"
7b9ea626-7072-2e77-e053-2a91aa0a9215,6,dobutamine,3616,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240220_7b9ea626-7072-2e77-e053-2a91aa0a9215.json,"DOBUTAMINE INJECTION, USP 250mg PER 20mL VIAL"
7d655d6d-01da-488c-bd4e-c7fbe0ace38c,5,testosterone,10379,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240215_7d655d6d-01da-488c-bd4e-c7fbe0ace38c.json,"These highlights do not include all the information needed to use TESTOSTERONE GEL, 1% safely and effectively.  See full prescribing information for TESTOSTERONE GEL, 1%.

 TESTOSTERONE gel 1%, for topical use, CIII Initial U.S. Approval: 1953"
7ee820e4-a479-4b7d-8730-101ac1f8015c,102,piroxicam,8356,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240113_7ee820e4-a479-4b7d-8730-101ac1f8015c.json,"These highlights do not include all the information needed to use PIROXICAM CAPSULES safely and effectively.  See full prescribing information for PIROXICAM CAPSULES.
PIROXICAM capsules, for oral useInitial U.S. Approval: 1982"
806b3e38-3b2a-4aaa-973c-e2d921bb353e,10,venlafaxine,39786,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_806b3e38-3b2a-4aaa-973c-e2d921bb353e.json,"Venlafaxine Tablets, USP
 
Rx only"
83aeddf8-6fed-487c-858b-2240f0a0e8af,1,indinavir,114289,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20120618_83aeddf8-6fed-487c-858b-2240f0a0e8af.json,"CRIXIVAN®
(INDINAVIR SULFATE)CAPSULES"
83aeddf8-6fed-487c-858b-2240f0a0e8af,1,indinavir,114289,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20120618_83aeddf8-6fed-487c-858b-2240f0a0e8af.json,"CRIXIVAN®
(INDINAVIR SULFATE)CAPSULES"
8993651b-fff6-4e3f-9b60-78587bc9bcee,2,sulfadiazine,10171,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231221_8993651b-fff6-4e3f-9b60-78587bc9bcee.json,"sulfADIAZINE Tablets, USP"
8b365514-c859-ff93-e053-2a95a90ac698,4,leflunomide,27169,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240110_8b365514-c859-ff93-e053-2a95a90ac698.json,"LEFLUNOMIDE TABLETS
   

Rx Only
   

These highlights do not include all the information needed to use
   

See full prescribing information for
   

Initial U.S. Approval"
8bf8e76c-27cb-42a4-aa9c-bdade68c463b,4,rasagiline,134748,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20231227_8bf8e76c-27cb-42a4-aa9c-bdade68c463b.json,These highlights do not include all the information needed to use RASAGILINE TABLETS safely and effectively. See full prescribing information for RASAGILINE TABLETS. RASAGILINE tablets for oral use Initial U.S. Approval: 2006
8fa41f19-0b2b-4b6a-aa5f-d28f8213a6bc,3,amphetamine,725,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240214_8fa41f19-0b2b-4b6a-aa5f-d28f8213a6bc.json,"Amphetamine Sulfate Tablets, USP, CII"
9678a98e-4aab-4d87-b5e1-37c3109e378e,16,tizanidine,57258,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240221_9678a98e-4aab-4d87-b5e1-37c3109e378e.json,"These highlights do not include all the information needed to use TIZANIDINE Tablets, USP safely and effectively. See full prescribing information for TIZANIDINE Tablets, USP.TIZANIDINE (tizanidine hydrochloride) Tablets USP, for oral useInitial U.S. Approval:1996"
988513ab-b06f-4dd0-93f7-d2d4531dcce4,33,agalsidase beta,338817,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_988513ab-b06f-4dd0-93f7-d2d4531dcce4.json,"These highlights do not include all the information needed to use FABRAZYME® safely and effectively. See full prescribing information for FABRAZYME®. 
 FABRAZYME® (agalsidase beta) for injection, for intravenous use  Initial U.S. Approval: 2003"
99fb821a-fe33-4468-9026-9729a8deff08,5,cyproheptadine,3013,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240118_99fb821a-fe33-4468-9026-9729a8deff08.json,CYPROHEPTADINE HYDROCHLORIDE TABLETS USPRx only
9e5c0ef3-3179-4d7b-bc76-901473c73ce8,20,varenicline,591622,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240220_9e5c0ef3-3179-4d7b-bc76-901473c73ce8.json,"These highlights do not include all the information needed to use VARENICLINE TABLETS safely and effectively. See full prescribing information for VARENICLINE TABLETS.



VARENICLINE tablets, for oral use 

Initial U.S. Approval: 2006"
a0aad470-3f38-af97-e053-2995a90a383a,16,pasireotide,1364105,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_a0aad470-3f38-af97-e053-2995a90a383a.json,"These highlights do not include all the information needed to use SIGNIFOR LAR safely and effectively. See full prescribing information for SIGNIFOR LAR.




SIGNIFOR ® LAR (pasireotide) for injectable suspension, for intramuscular use 


Initial U.S. Approval: 2012"
a3e4c8e5-bff0-4a8f-8401-e9866c846ee2,3,desflurane,27340,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231117_a3e4c8e5-bff0-4a8f-8401-e9866c846ee2.json,"These highlights do not include all the information needed to use Suprane (desflurane, USP) safely and effectively. See full prescribing information for Suprane (desflurane, USP).Suprane (desflurane, USP) Volatile Liquid for InhalationInitial U.S. Approval:  1992"
a4d0efe9-5e54-467e-9eb4-56fa7d53b60b,34,daratumumab,1721947,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240123_a4d0efe9-5e54-467e-9eb4-56fa7d53b60b.json,"These highlights do not include all the information needed to use DARZALEX safely and effectively. See full prescribing information for DARZALEX.
 



DARZALEX 
 ®(daratumumab) injection, for intravenous use
 

Initial U.S. Approval: 2015"
a4f9f620-e6e4-4a03-a9a7-79007c8c2cfe,6,human vaccinia immune globulin,597392,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20190522_a4f9f620-e6e4-4a03-a9a7-79007c8c2cfe.json,"These highlights do not include all the information needed to use CNJ-016 (vaccinia immune globulin intravenous, human), VIGIV safely and effectively. See full prescribing information for VIGIV. VIGIV (vaccinia immune globulin, human), 5% sterile solution for intravenous use.Initial U.S. Approval: 2005"
a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6,10,enasidenib,1940332,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240105_a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6.json,"These highlights do not include all the information needed to use IDHIFA safely and effectively. See full prescribing information for IDHIFA. 
IDHIFA® (enasidenib) tablets, for oral use Initial U.S. Approval: 2017"
a6826aa3-fabb-4ff1-a7a3-cd4c34e3a330,4,clevidipine,233603,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20221118_a6826aa3-fabb-4ff1-a7a3-cd4c34e3a330.json,"These highlights do not include all the information needed to use Cleviprex safely and effectively. See full prescribing information for Cleviprex.
 



Cleviprex (clevidipine) injectable emulsion, for intravenous use
 

Initial U.S. Approval: 2008"
a6d46c03-bb1d-417b-b8e5-3bffe352fe29,14,rucaparib,1862579,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240223_a6d46c03-bb1d-417b-b8e5-3bffe352fe29.json,"These highlights do not include all the information needed to use RUBRACA safely and effectively. See full prescribing information for RUBRACA.
 
RUBRACA 
 ®(rucaparib) tablets, for oral use
 
Initial U.S. Approval: 2016"
b4c2c9dc-a0bb-4d64-a667-a67ebe88392d,37,certolizumab pegol,709271,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20230105_b4c2c9dc-a0bb-4d64-a667-a67ebe88392d.json,"These highlights do not include all the information needed to use CIMZIA® safely and effectively. See full prescribing information for CIMZIA.
 



CIMZIA (certolizumab pegol) for injection, for subcutaneous use
 

CIMZIA (certolizumab pegol) injection, for subcutaneous use
 

Initial U.S. Approval: 2008"
b6b1d427-e19a-4fc1-b518-f58bacc46736,8,guanfacine,40114,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240217_b6b1d427-e19a-4fc1-b518-f58bacc46736.json,"Guanfacine Tablets, USP 


Rx only"
b7b679a9-6823-4ef8-8d31-3ab5058ffcfc,11,leuprolide,42375,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240210_b7b679a9-6823-4ef8-8d31-3ab5058ffcfc.json,"These highlights do not include all the information needed to use ELIGARD
®
 safely and effectively. See full prescribing information for ELIGARD.
ELIGARD (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 2002"
b8d657ac-dbda-4455-8bb5-3896951c3b67,4,zolmitriptan,135775,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_b8d657ac-dbda-4455-8bb5-3896951c3b67.json,"These highlights do not include all the information needed to use ZOLMITRIPTAN ORALLY DISINTEGRATING TABLETS safely and effectively. See full prescribing information for ZOLMITRIPTAN ORALLY DISINTEGRATING TABLETS.
 ZOLMITRIPTAN orally disintegrating tablets Initial U.S. Approval: 1997"
c36132b2-3ec7-4c43-a25e-75cbdbe3d88d,5,cyclosporine,3008,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_c36132b2-3ec7-4c43-a25e-75cbdbe3d88d.json,"CYCLOSPORINE, MODIFIED - cyclosporine capsule, liquid filledRx only Prescribing Information"
c391fe11-fd47-4a35-af6d-c823ab7b8838,11,letrozole,72965,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240117_c391fe11-fd47-4a35-af6d-c823ab7b8838.json,"These highlights do not include all the information needed to use
letrozole tablets
safely and effectively. See full prescribing information for
letrozole tablets.








LETROZOLE tablets, for oral use








Initial U.S. Approval:
1997"
c6c7c39e-e510-4f4a-bf7a-926f0e075d3a,10,protriptyline,8886,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231221_c6c7c39e-e510-4f4a-bf7a-926f0e075d3a.json,"Protriptyline Hydrochloride Tablets, USPRx Only"
c89e8f4d-96c0-44c6-906a-b803141920b1,27,cefuroxime,2194,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240215_c89e8f4d-96c0-44c6-906a-b803141920b1.json,"These highlights do not include all the information needed to use CEFUROXIME AXETIL TABLETS safely and effectively. See full prescribing information for CEFUROXIME AXETIL TABLETS.  CEFUROXIME AXETIL tablets, for oral use  Initial U.S. Approval: 1987"
c89e8f4d-96c0-44c6-906a-b803141920b1,27,cefuroxime,2194,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240215_c89e8f4d-96c0-44c6-906a-b803141920b1.json,"These highlights do not include all the information needed to use CEFUROXIME AXETIL TABLETS safely and effectively. See full prescribing information for CEFUROXIME AXETIL TABLETS.  CEFUROXIME AXETIL tablets, for oral use  Initial U.S. Approval: 1987"
c94fc2c5-e840-4f18-b7d8-d5eacb26d3a0,8,maribavir,2586068,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230509_c94fc2c5-e840-4f18-b7d8-d5eacb26d3a0.json,"These highlights do not include all the information needed to use LIVTENCITY safely and effectively. See full prescribing information for LIVTENCITY.
 LIVTENCITY™  (maribavir) tablets, for oral use Initial U.S. Approval: 2021"
caad4ada-2cf9-4e12-99df-6ca4388cf0f6,100,dexlansoprazole,816346,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240130_caad4ada-2cf9-4e12-99df-6ca4388cf0f6.json,"These highlights do not include all the information needed to use DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES.


DEXLANSOPRAZOLE delayed-release capsules, for oral use 

Initial U.S. Approval: 1995 (lansoprazole)"
cc0cb812-48f9-a138-e053-2a95a90a7666,7,chloroquine,2393,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240110_cc0cb812-48f9-a138-e053-2a95a90a7666.json,"Chloroquine Phosphate Tablets, USP"
d1f64796-6ba0-415c-a6a0-5456b21a7ed6,5,fenofibrate,8703,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240221_d1f64796-6ba0-415c-a6a0-5456b21a7ed6.json,"These highlights do not include all the information needed to use FENOFIBRATE TABLETS safely and effectively. See full prescribing information for FENOFIBRATE TABLETS.
 
FENOFIBRATE tablets, for oral use
 
Initial U.S. Approval: 1993"
d2daba09-f1c2-4764-a567-1291be4892b9,100,posaconazole,282446,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240124_d2daba09-f1c2-4764-a567-1291be4892b9.json,"These highlights do not include all the information needed to use
POSACONAZOLE DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for

POSACONAZOLE

DELAYED-RELEASE TABLETS
.



POSACONAZOLE

delayed-release tablets, for oral use

Initial U.S. Approval: 2006"
d4500795-3b07-4a7d-b432-73cafbb3dbc6,2,aztreonam,1272,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240110_d4500795-3b07-4a7d-b432-73cafbb3dbc6.json,"Aztreonam for Injection, USP"
d5929f91-6496-4c0e-97e8-0bd524e15763,3,bosutinib,1307619,acute liver injury,10023126,jaundice,../data/2024_latest_labels/train_xml/20220817_d5929f91-6496-4c0e-97e8-0bd524e15763.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF.
 BOSULIF® (bosutinib) tablets, for oral use Initial U.S. Approval: 2012"
dbf738c4-3fac-4422-a9d8-51d9c83a8789,3,infliximab,191831,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240110_dbf738c4-3fac-4422-a9d8-51d9c83a8789.json,"These highlights do not include all the information needed to use RENFLEXIS® safely and effectively. See full prescribing information for RENFLEXIS. 
RENFLEXIS (infliximab-abda) for injection, for intravenous use Initial U.S. Approval: 2017 RENFLEXIS (infliximab-abda) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of RENFLEXIS has been demonstrated for the condition(s) of use (e.g. indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to REMICADE (infliximab)."
dc8d68d1-0c5c-4004-b71d-22b83daf4270,6,bexarotene,233272,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240105_dc8d68d1-0c5c-4004-b71d-22b83daf4270.json,"These highlights do not include all the information needed to use BEXAROTENE CAPSULES safely and effectively.  See full prescribing information for BEXAROTENE CAPSULES.BEXAROTENE capsules, for oral useInitial U.S. Approval: 1999"
dd367eec-359a-4065-b5c3-7c0107c823fe,7,tolcapone,72937,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20210106_dd367eec-359a-4065-b5c3-7c0107c823fe.json,"Tolcapone Tablets

100 mg"
dddcdcc3-cd4d-4573-98ac-9468bea23a8b,7,oxytocin,7824,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231222_dddcdcc3-cd4d-4573-98ac-9468bea23a8b.json,"Pitocin®
 (Oxytocin Injection, USP) Synthetic"
de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa,24,cabazitaxel,996051,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/train_xml/20230720_de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa.json,"These highlights do not include all the information needed to use JEVTANA safely and effectively. See full prescribing information for JEVTANA.
 JEVTANA® (cabazitaxel) injection, for intravenous use Initial U.S. Approval: 2010"
df918ec2-0907-443f-a52a-b72866959644,22,filgrastim,68442,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20231208_df918ec2-0907-443f-a52a-b72866959644.json,"These highlights do not include all the information needed to use GRANIX safely and effectively.  See full prescribing information for GRANIX.GRANIX® (tbo-filgrastim) injection, for subcutaneous use Initial U.S. Approval: 2012"
efe2861a-f7ca-ae06-e053-2995a90a50e9,3,travoprost,283809,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240208_efe2861a-f7ca-ae06-e053-2995a90a50e9.json,"TRAVOPROST OPHTHALMIC SOLUTION. These highlights do not include all the information needed to use TRAVOPROST OPHTHALMIC SOLUTION (Ionic Buffered Solution) safely and effectively. See full prescribing information for TRAVOPROST OPHTHALMIC SOLUTION (Ionic Buffered Solution) .
 

TRAVOPROST ophthalmic solution (Ionic Buffered Solution)

Initial U.S. Approval: 2001"
f47d4365-40a8-445b-99cd-49edad6a8ffc,15,ketorolac,35827,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240206_f47d4365-40a8-445b-99cd-49edad6a8ffc.json,"Ketorolac Tromethamine Tablets USP, 10 mg 
 




Rx only"
f567d5c7-ea5d-49a7-a035-b47208135f73,9,quinine,9071,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231221_f567d5c7-ea5d-49a7-a035-b47208135f73.json,"These highlights do not include all the information needed to use 
QUININE SULFATE CAPSULES safely and effectively. See full prescribing information for
 QUININE SULFATE CAPSULES.


QUININE sulfate capsules, for oral use

Initial U.S. Approval: 2005"
fc2a08dd-4fb6-4ac4-9082-f99552fae25c,11,bromocriptine,1760,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231215_fc2a08dd-4fb6-4ac4-9082-f99552fae25c.json,Parlodel Capsules and Tablets
fc38f1bb-f175-4a81-8ed9-c8701efdea35,102,fosinopril,50166,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231128_fc38f1bb-f175-4a81-8ed9-c8701efdea35.json,"FOSINOPRILSODIUM TABLETS, USP10mg, 20mg and 40mgRx Only"
fd427d2d-b78b-412a-9c80-606bc88ad112,10,eletriptan,231049,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20231220_fd427d2d-b78b-412a-9c80-606bc88ad112.json,"These highlights do not include all the information needed to use ELETRIPTAN HYDROBROMIDE TABLETS safely and effectively. See full prescribing information for ELETRIPTAN HYDROBROMIDE TABLETS.


ELETRIPTAN hydrobromide tablets, for oral use 

Initial U.S. Approval: 2002"
fd638e5e-8032-e7ca-0179-95e96ab5d387,18,afatinib,1430438,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20220723_fd638e5e-8032-e7ca-0179-95e96ab5d387.json,"These highlights do not include all the information needed to use GILOTRIF safely and effectively.  See full prescribing information for GILOTRIF. 
GILOTRIF® (afatinib tablets), for oral use Initial U.S. Approval: 2013"
fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea,26,dabrafenib,1424911,gi bleed,10018830,haematemesis,../data/2024_latest_labels/train_xml/20230910_fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea.json,"These highlights do not include all the information needed to use TAFINLAR safely and effectively. See full prescribing information for TAFINLAR.
TAFINLAR® (dabrafenib) capsules, for oral useTAFINLAR® (dabrafenib) tablets for oral suspensionInitial U.S. Approval: 2013"
00fb869a-40e7-4c85-8380-c5e0cdee8018,4,bupivacaine,1815,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240224_00fb869a-40e7-4c85-8380-c5e0cdee8018.json,"HiGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use MARCAINE™ and MARCAINE™ WITH EPINEPHRINE safely and effectively. See full prescribing information for MARCAINE™ and MARCAINE™ WITH EPINEPHRINE.
  MARCAINE™ (bupivacaine hydrochloride) injection, for infiltration, perineural, caudal, epidural, or retrobulbar useMARCAINE™ WITH EPINEPHRINE (bupivacaine hydrochloride and epinephrine) injection, for infiltration, perineural, caudal, or epidural useInitial U.S. Approval: 1972"
03819118-86f6-4329-adaf-4599e7b71f46,29,buprenorphine,1819,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240217_03819118-86f6-4329-adaf-4599e7b71f46.json,"These highlights do not include all the information needed to use
 
BUPRENORPHINE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE
 
SUBLINGUAL TABLETS.

       

BUPRENORPHINE 
s
ublingual 
t
ablets, CIII

Initial U.S. Approval: 1981"
03af7d09-314a-fe85-e063-6294a90afa25,1,valsartan,69749,acute myocardial infarction,10000891,acute myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240127_03af7d09-314a-fe85-e063-6294a90afa25.json,"These highlights do not include all the information needed to use VALSARTAN TABLETS safely and effectively. See full prescribing information for VALSARTAN TABLETS.
 

VALSARTAN tablets, for ORAL use
 
Initial U.S. Approval: 1996"
0772eb61-ca42-39de-e063-6294a90a6632,1,sunitinib,357977,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20231012_0772eb61-ca42-39de-e063-6294a90a6632.json,"SUNITINIB MALATE
 

These highlights do not include all the information needed to use SUNITINIB MALATE CAPSULES safely and effectively. See full prescribing information for SUNITINIB MALATE CAPSULES.
 

Initial U.S. Approval: 2006"
08ce9fdd-1e84-4043-b085-91053f975b64,101,acitretin,16818,acute myocardial infarction,10000891,acute myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240127_08ce9fdd-1e84-4043-b085-91053f975b64.json,"®

Tablets"
10e39d3b-8621-16f8-e063-6294a90a254e,1,alvimopan,480639,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240209_10e39d3b-8621-16f8-e063-6294a90a254e.json,"ALVIMOPAN CAPSULES. These highlights do not include all the information needed to use ALVIMOPAN CAPSULES safely and effectively. See full prescribing information for ALVIMOPAN CAPSULES.
 

ALVIMOPAN capsules, for oral use
 
Initial U.S. Approval: 2008"
1aa40de5-c02d-49d6-8722-ed88c40c3ba6,2,felbamate,24812,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240101_1aa40de5-c02d-49d6-8722-ed88c40c3ba6.json,"Felbamate Tablets, USP

(400 mg and 600 mg)


Rx only"
1af01887-b69d-444b-91ed-ebfe12784440,13,basiliximab,196102,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20230802_1af01887-b69d-444b-91ed-ebfe12784440.json,"Simulect

®


(basiliximab)


For Injection


Rx only



	Prescribing Information"
1de49a4d-dc7e-48ff-b18c-e1414282fe71,102,imiquimod,59943,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240113_1de49a4d-dc7e-48ff-b18c-e1414282fe71.json,"These highlights do not include all the information needed to use IMIQUIMOD Cream safely and effectively. See full prescribing information for IMIQUIMOD Cream.
IMIQUIMOD cream, for topical useInitial U.S. Approval: 1997"
1fffe88d-50c8-45cf-ac7c-a62b665c89a8,16,sulindac,10237,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240126_1fffe88d-50c8-45cf-ac7c-a62b665c89a8.json,SULINDAC TABLETS USP
23b1f2f5-2d84-4a1e-997f-6489204878b2,102,captopril,1998,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240112_23b1f2f5-2d84-4a1e-997f-6489204878b2.json,"Captopril Tablets, USP

for oral use

Rx only"
24926986-7552-4f1a-8366-f035bbd07104,7,fluoxetine,4493,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_24926986-7552-4f1a-8366-f035bbd07104.json,"These highlights do not include all the information needed to use FLUOXETINE CAPSULES safely and effectively. See full prescribing information for FLUOXETINE CAPSULES.
 
FLUOXETINE capsules, for oral use
 
Initial U.S. Approval: 1987"
2a7300d3-95e3-427e-bf37-55fa654cc90a,9,olanzapine,61381,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_2a7300d3-95e3-427e-bf37-55fa654cc90a.json,"These highlights do not include all the information needed to use OLANZAPINE TABLETS safely and effectively. See full prescribing information for OLANZAPINE TABLETS.


OLANZAPINE
 tablets, for oral use 


Initial U.S. Approval: 1996"
31e79459-107f-4d69-a163-90014f1c4772,3,disopyramide,3541,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20230914_31e79459-107f-4d69-a163-90014f1c4772.json,Disopyramide phosphate capsules
33f3b99b-fa82-42e0-26bf-f49891ae3d22,38,ertapenem,325642,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240217_33f3b99b-fa82-42e0-26bf-f49891ae3d22.json,"These highlights do not include all the information needed to use INVANZ safely and effectively. See full prescribing information for INVANZ. 
INVANZ® (ertapenem for injection), for intravenous or intramuscular use Initial U.S. Approval: 2001"
4650d12c-b9c8-4525-b07f-a2d773eca155,26,teriflunomide,1310520,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/gold_xml/20240110_4650d12c-b9c8-4525-b07f-a2d773eca155.json,"These highlights do not include all the information needed to use AUBAGIO® safely and effectively. See full prescribing information for AUBAGIO. 
AUBAGIO (teriflunomide) tablets, for oral use Initial U.S. Approval: 2012"
49aa3d6d-2270-4615-aafa-b440859ab870,4,naltrexone,7243,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240216_49aa3d6d-2270-4615-aafa-b440859ab870.json,Naltrexone Hydrochloride Tablets USP 50 mg
4c486fc7-c8c4-4c6c-b30c-366dabaeaadd,14,gabapentin,25480,acute liver injury,10023126,jaundice,../data/2024_latest_labels/train_xml/20230830_4c486fc7-c8c4-4c6c-b30c-366dabaeaadd.json,"These highlights do not include all the information needed to use HORIZANT safely and effectively. See full prescribing information for HORIZANT. 
HORIZANT® (gabapentin enacarbil) Extended-Release Tablets for oral use Initial U.S. Approval: 2011"
5198b1c8-8dd6-4b8f-bd85-294ac468af53,10,fluvoxamine,42355,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_5198b1c8-8dd6-4b8f-bd85-294ac468af53.json,"These highlights do not include all the information needed to use FLUVOXAMINE MALEATE TABLETS safely and effectively. See full prescribing information for FLUVOXAMINE MALEATE TABLETS.
 

FLUVOXAMINE MALEATE tablets, for oral use
 
Initial U.S. Approval: 1994"
56b6ba36-9b49-4422-a2a4-7bfa0d941a5d,2,flutamide,4508,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20220115_56b6ba36-9b49-4422-a2a4-7bfa0d941a5d.json,EULEXINTM (flutamide) CAPSULES USP
5736aecc-cc1d-47dd-86c0-5fb2e9d70f61,5,cladribine,44157,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230420_5736aecc-cc1d-47dd-86c0-5fb2e9d70f61.json,CLADRIBINE INJECTION
58353438-3236-4596-9324-62fed9615cb7,12,dulaglutide,1551291,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/train_xml/20231213_58353438-3236-4596-9324-62fed9615cb7.json,"These highlights do not include all the information needed to use TRULICITY safely and effectively. See full prescribing information for TRULICITY.
TRULICITY (dulaglutide) injection, for subcutaneous useInitial U.S. Approval: 2014"
584abe73-8290-4484-ff8e-5890831c095e,21,sumatriptan,37418,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240222_584abe73-8290-4484-ff8e-5890831c095e.json,"These highlights do not include all the information needed to use IMITREX safely and effectively. See full prescribing information for IMITREX.IMITREX (sumatriptan) tablets, for oral useInitial U.S. Approval: 1992"
5c8cebcd-699f-4c4c-900b-94e0fe519345,100,propafenone,8754,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240208_5c8cebcd-699f-4c4c-900b-94e0fe519345.json,"These highlights do not include all the information needed to use PROPAFENONE HYDROCHLORIDE TABLETS safely and effectively.  See full prescribing information for PROPAFENONE HYDROCHLORIDE TABLETS.
PROPAFENONE HYDROCHLORIDE tablets, for oral useInitial U.S. Approval: 1989"
61c3d6c7-0d9c-4e46-b091-88d84893e14a,11,zolpidem,39993,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240224_61c3d6c7-0d9c-4e46-b091-88d84893e14a.json,"These highlights do not include all the information needed to use ZOLPIDEM TARTRATE TABLETS safely and effectively. See full prescribing information for ZOLPIDEM TARTRATE TABLETS.
 



ZOLPIDEM TARTRATE tablets, for oral use, C-IV
 

Initial U.S. Approval: 1992"
61e025f1-a38e-4af2-9e18-13ea12977cf5,2,soybean oil,9949,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231024_61e025f1-a38e-4af2-9e18-13ea12977cf5.json,"These highlights do not include all the information needed to use INTRALIPID® safely and effectively. See full prescribing information for INTRALIPID.
INTRALIPID 20% (lipid injectable emulsion), for intravenous useInitial U.S. Approval: 1975"
666f89b4-fd81-420a-a390-eb1cd4014f61,10,diflunisal,3393,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240210_666f89b4-fd81-420a-a390-eb1cd4014f61.json,Rx only
6f4998ac-0714-4f5d-8944-9e6902b9f0a6,12,levothyroxine,10582,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240220_6f4998ac-0714-4f5d-8944-9e6902b9f0a6.json,"These highlights do not include all the information needed to use LEVOTHYROXINE SODIUM TABLETS safely and effectively. See full prescribing information for LEVOTHYROXINE SODIUM TABLETS.
 

LEVOTHYROXINE SODIUM tablets, for oral use
 

Initial U.S. Approval: 2002"
7276803b-5b97-d886-e053-2a91aa0a184e,5,dofetilide,49247,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240124_7276803b-5b97-d886-e053-2a91aa0a184e.json,"Dofetilide Capsules
 

Rx Only
 















Rx only"
7652adc6-1aad-4422-b85c-0c6b11c23b73,7,gabapentin,25480,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240224_7652adc6-1aad-4422-b85c-0c6b11c23b73.json,"These highlights do not include all the information needed to use GABAPENTIN CAPSULES safely and effectively. See full prescribing information for GABAPENTIN CAPSULES.
 

GABAPENTIN capsules, for oral use
 

Initial U.S. Approval: 1993"
7f10bf63-06c8-477d-a13e-fb88e287617a,103,repaglinide,73044,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240116_7f10bf63-06c8-477d-a13e-fb88e287617a.json,"These highlights do not include all the information needed to use REPAGLINIDE TABLETS safely and effectively.  See full prescribing information for REPAGLINIDE TABLETS.REPAGLINIDE tablets, for oral useInitial U.S. Approval: 1997"
81d9e47e-ae81-4755-a5ee-546a038fadb4,7,mirtazapine,15996,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_81d9e47e-ae81-4755-a5ee-546a038fadb4.json,"These highlights do not include all the information needed to use MIRTAZAPINE TABLETS safely and effectively. See full prescribing information for MIRTAZAPINE TABLETS.
 

MIRTAZAPINE tablets, for oral use
 
Initial U.S. Approval: 1996"
8d5ace90-983b-48c4-baf1-b44f6af146de,2,carbamazepine,2002,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240221_8d5ace90-983b-48c4-baf1-b44f6af146de.json,"Carbamazepine Oral Suspension, USP
 
Rx only
 
Prescribing Information"
90f5c7ab-9f15-487d-ba69-ee4107434bcc,1,cytarabine,3041,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20230607_90f5c7ab-9f15-487d-ba69-ee4107434bcc.json,"Cytarabine Injection(For Intravenous, Intrathecal and Subcutaneous Use Only)"
983ce15f-cd37-4f3a-9e51-205860e80976,3,sodium phosphate,36709,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20100824_983ce15f-cd37-4f3a-9e51-205860e80976.json,DESCRIPTION
9c44bd5b-4464-40a4-8933-8680950f00f2,29,adalimumab,327361,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240210_9c44bd5b-4464-40a4-8933-8680950f00f2.json,"These highlights do not include all the information needed to use AMJEVITA™ safely and effectively. See full prescribing information for AMJEVITA. 
 AMJEVITA (adalimumab-atto) injection, for subcutaneous use    Initial U.S. Approval: 2016 
 AMJEVITA (adalimumab-atto) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of AMJEVITA has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to HUMIRA® (adalimumab)."
9c9d9f5c-bfd1-4e2a-be4a-697344ca6833,11,citalopram,2556,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240224_9c9d9f5c-bfd1-4e2a-be4a-697344ca6833.json,"These highlights do not include all the information needed to use citalopram tablets safely and effectively. See full prescribing information for citalopram tablets.
 


CITALOPRAM (Citalopram) tablets, for oral use
 


Initial U.S. Approval: 1998"
a6826aa3-fabb-4ff1-a7a3-cd4c34e3a330,4,clevidipine,233603,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20221118_a6826aa3-fabb-4ff1-a7a3-cd4c34e3a330.json,"These highlights do not include all the information needed to use Cleviprex safely and effectively. See full prescribing information for Cleviprex.
 



Cleviprex (clevidipine) injectable emulsion, for intravenous use
 

Initial U.S. Approval: 2008"
aa80b9f4-8a5d-3e14-e053-2a95a90a8aab,4,theophylline,10438,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240201_aa80b9f4-8a5d-3e14-e053-2a95a90a8aab.json,"Theophylline (Anhydrous) Extended-Release Tablets
 

400 mg and 600 mg"
b0075b72-c3cc-f844-e053-2a95a90a417f,5,meropenem,29561,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240104_b0075b72-c3cc-f844-e053-2a95a90a417f.json,"These highlights do not include all the information needed to use MEROPENEM FOR INJECTION safely and effectively. See full prescribing information for MEROPENEM FOR INJECTION
 







MEROPENEM for injection, for intravenous use
 







Initial U.S. Approval: 1996"
b7241707-7538-4d1a-91e7-3a25a91e0b9a,14,ifosfamide,5657,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231116_b7241707-7538-4d1a-91e7-3a25a91e0b9a.json,"These highlights do not include all the information needed to use IFEX (ifosfamide) safely and effectively.  See full prescribing information for IFEX.
IFEX (ifosfamide) for injection, intravenous useInitial U.S. Approval: 1988"
baac91ad-f8ee-4694-89f8-5c47a8eda39a,10,moexipril,30131,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240104_baac91ad-f8ee-4694-89f8-5c47a8eda39a.json,"Moexipril Hydrochloride Tablets USP

7.5 mg and 15 mg"
bda70104-d84b-4d3f-9ca0-5f4f1ca816ad,13,voriconazole,121243,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240215_bda70104-d84b-4d3f-9ca0-5f4f1ca816ad.json,"These highlights do not include all the information needed to use VORICONAZOLE TABLETS safely and effectively. See full prescribing information for VORICONAZOLE TABLETS.VORICONAZOLE tablets, for oral useInitial U.S. Approval: 2002"
c3658bc8-1524-43db-930e-66f9ac01b808,11,telmisartan,73494,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240124_c3658bc8-1524-43db-930e-66f9ac01b808.json,"These highlights do not include all the information needed to use TELMISARTAN TABLETS safely and effectively. See full prescribing information for TELMISARTAN TABLETS.  TELMISARTAN tablets, for oral useInitial U.S. Approval: 1998"
c394914b-2334-418e-bf86-9f9100323717,6,ketoconazole,6135,acute liver injury,10024670,liver disorder,../data/2024_latest_labels/latest_labels_ingredients/20240224_c394914b-2334-418e-bf86-9f9100323717.json,KETOCONAZOLE CREAM 2%
cf41a02d-c881-4b40-b99c-d5b79dbd645b,9,perphenazine,8076,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240215_cf41a02d-c881-4b40-b99c-d5b79dbd645b.json,"Perphenazine Tablets, USP"
de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa,24,cabazitaxel,996051,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230720_de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa.json,"These highlights do not include all the information needed to use JEVTANA safely and effectively. See full prescribing information for JEVTANA.
 JEVTANA® (cabazitaxel) injection, for intravenous use Initial U.S. Approval: 2010"
e03d32dd-878f-43ee-b8c2-3adad98bf66c,100,methimazole,6835,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240223_e03d32dd-878f-43ee-b8c2-3adad98bf66c.json,"Methimazole Tablets, USP

 Rx only"
e53960ab-42a1-40d1-9c7d-eb013fe7f18f,14,mogamulizumab,2054068,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20230428_e53960ab-42a1-40d1-9c7d-eb013fe7f18f.json,"These highlights do not include all the information needed to use POTELIGEO safely and effectively. See full prescribing information for POTELIGEO.
POTELIGEO® (mogamulizumab-kpkc) injection, for intravenous useInitial U.S. Approval: 2018"
e5b67402-8550-4604-97a0-c7b149fbf753,9,cholic acid,1440856,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20230404_e5b67402-8550-4604-97a0-c7b149fbf753.json,"These highlights do not include all the information needed to use CHOLBAM® safely and effectively. See full prescribing information for CHOLBAM. 
 CHOLBAM (cholic acid) capsules, for oral use  Initial U.S. Approval: 2015"
f34c08e6-fe74-4de3-9e36-a82c3c1c183b,9,moxifloxacin,139462,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240214_f34c08e6-fe74-4de3-9e36-a82c3c1c183b.json,"These highlights do not include all the information needed to use MOXIFLOXACIN TABLETS safely and effectively. See full prescribing information for MOXIFLOXACIN TABLETS.
 MOXIFLOXACIN tablets, for oral use Initial U.S. Approval: 1999"
f7573809-7741-04c9-e053-6294a90ab193,1,zileuton,40575,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20230321_f7573809-7741-04c9-e053-6294a90ab193.json,"ZILEUTON EXTENDED-RELEASE TABLETS. These highlights do not include all the information needed to use ZILEUTON EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for ZILEUTON EXTENDED-RELEASE TABLETS.
 

ZILEUTON extended-release tablets, for oral use
 

Initial U.S. Approval: 1996"
f7b3f443-e83d-4bf2-0e96-023448fed9a8,49,ticagrelor,1116632,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/gold_xml/20231104_f7b3f443-e83d-4bf2-0e96-023448fed9a8.json,"These highlights do not include all the information needed to use BRILINTA safely and effectively. See full prescribing information for BRILINTA.
BRILINTA® (ticagrelor) tablets, for oral useInitial U.S. Approval: 2011"
f82dcff5-4afa-45d8-bc8c-f0f7c0c96272,1,tolazamide,10633,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20080313_f82dcff5-4afa-45d8-bc8c-f0f7c0c96272.json,""
fa7d93e3-b69b-4e02-8146-89760cd8e9d6,6,avanafil,1291301,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20230910_fa7d93e3-b69b-4e02-8146-89760cd8e9d6.json,"These highlights do not include all the information needed to use 
STENDRA
 safely and effectively.  See full prescribing information for 
STENDRA
.



STENDRA

®

 (avanafil) 
tablets, for oral use

Initial U.S. Approval:  
2012"
fdbcc274-c343-4461-9db9-6ff1be15d727,10,bupropion,42347,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_fdbcc274-c343-4461-9db9-6ff1be15d727.json,"These highlights do not include all the information needed to use 
  BUPROPIONHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for 
  BUPROPIONHYDROCHLORIDE TABLETS. 
 


BUPROPION HYDROCHLORIDE tablets, for oral use
  
Initial U.S. Approval: 1985"
029a90b6-0722-49be-8400-3ec29526aafd,6,irbesartan,83818,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240224_029a90b6-0722-49be-8400-3ec29526aafd.json,"These highlights do not include all the information needed to use IRBESARTAN TABLETS safely and effectively. See full prescribing information for IRBESARTAN TABLETS.
 



IRBESARTAN tablets, for oral use
 

Initial U.S. Approval: 1997"
029a90b6-0722-49be-8400-3ec29526aafd,6,irbesartan,83818,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_029a90b6-0722-49be-8400-3ec29526aafd.json,"These highlights do not include all the information needed to use IRBESARTAN TABLETS safely and effectively. See full prescribing information for IRBESARTAN TABLETS.
 



IRBESARTAN tablets, for oral use
 

Initial U.S. Approval: 1997"
040a97e5-efd1-4a2f-b737-2f13e5366d70,7,selegiline,9639,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20231228_040a97e5-efd1-4a2f-b737-2f13e5366d70.json,Selegiline Hydrochloride Tablets USP 5 mg
083a3282-254f-4042-b0eb-70f76a279f10,100,vardenafil,306674,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240127_083a3282-254f-4042-b0eb-70f76a279f10.json,"These highlights do not include all the information needed to use VARDENAFIL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for VARDENAFIL HYDROCHLORIDE TABLETS.
 



VARDENAFIL HYDROCHLORIDE tablets, for oral use
 

Initial U.S. Approval: 2003"
0becbde8-6ec5-4830-a0d9-cfdb7b15eb84,11,minocycline,6980,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_0becbde8-6ec5-4830-a0d9-cfdb7b15eb84.json,"Minocycline Hydrochloride Capsules, USP
 

Rx only"
0e98593a-8424-48c8-acc0-671f4b566aee,9,carvedilol,20352,acute liver injury,10084058,congestive hepatopathy,../data/2024_latest_labels/latest_labels_ingredients/20240224_0e98593a-8424-48c8-acc0-671f4b566aee.json,"These highlights do not include all the information needed to use CARVEDILOL TABLETS safely and effectively. See full prescribing information for CARVEDILOL TABLETS.
 

CARVEDILOL tablets, for oral use
 
Initial U.S. Approval: 1995"
101b2d4d-4740-4225-94bc-aecc05d82c6b,10,risperidone,35636,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240224_101b2d4d-4740-4225-94bc-aecc05d82c6b.json,"These highlights do not include all the information needed to use RISPERIDONE TABLETS safely and effectively. See full prescribing information for RISPERIDONE TABLETS.
 

RISPERIDONE tablets, for oral use
 



Initial U.S. Approval: 1993"
116f655e-e32f-5030-e063-6394a90a64e5,1,amoxicillin,723,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240217_116f655e-e32f-5030-e063-6394a90a64e5.json,"These highlights do not include all the information needed to use AMOXICILLIN CAPSULES safely and effectively. See full prescribing information for AMOXICILLIN CAPSULES.
 

AMOXICILLIN capsules, for oral use
 
Initial U.S. Approval: 1974"
1522921b-d6c2-420d-ba0d-39ac16ba8b37,13,phenazopyridine,8120,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240222_1522921b-d6c2-420d-ba0d-39ac16ba8b37.json,"PHENAZOPYRIDINE HYDROCHLORIDE TABLETS, USP



Rx Only"
17e597bc-d663-4d8e-a5d3-39816b628996,8,stavudine,59763,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20190118_17e597bc-d663-4d8e-a5d3-39816b628996.json,"These highlights do not include all the information needed to use STAVUDINE FOR ORAL SOLUTION safely and effectively. See full prescribing information for STAVUDINE FOR ORAL SOLUTION.
STAVUDINE for oral solutionInitial U.S. Approval: 1994"
1a2c0a9a-c637-4485-ad4b-0b6d0b05fa20,3,dipyridamole,3521,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231014_1a2c0a9a-c637-4485-ad4b-0b6d0b05fa20.json,"Dipyridamole 5 mg/mL Injection, USP 10 mL Single Dose Vial"
1aa40de5-c02d-49d6-8722-ed88c40c3ba6,2,felbamate,24812,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240101_1aa40de5-c02d-49d6-8722-ed88c40c3ba6.json,"Felbamate Tablets, USP

(400 mg and 600 mg)


Rx only"
1e484a50-55db-4b85-8c57-6cd1b0353abd,32,macitentan,1442132,acute liver injury,10084058,congestive hepatopathy,../data/2024_latest_labels/latest_labels_ingredients/20230615_1e484a50-55db-4b85-8c57-6cd1b0353abd.json,"These highlights do not include all the information needed to use OPSUMIT safely and effectively. See full prescribing information for OPSUMIT.
 



OPSUMIT 
 ® (macitentan) tablets, for oral use
 

Initial U.S. Approval: 2013"
22174520-4b78-4841-96f7-530ba12d2cf1,8,paroxetine,32937,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240217_22174520-4b78-4841-96f7-530ba12d2cf1.json,"Paroxetine Tablets USP, film coated for oral use"
2265ef30-253e-11df-8a39-0800200c9a66,42,ipilimumab,1094833,gi bleed,10030210,oesophageal varices haemorrhage,../data/2024_latest_labels/latest_labels_ingredients/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011"
2265ef30-253e-11df-8a39-0800200c9a66,42,ipilimumab,1094833,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011"
24926986-7552-4f1a-8366-f035bbd07104,7,fluoxetine,4493,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240224_24926986-7552-4f1a-8366-f035bbd07104.json,"These highlights do not include all the information needed to use FLUOXETINE CAPSULES safely and effectively. See full prescribing information for FLUOXETINE CAPSULES.
 
FLUOXETINE capsules, for oral use
 
Initial U.S. Approval: 1987"
24ac0ee2-cd7b-4dda-a1bb-271e32331758,3,febuxostat,73689,gi bleed,10018830,haematemesis,../data/2024_latest_labels/train_xml/20191219_24ac0ee2-cd7b-4dda-a1bb-271e32331758.json,"These HIGHLIGHTS do not include all the information needed to use ULORIC safely and effectively. See full prescribing information for ULORIC. 
 ULORIC (febuxostat) tablet for oral use  Initial U.S. Approval: 2009"
26eb95ba-1f77-4496-a6ea-92bd63a40a3e,100,oxaprozin,32613,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231207_26eb95ba-1f77-4496-a6ea-92bd63a40a3e.json,"These highlights do not include all the information needed to use OXAPROZIN TABLETS safely and effectively. See full prescribing information for OXAPROZIN TABLETS.
OXAPROZIN tablets, for oral useInitial U.S. Approval: 1992"
2a7300d3-95e3-427e-bf37-55fa654cc90a,9,olanzapine,61381,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_2a7300d3-95e3-427e-bf37-55fa654cc90a.json,"These highlights do not include all the information needed to use OLANZAPINE TABLETS safely and effectively. See full prescribing information for OLANZAPINE TABLETS.


OLANZAPINE
 tablets, for oral use 


Initial U.S. Approval: 1996"
2d18cfc4-e0de-4814-a712-c1b7c504bff5,31,exenatide,60548,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231014_2d18cfc4-e0de-4814-a712-c1b7c504bff5.json,"These highlights do not include all the information needed to use BYDUREON BCISE safely and effectively. See full prescribing information for BYDUREON BCISE.
BYDUREON BCISE® (exenatide) extended-release injectable suspension, for subcutaneous useInitial U.S. Approval: 2005"
2dd58c88-142f-41ad-bc31-0a4fff074970,1,ceftibuten,20492,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20100115_2dd58c88-142f-41ad-bc31-0a4fff074970.json,"CEDAX® 
(ceftibuten capsules) and (ceftibuten for oral suspension)"
33f60b40-3fca-11de-8f56-0002a5d5c51b,24,iloperidone,73178,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20210916_33f60b40-3fca-11de-8f56-0002a5d5c51b.json,"These highlights do not include all the information needed to use FANAPT safely and effectively. See full prescribing information for FANAPT.


FANAPT® (iloperidone) tablets, for oral use

Initial U.S. Approval: 2009"
34ce1cdd-648e-4f1e-8512-bf3d4cc22eb9,11,praziquantel,8628,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240110_34ce1cdd-648e-4f1e-8512-bf3d4cc22eb9.json,"These highlights do not include all the information needed to use BILTRICIDE safely and effectively.  See full prescribing information for BILTRICIDE.BILTRICIDE (praziquantel) tablets, for oral use
Initial U.S. Approval: 1982"
35d0074e-212b-4a1f-9cd7-974ca08d2c95,21,ropinirole,72302,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240206_35d0074e-212b-4a1f-9cd7-974ca08d2c95.json,"These highlights do not include all the information needed to use ROPINIROLE TABLETS safely and effectively. See full prescribing information for ROPINIROLE TABLETS.
ROPINIROLE tablets, for oral use Initial U.S. Approval: 1997"
35d0074e-212b-4a1f-9cd7-974ca08d2c95,21,ropinirole,72302,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240206_35d0074e-212b-4a1f-9cd7-974ca08d2c95.json,"These highlights do not include all the information needed to use ROPINIROLE TABLETS safely and effectively. See full prescribing information for ROPINIROLE TABLETS.
ROPINIROLE tablets, for oral use Initial U.S. Approval: 1997"
39e62997-8781-449a-e054-00144ff88e88,7,nizatidine,42319,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20221228_39e62997-8781-449a-e054-00144ff88e88.json,"Nizatidine Oral Solution 

15 mg/mL 

 
Rx only"
3a1424d8-844c-4e24-9ebd-b2c2b61b61a3,6,fosamprenavir,358262,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231030_3a1424d8-844c-4e24-9ebd-b2c2b61b61a3.json,"These highlights do not include all the information needed to use FOSAMPRENAVIR CALCIUM TABLETS safely and effectively.  See full prescribing information for FOSAMPRENAVIR CALCIUM TABLETS. FOSAMPRENAVIR CALCIUM tablets, for oral useInitial U.S. Approval: 2003"
4314da8a-40e5-4aba-a32b-57b4166ade30,12,azithromycin,18631,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240224_4314da8a-40e5-4aba-a32b-57b4166ade30.json,"These highlights do not include all the information needed to use AZITHROMYCIN TABLETS safely and effectively. See full prescribing information for AZITHROMYCIN TABLETS.  AZITHROMYCIN tablets, for oral use Initial U.S. Approval: 1991"
44dcbf97-99ec-427c-ba50-207e0069d6d2,9,pitavastatin,861634,acute liver injury,10023126,jaundice,../data/2024_latest_labels/gold_xml/20240203_44dcbf97-99ec-427c-ba50-207e0069d6d2.json,"These highlights do not include all the information needed to use LIVALO® safely and effectively.  See full prescribing information for LIVALO.
 LIVALO (pitavastatin) tablets, for oral use Initial U.S. Approval: 2009"
4c9eb5d2-8d2c-4ce7-b45e-c92d3ce9532a,11,isosorbide,6057,acute myocardial infarction,10000891,acute myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240222_4c9eb5d2-8d2c-4ce7-b45e-c92d3ce9532a.json,"Isosorbide Mononitrate Tablets, USP




Rx only"
5108ca9c-b307-4cb2-8ea1-6553764f375a,13,escitalopram,321988,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_5108ca9c-b307-4cb2-8ea1-6553764f375a.json,"These highlights do not include all the information needed to use ESCITALOPRAM TABLETS safely and effectively. See full prescribing information for ESCITALOPRAM TABLETS.
 



ESCITALOPRAM tablets, for oral use
 








Initial U.S. Approval: 2002"
5198b1c8-8dd6-4b8f-bd85-294ac468af53,10,fluvoxamine,42355,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240224_5198b1c8-8dd6-4b8f-bd85-294ac468af53.json,"These highlights do not include all the information needed to use FLUVOXAMINE MALEATE TABLETS safely and effectively. See full prescribing information for FLUVOXAMINE MALEATE TABLETS.
 

FLUVOXAMINE MALEATE tablets, for oral use
 
Initial U.S. Approval: 1994"
52781229-ee82-43f9-a113-4419a611978d,1,rivastigmine,183379,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240111_52781229-ee82-43f9-a113-4419a611978d.json,"These highlights do not include all the information needed to use RIVASTIGMINE TARTRATE CAPSULES safely and effectively. See full prescribing information for RIVASTIGMINE TARTRATE CAPSULES.
 
RIVASTIGMINE TARTRATE capsules, for oral use
 
Initial U.S. Approval: 2000"
52781229-ee82-43f9-a113-4419a611978d,1,rivastigmine,183379,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240111_52781229-ee82-43f9-a113-4419a611978d.json,"These highlights do not include all the information needed to use RIVASTIGMINE TARTRATE CAPSULES safely and effectively. See full prescribing information for RIVASTIGMINE TARTRATE CAPSULES.
 
RIVASTIGMINE TARTRATE capsules, for oral use
 
Initial U.S. Approval: 2000"
52781229-ee82-43f9-a113-4419a611978d,1,rivastigmine,183379,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240111_52781229-ee82-43f9-a113-4419a611978d.json,"These highlights do not include all the information needed to use RIVASTIGMINE TARTRATE CAPSULES safely and effectively. See full prescribing information for RIVASTIGMINE TARTRATE CAPSULES.
 
RIVASTIGMINE TARTRATE capsules, for oral use
 
Initial U.S. Approval: 2000"
53bdb79c-c4cf-4818-b1f0-225e67a14536,24,clozapine,2626,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240209_53bdb79c-c4cf-4818-b1f0-225e67a14536.json,"These highlights do not include all the information needed to use CLOZAPINE TABLETS safely and effectively. See full prescribing information for CLOZAPINE TABLETS.
 
CLOZAPINE tablets, for oral use
 
Initial U.S. Approval: 1989"
55ad6325-16f6-4f0c-a1dc-734847052d0b,2,danazol,3102,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240126_55ad6325-16f6-4f0c-a1dc-734847052d0b.json,"Danazol Capsules, USP
 

Rx only"
5a1cbf7e-0352-aa3b-080c-222a6423ecd8,11,entecavir,306266,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240110_5a1cbf7e-0352-aa3b-080c-222a6423ecd8.json,"Entecavir Tablets, USP
 
Rx Only
 

These highlights do not include all the information needed to use ENTECAVIR TABLETS safely and effectively. See full prescribing information for ENTECAVIR TABLETS.
 

Initial U.S. Approval: 2005"
5c8cebcd-699f-4c4c-900b-94e0fe519345,100,propafenone,8754,acute myocardial infarction,10002388,angina unstable,../data/2024_latest_labels/latest_labels_ingredients/20240208_5c8cebcd-699f-4c4c-900b-94e0fe519345.json,"These highlights do not include all the information needed to use PROPAFENONE HYDROCHLORIDE TABLETS safely and effectively.  See full prescribing information for PROPAFENONE HYDROCHLORIDE TABLETS.
PROPAFENONE HYDROCHLORIDE tablets, for oral useInitial U.S. Approval: 1989"
5cd725a1-2fa4-408a-a651-57a7b84b2118,18,avelumab,1875534,acute myocardial infarction,10000891,acute myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240131_5cd725a1-2fa4-408a-a651-57a7b84b2118.json,"These highlights do not include all the information needed to use BAVENCIO safely and effectively. See full prescribing information for BAVENCIO.
 BAVENCIO® (avelumab) injection, for intravenous use Initial U.S. Approval: 2017"
5d31d815-50fa-4e78-8ebd-affc2514ce78,10,metoclopramide,6915,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240216_5d31d815-50fa-4e78-8ebd-affc2514ce78.json,"These highlights do not include all the information needed to use METOCLOPRAMIDE TABLETS safely and effectively. See full prescribing information for METOCLOPRAMIDE TABLETS.
 



METOCLOPRAMIDE tablets, for oral use
 

Initial U.S. Approval: 1979"
61492681-4be8-448b-b4c6-ef2261503d1a,12,metformin,6809,acute myocardial infarction,10002388,angina unstable,../data/2024_latest_labels/latest_labels_ingredients/20240224_61492681-4be8-448b-b4c6-ef2261503d1a.json,"These highlights do not include all the information needed to use METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS.
 

METFORMIN HYDROCHLORIDE extended-release tablets, for oral use
 

Initial U.S. Approval: 1995"
6fc9c8e2-6f34-aa43-e053-2a91aa0ac377,10,quetiapine,51272,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240221_6fc9c8e2-6f34-aa43-e053-2a91aa0ac377.json,"QUETIAPINE TABLETS. These highlights do not include all the information needed to use QUETIAPINE TABLETS safely and effectively. See full prescribing information for QUETIAPINE TABLETS.
 

Quetiapine tablets, for oral use
 

Initial U.S. Approval: 1997"
7036c6df-6527-4701-b484-6b962914b52a,7,tiagabine,31914,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240102_7036c6df-6527-4701-b484-6b962914b52a.json,Tiagabine Hydrochloride Tablets
7276803b-5b97-d886-e053-2a91aa0a184e,5,dofetilide,49247,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240124_7276803b-5b97-d886-e053-2a91aa0a184e.json,"Dofetilide Capsules
 

Rx Only
 















Rx only"
7499fc35-fae8-44ad-bbab-9a1a589bf3ee,20,etoposide,4179,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231201_7499fc35-fae8-44ad-bbab-9a1a589bf3ee.json,"These highlights do not include all the information needed to use ETOPOPHOS safely and effectively. See full prescribing information for ETOPOPHOS.
ETOPOPHOS® (etoposide phosphate) for injection, for intravenous useInitial U.S. Approval: 1983"
7652adc6-1aad-4422-b85c-0c6b11c23b73,7,gabapentin,25480,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240224_7652adc6-1aad-4422-b85c-0c6b11c23b73.json,"These highlights do not include all the information needed to use GABAPENTIN CAPSULES safely and effectively. See full prescribing information for GABAPENTIN CAPSULES.
 

GABAPENTIN capsules, for oral use
 

Initial U.S. Approval: 1993"
793062e5-5a0c-40f9-8d8b-ca0862cd8a37,11,aripiprazole,89013,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240217_793062e5-5a0c-40f9-8d8b-ca0862cd8a37.json,"These highlights do not include all the information needed to use ARIPIPRAZOLE TABLETS safely and effectively. See full prescribing information for ARIPIPRAZOLE TABLETS.
 



ARIPIPRAZOLE tablets, for oral use
 

Initial U.S. Approval: 2002"
7f10bf63-06c8-477d-a13e-fb88e287617a,103,repaglinide,73044,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240116_7f10bf63-06c8-477d-a13e-fb88e287617a.json,"These highlights do not include all the information needed to use REPAGLINIDE TABLETS safely and effectively.  See full prescribing information for REPAGLINIDE TABLETS.REPAGLINIDE tablets, for oral useInitial U.S. Approval: 1997"
819207a2-0c37-b275-e053-2a91aa0afb36,7,aminophylline,689,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240202_819207a2-0c37-b275-e053-2a91aa0afb36.json,"AMINOPHYLLINE INJ., USP 500mg (25mg/mL) 20mL VIAL"
8512d0c6-db4e-4673-b3b4-28975c18413f,12,olsalazine,32385,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231117_8512d0c6-db4e-4673-b3b4-28975c18413f.json,""
8512d0c6-db4e-4673-b3b4-28975c18413f,12,olsalazine,32385,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231117_8512d0c6-db4e-4673-b3b4-28975c18413f.json,""
88698921-cd8f-4d41-96e6-ff671913c5c3,7,nateglinide,274332,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231110_88698921-cd8f-4d41-96e6-ff671913c5c3.json,"These highlights do not include all the information needed to use NATEGLINIDE TABELTS safely and effectively. See full prescribing information for NATEGLINIDE TABELTS.
NATEGLINIDE tablets, for oral useInitial U.S. Approval: 2000"
8b6261f6-4bdc-462e-8af1-4064664c62f3,2,empagliflozin,1545653,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/train_xml/20221214_8b6261f6-4bdc-462e-8af1-4064664c62f3.json,"These highlights do not include all the information
needed to use JARDIANCE safely and effectively.  See full prescribing
information for JARDIANCE.
 JARDIANCE® (empagliflozin) tablets, for oral use Initial U.S. Approval: 2014"
8baba4ea-2855-42fa-9bd9-5a7548d4cec3,24,durvalumab,1919503,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20231223_8baba4ea-2855-42fa-9bd9-5a7548d4cec3.json,"These highlights do not include all the information needed to use IMFINZI safely and effectively.  See full prescribing information for IMFINZI.
IMFINZI® (durvalumab) injection, for intravenous useInitial U.S. Approval: 2017"
8bc2ddf8-d695-46b3-bf76-9f85ce6027e3,4,gallium,1310124,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20120323_8bc2ddf8-d695-46b3-bf76-9f85ce6027e3.json,Ganite® (gallium nitrate injection)
8bc6397e-4bd8-4d37-a007-a327e4da34d9,56,cetuximab,318341,acute myocardial infarction,10000891,acute myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230628_8bc6397e-4bd8-4d37-a007-a327e4da34d9.json,"These highlights do not include all the information needed to use ERBITUX safely and effectively. See full prescribing information for ERBITUX.ERBITUX® (cetuximab) injection, for intravenous useInitial U.S. Approval: 2004"
8bf8e76c-27cb-42a4-aa9c-bdade68c463b,4,rasagiline,134748,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20231227_8bf8e76c-27cb-42a4-aa9c-bdade68c463b.json,These highlights do not include all the information needed to use RASAGILINE TABLETS safely and effectively. See full prescribing information for RASAGILINE TABLETS. RASAGILINE tablets for oral use Initial U.S. Approval: 2006
8bf8e76c-27cb-42a4-aa9c-bdade68c463b,4,rasagiline,134748,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231227_8bf8e76c-27cb-42a4-aa9c-bdade68c463b.json,These highlights do not include all the information needed to use RASAGILINE TABLETS safely and effectively. See full prescribing information for RASAGILINE TABLETS. RASAGILINE tablets for oral use Initial U.S. Approval: 2006
8edd78a9-d762-4578-a610-28d6595f4bf3,1,melphalan,6718,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231218_8edd78a9-d762-4578-a610-28d6595f4bf3.json,Melphalan Hydrochloride for Injection(For Intravenous Infusion)
9914e793-a49c-eb00-1ab7-f606c786fe25,7,dactinomycin,3100,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240120_9914e793-a49c-eb00-1ab7-f606c786fe25.json,"These highlights do not include all the information needed to use COSMEGEN safely and effectively. See full prescribing information for COSMEGEN. 

COSMEGEN  ® (dactinomycin for injection) for intravenous use 

Initial U.S. Approval: 1964"
99e9d85a-ec8e-48d2-acd0-5dda3b741838,6,ceftriaxone,2193,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240214_99e9d85a-ec8e-48d2-acd0-5dda3b741838.json,"Ceftriaxone for Injection, USP


Rx Only"
9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f,6,ketoprofen,6142,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240206_9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f.json,KIPROFEN™ Capsules
a1787fad-3612-43e1-98fa-ce62361e0b3c,13,imatinib,282388,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240203_a1787fad-3612-43e1-98fa-ce62361e0b3c.json,"These highlights do not include all the information needed to use IMATINIB MESYLATE TABLETS safely and effectively.  See full prescribing information for IMATINIB MESYLATE TABLETS. IMATINIB MESYLATE tablets, for oral useInitial U.S. Approval: 2001"
a65803a2-0f7a-461e-b0ab-81ebb9e4f789,8,silver sulfadiazine,9793,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240223_a65803a2-0f7a-461e-b0ab-81ebb9e4f789.json,DESCRIPTION
b0c23a2c-b250-4c0d-9b2a-c1483faa2ca0,15,propylthiouracil,8794,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20240213_b0c23a2c-b250-4c0d-9b2a-c1483faa2ca0.json,"Propylthiouracil Tablets, USP"
b1b84d62-a369-a4b7-5c41-dd1f553a18f3,15,triptorelin,38782,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20231203_b1b84d62-a369-a4b7-5c41-dd1f553a18f3.json,"These highlights do not include all the information needed to use TRELSTAR safely and effectively. See full prescribing information for TRELSTAR.
TRELSTAR®  (triptorelin pamoate for injectable suspension), for intramuscular use  Initial U.S. Approval: 2000"
b1bd0d02-eccb-4449-82b9-9b552835029e,10,warfarin,11289,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20240222_b1bd0d02-eccb-4449-82b9-9b552835029e.json,"These highlights do not include all the information needed to use WARFARIN SODIUM TABLETS safely and effectively. See full prescribing information for WARFARIN SODIUM TABLETS.
 



WARFARIN SODIUM tablets, for oral use
 

Initial U.S. Approval: 1954"
b605b541-4bfd-db3e-9710-11c27f6dee6c,2,bortezomib,358258,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240105_b605b541-4bfd-db3e-9710-11c27f6dee6c.json,"These highlights do not include all the information needed to use BORTEZOMIB FOR INJECTION safely and effectively. See full prescribing information for BORTEZOMIB FOR INJECTION.
 BORTEZOMIB for injection, for subcutaneous or intravenous useInitial U.S. Approval: 2003"
b8d657ac-dbda-4455-8bb5-3896951c3b67,4,zolmitriptan,135775,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240224_b8d657ac-dbda-4455-8bb5-3896951c3b67.json,"These highlights do not include all the information needed to use ZOLMITRIPTAN ORALLY DISINTEGRATING TABLETS safely and effectively. See full prescribing information for ZOLMITRIPTAN ORALLY DISINTEGRATING TABLETS.
 ZOLMITRIPTAN orally disintegrating tablets Initial U.S. Approval: 1997"
ba1cca98-f350-4655-88e3-6ef990779fb9,1,telithromycin,274786,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20120511_ba1cca98-f350-4655-88e3-6ef990779fb9.json,"KETEK®
(telithromycin) Tablets"
c00d1607-ac36-457b-a34b-75ad74f9cf0a,32,saquinavir,83395,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20210630_c00d1607-ac36-457b-a34b-75ad74f9cf0a.json,"These highlights do not include all the information needed to use INVIRASE safely and effectively. See full prescribing information for INVIRASE. 
INVIRASE® (saquinavir mesylate) tablets, for oral use
 Initial U.S. Approval: 1995"
c0978fa8-53ff-4ca2-82a7-567fd3e958ca,16,remdesivir,2284718,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230908_c0978fa8-53ff-4ca2-82a7-567fd3e958ca.json,"These highlights do not include all the information needed to use VEKLURY safely and effectively. See full prescribing information for VEKLURY.
 VEKLURY® (remdesivir) for injection, for intravenous use  VEKLURY® (remdesivir) injection, for intravenous use Initial U.S. Approval: 2020"
c0d1c22b-566b-4776-bdbf-00f96dad0cae,9,filgrastim,68442,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20240202_c0d1c22b-566b-4776-bdbf-00f96dad0cae.json,"These highlights do not include all the information needed to use ZARXIO safely and effectively. See full prescribing information for ZARXIO.
ZARXIO® (filgrastim-sndz) injection, for subcutaneous or intravenous useInitial U.S. Approval: 2015ZARXIO (filgrastim-sndz) is biosimilar* to NEUPOGEN (filgrastim)."
c6c7c39e-e510-4f4a-bf7a-926f0e075d3a,10,protriptyline,8886,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231221_c6c7c39e-e510-4f4a-bf7a-926f0e075d3a.json,"Protriptyline Hydrochloride Tablets, USPRx Only"
d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f,8,mefenamate,257844,gi bleed,10018830,haematemesis,../data/2024_latest_labels/latest_labels_ingredients/20240120_d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f.json,Mefenamic Acid Capsules USPRx Only
d5929f91-6496-4c0e-97e8-0bd524e15763,3,bosutinib,1307619,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/train_xml/20220817_d5929f91-6496-4c0e-97e8-0bd524e15763.json,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF.
 BOSULIF® (bosutinib) tablets, for oral use Initial U.S. Approval: 2012"
dd3dcc9a-e40c-4677-9ee6-f318e7c7d835,31,vinorelbine,39541,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/latest_labels_ingredients/20230613_dd3dcc9a-e40c-4677-9ee6-f318e7c7d835.json,"These highlights do not include all the information needed to use VINORELBINE INJECTION safely and effectively. See full prescribing information for VINORELBINE INJECTION. 


VINORELBINE injection, for intravenous use 

Initial U.S. Approval: 1994"
e07862df-f324-4575-a1ef-f7e1cbab4c7a,11,granisetron,26237,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20240105_e07862df-f324-4575-a1ef-f7e1cbab4c7a.json,"These highlights do not include all the information needed to use Granisetron Hydrochloride Injection, USP safely and effectively. See full prescribing information for Granisetron Hydrochloride Injection, USP.  

GRANISETRON hydrochloride injection, USP for intravenous use

Initial U.S. Approval: 1993"
e0fa4bca-f245-4d92-ae29-b0c630a315c2,157,panitumumab,263034,acute kidney injury,10069339,acute kidney injury,../data/2024_latest_labels/latest_labels_ingredients/20230629_e0fa4bca-f245-4d92-ae29-b0c630a315c2.json,"These highlights do not include all the information needed to use 
VECTIBIX
 safely and effectively.  See full prescribing information for 
VECTIBIX
.

   

VECTIBIX

®

 
(panitumumab)
 
I
njection 
for 
intravenous 
use

Initial U.S. Approval: 
200
6"
e1114a58-9ab5-486e-85ed-360365b06396,1,methyldopa,6876,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20230105_e1114a58-9ab5-486e-85ed-360365b06396.json,"Methyldopa Tablets, USP"
e65d5108-22a2-4d87-a78d-15606f3cc9e2,3,nimodipine,7426,acute liver injury,10019717,hepatitis,../data/2024_latest_labels/latest_labels_ingredients/20231228_e65d5108-22a2-4d87-a78d-15606f3cc9e2.json,"Nimodipine Capsules


For Oral Use


Rx only"
ea3bbafb-d32a-d0d3-e053-2a95a90ac387,2,silodosin,720825,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240111_ea3bbafb-d32a-d0d3-e053-2a95a90ac387.json,"SILODOSIN capsules, for oral use
 

These highlights do not include all the information needed to use SILODOSIN CAPSULES safely and effectively. See full prescribing information for SILODOSIN CAPSULES.
 

Initial U.S. Approval: 2008"
ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,54,carfilzomib,1302966,acute myocardial infarction,10028596,myocardial infarction,../data/2024_latest_labels/train_xml/20221029_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.json,"These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. 
KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012"
f073b58e-56d6-4c8d-a2ce-b37719402d77,3,vinblastine,11198,acute myocardial infarction,10002383,angina pectoris,../data/2024_latest_labels/latest_labels_ingredients/20200101_f073b58e-56d6-4c8d-a2ce-b37719402d77.json,Vinblastine Sulfate Injection
f47d4365-40a8-445b-99cd-49edad6a8ffc,15,ketorolac,35827,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20240206_f47d4365-40a8-445b-99cd-49edad6a8ffc.json,"Ketorolac Tromethamine Tablets USP, 10 mg 
 




Rx only"
f9c6fd52-6e28-482c-8b76-bd111760a34c,10,fenoprofen,4331,acute liver injury,10023126,jaundice,../data/2024_latest_labels/latest_labels_ingredients/20231115_f9c6fd52-6e28-482c-8b76-bd111760a34c.json,"These highlights do not include all the information needed to use NALFON safely and effectively. See full prescribing information for NALFON.
 



NALFON (fenoprofen calcium, USP) capsules, for oral use
 

Initial U.S. Approval: 1982"
